US20160022778A1 - A method for treating tumor by using recombinant interferon with changed spatial configuration - Google Patents

A method for treating tumor by using recombinant interferon with changed spatial configuration Download PDF

Info

Publication number
US20160022778A1
US20160022778A1 US14/759,410 US201414759410A US2016022778A1 US 20160022778 A1 US20160022778 A1 US 20160022778A1 US 201414759410 A US201414759410 A US 201414759410A US 2016022778 A1 US2016022778 A1 US 2016022778A1
Authority
US
United States
Prior art keywords
administration
recombinant interferon
cancer
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/759,410
Inventor
Guangwen Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Superlab Far East Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US14/759,410 priority Critical patent/US20160022778A1/en
Assigned to SUPERLAB FAR EAST LIMITED reassignment SUPERLAB FAR EAST LIMITED NUNC PRO TUNC ASSIGNMENT (SEE DOCUMENT FOR DETAILS). Assignors: WEI, GUANGWEN
Publication of US20160022778A1 publication Critical patent/US20160022778A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to methods for treating tumors in subjects by using recombinant interferon, and to methods for treating solid tumors, including lung cancers in subjects.
  • the present invention further relates to non-surgical methods for eliminating tumors or reducing the sizes of tumors in subjects, or preventing postoperative tumor recurrence and/or metastases and/or prolonging tumor free survival in subjects by using a recombinant interferon (rSIFN-co) with changed spatial configuration, either alone, or in conjunction with radiotherapy, chemotherapy, and/or anti-tumor drugs such as biological agents, targeted drugs and the like.
  • rSIFN-co recombinant interferon
  • Cancer is one of the major causes of death in people around the world.
  • the total number of cases worldwide continues to increase.
  • WHO world health organization
  • the global cancer deaths will be increased by 45% (from U.S. Pat. No. 7,900,000 to Ser. No. 11/500,000) from 2007 to 2030, and the new cases of cancer will zoom from Ser. No. 11/300,000 in 2007 to Ser. No. 15/500,000 in 2030 in the same period, wherein the incidence rate and the death rate of the lung cancer ranks first in the global malignant tumors.
  • the amount of the worldwide new cases of lung cancer every year is more than 3,000,000 and increases continuously (see Gray, J. et al. Chest, 2007, 132, 56S-68S).
  • the number of deaths caused by lung cancer is more than 1,300,000 around the world every year, which is more than the sum of the number of cancer-related deaths caused by other three common cancers (breast cancer, prostate cancer and colorectal cancer).
  • the classic methods for treating cancer include surgical therapy, radiotherapy and chemotherapy.
  • the surgical therapy is not suitable for all types of solid tumors.
  • the surgical therapy may not eliminate cancer cells thoroughly due to metastatic lesions and the like, so as not to achieve the purpose of cure.
  • Radiotherapy is only suitable for the tumors situated at positions that are sensitive to rays, take muscles as tumor beds and have better blood circulation, and the radiotherapy may accidentally injure normal cells to cause various side effects, so as to affect the quality of life of the patients.
  • the effect of the chemotherapy as the systemic treatment means is determined by the types and the states of cancers. Chemotherapy can suppress the growth and the spread of the cancers more especially, and same with the radiotherapy, the chemotherapy can also accidentally injure normal cells to affect the quality of life of the patients.
  • Surgical therapy can be performed to eliminate tumors, improve the quality of life and provide time for follow-up treatment for some early or medium-term solid tumor patients; but for some advanced patients with metastasized solid tumors, the treatment methods in the prior art are only chemotherapy, radiotherapy or combining the chemotherapy, radiotherapy and other treatment methods when the quality of life is obviously affected and life is even threatened, these treatment methods are not ideal in effects and cannot achieve the purpose of eliminating the tumors and completely alleviating the condition of the patients.
  • the biotherapy has become the important treatment means for cancer treatment after surgical therapy, radiotherapy and chemotherapy has been performed.
  • Interferon is a kind of soluble protein produced by a variety of cells which has many important biological functions, including anti-viral, anti-tumor, and immunoregulatory functions. Interferons can be divided into type I, type II, and type III interferons according to the differences in the types of producing cells, receptors and biological activities, etc. Type I IFNs, which are mostly induced by viruses and synthetic double-stranded RNA, are also known as anti-viral interferons. There are three forms of type I interferons: interferon-alpha or alpha-interferon (IFN ⁇ ), interferon-beta (INF ⁇ ) and interferon omega (IFN ⁇ ).
  • IFN ⁇ interferon-alpha or alpha-interferon
  • IFN ⁇ interferon-beta
  • IFN ⁇ interferon omega
  • the amino acid sequence of a protein can determine the three-dimensional structure of the protein and further determine the functionality thereof.
  • synonymous mutation(s) of the nucleotide sequence encoding the protein that is, codon mutation(s) with no change in the amino acid sequence of the encoded protein
  • the nucleotide sequence with synonymous mutation(s) can express and generate proteins with different final spatial structure and different function compared with the wild type protein (see Sarfaty, C. K. et al. Science, 2007, 315:525-528).
  • rSIFN-co recombinant interferon
  • This recombinant interferon, rSIFN-co has the same amino acid sequence as that of INFERGEN®, but the encoding nucleotide sequences of this recombinant interferon, rSIFN-co, and that of INFERGEN® are different (i.e. synonymous mutations exists in the nucleotide sequence encoding the recombinant interferon, rSIFN-co), resulting in changes in spatial configuration of the recombinant interferon, rSIFN-co, and qualitative changes in its biological efficacy.
  • One of the objects of the present invention is to provide new methods for treating tumors in subjects by using the recombinant interferon, rSIFN-co encoded by the nucleotide sequence of SEQ ID NO: 2.
  • Another one of the objects of the present invention is to provide new methods for treating lung cancers in subjects by using the recombinant interferon encoded by the nucleotide sequence of SEQ ID NO: 2 (hereafter also be referred to as recombinant super-compound interferon or rSIFN-co).
  • the present invention provides:
  • a method for treating a tumor in a subject comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • lung cancer liver cancer
  • the solid tumor comprises lung cancer
  • the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • SCLC small cell lung cancer
  • NSCLC non small cell lung cancer
  • non-solid tumor comprises one or more of: leukemia, acute leukemia, chronic leukemia, chronic myelocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T-cell leukemia, hairy cell leukemia, polycythemia, myelodysplastic syndrome, multiple myeloma, lymphadenoma, Hodgkin's lymphoma, and Non-Hodgkin's lymphoma.
  • the administration route comprises one or more of: oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, and intravesical administration.
  • the duration of the treatment cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or optionally, the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration of recombinant interferon treatment can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • time interval between any two adjacent treatment cycles of the more treatment cycles is at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like; or optionally the time interval can be about 2 days to about 6 years, about 4 days to about 3 years, about 1 week to about 1 year, about 2 months to about 9 months, or about 3 months to about 6 months and the like.
  • chemotherapeutic drugs used in the first-line chemotherapy comprise platinum compounds, such as Cisplatin.
  • a method for treating tumor in a subject comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, and at least one other anti-cancer therapy, wherein the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon, and wherein the tumor is a cancer or solid tumor that is not indicated nor appropriate for surgery, or the tumor is a solid tumor that cannot be resected, and the combination of the recombinant interferon and the at least one other anti-cancer therapy eliminate the tumor or reduce the size of the tumor compared to the tumor before treatment.
  • another embodiment of the present invention provides:
  • a method for preventing tumor recurrence and/or metastasis or prolonging or maintaining a tumor-free status in a subject with a tumor after at least one anti-cancer therapy comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • lung cancer liver cancer
  • the solid tumor comprises lung cancer
  • the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • SCLC small cell lung cancer
  • NSCLC non small cell lung cancer
  • non-solid tumor comprises one or more of: leukemia, acute leukemia, chronic leukemia, chronic myelocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T-cell leukemia, hairy cell leukemia, polycythemia, myelodysplastic syndrome, multiple myeloma, lymphadenoma, Hodgkin's lymphoma, and Non-Hodgkin's lymphoma.
  • the administration route comprises one or more of: oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, and intravesical administration.
  • each prevention cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • time interval between any two adjacent prevention cycles of the more prevention cycles is at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like; or the time interval can also be about 2 days to about 6 years, about 4 days to about 3 years, about 1 week to about 1 year, about 2 months to about 9 months, or about 3 months to about 6 months and the like.
  • the at least one anti-cancer therapy comprises at least one of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy
  • the at least one anti-cancer therapy comprises at least one of: chemotherapy, radiotherapy, surgical therapy, and biotherapy.
  • the administration route comprises one or more of: infiltration administration, intrapleural administration, abdominal administration, pericardial administration, uterine administration, intravesical administration, intratumoral administration, pulmonary administration, nasal administration, percutaneous administration, transdermal administration, epidermal administration, and transmucosal administration.
  • another embodiment of the present invention provides:
  • a non-surgical method for eliminating a tumor in a subject or reducing the size of a tumor in a subject comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • lung cancer liver cancer
  • the solid tumor comprises lung cancer
  • the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • SCLC small cell lung cancer
  • NSCLC non small cell lung cancer
  • the administration route comprises one or more of: infiltration administration, intrapleural administration, abdominal administration, pericardial administration, uterine administration, intravesical administration, intratumoral administration, pulmonary administration, nasal administration, percutaneous administration, transdermal administration, epidermal administration, and transmucosal administration.
  • another embodiment of the present invention provides:
  • a method for eliminating or reducing the pleural effusion, ascites, and/or pericardial effusion in a subject with tumor comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • lung cancer liver cancer
  • the solid tumor comprises lung cancer
  • the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • SCLC small cell lung cancer
  • NSCLC non small cell lung cancer
  • the administration route comprises one or more of: infiltration administration, intrapleural administration, abdominal administration, and pericardial administration.
  • At least one targeted drug comprises at least one of: Gefitinib, Erlotinib, and recombinant human endostatin.
  • another embodiment of the present invention provides:
  • a method for treating tumor in a subject comprising topically or locally administering to the tumor lesions of the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • a method for eliminating or reducing metastatic tumor lesions in a subject comprising topically or locally administering to the metastatic tumor lesions of the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • tumor lesions comprise at least one of: bone lesions, muscular lesions, subcutaneous tissue lesions, prostatic lesions and lymph node lesions
  • tumor metastatic lesions comprise at least one of: bone metastatic lesions, muscular metastatic lesions, subcutaneous tissue metastatic lesions, prostatic metastatic lesions, and lymph node metastatic lesions
  • the tumor metastatic lesions comprise bone metastatic lesions.
  • topical or local administration comprises at least one of: infiltration administration, percutaneous administration, transdermal administration, epidermal administration and transmucosal administration, optionally, the topical and local administration comprises transdermal administration, or infiltration administration.
  • infiltration administration comprises one or more of: percutaneous infiltration administration, epidermal infiltration administration, transdermal infiltration administration, and transmucosal infiltration administration.
  • percutaneous administration, transdermal administration, epidermal administration, or transmucosal administration comprises percutaneous spray administration, transdermal spray administration, epidermal spray administration, or transmucosal spray administration, respectively.
  • (22) The method of any one of (18)-(21), wherein the duration of administration of induction dose and therapeutic dose is at least: about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • a method for eliminating or reducing the bone metastatic lesions of tumor in a subject comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by topical or local administration, wherein the topical or local administration comprises transdermal administration and/or infiltration administration, optionally, the recombinant interferon is administered to the bone metastatic lesions of tumor of the subject.
  • a method for eliminating or reducing the bone lesions of tumor such as bone metastatic lesions of tumor, muscular lesions of tumor such as muscular metastatic lesions of tumor, subcutaneous tissue lesions of tumor such as subcutaneous tissue metastatic lesions of tumor, prostatic lesions of tumor such as prostatic metastatic lesions of tumor, and/or lymph node lesions of tumor such as lymph node metastatic lesions of tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by any administration route through the skin, so that eliminating or reducing the bone lesions of tumor such as bone metastatic lesions of tumor, muscular lesions of tumor such as muscular metastatic lesions of tumor, subcutaneous tissue lesions of tumor such as subcutaneous tissue metastatic lesions of tumor, prostatic lesions of tumor such as prostatic metastatic lesions of tumor, and/or lymph node lesions of tumor such as lymph node metastatic lesions of tumor, optionally, the recombinant interferon is administered to the metastatic lesions of tumor of the
  • another embodiment of the present invention provides:
  • a method for treating lung cancer in a subject comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • SCLC small cell lung cancer
  • NSCLC non small cell lung cancer
  • the administration route comprises one or more of: oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, and intravesical administration.
  • lung cancer in the subject comprises tumor metastasis in at least one of: skin, mucosa, superficial lymph nodes, and subcutaneous tissue.
  • spray administration comprises at least one of: percutaneous spray administration, transdermal spray administration, epidermal spray administration, and transmucosal spray administration.
  • the administration route comprises at least one of: subcutaneous administration, intramuscular administration, inhalation administration, infiltration administration, intrapleural administration, abdominal administration, pericardial administration, intratumoral administration, and spray administration.
  • the method of (54), wherein the at least one other anti-cancer therapy comprises at least one of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • duration of the treatment cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • time interval between any two adjacent treatment cycles of the more treatment cycles is at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like; or the time interval can also be about 2 days to about 6 years, about 4 days to about 3 years, about 1 week to about 1 year, about 2 months to about 9 months, or about 3 months to about 6 months and the like.
  • a method for treating lung cancer in a subject comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 and one or more chemotherapeutic drugs in two or more treatment cycles, and then administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 and one or more targeted drugs in one or more treatment cycles.
  • another embodiment of the present invention provides:
  • a method for treating lung cancer in a subject comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by subcutaneous administration and/or intramuscular administration, wherein the recombinant interferon is administered in an amount in a range of about 2 ⁇ g to about 70 ⁇ g, optionally about 4 ⁇ g to about 50 ⁇ g, further optionally about 4 ⁇ g to about 30 ⁇ g by one subcutaneous administration and/or intramuscular administration, the recombinant interferon is administered by subcutaneous administration and/or intramuscular administration once every about 1 to about 7 days, optionally every about 1 to about 2 days, lasting at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months
  • lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • SCLC small cell lung cancer
  • NSCLC non small cell lung cancer
  • lung cancer in the subject comprises tumor metastasis in at least one of: skin, mucosa, superficial lymph nodes, and subcutaneous tissue.
  • spray administration comprises at least one of: percutaneous spray administration, transdermal spray administration, epidermal spray administration, and transmucosal spray administration.
  • the method of (40), wherein the at least one other anti-cancer therapy comprises one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • another embodiment of the present invention provides:
  • a method for treating lung cancer in a subject comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by subcutaneous administration and/or intramuscular administration, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 ⁇ g to about 10 ⁇ g each time, optionally about 4 ⁇ g to about 10 ⁇ g each time, further optionally about 4.5 ⁇ g to about 9 ⁇ g each time, such as about 4.5 ⁇ g each time or about 9 ⁇ g each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose in a range of about 10 ⁇ g to about 70 ⁇ g each time, optionally about 12 ⁇ g to about 50 ⁇ g each time, further optionally about 12 ⁇ g to about 30 ⁇ g each time.
  • lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • SCLC small cell lung cancer
  • NSCLC non small cell lung cancer
  • time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • the recombinant interferon is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days when the recombinant interferon is administered more times at an induction dose.
  • the administration route comprises at least one of: intrapleural administration, abdominal administration, and pericardial administration.
  • lung cancer in the subject comprises tumor metastasis in at least one of: skin, mucosa, superficial lymph nodes, and subcutaneous tissue.
  • another embodiment of the present invention provides:
  • a method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to brain comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 ⁇ g to about 10 ⁇ g each time, optionally about 4 ⁇ g to about 10 ⁇ g each time, further optionally about 4.5 ⁇ g to about 9 ⁇ g each time, such as about 4.5 ⁇ g each time or about 9 ⁇ g each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose in a range of about 10 ⁇ g to about 70 ⁇ g each time, optionally about 12 ⁇ g to about 50 ⁇ g each time, further optionally about 12 ⁇ g to about 30 ⁇ g each time, and the recombinant interferon
  • (10) The method of any one of (1)-(9), wherein the time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • duration of the inhalation administration is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • another embodiment of the present invention provides:
  • a method for treating cancer in a subject comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 ⁇ g to about 10 ⁇ g each time, optionally about 4 ⁇ g to about 10 ⁇ g each time, further optionally about 4.5 ⁇ g to about 9 ⁇ g each time, such as about 4.5 ⁇ g each time or about 9 ⁇ g each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 ⁇ g-about 70 ⁇ g each time, optionally about 12 ⁇ g to about 50 ⁇ g each time, further optionally about 12 ⁇ g to about 30 ⁇ g each time.
  • time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • (11) The method of any one of (1)-(10), wherein the duration of administration of induction dose and therapeutic dose is at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • the recombinant interferon is administered in an amount in a range of about 100 ⁇ g to about 2000 ⁇ g, optionally about 100 ⁇ g to about 1500 ⁇ g, further optionally about 150 ⁇ g to about 800 ⁇ g, still further optionally about 200 ⁇ g to about 600 ⁇ g by one inhalation administration, the recombinant interferon is administered by inhalation administration once every about 1 day to about 3 days, optionally every about 1 day, and the duration of the inhalation administration is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years,
  • the at least one other anti-cancer therapy comprises one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • another embodiment of the present invention provides:
  • a method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to lymph nodes comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 ⁇ g to about 10 ⁇ g each time, optionally about 4 ⁇ g to about 10 ⁇ g each time, further optionally about 4.5 ⁇ g to about 9 ⁇ g each time, such as about 4.5 ⁇ g each time or about 9 ⁇ g each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 ⁇ g to about 70 ⁇ g each time, optionally about 12 ⁇ g to about 50 ⁇ g each time, further optionally about 12 ⁇ g to about 30 ⁇ g each time, and the recombinant interferon is administered
  • time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • (11) The method of any one of (1)-(10), wherein the duration of administration of induction dose and therapeutic dose is at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • topical or local administration comprises at least one of: infiltration administration, percutaneous administration, transdermal administration, epidermal administration, and transmucosal administration when the lymph nodes are superficial lymph nodes.
  • another embodiment of the present invention provides:
  • a method for treating lung cancer in a subject, wherein the subject has pleural effusion, ascites and/or pericardial effusion comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by topical or local administration.
  • pleural effusion is a malignant pleural effusion
  • ascites is a malignant ascites
  • pericardial effusion is a malignant pericardial effusion
  • the local administration comprises at least one of: infiltration administration, intrapleural administration, abdominal administration, and pericardial administration.
  • duration of administration of induction dose and therapeutic dose is at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • the tumor is a solid tumor; optionally, the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head
  • the tumor is a tumor such as cancer or solid tumor without indications for surgery or not indicated or appropriate for surgery; and/or the subject is a medium-term, advanced cancer patient, or III or IV stage cancer patient, optionally, the subject is an advanced, or III or IV stage cancer patient.
  • the recombinant interferon is administered to the subject as monotherapy; or, further comprising one or more other anti-cancer therapies administered to the subject, optionally, other anti-cancer therapies are administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • the other anti-cancer therapies comprise one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • another embodiment of the present invention also provides:
  • a method of treating a tumor in a subject comprising administering to the subject a recombinant interferon that comprises an anti-tumor effect as a first line monotherapy.
  • the tumor comprises one of: lung cancer, uterine cancer, cervical cancer, and pancreatic cancer.
  • a method of treating a tumor in a subject comprising administering to the subject a recombinant interferon that comprises an antitumor effect as a second line monotherapy.
  • the tumor comprises one of: lung cancer, colorectal cancer, malignant melanoma, ovarian cancer, cervical cancer, liver cancer, breast cancer, gastrointestinal cancer, prostate cancer, neuroma, and squamous cell carcinoma.
  • liver cancer comprises HCC.
  • a method of treating a tumor in a subject comprising administering to the subject a recombinant interferon that comprises an anti-tumor effect as a first line therapy in combination with one or more other anti-cancer therapy.
  • lung cancer comprises at least one of non-small cell lung cancer and small cell lung cancer.
  • a method of treating a tumor in a subject comprising administering to the subject a recombinant interferon that comprises an anti-tumor effect as a second line therapy in combination with one or more other anti-cancer therapies.
  • tumor comprises one of: lung cancer, lymphoma, cervical cancer, and cholangioadenocarcinoma.
  • lung cancer comprises at least one of non-small cell lung cancer and small cell lung cancer.
  • lymphoma is non-Hodgkins lymphoma.
  • a method of preventing tumor recurrence in a subject comprising administering an amount of a recombinant interferon that comprises an amino acid sequence that is encoded by a nucleic acid sequence comprising the sequence of SEQ ID NO: 2 after surgery, chemotherapy, radiotherapy, cryoablation, radiofrequency ablation, biologics therapy, intervention therapy, and/or rSIFN-co therapy, whereby the recombinant interferon is administered after tumor bulk in the subject has been reduced.
  • a method of prolonging tumor-free survival in a subject comprising administering an amount of a recombinant interferon that comprises an amino acid sequence that is encoded by a nucleic acid sequence comprising the sequence of SEQ ID NO: 2 after surgery, chemotherapy, radiotherapy, cryoablation, radiofrequency ablation, biologics therapy, intervention therapy, and/or rSIFN-co therapy, whereby the recombinant interferon is administered after tumor bulk in the subject has been reduced.
  • FIG. 1 shows the comparative difference in the structures of the present recombinant interferon (rSIFN-co) and IFN- ⁇ 2b, wherein in a side view and a top view in the FIG. 1 , the red shows rSIFN-co, the green shows IFN- ⁇ 2b, the red is black in a black and white print drawing, and the green is grey in the black and white print drawing.
  • rSIFN-co present recombinant interferon
  • FIG. 2 shows the comparative difference of the three-dimensional structure of the recombinant interferon rSIFN-co of the present invention and the computation model structure of INFERGEN® (being indicated as am-Infergen or Infergen) of the US Amgen, wherein in a circle in the right drawing, a thin line in yellow is rSIFN-co, and a thick spiral in blue is am-Infergen. Meanwhile, in the right drawing, the red shows rSIFN-co, and the green shows am-Infergen, wherein the red is black in the black and white print drawing, and the green is grey in the black and white print drawing.
  • FIGS. 3 a - 3 b shows the treatment situation of patient 1, wherein an arrow in FIG. 3 a shows state of the original lesion observed in a CT image on 8 th November, Year 2, after 12 months of medication; and an arrow in FIG. 3 b shows state of the original lesion observed in a CT image on 1 st February, Year 3, after 15 months of medication, the year of the start of treatment being Year 1.
  • FIGS. 4 a - 4 b shows the treatment situation of patient 2, wherein FIG. 4 a shows a PET/CT imaging diagnosis before rSIFN-co medication, and an arrow indicates the lesion; and FIG. 4 b shows a PET/CT imaging diagnosis after rSIFN-co medication, and an arrow indicates the state of the original lesion after treatment.
  • FIGS. 5 a - 5 b and 6 a - 6 b show the treatment situation of patient 3, wherein FIG. 5 a shows a lung CT image before rSIFN-co medication, and an arrow indicates the lesion; FIG. 5 b shows head and chest CT imaging diagnoses after rSIFN-co medication, and an arrow indicates the state of the original lesion after treatment; FIG. 6 a shows a brain CT image before rSIFN-co medication, and an arrow indicates the lesion; and FIG. 6 b shows head and chest imaging diagnoses after rSIFN-co medication, and an arrow indicates the state of the original lesion after treatment.
  • FIGS. 7 a - 7 b and FIGS. 8 a - 8 b show the treatment situation of patient 4, wherein FIGS. 7 a and 8 a show imaging diagnoses before rSIFN-co medication: as shown in PET/CT after chemotherapy, arrows in the FIGS. 7 a and 8 a indicate the lesions; and FIGS. 7 b and 8 b show imaging diagnoses after rSIFN-co medication: as shown in PET/CT, an arrow indicates the state of the original lesion after treatment.
  • FIGS. 9 a - 9 b , 10 a - 10 b and 11 a - 11 b show the treatment situation of patient 5, wherein FIGS. 9 a , 10 a and 11 a show imaging diagnoses before rSIFN-co medication: as shown in PET/CT, and arrows in the FIGS. 9 a , 10 a and 11 a show the lesions; and FIGS. 9 b , 10 b and 11 b show imaging diagnoses after rSIFN-co medication: as shown in PET/CT, and arrows in the FIGS. 9 b , 10 b and 11 b show the states of the original lesions after treatment.
  • FIGS. 12 a - 12 b shows the treatment situation of patient 6, wherein FIG. 12 a shows a chest CT imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion; and FIG. 12 b shows a CT imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 13 a - 13 b and 14 a - 14 b show the treatment situation of patient 7, wherein FIGS. 13 a and 14 a show CT imaging diagnoses before rSIFN-co medication, and arrows show the original lesions; and FIGS. 13 b and 14 b show CT imaging diagnoses after rSIFN-co medication, and arrows show the states of the original lesions after treatment.
  • FIGS. 15 a - 15 b and 16 a - 16 b show the treatment situation of patient 8, wherein FIGS. 15 a and 16 a show CT imaging diagnoses before rSIFN-co medication, and arrows show the original lesions; and FIGS. 15 b and 16 b show CT imaging diagnoses after rSIFN-co medication, and arrows show the states of the original lesions after treatment.
  • FIGS. 171-17 b shows the treatment situation of patient 9, wherein FIG. 17 a shows a CT imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion; and FIG. 17 b shows a CT imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 18 and 19 a - 19 b show the treatment situation of patient 10, wherein the FIG. 18 shows pleural effusion change before and after the treatment;
  • FIG. 19 a shows a chest CT imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion;
  • FIG. 19 b shows a chest CT imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 20 , 21 a - 21 b , 22 a - 22 b and 23 a - 23 b show the treatment situation of patient 11, wherein FIG. 20 shows the biopsy of patient before treatment, FIGS. 21 a , 22 a and 23 a show PET/CT imaging diagnoses before rSIFN-co medication, and arrows show the original lesions; and FIGS. 21 b , 22 b and 23 b show PET/CT imaging diagnoses after rSIFN-co medication, and arrows show the states of the original lesions after treatment.
  • FIGS. 24 a - 24 b shows the treatment situation of patient 12, wherein FIG. 24 a shows a CT image at the beginning of the medicine administration, and an arrow shows the original lesion; and FIG. 24 b shows an imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 25 a - 25 b shows the treatment situation of patient 13, wherein FIG. 25 a shows a CT image at the early stage of the treatment, and an arrow shows suspicious lesions of inferior lobe of right lung; and FIG. 25 b shows a chest CT image at the later stage of the treatment, and an arrow shows the state of original suspicious lesions of inferior lobe of right lung after treatment.
  • FIGS. 26 a - 26 b shows the treatment situation of patient 14, wherein FIG. 26 a shows a CT image at the beginning of the medicine administration (after surgery), and an arrow shows the original lesion; and FIG. 26 b shows a CT image at the later stage of the treatment, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 27 a - 27 b shows the treatment situation of patient 15, wherein FIG. 27 a shows a pelvic cavity MRI imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion; and FIG. 27 b shows a pelvic cavity MRI imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIG. 28 shows a pathological diagnosis of patient 16, and an arrow shows adenocarcinoma cells.
  • FIGS. 29 a - 29 b shows the treatment situation of the patient 16, wherein FIG. 29 a shows a PEC/CT imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion; and FIG. 29 b shows a PEC/CT imaging diagnosis after rSIFN-co medication, and an arrow show the state of the original lesion after treatment.
  • rSIFN-co can be advantageously used to control cancer, either alone or in combination with other anti-cancer therapies, as a first line or second line monotherapy or in combination with other treatment modalities.
  • the advantages are: Firstly, the recombinant interferon (rSIFN-co) has broad-spectrum anti-tumor effects, which is effective to treat both solid tumors and non-solid tumors. At the same time, rSIFN-co has good synergetic effect with existing treatment means such as surgical therapy, chemotherapy, radiotherapy, other biotherapies and other anti-tumor drugs.
  • rSIFN-co has low toxicity, which means that little or no harm to normal cells has been observed when rSIFN-co is used in large doses.
  • rSIFN-co is convenient to use and can be directly applied to tumors located in any part of the body.
  • rSIFN-co can be used by subcutaneous or intramuscular injection to control systemic progression of tumor, by intrapleural or abdominal perfusion to eliminate effusion and intrapleural or abdominal tumors, by topical or local injection to eliminate primary or metastatic tumors, and by infiltration (transdermal) administration to treat tumor lesions in bone, skin, muscle, prostate and the like.
  • rSIFN-co can be administered by aerosol inhalation or by nasal spray.
  • rSIFN-co its effective rate on tumors, as a monotherapy and as one element of a combination therapy, is not lower than 90%.
  • rSIFN-co can be used after surgery in place of chemotherapy and effectively prevent recurrence and tumor metastasis or prolong the period of disease-free survival; with regard to advanced cancer cases or cancer cases that are not indicated for surgery, rSIFN-co can be used to eliminate or reduce the size of tumors without surgery; with regard to tumors that are not indicated for surgery, rSIFN-co can be used to transform the tumors into ones for which surgery is possible, that is, turning a non-resectable tumor into a resectable tumor, thereby creating conditions appropriate for surgery. Therefore, rSIFN-co, alone or in combination with other one or more anti-tumor therapy, is capable of controlling cancer in a large number of instances.
  • amino acid sequence of the present recombinant interferon as well as the nucleotide sequence encoding the same (together with a termination codon), are shown below as SEQ ID NO:1 and SEQ ID NO:2, respectively. These sequences are also referenced in U.S. Pat. Nos. 7,585,647; 7,364,724; 8,114,395 and 8,287,852:
  • interferon alfacon-1 interferon alfacon-1
  • rSIFN-co interferon alfacon-1
  • the red represents rSIFN-co
  • the green represents IFN- ⁇ 2b
  • the red is black in the black-and-white print drawing
  • the green is grey in the black-and-white print drawing
  • the computation model structure of the interferon alfacon-1 see KORN, A P, Journal of Interferon Research 1994, 14:1-9.
  • the present recombinant interferon is more effective than any interferon used clinically at present (including interferon alfacon-1 (INFERGEN®)).
  • interferon alfacon-1 interferon alfacon-1
  • the present recombinant interferon is capable of not only inhibiting DNA replication of HBV, but also inhibiting secretion of both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg).
  • the efficiency of inhibiting DNA replication of hepatitis B core antigen (HBcAg) by this interferon is about twice that of interferon alfacon-1 (INFERGEN®).
  • the in vitro pharmacodynamics of the present recombinant interferon shows that it is capable of not only inhibiting the DNA replication of HBV, but also inhibiting secretion of both hepatitis B surface antigen and hepatitis B e antigen.
  • the cytotoxicity of the present recombinant interferon is only 1 ⁇ 8 that of the current clinically used interferons, but its antiviral activity is as much as 5-20 times greater; meanwhile, the biological responses of the present recombinant interferon is more effective, more broad-spectrum and longer lasting in the human body (see CN 1740197A).
  • the present recombinant interferon shows higher antiviral activity and less side effects compared with any other interferons (including interferon alfacon-1 (INFERGEN®)).
  • this recombinant interferon possesses not only an antiviral activity 20 times as great as that of the interferons currently in clinical use, but also a more effective inhibiting tumor cell growth or promoting apoptosis function compared with recombinant human interferon ⁇ .
  • the present recombinant interferon has a different spatial configuration, enhanced biologic activities and/or different pharmacokinetics characteristics as compared with the interferon such as interferon alfacon-1 (INFERGEN®), which has the amino acid sequence of SEQ ID NO: 1, but is not encoded by the nucleotide sequence of SEQ ID NO: 2.
  • interferon alfacon-1 IFERGEN®
  • the present recombinant interferon has the amino acid sequence of SEQ ID NO: 1, such as consisting of the amino acid sequence of SEQ ID NO: 1.
  • the present recombinant interferon is encoded by the nucleotide sequence of SEQ ID NO: 2.
  • the present recombinant interferon has the amino acid sequence of SEQ ID NO: 1, and is encoded by the nucleotide sequence of SEQ ID NO: 2.
  • the recombinant interferon comprises the amino acid sequence of SEQ ID NO: 1, and is encoded by the nucleotide sequence of SEQ ID NO: 2.
  • the recombinant interferon is consisted of the amino acid sequence of SEQ ID NO: 1, and is encoded by the nucleotide sequence of SEQ ID NO: 2.
  • the present recombinant interferon in comparison with interferon such as interferon alfacon-1 (INFERGEN®), which has the amino acid sequence of SEQ ID NO: 1, but is not encoded by the nucleotide sequence of SEQ ID NO: 2, the present recombinant interferon has a changed spatial configuration and/or enhanced biologic activities and/or different pharmacokinetics characteristics.
  • the present recombinant interferon has a changed spatial configuration and enhanced biologic activities, changed spatial configuration and different pharmacokinetics characteristics, or changed spatial configuration, enhanced biologic activities and different pharmacokinetics characteristics.
  • the enhanced biological activities include: enhanced antiviral activity, enhanced tumor cell growth inhibition or proapoptotic effect, less side effects and/or could be used in large dose (e.g.
  • the enhanced biological activities can be enhanced antiviral activity and/or enhanced tumor cell (such as breast cancer cell or cervical cancer cell) growth inhibition or proapoptotic effect (see Zheng, J. et al. J Sichuan Univ (Med Sci Edi), 2010, 41(1), 29-34; Chen, Y, et al. J Sichuan Univ (Med Sci Edi), 2008, 39(5), 715-718).
  • the different pharmacokinetics characteristics include: after intramuscular injection of the recombinant interferon in subjects whose BMI ranged from about 18 to about 23, the time of blood sample collection was plotted against the concentration of 2-5 A oligonucleotidase in the serum of the subjects, and the resulting area under the curve of this chart is significantly greater and/or the half-life of this recombinant interferon in the body is longer than those of the interferon such as interferon alfacon-1 (INFERGEN®), which has the amino acid sequence of SEQ ID NO: 1, but is not encoded by the nucleotide sequence of SEQ ID NO: 2 after injection under the same conditions.
  • interferon alfacon-1 IFERGEN®
  • the present recombinant interferon has the amino acid sequence of SEQ ID NO: 1, and is encoded by the nucleotide sequence of SEQ ID NO: 2, wherein the recombinant interferon has increased inhibitory activities on the expression of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) of Hepatitis B Virus as compared to an interferon interferon such as interferon alfacon-1 (INFERGEN®), which has the amino acid sequence of SEQ ID NO: 1, but is not encoded by the nucleotide sequence of SEQ ID NO: 2.
  • HBsAg hepatitis B surface antigen
  • HBeAg hepatitis B e antigen
  • IFERGEN® interferon alfacon-1
  • the recombinant interferon (rSIFN-co) used in the present invention can be produced by the methods disclosed in, for example, U.S. Pat. No. 7,364,724, U.S. Pat. No. 7,585,647, U.S. Pat. No. 8,114,395, CN 1740197 A, CN 101001644 A, US 2009/0123417, US 2011/0158941 and WO 2011072487A1.
  • the present recombinant interferon can be produced by the method comprising the following steps: introducing a nucleotide sequence comprising SEQ ID NO: 2 that encodes the recombinant interferon into an isolated host cell; culturing the host cell under appropriate condition for expression of the recombinant interferon; and harvesting the recombinant interferon, wherein the recombinant interferon has an amino acid sequence of SEQ ID NO: 1, and the recombinant interferon inhibits secretion of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) of Hepatitis B Virus.
  • HBsAg hepatitis B surface antigen
  • HBeAg hepatitis B e antigen
  • the host cell is Escherichia coli , such as Escherichia coli LGM 194.
  • the nucleotide sequence comprising SEQ ID NO: 2 is under the control of the promoter P BAD .
  • the harvesting step comprises extraction of the interferon from the fermentation broth, collection of the inclusion bodies, denaturation and renaturation of the harvested interferon. Still further, the harvesting step also comprises separation and purification of the recombinant interferon.
  • the specific activity of the present recombinant interferon is in a range of about 4.4 ⁇ 10 8 IU/mg to about 1.0 ⁇ 10 9 IU/mg, and optionally greater than 5.5 ⁇ 10 8 IU/mg.
  • Such specific activity is the ratio of the biological activity and the content of protein.
  • the biological activity is measured by a method well-known by the person skilled in the art such as the biological activity measurement method for the interferon (i.e. the cell lesion inhibition method) published in the Appendix X C in Chinese Pharmacopoeia (the third book), Edition 2010; and the content of the protein is measured by a method well-known by the person skilled in the art such as the second method (i.e. the Lowry method) of protein measurement method published in the Appendix VI B in Chinese Pharmacopoeia (the third book), Edition 2010.
  • the present recombinant interferon can be effectively used for treating tumors, in particular, solid tumors such as lung cancers and the like.
  • Monotherapy using the present recombinant interferon, rSIFN-co can suppress the growth of the tumors in patients, reduce the size of tumors in the patients effectively, even non-surgically directly eliminate tumors in the patients, reduce and even eliminate malignant pleural effusion, malignant ascites and/or malignant pericardial effusion, reduce tumor markers, effectively prolong the survival and/or tumor-free survival of the tumor patients and prevent postoperative cancer recurrence and/or metastasis of the tumor in the patients, and effectively treat advanced cancer patients and the cancer patients that are not indicated or appropriate for surgery.
  • the present recombinant interferon can effectively eliminate the tumors of the patients so as to achieve the effect of cure in some embodiments.
  • the present recombinant interferon has less side effects, so that it can be used in larger doses.
  • the diseases and conditions suitable for the treatment and/or prevention method of the invention include tumors.
  • tumors refers to all uncontrolled and malignant neoplastic cell growth and proliferation as well as all cancerous cells and tissues, and abnormally or aberrantly proliferative cells.
  • the tumors include malignant tumors.
  • cancer refers to physiological conditions of mammal generally characterized by unregulated cell growth and/or proliferation. In the context, the terms “cancer” and “malignant tumor” can be used interchangeably.
  • the tumors include solid tumors and non-solid tumors, optionally, the solid tumors.
  • solid tumor refers to the abnormal growth or caking of tissues, and generally does not include cyst or liquid areas.
  • non-solid tumor refers to neoplasia of the hemopoietic system, such as lymphoma, myeloma and leukemia, or neoplasia without solid formation generally and with spread substantially.
  • the solid tumors include but not limited to lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • HCC hepatocellular
  • the non-solid tumors include but not limited to leukemia, acute leukemia, chronic leukemia, chronic myelocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T-cell leukemia, hairy cell leukemia, polycythemia, myelodysplastic syndrome, multiple myeloma, lymphadenoma, Hodgkin's lymphoma, and Non-Hodgkin's lymphoma.
  • the tumors are lung tumors, and include but not limited to abnormally proliferative or aberrantly proliferative lung cells and/or malignant lung tumor.
  • lung tumor refers to any lung tumors, therefore, such tumors can be primary lung tumors and/or metastatic lung tumors, for example, the tumors are formed in a way that tumors at other positions are metastasized to the lung through various metastasis modes.
  • the lung tumors can be benign (non-carcinous), preinvasive lesion (precancerous lesion), or malignant (carcinous) lung tumors, such as lung cancers.
  • the lung tumors are the lung cancers, and include but not limited to small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
  • SCLC small cell lung cancer
  • NSCLC non-small cell lung cancer
  • the term “lung cancer” refers to all types of lung cancers, and include but not limited to small cell lung cancer (SCLC) and the non-small cell lung cancer (NSCLC, including but not limited to adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma and sarcomatoid carcinoma).
  • the SCLC includes but not limited to complex small cell lung cancer
  • the NSCLC includes but not limited to adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma, sarcomatoid carcinoma, carcinoid and salivary gland cancer.
  • complex small cell lung cancer refers to one lung cancer, wherein the ingredients of the non-small cell lung cancer, such as large cell carcinoma, are mixed in the small cell lung cancer.
  • the lung tumors are preinvasive lesion (precancerous lesion), and include but not limited to squamous epithelial dysplasia of the lung, lung carcinoma in situ, atypical adenomatous hyperplasia of the lung, and diffuse and idiopathic neuroendocrine cell proliferation of the lung.
  • the metastatic lung tumors are the tumors formed in a way that breast cancer, colorectal cancer, stomach cancer, pancreatic cancer, renal cancer, malignant melanoma, prostate cancer, liver cancer, thyroid cancer and adrenal tumors and the like are metastasized to the lung.
  • the tumors are metastasized, and such metastasis can be in situ and in the distance.
  • metastasis refers to the spread of cancers or malignant tumors from the in-situ position to other in-vivo positions. Cancer cells can separate from in-situ tumors, penetrate into lymphatic vessels and blood vessels, and then grow in distant lesions in normal tissues at other in-vivo positions through blood circulation. The metastasis can be in situ or at the distance.
  • the lung tumors such as lung cancers can metastasize to lymph nodes, brain, central nervous system, bone, liver, adrenal, skin, intestine, thyroid, ovary, prostate and the like.
  • the present recombinant interferon can be used for treating these metastasized tumors such as metastasized lung cancers; particularly, the present recombinant interferon can relieve the symptoms caused by partial stress and invasion of the lung cancers to adjacent tissues, and treat the distant metastasis of the lung cancers.
  • the symptoms caused by the partial stress and invasion of the lung cancers include but not limited to dyscatabrosis caused by the metastasis and hyperplasia of lymph node around esophagus as well as dyspnea caused by the spread of tumors through the lung parenchyma lymphatic vessels.
  • the distant metastases of the lung cancers include but not limited to brain metastases of the lung cancers, central nervous system metastases of the lung cancers, bone metastases of the lung cancers, liver metastases of the lung cancers, adrenal metastases of the lung cancers, and other metastases such as skin metastases, thyroid metastases, ovary metastases, prostate metastases and the like of the lung cancers.
  • the tumors can be multiple primary cancers, for example, in the condition that the tumors are the lung cancers, such lung cancers can be multiple primary lung cancers such as the multiple primary lung cancers at different pulmonary segments or pulmonary lobes.
  • the term “multiple primary cancers” refers to more than two kinds of multiple primary malignant tumors that are formed at the same time or successively on a same body. Such multiple primary malignant tumors must be confirmed to be malignant and non-external metastasis tumors by histology.
  • multiple primary lung cancers refers to more than two multiple primary malignant tumors which are identical in histology and independent in existence, do not have metastasis between each other, and are generated at different pulmonary segments or pulmonary lobes.
  • the disease suitable for the treatment and/or prevention method of the invention also includes cancer emergencies, for example advanced cancer emergencies such as pleural effusion, ascites and/or pericardial effusion.
  • advanced cancer emergencies such as pleural effusion, ascites and/or pericardial effusion.
  • the pleural effusion, ascites and/or pericardial effusion are malignant pleural effusion, malignant ascites and/or malignant pericardial effusion.
  • the malignant pleural effusion can be caused by pleural primary tumors or pleural metastasized tumors, and is the common emergencies in the advanced lung cancers.
  • the pleural primary tumors include malignant and diffuse mesothelioma, and the pleural metastasized tumors are originated from lung cancer, breast cancer, lymphoma, ovarian cancer, endometrial cancer, cervical cancer, stomach cancer, colorectal cancer, pancreatic cancer, bladder cancer, liver cancer and the like.
  • the malignant pericardial effusion can be caused by lung cancer, breast cancer and the like.
  • the malignant pericardial effusion can be caused in a way that the lung cancer can be metastasized or can directly invade pericardium, which is also the common expression of the advanced lung cancers.
  • the malignant ascites can be caused by malignant tumors, wherein excessive liquid is accumulated in enterocoelia, and the malignant ascites is one of the advanced emergencies of cancers, and the malignant ascites are generally caused by ovarian cancer, cervical cancer, endometrial cancer, digestive tract tumor, lymphoma, breast cancer, peritoneal mesothelioma and the like.
  • the subject suitable for the treatment and/or prevention method of the invention includes mammal, which comprises but not limited to human and non-human mammal, optionally, the subject is human.
  • the terms “subject” and “patient” can be used interchangeably.
  • the subject with tumors is the subject previously diagnosed with tumors such as malignant tumors.
  • the subjects include but not limited to a subject with tumors such as malignant tumors that are not capable of being resected, a subject with tumors such as malignant tumors that are capable of being resected, a subject with cancers, a subject with metastasized tumors such as metastasized malignant tumors, and/or a subject with pleural effusion, ascites and/or pericardial effusion such as malignant pleural effusion, malignant ascites and/or malignant pericardial effusion.
  • the tumor is optionally resected by a surgical resection.
  • the solid tumors are capable of being resected or are not capable of being resected, such as solid tumors that are capable of being resected or are not capable of being resected surgically. In some embodiments, the solid tumors that are capable of being resected or are not capable of being resected, such as solid tumors that are capable of being resected or are not capable of being resected surgically, are advanced, or stage III or stage IV solid tumors. In some embodiments, the subjects are the subjects with or without indications for cancers or tumors surgery such as lung cancers surgery. In some embodiments, the solid tumors are solid tumors with or without indications for surgery such as indications for tumor surgery. In some embodiments, the solid tumors with or without indications for surgery such as indications for tumor surgery, are advanced, or stage III or stage IV solid tumors. In some embodiments, the solid tumors are lung cancers.
  • the term “indication for surgery” or “indicated for surgery” or “appropriate for surgery” refers to a surgical method which is employed when a disease is in accordance with the standard specified by treatment routine and cannot be cured by a non-surgical method and the surgical method can be employed for being helpful for the treatment of the disease.
  • the cancers without indications or not indicated for surgery include: (1) non-solid tumors or systematic tumors, such as leukemia, malignant lymphoma, bone tumor and the like; (2) cancers with extensive systematic metastases for which surgical treatment is of no value; (3) cancers at a position which is difficult for surgical resection, such as nasopharyngeal carcinoma, upper esophageal carcinoma, radix linguae carcinoma and the like; (4) cancers which easily metastasize at a very early stage, such as undifferentiated small cell lung cancer, so that surgical resection is generally not suggested; and (5) cancers with carcinoma cells which infiltrate into surrounding tissues while growing, have unclear boundary and cannot be completely resected by surgery, such as tonsil carcinoma, pancreas carcinoma and the like.
  • the solid tumors without indications or not indicated for surgery include: (1) systematic solid tumors such as bone tumor and the like; (2) solid tumors with extensive systematic metastases for which surgical treatment is of no value; (3) solid tumors at a position which is difficult for surgical resection, such as nasopharyngeal carcinoma, upper esophageal carcinoma, radix linguae carcinoma and the like; (4) solid tumors which easily metastasize at a very early stage, such as undifferentiated small cell lung cancer; and (5) solid tumors with carcinoma cells which infiltrate into surrounding tissues while growing, have unclear boundary and cannot be completely resected by surgery, such as tonsil carcinoma, pancreas carcinoma and the like.
  • tumors that are capable of being resected are tumors which are limited to primary organs and are suitable for surgical therapy, such as malignant tumors.
  • a subject with tumors such as malignant tumors that are not capable of being resected also includes a subject with tumors such as malignant tumors that are not capable of being resected surgically.
  • Such surgery can include surgical procedures, minimally invasive operation and the like.
  • the subject with tumors such as malignant tumors that are capable of being resected includes a subject with tumors such as malignant tumors which can be resected surgically.
  • the subjects include but not limited to early cancer patients, medium-term and advanced cancer patients, optionally medium-term or advanced cancer patients.
  • the term “early cancer” includes cancer in situ and stage I cancer
  • the term “medium-term cancer” includes stage II and stage III cancers
  • the term “advanced cancer” refers to metastatic cancers with extensive infiltration in situ or with metastises at remote organs, such as stage IV cancer.
  • the subjects include but not limited to stage 0, I, II, III or IV cancer patients, optionally stage III or stage IV cancer patients; and the subjects with metastasized tumors such as metastasized malignant tumors includes but not limited to subjects with tumors such as malignant tumors which are metastasized in situ or in the distance.
  • stage 0 I, II, III, or IV tumor or cancer
  • the stages of the tumor or cancer is defined by the TNM staging method well known in the art (see AJCC Cancer Staging Manual (Sixth Edition), Greene, F. L. et al. editor. LIAONING SCIENCE AND TECHNOLOGY PUBLISHING HOUSE, August 2005).
  • the subjects are medium-term, advanced, or Stage III or Stage IV cancer patients. In some embodiments, the subjects are advanced, or Stage III or Stage IV cancer patients.
  • the subjects with malignant pleural effusion, malignant ascites and/or malignant pericardial effusion include the subjects with malignant pleural effusion, malignant ascites and/or malignant pericardial effusion caused by cancers such as advanced, or Stage III or Stage IV cancers.
  • the cancers are lung cancers.
  • the subjects can be lung cancer patients, such as patients of lung cancer that is not capable of being resected surgically, the medium-term and advanced lung cancer patients, the Stage 0, I or II lung cancer patients, or Stage III or IV lung cancer patients, and the metastasized lung cancer patients or the lung cancer patients with malignant pleural effusion, malignant ascites and/or malignant pericardial effusion.
  • the lung cancer patients include but not limited to small cell lung cancer patients and non-small cell lung cancer patients.
  • other therapies or drugs can be administered to the subject before, simultaneously, and/or after administration of the present recombinant interferon.
  • the therapies are optionally anti-cancer therapies
  • the drugs are optionally anti-tumor drugs.
  • the term “administration” refers to giving a substance to achieve the therapeutic purposes.
  • the term “combination therapy” refers to employing two or more treatment means for the subjects in the process of the treatment period, such as employing the present recombinant interferon and extra treatment means. The extra treatment means can be employed for the subjects before, simultaneously, and/or after administration of the present recombinant interferon.
  • anti-cancer therapy refers to a useful therapy in the cancer treatment.
  • the other anti-cancer therapies include but not limited to chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immune therapy, targeted therapy, traditional Chinese medicine therapy and any combination thereof.
  • the other anti-cancer therapies can be easily determined by the person skilled in the art.
  • the other anti-cancer therapies are optionally chemotherapy, radiotherapy, surgical therapy, targeted therapy and/or biotherapy.
  • the other anti-cancer therapies are optionally chemotherapy and/or radiotherapy.
  • chemotherapy refers to a drug therapy affecting cell growth and cell division, namely, the drug therapy is taken as a cell proliferation inhibitor or is used for inducing cell death (cell apoptosis). Compared with normal cells, cancer cells grow and divide uncontrollably so that the chemotherapy should be more effective to the cancer cells.
  • chemotherapy includes arterial infusion chemotherapy and embolism-form chemotherapy.
  • the chemotherapy can be the common first-line chemotherapy for the cancers.
  • chemotherapeutic drugs used in the first-line chemotherapy for treating lung cancer include but not limited to platinum compounds such as Cisplatin.
  • chemotherapeutic drugs used in the chemotherapy for the cancers in the invention include but not limited to alkylating agents such as nitrogen mustards including but not limited to chlormethine hydrochloride, chlorambucil, phenylalanine mustard, chlornaphazine, estramustine, cyclophosphamide, ifosfamide, Mechlorethamine, mustron, Melphalan, novembichin, phenesterin, Prednimustine, Trofosfamide and Uramustine; ethyleneimines and methyl melamines including but not limited triethylenemelamine, Thiotepa, MST-16, altretamine, triethylene melamine, triethylene phosphamide, triethylene Thiophosphoramide and trimethylol melamine; sulfoacid alkyl esters including but not limited to busulfan, improsulfan and piposulfan; and nitrosoureas including but not limited to carmustine, Semustine, Strept
  • chemotherapy protocols used for treating cancers such as lung cancers in the invention include but not limited to a CMC protocol (cyclohexyl nitrosourea, cyclophosphamide and Methotrexate), an EP protocol (etoposide and Cisplatin), an IVP protocol (ifosfamide, vindesine and Cisplatin), an ICE protocol (ifosfamide, Cisplatin and etoposide), a NIP protocol (Navelbine, ifosfamide and Cisplatin), a Paclitaxel+DDP/CBP protocol (Paclitaxel and Cisplatin/carboplatin), a docetaxel+DDP/CBP protocol (docetaxel and Cisplatin/carboplatin), a topotecan+DDP protocol (topotecan and Cisplatin), an IP protocol (Irinotecan and carboplatin), a MVP protocol (mitomycin, vindesine and Cisplatin),
  • chemotherapy protocols used for treating tumors such as cancers in the invention include but not limited to an FOLFOX protocol (see Newest Chemotherapy Development of Malignant Tumors , July, 2009, chief editor: Zheng Cuiping, Beijing: People's Military Medical Press, 1031), a DP protocol (see Newest Chemotherapy Development of Malignant Tumors , July, 2009, chief editor: Zheng Cuiping, Beijing: People's Military Medical Press, 232), a CHOPE protocol, a MTX protocol, a GCE protocol, an ESAP protocol, a CMOP protocol, a CHOP protocol (see Practical Anti - tumor Pharmacotherapeutics, 2002, chief editor: Liu Xinchun etc., Beijing: People's Medical Publishing House, 1031), a bleomycin+CHOP+Methotrexate protocol, a GP+Endostar protocol, a GP-T2 protocol, a TP protocol (see Practical Anti - tumor Pharmacotherapeutics, 2002, chief
  • the term “radiotherapy” refers to employing high-energy radiation for treating tumors such as cancers.
  • the radiotherapy includes external radiation such as external radiotherapy from a linear accelerator, and brachytherapy for which radioactive sources are placed near the surface of the human body or in the body cavity.
  • the radioactive sources include but not limited to ⁇ , ⁇ and ⁇ rays generated by radioactive nuclides, and electron beams, proton beams. Neutron beams, ⁇ meson beams and other heavy particle beams generated by various accelerators.
  • the radioactive nuclides include but not limited to 137 Cs, 60 Co, 131 I, 125 I, 32 P, 198 Au, 192 Ir, 90 Y, 186 Re and 109 Pd. Such radioactive sources can perform radiation in vitro and/or in vivo.
  • the typical radiotherapy is employed as one-time administration, and the usual dose is in the range of about 1 to about 200 grays/day, such as about 2 to about 150 grays/day, about 5 to about 100 grays/day, about 10 to about 70 grays/day, about 10 to about 50 grays/day and the like.
  • the radiotherapy used in the invention includes but not limited to two-dimensional conventional radiotherapy, three-dimensional conformal radiotherapy (3D-CRT), proton radiotherapy, brachytherapy, intensity modulated radiotherapy (IMRT), stereotactic radiotherapy (SRT), respiratory gating four-dimensional radiotherapy (4DRT) and gamma knife therapy, such as systematic gamma knife therapy and head gamma knife therapy.
  • 3D-CRT three-dimensional conformal radiotherapy
  • IMRT intensity modulated radiotherapy
  • SRT stereotactic radiotherapy
  • RDT respiratory gating four-dimensional radiotherapy
  • gamma knife therapy such as systematic gamma knife therapy and head gamma knife therapy.
  • the term “targeted therapy” refers to a therapy aiming at identifying specific target molecules which can be, for example, play a role in tumorigenesis or tumor proliferation or cell repairing. Such identification may be, for example, lead to the combination between the targeted therapy and the target molecules, and can enhance or reduce the activity of the target molecules.
  • Drugs used for the targeted therapy includes antibodies, in particular to monoclonal antibodies and small molecule drugs.
  • Potential targets include EGFR receptors, which playing a role in vasculogenesis, VEGFA ligands, which being important in vasculogenesis, or PARP1, which being important in cell repairing, because the tumors with cancer gene defect can be more sensitive to the chemical therapy due to the suppression to the PARP1.
  • the targeted drug includes but not limited to an anti-angiogenesis drug, Kinase inhibitor, pan Kinase inhibitor or growth factor inhibitor.
  • the anti-angiogenesis drug includes but not limited to EGF inhibitor, EGFR inhibitor, VEGF inhibitor, VEGFR inhibitor, TIE2 inhibitor, IGF1R inhibitor, COX-II (cyclo-oxygenase-II) inhibitor, MMP-2 (matrix metalloproteinase-2) inhibitor and MMP-9 (matrix metalloproteinase-9) inhibitor.
  • a targeted drug that can be used herein includes but not limited to at least one of: Gefitinib (Iressa), Erlotinib (TARCEVA®), Lapatinib (GSK572016), Vatalanib (PTK787), Imatinib (GLEEEVEC®), Dasatinib (Sprycel), Sunitinib (SUTENT®), Nilotinib (Tasigna), Semaxanib (SU5416), Pazopanib (GW-786034), Erbitux (IMC-C225), Panitumumab (Vectibix), Trastuzumab (Herceptin), Recombinant Human Endostatin (Endostar), Sorafenib (NEXAVAR®), Bevacizumab (Avastin), Alemtuzumab (Campath), Gemtuzumab (Mylotarg), ibritumomab tiuxetan (Zevalin), tositumom
  • the targeted drug in the targeted therapy used for treating cancers such as lung cancers in the invention includes but not limited to Gefitinib (Iressa), Erlotinib (TARCEVA®), and Recombinant Human Endostatin (Endostar).
  • the dose and duration of the drugs and/or the radioactive sources used in the chemical therapy, radiotherapy and/or targeted therapy can be easily determined by skilled physicians according to the experience and the practical situations of patients such as age, weight, general health state, gender, diet, administration time, drug interaction and illness severity.
  • surgical therapy refers to an invasive cancer therapy aiming at physically eliminating cancer cells.
  • the surgical therapy includes, for example, tumor resection and lymph node dissection.
  • gene therapy refers to a therapy by delivering recombinant genetic materials by virus or non-virus carriers ex vivo or in vivo so as to treat or prevent diseases or medical conditions, such as cancers.
  • ablation therapy refers to a well known tissue damage method, such as high-temperature ablation such as radio frequency, microwave and laser ablation, low-temperature ablation such as cryocare knife cryotherapy, chemical ablation, radioactive ablation and the like.
  • the term “immunotherapy” refers to a treatment strategy which is employed for regulating the immune system so as to prevent and/or treat specific diseases such as cancers.
  • vaccination is one immunotherapy.
  • the vaccine used in the present immunotherapy includes but limited to ALLOVECTIN® vaccine, LEUVECTIN® vaccine, VAXID® vaccine and the like.
  • the term “interventional therapy” refers to a treatment method with smallest trauma for performing local treatment to the lesion under the condition that the lesion is not operated through tiny channels made on the skin or original channels of the human body under the guidance of imaging equipment (such as a Digital Subtraction Angiography, a perspective machine, CT, MR and B ultrasonic).
  • the interventional therapy includes but not limited to transcatheter arterial chemoembolization, arterial infusion chemotherapy, high-temperature ablation such as radio frequency, microwave and laser ablation, low-temperature ablation such as cryocare knife cryotherapy, chemical ablation, radioactive ablation, gene drug arterial infusion, stent implantation and the like.
  • biotherapy refers to all treatment methods employing modern biotechnologies and the products (small molecule compounds, polypeptide, polysaccharide, protein, cells, tissues, genes, RNAs and the like) thereof.
  • the biotherapy can directly or indirectly mediate anti-tumor and tumor-killing effects.
  • the biotherapy used for treating the tumors includes but not limited to the application of non-specific immunologic stimulant, Biological Response Modifier (BRM), a tumor cell factor treatment and immunological effect cell treatments such as NK cell anti-tumor therapy, biology supporting therapy, tissue and cell transplanting therapy and the like.
  • BRM Bio Response Modifier
  • traditional Chinese medicine therapy refers to all methods employing the traditional Chinese medicine and drugs guided by Chinese medicine theories for treating diseases such as cancers.
  • interferon such as interferon ⁇ including interferon ⁇ -1a, interferon ⁇ -1b, interferon ⁇ -2a, interferon ⁇ -2b and the like, interferon ⁇ including interferon ⁇ -1a, interferon ⁇ -1b and the like, interferon ⁇ including interferon ⁇ -1b and the like, consensus interferon such as interferon ⁇ -con1, long-acting interferon such as PEGylation interferon, fusion protein of interferon and albumin, and fusion protein of interferon and IgG Fc fragment; colony stimulating factors (CSF) such as macrophage-colony stimulating factor (M-CSF), granulocyte-macrophage (GM-CSF) and granulocyte-colony stimulating
  • the present recombinant interferon can be incorporated into pharmaceutical compositions, so as to be administered to subjects.
  • the pharmaceutical composition comprises the present recombinant interferon and pharmaceutically acceptable carriers.
  • the “pharmaceutically acceptable carrier” herein includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
  • Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the present recombinant interferon.
  • compositions of the invention may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, aqueous solutions, tablets, capsules, oral solutions, patchs, sprays, suppositorys, powders and lyophilized powders.
  • liquid solutions e.g., injectable and infusible solutions
  • dispersions or suspensions e.g., aqueous solutions
  • aqueous solutions e.g., injectable and infusible solutions
  • aqueous solutions e.g., tablets, capsules, oral solutions, patchs, sprays, suppositorys, powders and lyophilized powders.
  • Typical pharmaceutical compositions are in the form of injectables or infusible solutions, lyophilized powders, sprays, and aqueous solutions.
  • the pharmaceutical composition can be prepared by any well known method in the pharmaceutical field with reference to: Gilman, etc., (editor) 1990 , The Pharmacological Bases of Therapeutics , the 8 th version, Pergamon Press; A. Gennaro (editor), Remington's Pharmaceutical Sciences , the 18 th version, 1990, Mack Publishing Co., Easton, Pa.; Avis, etc., (editor) 1993 , Pharmaceutical Dosage Forms: Parenteral Medications Dekke, New York; Lieberman, etc., (editor) 1990 , Pharmaceutical Dosage Forms: Tablets Dekker, New York; and Lieberman, etc., (editor) 1990 , Pharmaceutical Dosage Forms: Disperse Systems Dekker, New York.
  • systemic administration refers to a mode for administering compositions or drugs to a subject, in a manner that leads to systemic circulation of the drugs or compositions in the subject, such as the spreading or distribution of the administered compositions or drugs to all parts of the body.
  • systemic administration include, but are not limited to: intravenous injection, intra-arterial injection, intramuscular injection, subcutaneous injection, intra-lymphatic injection, oral administration, and the like.
  • local administration refers to administering a composition or drug into a limited or partial anatomy space.
  • Examples of local administration include but are not limited to: intratumoral, intra-lymph node, intra-pleural space, intraperitoneal cavity and the like.
  • topical administration refers to administering a drug or composition on the surface of skin or mucous membrane.
  • topical administration includes but is not limited to spraying the drug or composition onto the skin of a subject.
  • the present recombinant interferon can be administered to the subject by at least one administration route, the administration route comprises but not limited to: oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, and intravesical administration.
  • the administration route comprises but not limited to: oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular,
  • the present recombinant interferon can be administered to the subject by injection route, such as subcutaneous, intramuscular, intravenous, intra-arterial, intracerebral, intraperitoneal and/or intratumoral injection.
  • the present recombinant interferon can be administered to the subject by inhalation, such as pulmonary inhalation and nasal inhalation.
  • the inhalation can be dry powder inhalation and/or aerosol inhalation.
  • the present recombinant interferon can be administered to the subject by perfusion, such as intrapleural perfusion, abdominal perfusion, pericardial perfusion, uterine perfusion and/or intravesical perfusion.
  • the present recombinant interferon can be administered to lesion (such as the surfaces of skin and mucosa, superficial lymph nodes and/or subcutaneous tissue) by spray, such as percutaneous, epidermal, transdermal and/or transmucosal spray administration.
  • the infiltration administration includes pulmonary infiltration administration, percutaneous infiltration administration, epidermal infiltration administration, transmucosal infiltration administration, intrapleural infiltration administration, abdominal infiltration administration, uterine infiltration administration, vaginal infiltration administration, intravesical infiltration administration, pericardial infiltration administration and the like.
  • compositions suitable for injection/perfusion include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the composition must be sterile and should be fluid so as to be administered using a syringe.
  • Such compositions should be stable during manufacture and storage and must be preserved against contamination from microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (such as glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures.
  • compositions that can delay absorption include agents such as aluminum monostearate and gelatin.
  • Sterile injection/perfusion solutions can be prepared by incorporating the present recombinant interferon in the required amount in an appropriate solvent with one or a combination of ingredients as required, followed by sterilization.
  • dispersions are prepared by incorporating the present recombinant interferon into a sterile vehicle that contains a basic dispersion medium, and the other required ingredients.
  • Sterile powders for the preparation of sterile injection/perfusion solutions, methods of preparation include vacuum drying and freeze-drying that yield a powder containing the active ingredient and any desired ingredient from a sterile solutions.
  • the present recombinant interferon can be delivered by any of a variety of inhalation devices know in the art for administration of a therapeutic agent by inhalation. These devices include metered dose inhalers, nebulizers, dry powder generators, sprayers, and the like. Other devices suitable for inhalation administration of the present recombinant interferon are also known in the art.
  • Metered dose inhalers like the Ventolin® metered dose inhaler, typically use a propellent gas and require actuation during inspiration (See, e.g., WO 94/16970, WO 98/35888).
  • Dry powder inhalers like TurbuhalerTM (Astra), Rotahaler® (Glaxo), Diskus® (Glaxo), SpirosTM inhaler (Dura), devices marketed by Inhale Therapeutics, and the Spinhaler® powder inhaler (Fisons), use breath-actuation of a mixed powder (U.S. Pat. No. 4,668,218 Astra, EP 237507 Astra, WO 97/25086 Glaxo, WO 94/08552 Dura, U.S. Pat. No.
  • Nebulizers like AERxTM Aradigm, the Ultravent® nebulizer (Mallinckrodt), the Acorn II® nebulizer (Marquest Medical Products) (U.S. Pat. No. 5,404,871 Aradigm, WO 97/22376), and the AP-100200 type spray inhaler (Taiwan Albert incorporated company). Producing aerosols from solutions, while metered dose inhalers, dry powder inhalers, etc. generate small particle aerosols.
  • the present recombinant interferon is delivered by a nebulizer.
  • the inhalation devices for administering the present recombinant interferon have several desirable features.
  • delivery by the inhalation device is advantageously reliable, reproducible, and accurate.
  • the inhalation device can optionally deliver small dry particles or aerosol, e.g., less than about 10 ⁇ m, for example about 0.5 ⁇ m to about 5 ⁇ m, for good respirability.
  • a spray including the present recombinant interferon can be produced by forcing a suspension or solution of the recombinant interferon through a nozzle under pressure.
  • the nozzle size and configuration, the applied pressure, and the liquid feed rate can be chosen to achieve the desired output and particle size.
  • An electrospray can be produced, for example, by an electric field in connection with a capillary or nozzle feed.
  • particles delivered by a sprayer have a particle size less than about 10 ⁇ m, optionally, in the range of about 0.5 ⁇ m to about 5 ⁇ m.
  • Formulations of the present recombinant interferon suitable for use with a sprayer typically include ones at a concentration in a range of about 0.01 mg to about 5 mg, such as about 0.03 mg to about 2 mg, about 0.05 mg to about 1 mg, and about 0.1 mg to about 0.5 mg of the recombinant interferon per ml of solution.
  • the formulation can include an excipient or agent for stabilization of the present recombinant interferon, such as a buffer, a reducing agent, a bulk protein, or a carbohydrate.
  • Bulk proteins useful in formulating the recombinant interferon include albumin, protamine, or the like.
  • Typical carbohydrates useful in formulating the recombinant interferon include sucrose, mannitol, lactose, trehalose, glucose, or the like.
  • the present recombinant interferon formulation can also include a surfactant, which can reduce or prevent surface-induced aggregation of the recombinant interferon caused by atomization of the solution in forming an aerosol.
  • Effective amount of the present recombinant interferon can be administered to the subjects such as cancer subjects, and such effective amount can be a therapeutically effective amount or a prophylactically effective amount according to the method of the invention.
  • the term “effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
  • a therapeutically effective amount of the present recombinant interferon may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the recombinant interferon to elicit a desired response in the individual.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the recombinant interferon are outweighed by the therapeutically beneficial effects.
  • prophylactically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically but no surely, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
  • the present recombinant interferon can be administered to the subjects such as the cancer subjects in different amounts of single doses.
  • the single doses of the present recombinant interferon can be in the range of about 2 ⁇ g to about 2000 ⁇ g, optionally about 4 ⁇ g to about 1500 ⁇ g, and further optionally about 9 ⁇ g to about 1000 ⁇ g.
  • the term “single dose” refers to an amount of drug which can be at administered one time, that can be therapeutically or prophylactically effective by itself or cumulatively with other single doses.
  • Such administration includes systemic administration, local administration and/or topical administration.
  • the single dose of the recombinant interferon can be in the range of about 4 ⁇ g to about 70 ⁇ g, optionally, about 4 ⁇ g to about 50 ⁇ g, and further optionally, about 4 ⁇ g to about 30 ⁇ g, wherein the single dose can be about 4 ⁇ g, about 4.5 ⁇ g, about 5 ⁇ g, about 6 ⁇ g, about 7 ⁇ g, about 8 ⁇ g, about 9 ⁇ g, about 10 ⁇ g, about 11 ⁇ g, about 12 ⁇ g, about 13 ⁇ g, about 13.5 ⁇ g, about 14 ⁇ g, about 15 ⁇ g, about 16 ⁇ g, about 17 ⁇ g, about 18 ⁇ g, about 19 ⁇ g, about 20 ⁇ g, about 21 ⁇ g, about 22 ⁇ g,
  • the single dose of the recombinant interferon can be in a range of about 60 ⁇ g to about 600 ⁇ g, optionally, about 60 ⁇ g to about 500 ⁇ g, further optionally, about 80 ⁇ g to about 400 ⁇ g, and still further optionally, about 100 ⁇ g to about 250 ⁇ g, wherein the single dose can be about 60 ⁇ g, about 70 ⁇ g, about 80 ⁇ g, about 90 ⁇ g, about 100 ⁇ g, about 110 ⁇ g, about 120 ⁇ g, about 130 ⁇ g, about 140 ⁇ g, about 150 ⁇ g, about 160 ⁇ g, about 170 ⁇ g, about 180 ⁇ g, about 190 ⁇ g, about 200 ⁇ g, about 210 ⁇ g, about 220 ⁇ g, about 230 ⁇ g, about 240 ⁇ g, about 250 ⁇ g, about 260 ⁇ g, about 270 ⁇ g, about
  • the single dose of the recombinant interferon can be in a range of about 100 ⁇ g to about 2000 ⁇ g, optionally, about 100 ⁇ g to about 1500 ⁇ g, further optionally, about 150 ⁇ g to about 800 ⁇ g, and still further optionally, about 200 ⁇ g to about 600 ⁇ g, wherein the single dose can be about 100 ⁇ g, about 110 ⁇ g, about 120 ⁇ g, about 130 ⁇ g, about 140 ⁇ g, about 150 ⁇ g, about 160 ⁇ g, about 170 ⁇ g, about 180 ⁇ g, about 190 ⁇ g, about 200 ⁇ g, about 210 ⁇ g, about 220 ⁇ g, about 230 ⁇ g, about 240 ⁇ g, about 250 ⁇ g, about 260 ⁇ g, about 270 ⁇ g, about 280 ⁇ g
  • the single dose of the recombinant interferon can be in a range of about 30 ⁇ g to about 2000 ⁇ g, optionally, about 100 ⁇ g to about 1500 ⁇ g, further optionally, about 150 ⁇ g to about 1000 ⁇ g, still optionally, about 200 ⁇ g to about 800 ⁇ g, and still further optionally, about 200 ⁇ g to about 400 ⁇ g, wherein the single dose can be about 30 ⁇ g, about 40 ⁇ g, about 50 ⁇ g, about 60 ⁇ g, about 70 ⁇ g, about 80 ⁇ g, about 90 ⁇ g, about 100 ⁇ g, about 110 ⁇ g, about 120 ⁇ g, about 130 ⁇ g, about 140 ⁇ g, about 150 ⁇ g, about 160 ⁇ g, about 170 ⁇ g, about 180 ⁇ g, about
  • the single dose of the recombinant interferon can be in a range of about 6 ⁇ g to about 100 ⁇ g, optionally, about 10 ⁇ g to about 40 ⁇ g, and further optionally, about 20 ⁇ g to about 40 ⁇ g, wherein the single dose can be about 6 ⁇ g, about 7 ⁇ g, about 8 ⁇ g, about 9 ⁇ g, about 10 ⁇ g, about 11 ⁇ g, about 12 ⁇ g, about 13 ⁇ g, about 14 ⁇ g, about 15 ⁇ g, about 16 ⁇ g, about 17 ⁇ g, about 18 ⁇ g, about 19 ⁇ g, about 20 ⁇ g, about 21 ⁇ g, about 22 ⁇ g, about 23 ⁇ g, about 24 ⁇ g, about
  • the present recombinant interferon can be administered to the subjects through different administration protocols.
  • the present recombinant interferon can be administered to the subject about 1, 2, 3, 4, 5, 6, 7, 8, or more times per day, or the present recombinant interferon can be administered to the subject once at the time interval of every about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days, every month, every 2 months, or longer time.
  • the present recombinant interferon can be administered to the subject once at the time interval of every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, every 2 weeks, every 3 weeks, every month, every 2 months, every 3 months, every half year, every 1 year, or a longer time.
  • treatment cycle refers to a biological or medical response time length reached by the present recombinant interferon or the pharmaceutical composition comprising the recombinant interferon, and explored for researchers, veterinarians, medical practitioners or other clinicians observed in tissues, systems, animals, individuals or human beings.
  • the duration of such one treatment cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • the present recombinant interferon can be administered for a long time, namely, namely, the lasting prolonged time in one treatment cycle includes over the life time of the subject so as to improve or control or limit the symptom of the subjects.
  • the present recombinant interferon can be administered to the subjects one or more times.
  • the present recombinant interferon can be administered to the subjects in more treatment cycles.
  • treatment cycles can be 2, 3, 4, 5, 6, 7, 8, 9, 10, or more treatment cycles; and the duration of the treatment cycles can include over the life time of the subject.
  • the time intervals i.e.
  • the time interval can be at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like; and such time interval can also be about 2 days to about 6 years, about 4 days to about 3 years, about 1 week to about 1 year, about 2 months to about 9 months, or about 3 months to about 6 months and the like.
  • the dose in every administration can be the same or different, for example, the present recombinant interferon is administered for one or more times in a lower dose, and then the present recombinant interferon is administered for one or more times in an increased or gradually-increased dose; or, the present recombinant interferon is administered for one or more times in a smaller dose, then the present recombinant interferon is administered for one or more times in an increased or gradually-increased dose, and the present recombinant interferon is administered for one or more times in a decreased or gradually-decreased dose; or, the present recombinant interferon is administered for one or more times in a larger dose, and then the present recombinant interferon is administered for one or more times in a decreased or gradually-decreased dose; or, the present recombinant interferon is administered for one or more times in a larger dose, then the present recombinant interferon is administered for one or more times in a
  • the later increasingly administered dose can be about 110% to about 500%, including, for example about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 220%, about 240%, about 260%, about 280%, about 300%, about 350%, about 400%, about 450% and about 500%, of the previously administered dose.
  • the later gradually-increased administered dose can be about 110% to about 500% including, for example about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 220%, about 240%, about 260%, about 280%, about 300%, about 350%, about 400%, about 450% and about 500%, of the previously administered dose sequentially.
  • the gradually-increased dose can be increased by 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, or more times, and then the last dose can be kept till the end of the treatment cycle.
  • the later decreasingly administered dose can be about 5% to about 99% including, for example, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% and about 99%, of the previously administered dose.
  • the later gradually-decreased administered dose can be about 5% to about 99% including, for example, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% and 99%, of the previously administered dose sequentially.
  • the gradually-decreased dose can be decreased by 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, or more times, and then the last dose can be kept till the end of the treatment cycle.
  • the single doses of the present recombinant interferon in two different treatment cycles can be the same or different.
  • the single dose can be gradually increased or decreased. Compared with the previously administered dose, the increasing or decreasing degree is as mentioned above.
  • the gradually increasing or the gradually decreasing can be linear increasing or decreasing, for example, the first administered drug is 9 ⁇ g, then the later increased dose is 18 ⁇ g, 36 ⁇ g, 72 ⁇ g and the like sequentially, namely, the sequential increasing rate is 100%; or, the gradually increasing or the gradually decreasing can be non-linear increasing or decreasing, for example, the first administered drug is 9 ⁇ g, then the later increased dose can be 15 ⁇ g, 18 ⁇ g, 21 ⁇ g and the like, namely, compared with the previous administered drug, the drug increasing degree at every time can be different.
  • administration dosage and the administration protocol can be changed reasonably by the person skilled in the art based on the teaching of the invention, with the type and severity of the disorder to be released, the subject, the administration methods and the like.
  • the present invention provides a method for treating a tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the present invention provides a method for treating tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, and at least one other anti-cancer therapy, wherein the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon, and wherein the tumor is a cancer or solid tumor that is not indicated nor appropriate for surgery, or the tumor is a solid tumor that cannot be resected, and the combination of the recombinant interferon and the at least one other anti-cancer therapy eliminate the tumor or reduce the size of the tumor compared to the tumor before treatment.
  • the present invention provides a method for preventing tumor recurrence and/or metastasis or prolonging or maintaining a tumor-free status in a subject with a tumor after at least one anti-cancer therapy, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the present invention provides a non-surgical method for eliminating a tumor in a subject or reducing the size of a tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the present invention provides a method for eliminating or reducing the pleural effusion, ascites, and/or pericardial effusion in a subject with tumor, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the present invention provides a method for treating tumor in a subject, comprising topically or locally administering to the tumor lesions of the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the present invention provides a method for eliminating or reducing metastatic tumor lesions in a subject, comprising topically or locally administering to the metastatic tumor lesions of the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the present invention provides a method for eliminating or reducing the bone metastatic lesions of tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by topical or local administration, wherein the topical or local administration comprises transdermal administration and/or infiltration administration, optionally, the recombinant interferon is administered to the bone metastatic lesions of tumor of the subject.
  • the present invention provides a method for eliminating or reducing the bone lesions of tumor such as bone metastatic lesions of tumor, muscular lesions of tumor such as muscular metastatic lesions of tumor, subcutaneous tissue lesions of tumor such as subcutaneous tissue metastatic lesions of tumor, prostatic lesions of tumor such as prostatic metastatic lesions of tumor, and/or lymph node lesions of tumor such as lymph node metastatic lesions of tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by any administration route through the skin, so that eliminating or reducing the bone lesions of tumor such as bone metastatic lesions of tumor, muscular lesions of tumor such as muscular metastatic lesions of tumor, subcutaneous tissue lesions of tumor such as subcutaneous tissue metastatic lesions of tumor, prostatic lesions of tumor such as prostatic metastatic lesions of tumor, and/or lymph node lesions of tumor such as lymph node metastatic lesions of tumor, optionally, the recombinant interferon is administered to the meta
  • the present invention provides a method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the present invention provides a method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 and one or more chemotherapeutic drugs in two or more treatment cycles, and then administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 and one or more targeted drugs in one or more treatment cycles.
  • the present invention provides a method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by subcutaneous administration and/or intramuscular administration, wherein the recombinant interferon is administered in an amount in a range of about 2 ⁇ g to about 70 ⁇ g, optionally about 4 ⁇ g to about 50 ⁇ g, further optionally about 4 ⁇ g to about 30 ⁇ g by one subcutaneous administration and/or intramuscular administration, the recombinant interferon is administered by subcutaneous administration and/or intramuscular administration once every about 1 to about 7 days, optionally every about 1 to about 2 days, lasting at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months
  • the present invention provides a method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by subcutaneous administration and/or intramuscular administration, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 ⁇ g to about 10 ⁇ g each time, optionally about 4 ⁇ g to about 10 ⁇ g each time, further optionally about 4.5 ⁇ g to about 9 ⁇ g each time, such as about 4.5 ⁇ g each time or about 9 ⁇ g each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose in a range of about 10 ⁇ g to about 70 ⁇ g each time, optionally about 12 ⁇ g to about 50 ⁇ g each time, further optionally about 12 ⁇ g to about 30 ⁇ g each time.
  • the present invention provides a method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to brain, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 ⁇ g to about 10 ⁇ g each time, optionally about 4 ⁇ g to about 10 ⁇ g each time, further optionally about 4.5 ⁇ g to about 9 ⁇ g each time, such as about 4.5 ⁇ g each time or about 9 ⁇ g each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose in a range of about 10 ⁇ g to about 70 ⁇ g each time, optionally about 12 ⁇ g to about 50 ⁇ g each time, further optionally about 12 ⁇ g to about 30 ⁇ g each time, and the
  • the present invention provides a method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to bone or liver, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 ⁇ g to about 10 ⁇ g each time, optionally about 4 ⁇ g to about 10 ⁇ g each time, further optionally about 4.5 ⁇ g to about 9 ⁇ g each time, such as about 4.5 ⁇ g each time or about 9 ⁇ g each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 ⁇ g-about 70 ⁇ g each time, optionally about 12 ⁇ g to about 50 ⁇ g each time, further optionally about 12 ⁇ g to about 30 ⁇ g each time.
  • the present invention provides a method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to lymph nodes, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 ⁇ g to about 10 ⁇ g each time, optionally about 4 ⁇ g to about 10 ⁇ g each time, further optionally about 4.5 ⁇ g to about 9 ⁇ g each time, such as about 4.5 ⁇ g each time or about 9 ⁇ g each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 ⁇ g to about 70 ⁇ g each time, optionally about 12 ⁇ g to about 50 ⁇ g each time, further optionally about 12 ⁇ g to about 30 ⁇ g each time, and the recombinant
  • the present invention provides a method for treating lung cancer in a subject, wherein the subject has pleural effusion, ascites and/or pericardial effusion, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by topical or local administration.
  • the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for treating tumors in a subject.
  • the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 and other anti-tumor drugs in preparation of drugs for treating tumors in a subject.
  • the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for preventing tumor recurrence and/or metastasis after anti-tumor therapies in a subject.
  • the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for eliminating a tumor or reducing the size of a tumor in a subject by non-surgical method.
  • the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for eliminating or reducing pleural effusion, ascites, and/or pericardial effusion in a subject with tumor.
  • the present invention provides a uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for treating lung cancer in a subject.
  • the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for treating lung cancer in a subject in combination with chemotherapeutic drugs, targeted drugs.
  • the subject is an early, medium-term, or advanced cancer patient, optionally, the subject is a medium-term, or advanced cancer patient, further optionally, the subject is an advanced cancer patient, such as an advanced lung cancer patient.
  • the subject can be a stage 0, I, II, III, or IV cancer patient, optionally, the subject is an stage III or stage IV cancer patient, such as an stage III or stage IV lung cancer patient.
  • stage III or stage IV cancer patient such as an stage III or stage IV lung cancer patient.
  • Such cancer patient can be a patient with metastasized tumors, such as the tumors which are metastasized in situ or in the distance.
  • the subject is a medium-term, advanced cancer patient, or stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • the tumor is a cancer or a solid tumor with or without indications for surgery.
  • the tumor in a subject is a tumor that is capable of being resected. In some embodiments, the tumor in a subject is a tumor that is not capable of being resected. In some embodiments, the surgeries include but not limited to surgical procedures.
  • the subject is a subject with solid tumors.
  • the solid tumor is a solid tumor that is capable of or is not capable of being resected.
  • the solid tumor that is capable of or is not capable of being resected is an advanced solid tumor.
  • the solid tumor is a solid tumor with or without indications for surgery, such as indications for tumor surgery.
  • the solid tumor with or without indications for surgery such as indications for tumor surgery is an advanced, or stage III or stage IV solid tumor.
  • the tumor is a solid tumor.
  • the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sar
  • the tumor is a non-solid tumor.
  • the non-solid tumor comprises one or more of leukemia, acute leukemia, chronic leukemia, chronic myelocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T-cell leukemia, hairy cell leukemia, polycythemia, myelodysplastic syndrome, multiple myeloma, lymphadenoma, Hodgkin's lymphoma, or Non-Hodgkin's lymphoma.
  • the effective amount is a therapeutically effective amount or a prophylactically effective amount.
  • the present recombinant interferon can be administered to the subject in single dose of about 2 ⁇ g to about 2000 ⁇ g, optionally, about 4 ⁇ g to about 1500 ⁇ g, further optionally, about 9 ⁇ g to about 1000 ⁇ g, and still further optionally, about 9 ⁇ g to about 600 ⁇ g.
  • the therapeutically effective amount is about 2 ⁇ g to about 70 ⁇ g, optionally about 4 ⁇ g to about 50 ⁇ g, further optionally about 4 ⁇ g to about 30 ⁇ g, and still further optionally, about 9 ⁇ g to about 30 ⁇ g.
  • the prophylactically effective amount is about 2 ⁇ g to about 70 ⁇ g, optionally about 4 ⁇ g to about 50 ⁇ g, further optionally about 4 ⁇ g to about 30 ⁇ g, and still further optionally, about 9 ⁇ g to about 30 ⁇ g.
  • the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by at least one of: systemic administration, topical administration, and local administration.
  • the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by an administration route, the administration route comprises one or more of oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, or intravesical administration.
  • the administration route comprises one or more of oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal,
  • the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by subcutaneous, intramuscular, inhalation, infiltration, intrapleural, abdominal, pericardial, intratumoral, spary administration or any combination thereof.
  • the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by intramuscular and/or subcutaneous administration.
  • the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant are administered to the operative site, which can be administered to the subject by topical or local administration, such as infiltration, intrapleural, abdominal, pericardial, uterine, intravesical, intratumoral, pulmonary, nasal, percutaneous, transdermal, epidermal, and/or transmucosal administration.
  • the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by injection, such as subcutaneous, intramuscular, intravenous, intra-arterial, intracerebral, intraperitoneal, intratumoral, intra-articular, intrathecal and intra-bone injection and the like.
  • the inhalation when administering by inhalation, can be pulmonary and/or nasal inhalation.
  • the inhalation administration can be dry powder inhalation or aerosol inhalation.
  • the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be further administered to the subject by perfusion, such as intrapleural, abdominal, uterine, intravesical, and/or pericardial perfusion.
  • the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be further administered to the subject by spray, such as percutaneous, epidermal, transdermal and/or transmucosal spray.
  • the single dose can be about 2 ⁇ g to about 70 ⁇ g, optionally about 4 ⁇ g to about 50 ⁇ g, and further optionally about 4 ⁇ g to about 30 ⁇ g, including but not limited to about 2 ⁇ g, about 3 ⁇ g, about 4 ⁇ g, about 4.5 ⁇ g, about 9 ⁇ g, about 13.5 ⁇ g, about 15 ⁇ g, about 18 ⁇ g, about 21 ⁇ g, about 25.5 ⁇ g, about 30 ⁇ g, about 40 ⁇ g, about 50 ⁇ g, about 60 ⁇ g, and about 70 ⁇ g.
  • the present recombinant interferon is administered by subcutaneous and/or intramuscular administration once every about 1 day to about 7 days, optionally once every about 1 day to about 2 days.
  • the injection lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about
  • the single dose of the recombinant interferon can be in the range of about 60 ⁇ g to about 600 ⁇ g, optionally about 60 ⁇ g to about 500 ⁇ g, further optionally about 80 ⁇ g to about 400 ⁇ g, and still further optionally about 100 ⁇ g to about 250 ⁇ g.
  • the present recombinant interferon is administered via intratumoral administration once every about 1 day to about 10 days, optionally once every about 1 day to about 7 days such as every about 1, 2, 3, 4, 5, 6 or 7 days.
  • the intratumoral administration such as intratumoral injection lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • the protocol of intratumoral administration is as follow: the recombinant interferon is administered by intratumoral injection once every about 1 day for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 3 days to about 5 days for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 7 days, the intratumoral administration is stopped when the tumor disappears or becomes too small to conduct the intratumoral injection, wherein the recombinant interferon is administered in an amount of about 60 ⁇ g to about 600 ⁇ g, optionally about 60 ⁇ g to about 500 ⁇ g, further optionally about 80 ⁇ g to about 400 ⁇ g, still further optionally about 100 ⁇ g to about 250 ⁇ g by once intratumoral injection.
  • the single dose of the recombinant interferon can be about 100 ⁇ g to about 2000 ⁇ g, optionally about 100 ⁇ g to about 1500 ⁇ g, further optionally about 150 ⁇ g to about 800 ⁇ g, and still further optionally about 200 ⁇ g to about 600 ⁇ g, including but not limited to about 100 ⁇ g, about 200 ⁇ g, about 300 ⁇ g, about 400 ⁇ g, about 500 ⁇ g, about 600 ⁇ g, about 700 ⁇ g, about 800 ⁇ g, about 900 ⁇ g and about 1000 ⁇ g.
  • the present recombinant interferon is administered via inhalation once every about 1 day to about 3 days, optionally every about 1 day.
  • the inhalation lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • the single dose of the recombinant interferon can be about 30 ⁇ g to about 2000 ⁇ g, optionally about 100 ⁇ g to about 1500 ⁇ g, further optionally about 150 to about 1000 ⁇ g, still optionally about 200 to about 800 ⁇ g, and still further optionally about 200 to about 400 ⁇ g.
  • the present recombinant interferon is administered via intrapleural, abdominal and/or pericardial administration once every about 1 day to about 10 days, optionally once every about 1 day to about 7 days such as every about 1, 2, 3, 4, 5, 6, or 7 days.
  • the perfusion lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • the single dose of the recombinant interferon can be about 6 ⁇ g to about 100 ⁇ g, optionally about 10 ⁇ g to about 40 ⁇ g, and further optionally about 20 ⁇ g to about 40 ⁇ g.
  • the present recombinant interferon is administered by spray administration about 1 to about 6 times such as about 1, 2, 3, 4, 5, or 6 times per day.
  • the spray lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • the present recombinant interferon can be administered to the subject about 1, 2, 3, 4, 5, 6, 7, 8, or more times per day, or the present recombinant interferon can be administered to the subject once at the time interval of every about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days, every month, every 2 months, or a longer time.
  • the present recombinant interferon can be administered to the subject once at the time interval of every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, every 2 weeks, every 3 weeks, every month, every 2 months, every 3 months, every half year, every 1 year, or a longer time.
  • the present recombinant interferon is administered in one or more treatment cycles.
  • the more cycles can be 2, 3, 4, 5, 6, 7, 8, 9, 10, or more treatment cycles.
  • duration of the one treatment cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • the present recombinant interferon can be administered for a long
  • the present recombinant interferon could be administered in more treatment cycles.
  • the treatment cycles are 2 or more treatment cycles.
  • the duration of the multiple treatment cycles may include over the life time of the subject.
  • the time intervals of any two adjacent treatment cycles in all the treatment cycles can be the same or different.
  • the time intervals can be at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like; or the time intervals can be about 2 days to about 6 years, about 4 days to about 3 years, about 1 weeks to about 1 years, about 2 months to about months, about 3 months to about 6 months and the like.
  • the present recombinant interferon when the present recombinant interferon is administered more times in one treatment cycle, the present recombinant interferon can be administered for one or more times in a smaller dose, then the present recombinant interferon is administered for one or more times in an increased or gradually-increased dose.
  • the present recombinant interferon when the present recombinant interferon is systemically administered via subcutaneous, intramuscular administration (such as subcutaneous, intramuscular injection), the present recombinant interferon can be administered once at a smaller dose such as about 4.5 ⁇ g or 9 ⁇ g, then the recombinant interferon can be administered for more times in an increased (such as to be about 15 ⁇ g, about 18 ⁇ g, about 21 ⁇ g) or gradually-increased dose. In embodiments, the present recombinant interferon is administered once every about 1 day to abut 2 days.
  • the duration for administration of the present recombinant interferon is about 1 week to about 2 years, optionally about 2 weeks to about 1 year, or further optionally about 1 month to about 9 months, including about 2 months to about 6 months, or over the life time of the subject.
  • the gradually-increased administered dose can be about 110% to about 500% of the previously administered dose sequentially.
  • a smaller dose of the present recombinant interferon (such as about 4.5 ⁇ g or about 9 ⁇ g) can be administered, followed by about 12 ⁇ g to about 18 ⁇ g (such as about 13.5 ⁇ g, about 15 ⁇ g, about 18 ⁇ g), and then about 15 ⁇ g to about 30 ⁇ g (such as about 18 ⁇ g, about 21 ⁇ g, about 25.5 ⁇ g, about 30 ⁇ g), once every about 2 days, and for about 2 months to about 3 years, or over the life time of the subject.
  • the recombinant interferon can be administered one or more times at an induction dose, and then one or more times at a therapeutic dose.
  • the induction dose is about 2 ⁇ g to about 10 ⁇ g each time, optionally about 4 ⁇ g to about 10 ⁇ g each time, further optionally about 4.5 ⁇ g to 9 ⁇ g each time, for example, about 4.5 ⁇ g each time or about 9 ⁇ g each time.
  • the therapeutic dose is about 10 ⁇ g to about 70 ⁇ g each time, optionally about 12 ⁇ g to about 50 ⁇ g each time, further optionally about 12 ⁇ g to about 30 ⁇ g each time.
  • the induction dose is about 4 ⁇ g to about 10 ⁇ g each time, and the therapeutic dose is about 12 ⁇ g to about 50 ⁇ g each time. In some embodiments, the induction dose is usually lower than the therapeutic dose. In some embodiments, the time interval between administration of the induction dose and the therapeutic dose is about 1 day to about 1 month, optionally about 1 day to 1 week, further optionally about 1 day to about 3 days, including, for example, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks and about 1 month.
  • the induction dose when administered more times, it is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 day to about 2 days, including, for example every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
  • the therapeutic dose when the therapeutic dose is administered more times, it is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 day to about 2 days, including, for example, every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
  • the total administration time of the induction and therapeutic dose should last at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, o or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • the treatment has reduced the tumor size of the subject, for example, by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 100% or more, or even completely eliminate the tumor, according to the tumor size at the beginning of treatment.
  • the treatment has reduced the number of cancer cells in tumor, malignant pleural effusion, malignant ascites and/or malignant pericardial effusion of the subjects, for example, by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 100% or more, or even the number of cancer cells is zero, according to the number of cancer cells at the beginning of treatment.
  • the treatment has inhibited (including reduced to some degree and/or terminated) the infiltration of tumor cells into peripheral organs; inhibited or prevented tumor metastasis, such as the in-situ or distant metastasis of tumors, or micrometastasis of tumors; reduced the size of the lesions; brought about downstaging of tumor; and also inhibited or killed micrometastasis in the blood and lymphatic channels; thereby allowing complete resection of initially unresectable tumors or helping to resect tumor which is capable of being resected, such resection is for example a surgical resection.
  • the method it can be a “neoadjuvant method” or an “introducing method”.
  • neoadjuvant method or “introducing method” refers to a therapy given prior to surgery, the goal of the therapy is to reduce the size of the lesions, bring about downstaging of tumor, inhibit or kill micrometastases in the blood and lymphatic channels, reduce the tumor size thereby allowing more conveniently resect tumors or completely resect of initially unresectable tumors.
  • the present recombinant interferon can be further administered to the subject to prevent recurrence and/or metastasis of the tumors after resection of the tumors.
  • the method has reduced or eliminated malignant pleural effusion, malignant ascites and/or malignant pericardial effusion, for example, by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 100% or more, or even completely eliminated malignant pleural effusion, malignant ascites and/or malignant pericardial effusion, according to the volume of malignant pleural effusion, malignant ascites and/or malignant pericardial effusion at the beginning of treatment.
  • the method for preventing recurrence of tumor has reduced the possibility of tumor recurrence after the subject with tumors received treatment.
  • the subject with tumors has been identified and treated prior to administration of the present recombinant interferon (rSIFN-co); such treatments may be the method with the present recombinant interferon, or one or more other different anti-cancer therapies such as chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, traditional Chinese medicine therapy or any combination thereof.
  • the treatment results can be clinical or basic healing.
  • such preventive therapies can inhibit or eliminate possible micrometastasis in the blood channel and lymphatic channel, so as to prevent recurrence and/or metastasis of the tumor, such micrometastasis can or cannot be clinically detected.
  • the present recombinant interferon could delay the growth of tumor in the subject, for example, by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or more, according to the tumor growth speed at the beginning of the treatment.
  • the present recombinant interferon is administered to the subject as monotherapy.
  • further comprising one or more other anti-cancer therapies administered to the subject optionally, other anti-cancer therapies are administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • the other anti-cancer therapies comprise one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • the other anti-cancer therapies comprise one or more of chemotherapy, radiotherapy, surgical therapy, targeted therapy, and biotherapy.
  • the other anti-cancer therapies comprise chemotherapy, radiotherapy, or both.
  • the other anti-cancer therapies comprise chemotherapy such as first-line chemotherapy, for example, chemotherapeutic drugs and/or chemotherapeutic protocols comprising platinum compounds, such as Cisplatin.
  • chemotherapeutic drugs used in the chemotherapy combined with the present recombinant interferon include but not limited to platinum compounds such as Cisplatin, Carboplatin, Eloxatin and the like; Paclitaxel compounds such as Docetaxel (Docetaxel Injection, Taxotere) and the like; cytidine antimetabolite such as Gemcitabine (Gemzar) and the like; antifolic antimetabolite such as Pemetrexed (Alimta) and the like; pyrimidine antimetabolite such as Capecitabine (Xeloda) and the like; as well as any combination of the chemotherapeutic agents.
  • platinum compounds such as Cisplatin, Carboplatin, Eloxatin and the like
  • Paclitaxel compounds such as Docetaxel (Docetaxel Injection, Taxotere) and the like
  • cytidine antimetabolite such as Gemcitabine (Gemzar) and the like
  • antifolic antimetabolite such as
  • the following chemotherapy protocols are used, including but not limited to chemotherapy protocols containing platinum compounds, such as GP, TP, EP, GP-T2 protocols and the like.
  • the chemotherapy protocol applied in conjunction with the present recombinant interferon includes Cisplatin nebulized inhalation, Cisplatin pericardial perfusion and the like.
  • the targeted drugs used in the targeted therapy combined with the present recombinant interferon include but not limited to Gefitinib, Erlotinib and/or recombinant human endostatin and the like.
  • other anti-cancer therapies applied in combination with the present recombinant interferon include any combination of the chemotherapeutic drugs/chemotherapy protocols and targeted drugs.
  • other anti-cancer therapies applied in combination with the present recombinant interferon include GP protocol combined with recombinant human endostatin, EP protocol combined with Cisplatin nebulized inhalation and the like.
  • the method of the present invention is a non-surgical therapy.
  • the tumor lesions are divided into measurable lesions and un-measurable lesions, wherein the measurable lesions are defined as target lesions; the longest diameter represents the size of each lesion; at most 5 lesions can be selected in each involved organ, the sum of the measured lesions of all the involved organ is not more than 10, and the sum of the longest diameters of all the lesions is the overall diameter of the target lesion.
  • the un-measurable lesions are defined as non-target lesions, only the existence of the lesions are recorded and tracked, but the sizes of the lesions are not measured.
  • the curative effect evaluation standard of the target lesion is divided into 4 grades, the curative effect evaluation standard of the non-target lesion is divided into 3 grades, and the overall curative effect evaluation is obtained by combining the curative effects of the two kinds of lesions. It is specifically described as follows:
  • the curative effect evaluation standard of the target lesions (1) CR (complete remission): all the target lesions disappear; (2) PR (partial remission): the overall diameter of the target lesions is decreased by more than 30%; (3) NC or SD (no change or stable disease): the target lesions are neither decreased to “PR” nor increased to “PD”; and (4) PD (progression disease): the overall diameter of the target lesions is increased by more than 20%, or one or more new lesions appear.
  • the curative effect evaluation standard of the non-target lesion (1) CR: all the non-target lesions disappear, and the tumor marker level is normal; (2) IR (incomplete response)/SD: one or more non-target lesions is/are not changed, and/or the tumor markers exceed the normal limit; and (3) PD: one or more new lesions appear, and/or the non-target lesions are obviously developed.
  • the recombinant interferon has the beneficial effects as follows:
  • the recombinant interferon rSIFN-co used in the present invention has obvious different structural features and physiological activities compared with the existing interferons such as INFERGEN® (interferon alfacon-1) of the US Amgen.
  • the recombinant interferon can be singly used and/or can be combined with radiotherapy, chemotherapy, biological agents, and/or targeted drugs and the like, so as to non-surgically eliminate or reduce the tumors of the solid tumor subjects, particularly advanced tumors; specifically, the recombinant interferon can eliminate or reduce the solid tumors without indications for surgery, particularly the advanced solid tumors without indications for surgery.
  • the recombinant interferon can be singly administered through topical or local administration such as intratumoral injection/epidermal spray administration and the like, or through the combination of the topical or local administration together with the systemic administration (using the present recombinant interferon or radiotherapy/other anti-tumor drugs and the like), so as to non-surgically (namely, without surgery) eliminate or reduce the solid tumors.
  • topical or local administration such as intratumoral injection/epidermal spray administration and the like
  • systemic administration using the present recombinant interferon or radiotherapy/other anti-tumor drugs and the like
  • the recombinant interferon has obvious effect in replacing the chemotherapy drugs for preventing post-surgery recurrence or metastasis of the tumors, particularly various metastatic lesions such as bone metastasis which cannot be eliminated by existing treatment means; however, drugs can be directly administered to the lesions by the present invention, especially by the topical or local administration, to obviously reduce or eliminate the tumors.
  • the recombinant interferon can be singly administered through intrapleural or abdominal perfusion so as to for effectively eliminate or decrease malignant pleural effusion and/or malignant ascites.
  • cancer can be controlled by the rSIFN-co combination therapy.
  • the present recombinant interferon rSIFN-co
  • rSIFN-co has broad-spectrum anti-tumor effects, which is effective on both solid tumors and non-solid tumors while, at the same time, rSIFN-co has a good synergetic effect with existing treatment means such as surgical therapy, chemotherapy, radiotherapy, biotherapy and other anti-tumor drugs.
  • rSIFN-co has low toxicity which means no harm to normal cells has been observed when rSIFN-co is used in large doses.
  • rSIFN-co is convenient to use and can be directly applied to tumors in any position.
  • the rSIFN-co can be used by subcutaneous/intramuscular injection to control systemic progress of tumor, by intrapleural/abdominal perfusion to eliminate effusion and intrapleural/abdominal tumors, by topical or local injection to eliminate primary or metastatic tumors, and by infiltration (transdermal) administration to treat tumor lesions in bone, skin, muscle, prostate and the like; and rSIFN-co can also be administered by aerosol inhalation. According to above three advantages of rSIFN-co, effective rate of the combination therapy is no lower than 90%.
  • rSIFN-co can be used after surgery to replace chemotherapy and effectively prevent recurrence and metastasis; with regard to advanced cancer cases or cancer cases without indications for therapy, rSIFN-co can be used to eliminate tumors without surgery; with regard to cases without indications for surgery, rSIFN-co can be used to transformed the cases into ones with indications for surgery, thereby creating surgical conditions. Therefore, we believe the rSIFN-co combination therapy is capable of curing cancer.
  • the present invention provides a method for eliminating or reducing the malignant pleural effusion, malignant ascites, and/or malignant pericardial effusion in a subject with tumor, the method comprises administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the tumor is a solid tumor.
  • the recombinant interferon is administered to the subject by an administration route comprising one or more of: infiltration administration, intrapleural administration, abdominal administration, pericardial administration, thoracic administration and intraperitoneal administration.
  • the recombinant interferon is administered in an amount in a range of about 30 ⁇ g to about 2000 ⁇ g by one administration.
  • the recombinant interferon is additionally administered to the subject by systemic administration.
  • the subject is administered with at least one other anti-cancer drug.
  • the other anti-cancer drug is chemotherapeutic drug, targeted drug, or biological drug.
  • the present invention provides a method for preventing tumor recurrence or metastasis, or prolonging or maintaining a tumor-free status in a subject with a tumor, the method comprises administering to the subject a recombinant interferon encoded by the nucleotide sequence SEQ ID NO: 2, and the subject has been treated with at least one anti-cancer therapy before the administration of said recombinant interferon.
  • the anti-cancer therapy is chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, or traditional Chinese medicine therapy.
  • the recombinant interferon is administered to the subject in a single dose of the range of about 2 ⁇ g to about 2000 ⁇ g.
  • the present invention provides a method for eliminating or reducing metastatic tumor lesion in a subject, the method comprises administering a recombinant interferon encoded by SEQ ID NO: 2 topically or locally to the tumor lesion.
  • the metastatic tumor lesion comprises at least one of a bone lesion, a muscular lesion, a subcutaneous tissue lesion, a prostatic lesion, and a lymph node lesion.
  • the recombinant interferon is administered to the lesion by an administration route comprising at least one of infiltration administration, percutaneous administration, transdermal administration, epidermal administration and transmucosal administration. In another embodiment, the recombinant interferon is administered topically. In another embodiment, the recombinant interferon is further administered systemically.
  • the present invention provides a non-surgical method for eliminating a tumor in a subject or reducing the size of a tumor in a subject, the method comprises administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • the tumor is a non-resectable tumor.
  • the recombinant interferon is administered to the subject by at least one of systemic administration, local administration, and topical administration.
  • the local administration or topical administration comprises one or more of intratumoral administration and spray administration.
  • the subject is administered at least one other anti-cancer therapy.
  • the anti-cancer therapy is chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, or traditional Chinese medicine therapy.
  • the present invention provides a method for treating lung cancer in a subject, the method comprises administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, and the recombinant interferon is administered to the subject by at least one of systemic administration, topical administration, and local administration.
  • the recombinant interferon is administered systemically and via inhalation.
  • the systemic administration comprises at least one of subcutaneous administration and intramuscular administration
  • inhalation comprises at least one of: pulmonary inhalation and nasal inhalation.
  • the recombinant interferon is administered locally by perfusion.
  • the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • Preparation procedures raw materials were weighed by the ingredients and dissolved by sterile and pyrogen-free water for injected; then filtered by a membrane of 0.22 ⁇ m pore diameter for sterilization, and preserved at 6-10° C.; the materials were sampled for sterile and pyrogen inspections and then separately loaded in vials after qualified inspections, each with a single dose of 0.3-0.5. And then, the materials were put into freeze dryer for freezing and drying.
  • Preparation procedures raw materials were weighed by the ingredients and dissolved by sterile and pyrogen-free water for injection; then filtered by a membrane of 0.22 ⁇ m pore diameter for sterilization, and preserved at 6-10° C.; the materials were sampled for sterile and pyrogen inspections and then separately loaded in sealed containers after qualified inspections, each with a single dose of 0.3-0.5. And then, the finished product were preserved at 2-10° C. in dark places.
  • the ingredient content percentages in the table below are based on weight percentages.
  • the preparation method refers to conventional preparation method of spray.
  • the recombinant interferon inhalant of the present invention was prepared according to conventional preparation methods of interferon inhalant.
  • Table 2 Summary of Clinical Treatment of Multiple Types of Cancers in 58 Patients
  • rSIFN-co therapy began on From April 20, Year The size of PR lung began at January, Year 1: April 14, Year 1. Intramuscular 1 to September 3, the primary adenocarcinoma Taxotere and Carboplatin. injection of rSIFN-co was done once Year 1, Endostar ⁇ circle around (5) ⁇ lesions on One cycle of 21 days was every other day: 9 ⁇ g for the 1st was administrated upper lobe of provided. time, 15 ⁇ g for the 2nd time, 18 ⁇ g every day: 7.5 mg/m 2 right lung for the 3rd time and 21 ⁇ g for the 4th per dose, reduced from time and thereafter.
  • Intramuscular Gamma knife lesion of injection of rSIFN-co was done once radiotherapy for the about every other day: 9 ⁇ g for the 1st brain lesions was 5.1 ⁇ 3.2 cm on time, 18 ⁇ g for the 2nd time and conducted. the upper lobe 21 ⁇ g for the 3rd time and thereafter. of right lung Aerosol inhalation of rSIFN-co was disappeared. simultaneously performed: The enlarged 200 ⁇ g/every other day. lymph nodes From July 14, Year 1, 18 ⁇ g of in the rSIFN-co was used in intramuscular mediastinum injection. Aerosol inhalation of and the 400 ⁇ g of rSIFN-co was metastatic simultaneously performed every lesions in the other day.
  • Intramuscular lesions of left lung injection of rSIFN-co was about performed once every other day: 2.0 ⁇ 2.0 cm in 18 ⁇ g for 1st time, 21 ⁇ g for 2nd time left lung and thereafter. Such administration basically continued for almost 1 year till disappeared March, Year 2. and malignant Intrapleural perfusion of rSIFN-co pleural was done once every 8 days from effusion April 29, Year 1: 9 ⁇ g ⁇ 4 vials for 1st disappeared. and 2nd time and 9 ⁇ g ⁇ 5 vials for 3rd time. Three perfusions were provided totally. Four CT-guided interventional operations were performed in July and August Year 2.
  • the rSIFN-co was injected into relatively large lesions in lungs and 21 ⁇ g ⁇ 10 vials were used each time.
  • An aerosol CHOP (11) around mesenteric times of CHOPE regimen preparation of rSIFN-co (72 ⁇ g/ml) chemotharepy were nasopharynx lymph nodes and two times of MTX was sprayed onto the nasopharynx provided from July and regimen) began on August, Year 1.
  • quincunx 15 ⁇ g ⁇ 10 vials per due to at Chemotherapy was treatment. Two times later, local myelosuppression. submaxillary administered 6 times (3 subcutaneous injection was region, neck times of large-dosed performed every other day: 30 ⁇ g per and clavicular CHOPE regimen, 2 times treatment. Till August 27, Year 3 region shrank of CMOP regimen and 1 (more than 2 months), for a total of from 7.4 cm ⁇ time of a regimen of 10 times.
  • 2.4 cm ⁇ “bleomycin + CHOP (11) + 14.6 cm to Methotrexate”) began on 1.1 cm ⁇ January, Year 3, in 1.5 cm. combination with stem cell therapy.
  • the second course was performed from December Year 2 to July Year 3 during which intramuscular injection was done every other day with 21 ⁇ g per dose.
  • the third course was performed from February 21, Year 4 to May 21, Year 4 during which intramuscular injection was done every other day with 18 ⁇ g per dose.
  • 14 Male 44 Non small cell IIIb Upper lobe of right lung Treatment of rSIFN-co began on After surgery, CR lung cancer was resected on October November 6, Year 1. Intramuscular no tumor (poorly 20, Year 1. injection of rSIFN-co was recurrence or differentiated administered once every other day: metastasis adenocarcinoma) 18 ⁇ g for 1st time, 21 ⁇ g for 2nd time was found at and thereafter.
  • Intramuscular injection of rSIFN-co was provided every other day with 15 ⁇ g per dose.
  • Intramuscular injection of rSIFN-co and Aerosol inhalation were administered for 3 months from November Year 4.
  • Intramuscular injection was done once every other day with 15 ⁇ g per dose. Aerosol inhalation was performed every day and a total of 300 ⁇ g was used for one day.
  • 15 Male 68 Lung cancer IV Treatment with Gamma Treatment of rSIFN-co began on Mass of about PR with systemic Knife was done under local June 25, Year 3.
  • the rSIFN-co was 11.3 ⁇ 4.9 cm in metastases anesthesia on April 27, Year injected into lymph nodes of groin pelvic cavity 3. Intramuscularly every day: 15 ⁇ g ⁇ 6 reduced in Sr-89 therapy was done by vials for 1 st time, 15 ⁇ g ⁇ 8 vials for size to Nuclear Medicine 2nd time and 15 ⁇ g ⁇ 10 vials for 3rd 7.52 ⁇ 7.67 ⁇ Department on April 30, time and thereafter. Eleven 6.72 cm Year 3.
  • lymph nodes combined with 15 mg of Endostar on day once every other day: 9 ⁇ g for 1st at bilateral bone 1 ⁇ 10 and 200 mg of time, 15 ⁇ g for 2nd time, 18 ⁇ g for shoulder metastases at temozolomide on day 1 ⁇ 5, 3rd time and thereafter. Meanwhile, joints and bilateral hip oral administration.
  • the drug was locally applied by axillae joints, bilateral Targeted radiotherapy spraying onto the skin surface of the disappeared; femurs, (50Gy/25f) was done on right shouder: 70 ⁇ g- recurrence bilateral November 2, Year 1 and the 139 ⁇ g/dose/site, 4-5 doses/day. and metastatic humeri, ribs targets were right maxillary Spraying was provided to skin lesions at and bilateral sinus + 1 ⁇ 4 of the left surface of the left shoulder and other residual right shoulder joints.
  • liver metastases was eliminated, surgery of the lower left performed on March while no lung cancer was performed 17, Year 2. apparent on January 6, Year 2. Hepatic local change in Radiofrequency ablation of perfusion of liver the liver metastases was “Paclitaxel + metastases performed on January 13, Carboplatin” was was observed. Year 2. performed on April 21, Year 2.
  • Lung tumor PR treatments were performed rSIFN-co began on July 9, Year 2; shrunk, and in March, April and May of Intramuscular injection once every swollen Year 1; Began taking other day: 9 ⁇ g for the 1st time, lymph nodes Gefitinib on June 10, Year 1. 13.5 ⁇ g for the 2nd time, and 18 ⁇ g disappeared. for the 3rd time and thereafter; Aerosol inhalation of 300 ⁇ g per day.
  • Perfusion of rSIFN-co at 21 ⁇ g ⁇ 5 vials once every 6-8 days began on September 22, Year 2, depending on the subject's pleural effusion level and tolerance.
  • Perfusion of rSIFN-co at 21 ⁇ g ⁇ 6 to 8 or 10 vials once every 4 days began on October 21, Year 2, depending on the subject's pleural effusion level and tolerance.
  • rSIFN-co began on March 17, Year ablation targeting of colon, with Six chemotherapy 4; right lung metastases lung treatments had been Intramuscular injection once every was performed on metastases performed from May Year other day: March 28, Year 4; after surgery 1 to September Year 1, with 9 ⁇ g for the first time, Argon-helium the regimen of XELOX, 21 ⁇ g for the second time and cryosurgery targeting capecitabine tablets thereafter.
  • Radiofrequency Oxaliplatin 150 mg ablations targeting intravenous drip, QD, d1; left lung metastases cetuximab 600 mg, were performed 2 intravenous drip, QD, d1; times on May 5, Year irinotecan 240 mg, 4and June 13, Year 4, intravenous drip, QD, d2; respectively; fluorouracil 2500 mg, The right lower lung continuous intravenous drip metastases were for 48 hours; treated by ion TCM treatment had been implantation on May performed from November 27, Year 4. Year 2 to August Year 3. 2 courses of chemotherapy in December Year 4: capecitabine tablets 3000 mg, oral, d1-d14. Systemic chemotherapy on March 9, Year 5, cetuximab + alimta.
  • Avastin and NK cells were added for treatment on March 23, Year 5. Radiotherapy of hepatic metastases from April 21, Year 5 to May 19, Year 5. 41 Male 57 Colon cancer IV Hepatic interventions were Treatment by administering NC/SD with hepatic performed 2 times in rSIFN-co began on September 30, Year 1; metastases August Year 1 and on Intramuscular injection once every September 12, Year 1, other day: respectively.
  • the 3rd TACE was performed on August 2, Year 2.
  • Argon-helium cryoablation targeting multiple intrahepatic lesions was performed in September Year 2.
  • the 2nd argon-helium cryoablation was performed on November 7, Year 2.
  • Wedge resection of rSIFN-co began on September 5, Year 4; metastases left lung superior lobe
  • Intramuscular injection of 9 ⁇ g every masses was performed on other day from September 5, Year 4 July 6, Year 4. to September 9, Year 4.
  • Intramuscular injection of 9 ⁇ g at the 1st time Intramuscular injection of 18 ⁇ g from the 2nd time and thereafter.
  • Intramuscular injection of 9 ⁇ g at the radiotherapy was lesions were Radiofrequency ablation 1st time; Intramuscular injection of performed 24 times, eliminated or targeting a large pelvic 21 ⁇ g from the 2nd time and beginning December shrank. lymph node was performed thereafter; 12, Year 1 (60Gy on June 26, Year 1. Intraperitoneal perfusion, 7 times, 2.5 ⁇ 24 times).. I-125 particle implantation 21 ⁇ g ⁇ 8 vials each time. was performed on July 18, Year 1. 54 Female 46 Gastrointestinal Ib Duodenal tumorectorny Treatment by administering No signs of CR stromal was performed on July 13, Year 1. rSIFN-co began on December Year apparent tumors Radiotherapy was 1.
  • Non-small-cell lung cancer the primary lesions in the right pulmonary hilum and the mediastinal lymph node metastasis disappeared after treatment by intramuscular injection of recombinant super-compound interferon (rSIFN-co) in combination with radiotherapy.
  • rSIFN-co super-compound interferon
  • Patient 1 Gender Male Age: 53
  • Pathological diagnosis Squamous cell carcinoma Clinical and pathological staging ⁇ circle around (1) ⁇ : T 3 N 2 M 0.
  • Regimens before administration of DP Regimen ⁇ circle around (8) ⁇ was provided from October 14, rSIFN-co: Year 1 to November 25, Year 1: 75 mg of Taxotere and 75 mg of Cisplatin on Day 1. Two cycles of chemotherapy were performed in total, each lasting for 21 days.
  • Regimens administration of rSIFN-co The rSIFN-co therapy started in November, Year combined with radiotherapy 1.
  • Intramuscular injection of rSIFN-co was done once every other day: 9 ⁇ g for the 1st time, 15 ⁇ g for the 2nd time and 18 ⁇ g for the 3rd time and thereafter. Therapy continued till February, Year 3, during which rSIFN-co treatment had been stopped for 1 month in April, Year 2, leading to a total treatment duration of 15 months.
  • Non-small-cell lung adenocarcinoma with systemic metastases on body parts including bilateral lungs, liver and lymph nodes/Intramuscular injection and aerosol inhalation of rSIFN-co combined with chemotherapy (GP regimen) and administration of recombinant human endostatin (Endostar).
  • GP regimen chemotherapy
  • Endostar recombinant human endostatin
  • Patient 2 Gender Male Age: 40 Pathological diagnosis: Lung Adenocarcinoma Clinical and pathological staging ⁇ circle around (1) ⁇ : T 3 N 3 M 1.
  • IV Regimens before administration of Systematic chemotherapy began at January, Year rSIFN-co: 1: Taxotere and Carboplatin. One cycle of 21 days was provided.
  • rSIFN-co aerosol inhalation of rSIFN-co was done once every day: 300 ⁇ g for the 1st time, 500 ⁇ g for the 2nd time, 600 ⁇ g for the 3rd time and thereafter.
  • Administration of rSIFN-co ended in April Year 2. From April 20, Year 1 to September 3, Year 1, Endostar 5 was administrated every day: 7.5 mg/m 2 per dose, 1.2 ⁇ 10 ⁇ circle around (5) ⁇ U/m 2 . Four cycles were performed totally with each lasting for 14 days. Meanwhile, GP regimen was combined: 1600 mg of Gemcitabine on days 1 and 8 and 40 mg of Cisplatin on days 1 ⁇ 3. Four cycles were performed, each being 15 days.
  • Cisplatin One intrapericardial infusion with Cisplatin (30 mg) was performed on July 19, Year 1. Aerosol inhalation of Cisplatin was added from December 23, Year 1 to January 14, Year 2: 10 mg/dose, 2 doses per day. The second course of Endostar treatment was provided from January 18, Year 2 to January 30, Year 2 with same dosage. Chemotherapy using Pemetrexed ⁇ circle around (6) ⁇ proceeded from December 25, Year 1 to January 19, Year 2: iv. 500 mg/m 2 , every 3 to 4 weeks.
  • Patient 3 Gender Female Age: 51 Pathological diagnosis: None Clinical and pathological staging ⁇ circle around (1) ⁇ : T 2 N 2 M 1 .
  • IV Regimens before administration of None rSIFN-co Regimens: administration of rSIFN-co Treatment with rSIFN-co started on May 29, combined with Gamma knife treatment Year 1.
  • Intramuscular injection of rSIFN-co was done once every other day: 9 ⁇ g for the 1st time, 18 ⁇ g for the 2nd time and 21 ⁇ g for the 3rd time and thereafter. Aerosol inhalation of rSIFN-co was simultaneously performed: 200 ⁇ g/every other day.
  • Irregular increased density shadows were found about 5.1 ⁇ 3.2 cm was found at the apex of at upper lobe of right lung near mediastinum, right lung, which had an obscure suggesting the possible occurrence of boundary and connected to anterior inflammation in the right lung.
  • the thorax was pleural membrane. Enlarged lymph nodes symmetrical, and the perivascular space in were found in neighboring mediastinum. mediastinum was clear with no enlarged lymph Diagnostic imaging showed that it was a node found. (See the original location of the space-occupying lesion in the apex of lesions indicated by arrow in FIG. 5b) right lung. 2.
  • Irregular low-density shadows could be seen in Brain CT scans on May 14, Year 1 (see the right frontal lobe and left temporal lobe.
  • FIGS. 5a-5b After 3-month of treatment, the mass at the apex of right lung completely disappeared.
  • chemotherapy anerosol inhalation of Cisplatin and EP regimen
  • interventional therapy for supraclavicular lesions.
  • Patient 4 Gender Male Age: 49 Pathological diagnosis: Small-cell lung cancer Clinical and pathological staging ⁇ circle around (1) ⁇ : T 4 N 3 M 1 .
  • IV Regimes before administration of rSIFN-co The first cycle of EP ⁇ circle around (7) ⁇ chemotherapy was conducted from March 25, Year 1 to Apr 9, Year 1: 100 mg of Etoposide and 30 mg of Cisplatin.
  • Regimes administration of rSIFN-co The treatment of rSIFN-co began on April 12, combined with chemotherapy and Year 1. Intramuscular injection was done interventional therapy once every other day: 9 ⁇ g for the 1st time, 15 ⁇ g for the 2nd time and 18 ⁇ g for the 3rd time and thereafter.
  • Aerosol inhalation of rSIFN-co was performed once every other day: 0.5 ⁇ 2 ml/dose (200 ⁇ g/ml). From July 16, Year 1, 21 ⁇ g of rSIFN-co was used in intramuscular injection. Aerosol inhalation of rSIFN-co continued but the amount per dose was changed to 200 ⁇ g. The first cycle finished by the end of March Year 2 (lasting for almost 1 year). The administration of rSIFN-co was stopped for 1 month because Aerosol inhalation of Cisplatin (one dose per day and 10 mg per dose) was performed throughout September Year 1.
  • the 2nd cycle of treatment proceeded from October 9, Year 2 to January 26, Year 3 during which 18 ⁇ g of rSIFN-co was intramuscularly injected every other day.
  • Five cycles of EP chemotherapy were conducted from March 25, Year 1 to September 10, Year 1 and the same regimen as mentioned above was used.
  • An interventional cryoablation was conducted on the supraclavicular lesions on September 3, Year 2.
  • a 15-day regimen of aerosol inhalation of Cisplatin was added: 10 mg per dose, 1 dose per day. Two cycles were done, each lasting for 15 days.
  • rSIFN-co PET/CT scans on April 8, Year 1 (see the PET/CT scans on December 24, Year 1 (see lesions indicated by arrows in FIG. 7a-8a) the original lesion locations indicated by after the chemotherapy: arrows in FIG. 7a-8a): 1.
  • PET showed 2.
  • the nodules on right clavicle were abnormal radioactive concentration and the significantly downsized. PET showed SUV value was 4.1. abnormal radioactive concentration with a 2.
  • Nodules of about 2.6 ⁇ 2.2 cm were SUV value of 4.7; observed at right clavicle, the boundaries of 3. The nodules around the mediastinal which were obscure. PET showed abnormal brachiocephalic trunk, right brachiocephalic radioactive concentration and the SUV value veins, and trachea were not clearly observed. was 9.1. superior vena cava; 3. Multiple nodules of about 5.5 cm ⁇ 4.9 cm 4. Multiple nodules were found around the appeared around the mediastinal superior vena cava. PET did not show an brachiocephalic trunk, right brachiocephalic obvious radioactive concentration, indicating veins, superior vena cava, and trachea. The the suppression on the lesions' metabolism.
  • PET Streaky shadows were found in the upper showed abnormal radioactive concentration lobe of right lung while patchy shadows were and the SUV value was 11.5). Metastasis of found in dorsal segment of lower lobe. PET lymph nodes should be taken into account. scan did not show obvious radioactive 4. The superior vena cava could not be concentration; excluded. 2. After cryotherapy was conducted for the right supraclavicular metastasis, no obvious nodules or masses were found in the right clavicle and PET image did not show obvious radioactive concentration. PET scans on other parts showed similar metabolic images as before.
  • PET/CT on February 7, Year 4 (after treatment of “small-cell cancer of right lung” and compared to PET/CT scans taken on July 26, Year 3): 1.
  • the posterior wall of left nasopharynx was thickened slightly and PET imaging showed radioactive concentration, suggesting the possible occurrence of an inflammatory lesion; 2.
  • Multiple nodules were at deep cervical and submentum and PET imaging did not show abnormal radioactive concentration, suggesting the possible occurrence of inflammatory hyperplasia of lymph nodes; 3.
  • the wall of greater gastric curvature was slightly thickened and PET imaging did not show radioactive concentration. Inflammatory lesion could be taken into consideration; 4.
  • PET/CT scans on other parts did not show significant changes.
  • Description of FIGS. 7a-7b After 8 months of treatment, the lesions on the apex of the right lung disappeared.
  • Description of FIGS. 8a-8b After 8 months of treatment, the metastatic lesions in mediastinum disappeared.
  • Non-small-cell lung cancer with metastases to the right humerus after surgeries/Intramuscular injection and aerosol inhalation of rSIFN-co combined with chemotherapy (aerosol inhalation of Cisplatin). After treatment, the metastatic lesions in right lung hilum, paratracheal lymph nodes and several sites of spinal metastases disappeared.
  • Patient 5 Gender Female Age: 42 Pathological diagnosis ⁇ circle around (1) ⁇ : Metastatic adenocarcinoma (in right humerus) (moderately differentiated adenocarcinoma) Clinical and pathological staging ⁇ circle around (1) ⁇ : T 2 N 2 M 1.
  • IV Regimes before administration of rSIFN-co A surgical repair of right humerus was performed on February 23, Year 1. After that surgery, patient was given 4 courses of DP ⁇ circle around (8) ⁇ chemotherapy: 75 mg of Taxotere and 75 mg of Cisplatin on day 1.
  • Regimes administration of rSIFN-co Treatment with rSIFN-co began on April 15, combined with chemotherapy Year 1.
  • Intramuscular injection was performed once every other day: 9 ⁇ g for the 1st time and 21 ⁇ g for the 2nd time and thereafter.
  • the treatment was provided for a total of 3 months till September 15, Year 1, during which rSIFN-co administration was suspended for 1 month due to chemotherapy (the chemotherapy regimen shown below related to aerosol inhalation of Cisplatin) and for 1 month because of the patient's physical condition.
  • Aerosol inhalation of rSIFN-co was added on September 16, Year 1: 1 ml (200 ⁇ g/ml) per day. Till February, Year 2, the co-administration regimen was provided for 5 months. From September 15, Year 2, intramuscular injection of 15 ⁇ g was provided every other day.
  • Aerosol inhalation of Cisplatin began on September 16, Year 1: 10 mg per dose and 2 doses per day. Eight cycles were conducted with each cycle being 15 days.
  • Response to rSIFN-co treatment CR ⁇ circle around (2) ⁇ (radioactive concentrations at the primary lesion of right lung tumor, right humerus and the T6 vertebra evidently decreased. Metastatic lesions on pelvis and lumbar vertebrae as well as enlarged paratracheal lymph nodes disappeared.) Survival: After about 40 months (February Year 1 to July Year 4), the patient remained alive with a normal life. No recurrence or metastasis was observed upon imaging.
  • rSIFN-co PET/CT scans on February 26, Year 1 after PET/CT scans on March 2, Year 2 (see original surgery (See lesions indicated by arrows in locations of lesions indicated by arrows in FIG. FIG. 9a-11a): 9b-11b): 1.
  • the mass on the soft tissue of anterior 24 mm ⁇ 19 mm ⁇ 18 mm was found at the front segment of upper lobe of right lung did not end of right lung' upper lobe. change in shape, size and density. The extent of 2.
  • FIGS. 9a-9b After treatment, the radionuclide metabolism reduced significantly in the primary lesions of right lung.
  • Description of FIGS. 10a-10b The radioactive concentration of the lesions at upper segment of right humerus decreased.
  • Description of FIGS. 11a-11b Metastatic lesions on pelvis disappeared.
  • Non-small-cell lung cancer with multiple lymph node metastases in mediastinum, left segment of neck, right and root segment of neck, left supraclavicular fossa; left-sided pleural effusion; multiple bone metastases in vertebral column, bilateral ribs, right clavicle joint, sternum and left sacrum, and obvious generalized pain/Intramuscular injection, aerosol inhalation and local spraying of rSIFN-co combined with chemotherapy (GP regimen) and Gefinitib (Iressa) therapy. After the treatment, primary lesions on left lung disappeared and metastatic lesions around the body shrank. Further, generalized pain was relieved.
  • Intramuscular injection of rSIFN-co started on December 12, Year 1, once every other day: 9 ⁇ g for 1st time, 15 ⁇ g for 2nd time and 18 ⁇ g for 3rd time and thereafter.
  • Local spraying on bone metastases began on March 12, Year 2: 70 ⁇ g ⁇ 139 ⁇ g/does/site, 4 ⁇ 5 doses/day.
  • the second cycle of GP Regimen ⁇ circle around (9) ⁇ started on October 14, Year 1 (the regimen was exactly the same as mentioned above).
  • Gefinitib was taken from November 24, Year 1: 1 pill/dose (250 mg/pill), 1 dose/day.
  • rSIFN-co Chest CT scans on September 21, Year 1 CT scans on November 15, Year 1: (see primary lesions indicated by arrows Shadows of soft tissues of about 3.6 ⁇ 4.2 cm were in FIG. 12a): found; sheet-like density shadows were scattered A blocky shadow (9 ⁇ 3.5 cm) of high and had obscure boundaries; no enlarged lymph density was found around left nodes were seen in the mediastinum (the original mediastinum and CT value was 39Hu. ones disappeared). The boundaries between this shadow and CT scans on December 12, Year 1 (see original part of great vessels in mediastinum locations of lesions indicated by arrows in FIG.
  • pleura were obscure. Patchy shadow of Sheet-like and single-sheet-like shadows with inflammatory exudation with high density increased density were scattered in both lungs. could be seen in lung. Enlarged lymph The boundaries were obscure and two hila were nodes were found in mediastinum. A few not larger. The tracheas were clear and no patchy shadows with high density were enlarged lymph nodes were seen in the seen inhomogeneous in upper segment of mediastinum. Pneumonia of both lungs might right lung, boundaries of which were happen. clear. Arched effusions were found on left Bone scans on December 6, Year 1: posterior side.
  • Diagnosis conclusion lung cancer in left shadows with abnormal radioactive concentration mediastinum combined with pleural could be seen in right sternoclavicular joints, ribs, effusion and obstructive pneumonia; spinal column and pelvis. Radioactive multiple patchy shadows were present in distributions in other parts were basically uniform hilum, suggesting the possible occurrence and symmetrical. of metastases. Diagnosis conclusion: systemic bone metastases Color Doppler ultrasound on September shrank in size and were relieved to some extent 30, Year 1: than before.
  • hypoechoic nodules were at left PET/CT scans on December 29, Year 1: segment of neck, which had clear A nodule with diameter of about 8 mm was boundaries and had no hilum of lymph observed at the apex of left lung and radioactive nodes. The big hypoechoic nodule was distribution was slightly increased. Patchy 1.0 cm ⁇ 0.7 cm in size. One hypoechoic shadows with slightly higher (than normal) nodule of about 1.2 cm ⁇ 0.8 cm was at left density and fabric lesions were found in supraclavicular fossa. It had clear surrounding area of lung and the radioactive boundary but had no hilum of lymph distribution was slight increased. Scattered, node.
  • hypoechoic nodule of about patchy shadows with slightly higher density were 1.4 cm ⁇ 1.1 cm was at root segment of neck found in both lungs and the radioactive on the right side. It had clear boundary distribution was not obviously abnormal. but had no hilum of lymph node.
  • hypoechoic increase of FDG metabolism was found on at nodules were found at left segment of lesions of the apex of left lung, suggesting the neck, left supraclavicular fossa and root inactivation of most tumor cells; 2. Asymmetric segment of neck on the right side.
  • Patient 7 Gender Female Age: 53 Pathological diagnosis: metastatic adenocarcinoma (lymph nodes at left clavicle) Clinical and pathological staging ⁇ circle around (1) ⁇ : T 4 N 3 M 1.
  • IV Regimens before administration of None rSIFN-co Regimens: administration of rSIFN-co Treatment with rSIFN-co began on July 31, Year combined with administration of other 1.
  • Intramuscular injection was done once every biological agents other day: 9 ⁇ g for 1 st time, 18 ⁇ g for 2nd time and 21 ⁇ g for 3 rd time and thereafter. Seventy-five times of intramuscular injection were done till January 2, Year 2 (totally 5 months).
  • Iressa (Gefinitib) ⁇ circle around (10) ⁇ produced in India was administered in combination for 1 year: 1 pill/dose (250 mg/pill), 1 dose/day.
  • Response to rSIFN-co treatment PR ⁇ circle around (2) ⁇ (primary lesions in right lung and metastatic lesions in both lungs and several bones shrank with radioactive concentration decreased; metastasis in liver disappeared.)
  • the disease was diagnosed as lung cancer in CT imaging on July 2, Year 1: July. Specifically, patchy nodular lesions in the see lesions indicated by arrows in FIG. lower lobe of right lung and circumjacent 14a. spot-like shadows with high density were seen. Condition was improved as compared with previous CT scans. 2. The size and shape of liver were normal. Density of liver is even and no focal density abnormality was found. CT scans on March 3, Year 2: Compared with the imaging on October 22, Year 1, no new lesion was found and partial sclerotin radiation was reduced. Multiple bone metastases existed with lung cancer, but improved after treatment. Description of FIGS. 13a-13b: After treatment, systemic metastatic lesions at bones partially disappeared or shrank. Description of FIGS. 14a-14b: After treatment, metastatic lesions in both lungs disappeared and lesions in right lung evidently shrank.
  • Patient 8 Gender Female Age: 68 Clinical and pathological staging ⁇ circle around (1) ⁇ : T 4 N 2 M 1.
  • IV Regimens before administration of None rSIFN-co Regimens: administration of rSIFN-co Treatment with rSIFN-co began on July 21, Year combined with other biological therapies 1
  • Intramuscular injection was done once every other day: 9 ⁇ g for 1st time, 15 ⁇ g for 2nd time and 18 ⁇ g for 3rd time and thereafter. Meanwhile, aerosol inhalation of rSIFN-co of 600 ⁇ g was performed once a day.
  • Administration of rSIFN-co continued for 3 months till October 31, Year 1.
  • a density shadow of soft tissue lung markings increased and disordered and mass (3.0 ⁇ 3.9 cm) was found in lower transmittance of lung field was elevated. Lesions lobe of right lung.
  • Patient 9 Gender Male Age: 55 Pathological diagnosis: Squamous cell carcinoma Clinical and pathological staging ⁇ circle around (1) ⁇ : T 2 N 1 M 0. IIb Regimens before administration of None rSIFN-co: Regimens: rSIFN-co combined with Treatment with rSIFN-co began on March 18, chemotherapy. Year 1. Aerosol inhalation of rSIFN-co of 600 ⁇ g was performed once a day. A course completed till July 20, Year 1 (for 4 months) with 100 doses of aerosol inhalation done.
  • FIGS. 17a-17b After treatment of 4 months, soft tissue masses at hilum of lower lobe of right lung evidently shrank.
  • Non-small-cell lung cancer with metastases in lung and pleura pleural effusion/Intramuscular injection of rSIFN-co alone or intrapleural perfusion of rSIFN-co alone.
  • pleural effusion/Intramuscular injection of rSIFN-co alone or intrapleural perfusion of rSIFN-co alone After treatment, primary lesions on the apical segment of upper lobe of left lung were cleared up and metastatic lesions on lingual segment of left lung shrank.
  • Cytological diagnosis before Cytological diagnosis after administration of administration of rSIFN-co rSIFN-co: Pleural fluid smear (March 2, Year 1): Pleural fluid smear and cell mass (September 18, poorly differentiated cancer cells were Year 1): found. Lymphocytes, neutrophils and necrotic materials were found, no tumor cells was found. Diagnostic imaging before administration Diagnostic imaging after administration of of rSIFN-co: rSIFN-co: Chest CT scans on February 23, Year 1: CT scans on August 1, Year 1 (see original 1. A mass of 2.0 ⁇ 2.0 cm was found at locations of lesions indicated by arrows in FIG. apical segment of the upper lobe of the 19b): left lung, suggesting the possible 1.
  • Non-hodgkin lymphoma/Aerosol inhalation (though nasopharynx and Oral Cavity) of rSIFN-co and local injection into enlarged lymph nodes at neck combined with radiotherapy. After local administration, lesions in the nasal cavity, oropharynx, neck and submaxillary region disappeared or shrank.
  • Chemotherapy was administered 6 times (3 times of large-dosed CHOPE regimen, 2 times of CMOP regimen and 1 time of a regimen of “bleomycin + CHOP (11) + Methotrexate”) began on January, Year 3, in combination with stem cell therapy.
  • chemotherapy and radiotherapy An aerosol preparation of rSIFN-co (72 ⁇ g/ml) was sprayed onto the nasopharynx and Oral Cavity 2 ⁇ 3 times every day. Administration continued till August 27, Year 3 with 5 days of suspension because of chemotherapy (see chemotherapy describebd below). Local injections on lymph nodes in neck started on June 11, Year 3.
  • Injection was performed every other day by injection at multiple sites in a quincunx: 15 ⁇ g ⁇ 10 vials per treatment. Two times later, local subcutaneous injection was performed every other day: 30 ⁇ g per treatment. Till August 27, Year 3 (more than 2 months), for a total of 10 times.
  • Four cycles of CHOP (11) chemotharepy were provided from July Year 3 to November 28, Year 3 with each cycle lasting for 21 days. Radiotherapy began on June 11, Year 3 (scheduled for 25 times) and stopped on July 5, Year 3 as the patient was weak due to myelosuppression.
  • FIGS. 21a-21b After treatment, a large number of primary enlarged lymph nodes at neck disappeared.
  • Description of FIGS. 22a-22b After treatment, primary lesions at bilateral mandible disappeared.
  • Description of FIGS. 23a-23b After treatment, primary lesions at pharyngeal disappeared.
  • Patient 12 Gender Male Age: 67 Cytologic diagnosis: Lung adenocarcinoma Clinical and pathological staging ⁇ circle around (1) ⁇ : T 3 N 0 M 0. II b Regimens before administration of From August 16, Year 1, two cycles of GP rSIFN-co: regimen ⁇ circle around (9) ⁇ were provided: 1000 mg/m 2 of Gemcitabine on day 1 and 8 and 75 mg/m 2 of Cisplatin on day 1. Intrathoracic injection of Cisplatin was also performed for 5 times. 1 dose every 7 days, 30-40 mg per dose. Regimens: administration of rSIFN-co Treatment with rSIFN-co began on November alone 10, Year 1.
  • Intramuscular injection of rSIFN-co was provided once every two days: 9 ⁇ g for 1st time, 18 ⁇ g for 2nd time and 21 ⁇ g for 3rd time and thereafter. Administration lasted for almost 1 year till October 27, Year 2.
  • Response to rSIFN-co treatment PR ⁇ circle around (2) ⁇ (the mass reduced from about 3.1 ⁇ 4.2 cm to 2.2 ⁇ 1.5 cm after 2 months' treatment, and the lesion further reduced in size after administration for 3 months.)
  • Survival about 28 months (from Augugst 11, Year 1 to Year 4) Diagnostic imaging before Diagnostic imaging after administration of administration of rSIFN-co: rSIFN-co: Chest CT scans on October 10, Year 1 CT scans on January 10, Year 2: after chemotherapy: The mass was about 2.2 ⁇ 1.5 cm on lower A shadow of tumor mass of about segment of right hilum which was significantly 3.1 ⁇ 4.2 cm was found at opening segment smaller than before.
  • FIG. 24b Lung tissue was compressed by about After 3 months' treatment, the mass on lower 10% in size and not much pleural effusion segment of right hilum evedently shrank. were seen in right-sided thoracic cavity.
  • Non-small-cell lung cancer after surgeries/Intramuscular injection of rSIFN-co alone. After the treatment, no tumor recurrence or metastasis was found in right lung and the whole body.
  • Patient 13 Gender Male Age: 63
  • Pathological diagnosis poorly differentiated adenocarcinoma (upper lobe of right lung)
  • Clinical and pathological staging ⁇ circle around (1) ⁇ T 4 N 2 M 0.
  • IIIb Regimens before administration of On October 15, Year 1, resection of upper lobe of rSIFN-co: right lung and lymph node dissection were done as well as wedge resection of nodules on lower lobe of right lung.
  • Postoperative pathology report Poorly differentiated adenocarcinoma occured on upper lobe of right lung; the tumor was 4.5 ⁇ 4.5 ⁇ 4 cm in size and grew to regions below visceral pleura.
  • the third course was performed from February 21, Year 4 to May 21, Year 4 during which intramuscular injection was done every other day with 18 ⁇ g per dose.
  • Response to rSIFN-co CR ⁇ circle around (2) ⁇ (After surgery on primary lesions, no tumor recurrence or metastasis occurred.) Survival: After 45 months (from September 13, Year 1 to July Year 5), the patient remained alive and had normal life. No recurrence or metastases was observed on imaging test. Diagnostic imaging before Diagnostic imaging after administration of administration of rSIFN-co: rSIFN-co: CT scans on May 25, Year 3: see the suspicious lesion at lower lobe of right lung indicated by arrows in FIG. 25a. Chest CT scans on February 11, Year 4: 1.
  • FIGS. 25a-25b After treatment, the space occupying at lower lobe of right lung disappeared and no tumor recurrence or metastasis was found.
  • Non-small-cell lung adenocarcinoma after surgery/Intramuscular injection of rSIFN-co alone. After the treatment, no tumor recurrence and metastasis was found.
  • Patient 14 Gender Male Age: 44 Pathological diagnosis: Poorly differentiated adenocarcinoma Clinical and pathological staging ⁇ circle around (1) ⁇ : T 4 N 3 M 0 , IIIb Regimens before administration of Upper lobe of right lung was resected on October rSIFN-co: 20, Year 1. Postoperative pathology report: Examination on October 27, Year 1: (masses at upper lobe of the right lung) part of lung tissue was resected. Alveolar epithelium hyperplasia and chronic inflammatory cell infiltration were observed under microscope. Fibroplasia happened at the side of pleura with collagenization. Focal hemorrhage and necrosis were also observed while poorly differentiated adenocarcinoma was found.
  • Intramuscular injection was done once every other day with 15 ⁇ g per dose. Aerosol inhalation was performed every day and a total of 300 ⁇ g was used for one day.
  • Response to rSIFN-co treatment CR ⁇ circle around (2) ⁇ (after surgery, no tumor recurrence or metastasis was found at primary lesions.)
  • Survival After about 44 months (from October 14, Year 1 to July Year 5), the patient remained alive and had a normal life. No initial recurrence or metastases was observed upon imaging.
  • rSIFN-co Chest CT scans on October 13, Year 1: CT scans on February 22, Year 3 (see the original Peripheral lung cancer was found in surgical site indicated by arrow in FIG. 26b): posterior segment of right upper lobe; the High-density stripe-like shadows were found in tumor of about 4.0 ⁇ 2.9 cm in size grew residual part of upper lobe of right lung and local into posterosuperior segment of bronchiectasia happened, which were mainly right-sided pleura and implantation postoperative changes. No significant change was metastasis happened at right-sided pleura; found in lesions as compared with previous CT.
  • Non-small-cell lung cancer with systemic metastases local injection of rSIFN-co into enlarged lymph nodes in groin. After local injections, metastatic lesions in the lymph nodes in pelvic cavity and inguinal area were cleared up or shrank.
  • the rSIFN-co was injected into lymph nodes of groin Intramuscularly every day: 15 ⁇ g ⁇ 6 vials for 1st time, 15 ⁇ g ⁇ 8 vials for 2nd time and 15 ⁇ g ⁇ 10 vials for 3rd time and thereafter. Eleven injections were done till July 20, Year 3 (Severe diarrhea occurred after 3 injections and administration was stopped for 2 weeks; after that injection was performed every day and 8 injections in total were continuasly provided). Discontinuous local injection in lymph nodes were performed for 6 times from August 18, Year 3 to September 16, Year 3: 15 ⁇ g ⁇ 10 vials for each time.
  • Rectal cancer after a surgery/Intramuscular injection of rSIFN-co alone. After the treatment, no tumor recurrence or metastasis was found.
  • Patient 16 Gender Female Age: 63 Pathological diagnosis: Well to moderately differentiated adenocarcinoma was found in rectum and mucinous adenocarcinoma was found in part of rectum. Cancer invaded into deep muscularis of intestinal wall and formed cancerous nodules in mesorectum (see the cancer cells indicated by arrows in FIG. 28) Clinical and pathological staging ⁇ circle around (1) ⁇ : T 4 N 1 M x . IIIb Regimens before administration of Laparoscopic-assisted abdominal perineal radical rSIFN-co: resection of rectal cancer was done on May 16, Year 1. Regimens: administration of rSIFN-co Treatment of rSIFN-co began on May 23, Year 1.
  • Intramuscular injection of rSIFN-co was provided once every other day: 21 ⁇ g for each time.
  • the first course of 8 months ended on February Year 2.
  • the second course was provided from January Year 3 to April Year 3.
  • Intramuscular injection of rSIFN-co was provided once every other day with 9 ⁇ g each time and continued for 3 months.
  • the third course was administered from December Year 3 to March Year 4.
  • Intramuscular injection was performed every other day with 15 ⁇ g each time.
  • Response to rSIFN-co treatment CR ⁇ circle around (2) ⁇ (after surgery, no tumor recurrence or metastasis occurred at primary lesions.)
  • Survival After about 49 months (from May Year 1 to July Year 5), the patient remained alive.
  • FIGS. 29a-29b During 25 months after surgery, no recurrence or systemic metastasis occurred in the cured primary lesions.
  • Patient 17 Gender Female Age: 25 Cytologic diagnosis: Cervical smear on May 11, Year 1 showed high-grade intraepithelial lesion.
  • Clinical and pathological staging ⁇ circle around (1) ⁇ Ib1 Regimens before administration of none rSIFN-co: Regimens: administration of rSIFN-co Treatment of rSIFN-co began on May 14, Year 1. alone Intramuscular injection of rSIFN-co was provided once every other day: 9 ⁇ g for 1st time, 15 ⁇ g for 2nd time and 18 ⁇ g for 3rd time and thereafter. Meanwhile, uterine perfusion was done once a day: at 1000 ⁇ g per dose, for 2 hours.
  • Prostatic cancer/Intramuscular injection of rSIFN-co and local spraying to skin surface where prostate biopsy was done
  • rSIFN-co combined with local radiotherapy.
  • the prostate tumor and two lymph nodes in right-sided ischiorectal fossa were eliminated; the posterior wall of fundus of urinary bladder, bilateral seminal vesicles and anterior rectal wall infected by lesions recovered; and the level of tumor marker (PSA) become normal.
  • PSA tumor marker
  • Patient 18 Gender Male Age: 64 Pathological diagnosis: Adenocarcinoma was found in the 1st-10th prostate biopsy. Clinical and pathological staging ⁇ circle around (1) ⁇ : T 4 N 1 M 0. IV Regimens before administration of none rSIFN-co: Regimens: administration of rSIFN-co Treatment of rSIFN-co began on November 15, combined with radiotherapy Year 1. Intramuscular injection of rSIFN-co was provided once every other day: 9 ⁇ g for 1st time, 15 ⁇ g for 2nd time, 18 ⁇ g for 3rd time and 24 ⁇ g for 4th time and thereafter.
  • the amount of rSIFN-co to be intramuscularly injected changed to 21 ⁇ g from December 15, Year 1 to July 1, Year 2.
  • Radiotherapy on prostate (EBRT) ⁇ circle around (12) ⁇ was performed for 38 times from December 5, Year 1 to February 26, Year 2.
  • the prostate was smaller in size and left and irregular mass shadows of about posterior part protruded slightly. No obvious 4.7 ⁇ 4.3 ⁇ 5.6 cm in size were formed with abnormality was found in each imaging sequence obsecure border and inhomogeneous signal. signals. Inhomogeneous reinforcement 2.
  • Bladder wall was inhomogeneously thickened: happened in enhanced scan. All these inflammation? suggested the occurrence of prostatic 3.
  • Two lymph nodes in right-sided ischiorectal fossa were found with diameter of about 1 cm, suggesting the occurrence of metastasis. 3.
  • Patient 19 Gender Female Age: 43 Pathological diagnosis: Tumors were found in the neoplasma inside the right maxillary sinus. Malignant melanoma was proved by immunohistochemistry: (HMB45 (part+), MART1 ( ⁇ ), S100 ( ⁇ ), CD63 (+), NSE ( ⁇ ), PCK ( ⁇ ), EMA (+), CD56 ( ⁇ ) and KI671 25%). Clinical and pathological staging ⁇ circle around (1) ⁇ : pT 3 NxM 1 . IV Regimens before administration of rSIFN-co: Two cycles were provided on October 30, Year 1 and November 30, Year 1: 15 mg of Endostar on day 1 ⁇ 10 and 200 mg of temozolomide on day 1 ⁇ 5, oral administration.
  • Targeted radiotherapy (50Gy/25f) was done on November 2, Year 1 and the targets were right maxillary sinus + 1 ⁇ 4 of the left maxillary sinus, bilateral ethmoid sinus, frontal sinus and the adjacent tissues of the right eyeball. Radiotherapy ended on December 7, Year 1.
  • Regimens administration of rSIFN-co alone Treatment of rSIFN-co began on December 21, Year 1. Intramuscular injection of rSIFN-co was provided once every other day: 9 ⁇ g for 1st time, 15 ⁇ g for 2nd time, 18 ⁇ g for 3rd time and thereafter.
  • the drug was locally applied by spraying onto the skin surface of the right shouder: 70 ⁇ g-139 ⁇ g/ dose/site, 4-5 doses/day. Spraying was provided to skin surface of the left shoulder and other sites with bone metastasis began on February 27, Year 2: 70 ⁇ g-139 ⁇ g/dose/site, 4-5 doses/day.
  • Radiotherapy of lung cancer refer to Modern Lung Cancer Pathology and Clinical Practice /Edited by Xiong Min and Wu Yilong, (Beijing: Science Press, 2003 June), p 324-365;

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)

Abstract

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and/or preventing postoperative tumor recurrence and/or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and/or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

Description

    FIELD OF THE INVENTION
  • The present invention relates to methods for treating tumors in subjects by using recombinant interferon, and to methods for treating solid tumors, including lung cancers in subjects. The present invention further relates to non-surgical methods for eliminating tumors or reducing the sizes of tumors in subjects, or preventing postoperative tumor recurrence and/or metastases and/or prolonging tumor free survival in subjects by using a recombinant interferon (rSIFN-co) with changed spatial configuration, either alone, or in conjunction with radiotherapy, chemotherapy, and/or anti-tumor drugs such as biological agents, targeted drugs and the like.
    • BACKGROUND OF THE INVENTION
  • Cancer is one of the major causes of death in people around the world. The total number of cases worldwide continues to increase. According to the statistics of the world health organization (WHO), it is estimated that the global cancer deaths will be increased by 45% (from U.S. Pat. No. 7,900,000 to Ser. No. 11/500,000) from 2007 to 2030, and the new cases of cancer will zoom from Ser. No. 11/300,000 in 2007 to Ser. No. 15/500,000 in 2030 in the same period, wherein the incidence rate and the death rate of the lung cancer ranks first in the global malignant tumors. According to the statistical data, the amount of the worldwide new cases of lung cancer every year is more than 3,000,000 and increases continuously (see Gray, J. et al. Chest, 2007, 132, 56S-68S). The number of deaths caused by lung cancer is more than 1,300,000 around the world every year, which is more than the sum of the number of cancer-related deaths caused by other three common cancers (breast cancer, prostate cancer and colorectal cancer).
  • The classic methods for treating cancer include surgical therapy, radiotherapy and chemotherapy. However, the surgical therapy is not suitable for all types of solid tumors. The surgical therapy may not eliminate cancer cells thoroughly due to metastatic lesions and the like, so as not to achieve the purpose of cure. Radiotherapy is only suitable for the tumors situated at positions that are sensitive to rays, take muscles as tumor beds and have better blood circulation, and the radiotherapy may accidentally injure normal cells to cause various side effects, so as to affect the quality of life of the patients. The effect of the chemotherapy as the systemic treatment means is determined by the types and the states of cancers. Chemotherapy can suppress the growth and the spread of the cancers more especially, and same with the radiotherapy, the chemotherapy can also accidentally injure normal cells to affect the quality of life of the patients.
  • Surgical therapy can be performed to eliminate tumors, improve the quality of life and provide time for follow-up treatment for some early or medium-term solid tumor patients; but for some advanced patients with metastasized solid tumors, the treatment methods in the prior art are only chemotherapy, radiotherapy or combining the chemotherapy, radiotherapy and other treatment methods when the quality of life is obviously affected and life is even threatened, these treatment methods are not ideal in effects and cannot achieve the purpose of eliminating the tumors and completely alleviating the condition of the patients.
  • According to the mass data, the existing methods for treating cancer, in particular, chemotherapy, cannot obtain the satisfied treatment effect for advanced lung cancer patients, and the number of complete remission (CR) cases is few and is even zero. For example, in the clinical trial of 78 cases which employed cis-platinum for combining Navelbine, Gemzar and Taxotere, respectively, to treat advanced non-small cell lung cancers, no complete remission appeared in any case (see Song, Y. et al, Journal of Modern Oncology, 2005, 13(4), 494-496); however, in the clinical observation of 1155 cases which employed four chemotherapy protocols (Cisplatin+Paclitaxel, Cisplatin+Gemcitabine, Cisplatin+Docetaxel, and Carboplatin+Paclitaxel) for treating the advanced non-small cell lung cancers, complete response was observed, but the complete response (CR) rate was less than 1% (see Schiller, J. H. et al. N Engl J Med, 2002, 346(2), 92-98); and in a random, double-blind, control and multicenter III-stage clinical research which employed recombinant human endostatin for combining NP to treat the advanced non-small cell lung cancers, the 486 evaluable cases in the test group and the control group yielded no cases of complete remission (see Wang, J. W. et al, Chinese Journal of Lung Cancer, 2005, 8(4), 283-290).
  • In the recent 20 years, due to the in depth research on the cell biology, molecular biology, tumor immunology and the like and the development of the bio-engineering technology, the biotherapy has become the important treatment means for cancer treatment after surgical therapy, radiotherapy and chemotherapy has been performed.
  • Since Isaacs and Lindenmann discovered interferon (IFN), interferon has been widely researched. Interferon (IFN) is a kind of soluble protein produced by a variety of cells which has many important biological functions, including anti-viral, anti-tumor, and immunoregulatory functions. Interferons can be divided into type I, type II, and type III interferons according to the differences in the types of producing cells, receptors and biological activities, etc. Type I IFNs, which are mostly induced by viruses and synthetic double-stranded RNA, are also known as anti-viral interferons. There are three forms of type I interferons: interferon-alpha or alpha-interferon (IFNα), interferon-beta (INFβ) and interferon omega (IFNω).
  • In recent years, many companies in the world have engaged in the research of interferon. For example, U.S. Pat. Nos. 4,695,623 and 4,897,471 disclosed new types of human interferon polypeptides which possessed amino acid sequences containing the common or predominant amino acids found in naturally occurring α-interferon polypeptides. One new type of interferon was named IFN-con (consensus interferon α). Compared with leukocyte interferon or other type I interferons, studies have shown that recombinant IFN-con has higher anti-viral, anti-proliferative and natural killer cell activities in vitro. By the end of 1997, the FDA had approved the use of human IFN-con, which was produced by US Amgen and sold under the brand name INFERGEN® (interferon alfacon-1), for clinical treatment of hepatitis C.
  • It is generally known that the amino acid sequence of a protein can determine the three-dimensional structure of the protein and further determine the functionality thereof. However, in recent years, evidence shows that synonymous mutation(s) of the nucleotide sequence encoding the protein (that is, codon mutation(s) with no change in the amino acid sequence of the encoded protein) can affect the spatial structure and the function of the encoded protein, namely, the nucleotide sequence with synonymous mutation(s) can express and generate proteins with different final spatial structure and different function compared with the wild type protein (see Sarfaty, C. K. et al. Science, 2007, 315:525-528).
  • A recombinant interferon (rSIFN-co) which has enhanced therapeutic effects, smaller side effects and can be used in a larger doses was disclosed in U.S. Pat. No. 7,364,724, U.S. Pat. No. 7,585,647, U.S. Pat. No. 8,114,395, CN 1740197 A, CN 101001644 A, US 2009/0123417, US 2011/0158941 and WO 2011072487A1. This recombinant interferon, rSIFN-co, has the same amino acid sequence as that of INFERGEN®, but the encoding nucleotide sequences of this recombinant interferon, rSIFN-co, and that of INFERGEN® are different (i.e. synonymous mutations exists in the nucleotide sequence encoding the recombinant interferon, rSIFN-co), resulting in changes in spatial configuration of the recombinant interferon, rSIFN-co, and qualitative changes in its biological efficacy.
    • SUMMARY OF THE INVENTION
  • One of the objects of the present invention is to provide new methods for treating tumors in subjects by using the recombinant interferon, rSIFN-co encoded by the nucleotide sequence of SEQ ID NO: 2. Another one of the objects of the present invention is to provide new methods for treating lung cancers in subjects by using the recombinant interferon encoded by the nucleotide sequence of SEQ ID NO: 2 (hereafter also be referred to as recombinant super-compound interferon or rSIFN-co).
  • The present invention is illustrated by the various embodiments described below. However, the present invention is not limited by these illustrative embodiments and should be interpreted to include those embodiments taught by the description herein and as understood by persons skilled in the art. Illustrative examples of the various embodiments of the present invention include:
  • In one aspect, the present invention provides:
  • (1) A method for treating a tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • (2) The method of (1), wherein the tumor in the subject comprises a metastasized tumor.
  • (3) The method of (1) or (2), wherein the subject is an early, medium-term, or advanced cancer patient, optionally, the subject is a medium-term, or advanced cancer patient, further optionally, the subject is an advanced cancer patient.
  • (4) The method of (1) or (2), wherein the subject is a stage 0, I, II, III, or IV cancer patient, optionally, the subject is a stage III or stage IV cancer patient.
  • (5) The method of any one of (1)-(4), wherein the tumor is a cancer or a solid tumor that is indicated or appropriate for surgery.
  • (6) The method of any one of (1)-(4), wherein the tumor is a cancer or a solid tumor that is not indicated nor appropriate for surgery.
  • (7) The method of any one of (1)-(5), wherein the tumor is a tumor that is capable of being resected.
  • (8) The method of any one of (1)-(4) and (6), wherein the tumor is a tumor that is not capable of being resected.
  • (9) The method of (7) or (8), wherein the tumor is resected by a surgical resection.
  • (10) The method of any one of (1)-(9), wherein the tumor is a solid tumor.
  • (11) The method of (10), wherein the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • (12) The method of (11), wherein the solid tumor comprises lung cancer, optionally, the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • (13) The method of any one of (1)-(4), wherein the tumor is a non-solid tumor.
  • (14) The method of (13), wherein the non-solid tumor comprises one or more of: leukemia, acute leukemia, chronic leukemia, chronic myelocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T-cell leukemia, hairy cell leukemia, polycythemia, myelodysplastic syndrome, multiple myeloma, lymphadenoma, Hodgkin's lymphoma, and Non-Hodgkin's lymphoma.
  • (15) The method of any one of (1)-(14), wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, local administration, and topical administration.
  • (16) The method of any one of (1)-(15), wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises one or more of: oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, and intravesical administration.
  • (17) The method of any one of (1)-(16), wherein an effective amount of recombinant interferon encoded by the nucleotide sequence of SEQ ID NO: 2 is administered to the subject, optionally, the effective amount is a therapeutically effective amount.
  • (18) The method of any one of (1)-(17), wherein the recombinant interferon is administered to the subject in a single dose in a range of about 2 μg to about 2000 μg, optionally, the recombinant interferon is administered to the subject in a single dose in a range of about 4 μg to about 1500 μg, further optionally, the recombinant interferon is administered to the subject in a single dose in a range of about 9 μg to about 1000 μg.
  • (19) The method of any one of (1)-(18), wherein the recombinant interferon is administered in one or more treatment cycles, optionally, the more treatment cycles comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 treatment cycles, further optionally, the number of treatment cycles comprises more than 10 treatment cycles.
  • (20) The method of (19), wherein the duration of the treatment cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or optionally, the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration of recombinant interferon treatment can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (21) The method of (19) or (20), wherein the time interval between any two adjacent treatment cycles of the more treatment cycles is at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like; or optionally the time interval can be about 2 days to about 6 years, about 4 days to about 3 years, about 1 week to about 1 year, about 2 months to about 9 months, or about 3 months to about 6 months and the like.
  • (22) The method of any one of (1)-(21), wherein the recombinant interferon is administered to the subject as monotherapy.
  • (23) The method of any one of (1)-(21), further comprising at least one other anti-cancer therapy administered to the subject, optionally, the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • (24) The method of (23), wherein the at least one other anti-cancer therapy comprises at least one of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • (25) The method of (24), wherein the at least one other anti-cancer therapy comprises at least one of: chemotherapy, radiotherapy, surgical therapy, targeted therapy, and biotherapy.
  • (26) The method of (25), wherein the at least one other anti-cancer therapy comprises at least one of: chemotherapy and radiotherapy.
  • (27) The method of any one of (24)-(26), wherein the chemotherapy is administered as first-line chemotherapy, optionally, one or more chemotherapeutic drugs used in the first-line chemotherapy comprise platinum compounds, such as Cisplatin.
  • (28) The method of any one of (24)-(27), wherein the targeted therapy comprises at least one of: Gefitinib, Erlotinib, and recombinant human endostatin.
  • (29) The method of any one of (1)-(28), wherein the therapies eliminate the tumor or reduce the size of the tumor as compared to the tumor before treatment.
  • (30) The method of (29), wherein the reduced size of the tumor converts the tumor to a resectable tumor.
  • (31) The method of (30), wherein the tumor is indicated for a surgical resection.
  • (32) The method of any one of (1)-(28), wherein the tumor, such as cancer or solid tumor, that is not earlier indicated nor appropriate for surgery becomes one that is indicated or appropriate for surgery.
  • (33) The method of (32), further comprising surgery to resect the tumor.
  • (34) The method of any one of (30)-(31) and (33), further comprising administering to the subject the recombinant interferon after resecting the tumor, to prevent tumor recurrence and/or metastasis, or to prolong or maintain a tumor-free status, optionally, a prophylactically effective amount of the recombinant interferon is administered to the subject to prevent tumor recurrence and/or metastasis, and/or to prolong or maintain a tumor-free status.
  • (35) A method for treating tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, and at least one other anti-cancer therapy, wherein the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon, and wherein the tumor is a cancer or solid tumor that is not indicated nor appropriate for surgery, or the tumor is a solid tumor that cannot be resected, and the combination of the recombinant interferon and the at least one other anti-cancer therapy eliminate the tumor or reduce the size of the tumor compared to the tumor before treatment.
  • (36) The method of embodiment 35, wherein the subject is a medium-term, advanced cancer patient, or stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • (37) The method of any one of (1)-(29) and (35)-(36), wherein the therapies are the non-surgical therapies.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for preventing tumor recurrence and/or metastasis or prolonging or maintaining a tumor-free status in a subject with a tumor after at least one anti-cancer therapy, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • (2) The method of (1), wherein the tumor in the subject comprises a metastasized tumor.
  • (3) The method of (1) or (2), wherein the subject is an early, medium-term, or advanced cancer patient.
  • (4) The method of (1) or (2), wherein the subject is a stage 0, I, II, III, or IV cancer patient.
  • (5) The method of any one of (1)-(4), wherein the tumor is a cancer or solid tumor that is indicated or appropriate for surgery.
  • (6) The method of any one of (1)-(4), wherein the tumor is a cancer or solid tumor that is not indicated nor appropriate for surgery.
  • (7) The method of any one of (1)-(4), wherein the tumor is a tumor that is capable of being resected.
  • (8) The method of any one of (1)-(4), wherein the tumor is a tumor that is not capable of being resected.
  • (9) The method of (7) or (8), wherein the tumor is resected by a surgical resection.
  • (10) The method of any one of (1)-(9), wherein the tumor is a solid tumor.
  • (11) The method of (10), wherein the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • (12) The method of (11), wherein the solid tumor comprises lung cancer, optionally, the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • (13) The method of any one of (1)-(4), wherein the tumor comprises a non-solid tumor.
  • (14) The method of (13), wherein the non-solid tumor comprises one or more of: leukemia, acute leukemia, chronic leukemia, chronic myelocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T-cell leukemia, hairy cell leukemia, polycythemia, myelodysplastic syndrome, multiple myeloma, lymphadenoma, Hodgkin's lymphoma, and Non-Hodgkin's lymphoma.
  • (15) The method of any one of (1)-(14), wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, local administration, and topical administration.
  • (16) The method of any one of (1)-(15), wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises one or more of: oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, and intravesical administration.
  • (17) The method of any one of (1)-(16), wherein an effective amount of recombinant interferon encoded by the nucleotide sequence of SEQ ID NO: 2 is administered to the subject, optionally, the effective amount is a prophylactically effective amount.
  • (18) The method of any one of (1)-(17), wherein the recombinant interferon is administered to the subject in a single dose in the range of about 2 μg to about 2000 μg, optionally, the recombinant interferon is administered to the subject in a single dose in the range of about 4 μg to about 1500 μg, more optionally, the recombinant interferon is administered to the subject in a single dose in the range of about 9 μg to about 1000 μg.
  • (19) The method of any one of (1)-(18), wherein the recombinant interferon is administered in one or more prevention cycles, optionally, the more prevention cycles comprises 2, 3, 4, 5, 6, 7, 8, 9, or 10 prevention cycles, or optionally, more than 10 prevention cycles.
  • (20) The method of (19), wherein the duration of each prevention cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (21) The method of (19) or (20), wherein the time interval between any two adjacent prevention cycles of the more prevention cycles is at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like; or the time interval can also be about 2 days to about 6 years, about 4 days to about 3 years, about 1 week to about 1 year, about 2 months to about 9 months, or about 3 months to about 6 months and the like.
  • (22) The method of any one of (1)-(21), wherein the at least one anti-cancer therapy comprises at least one of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy, optionally, the at least one anti-cancer therapy comprises at least one of: chemotherapy, radiotherapy, surgical therapy, and biotherapy.
  • (23) The method of (22), wherein the at least one anti-cancer therapy comprises surgical therapy.
  • (24) The method of (23), wherein the recombinant interferon is administered to the operative site of the surgical therapy.
  • (25) The method of (24), wherein the recombinant interferon is administered to the operative site by topical or local administration.
  • (26) The method of (24) or (25), wherein the recombinant interferon is administered to the operative site by an administration route, the administration route comprises one or more of: infiltration administration, intrapleural administration, abdominal administration, pericardial administration, uterine administration, intravesical administration, intratumoral administration, pulmonary administration, nasal administration, percutaneous administration, transdermal administration, epidermal administration, and transmucosal administration.
  • (27) The method of (26), wherein the intrapleural administration, abdominal administration, pericardial administration, uterine administration, or intravesical administration comprises intrapleural perfusion administration, abdominal perfusion administration, pericardial perfusion administration, uterine perfusion administration, or intravesical perfusion administration, respectively.
  • (28) The method of (26), wherein the intratumoral administration comprises intratumoral injection.
  • (29) The method of (26), wherein the pulmonary administration or nasal administration comprises pulmonary inhalation administration or nasal inhalation administration, respectively.
  • (30) The method of (26), wherein the percutaneous administration, transdermal administration, epidermal administration, or transmucosal administration comprises percutaneous spray administration, transdermal spray administration, epidermal spray administration, or transmucosal spray administration, respectively.
  • (31) The method of any one of (25)-(30), wherein the recombinant interferon is further administered to the subject by systemic administration before, simultaneously, and/or after the topical or local administration of the recombinant interferon.
  • (32) The method of (31), wherein the systemic administration comprises at least one of: subcutaneous and intramuscular administration, optionally, the protocols in (24)-(32) also apply to the above-specified method for treatment of tumor in a subject.
  • (33) The method of any one of (1)-(32), wherein the recombinant interferon is administered to the subject as monotherapy.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A non-surgical method for eliminating a tumor in a subject or reducing the size of a tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • (2) The method of (1), wherein the tumor is a cancer or a solid tumor that is indicated or appropriate for surgery.
  • (3) The method of (1), wherein the tumor is a cancer or a solid tumor that is not indicated nor appropriate for surgery.
  • (4) The method of (1), wherein the tumor is a tumor that is capable of being resected.
  • (5) The method of (1), wherein the tumor is a tumor that is not capable of being resected.
  • (6) The method of (4) or (5), wherein the tumor is resected by a surgical resection.
  • (7) The method of any one of (1)-(6), wherein the subject is an early, medium-term, or advanced cancer patient, optionally, the subject is a medium-term, or advanced cancer patient, or further optionally, the subject is an advanced cancer patient.
  • (8) The method of any one of (1)-(6), wherein the subject is a stage 0, I, II, III, or IV cancer patient, optionally, the subject is a stage III or IV cancer patient.
  • (9) The method of any one of (1)-(8), wherein the subject is a medium-term, or advanced cancer patient, or a stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • (10) The method of any one of (1)-(9), wherein the tumor is a solid tumor.
  • (11) The method of (10), wherein the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • (12) The method of (11), wherein the solid tumor comprises lung cancer, optionally, the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • (13) The method of any one of (1)-(12), wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, local administration, and topical administration, optionally, the recombinant interferon is administered to the subject by topical or local administration, further optionally, the recombinant interferon is administered to the subject by local administration.
  • (14) The method of any one of (1)-(13), wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises one or more of: infiltration administration, intrapleural administration, abdominal administration, pericardial administration, uterine administration, intravesical administration, intratumoral administration, pulmonary administration, nasal administration, percutaneous administration, transdermal administration, epidermal administration, and transmucosal administration.
  • (15) The method of (14), wherein the intratumoral administration comprises intratumoral injection.
  • (16) The method of (15), wherein the recombinant interferon is administered in an amount in a range of: about 60 μg to about 600 μg, optionally about 60 μg to about 500 μg, further optionally, about 80 μg to about 400 μg, still optionally about 100 μg to about 250 μg, by one intratumoral injection.
  • (17) The method of (15) or (16), wherein the recombinant interferon is administered by intratumoral injection once every about 1 day to about 10 days, optionally, every about 1 day to about 7 days, such as every about 1, 2, 3, 4, 5, 6, or 7 days.
  • (18) The method of any one of (14)-(17), wherein the protocol of intratumoral administration is as follows: the recombinant interferon is administered by intratumoral injection once every about 1 day for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 3 days to about 5 days for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 7 days, the intratumoral administration is stopped when the tumor disappears or becomes too small to conduct the intratumoral injection.
  • (19) The method of (14), wherein the intrapleural administration, abdominal administration, pericardial administration, uterine administration, or intravesical administration comprises intrapleural perfusion administration, abdominal perfusion administration, pericardial perfusion administration, uterine perfusion administration, or intravesical perfusion administration, respectively.
  • (20) The method of (14), wherein the pulmonary administration, or nasal administration comprises pulmonary inhalation administration, or nasal inhalation administration, respectively.
  • (21) The method of (14), wherein the percutaneous administration, transdermal administration, epidermal administration, or transmucosal administration comprises percutaneous spray administration, transdermal spray administration, epidermal spray administration, or transmucosal spray administration, respectively.
  • (22) The method of any one of (13)-(21), wherein the recombinant interferon is further administered to the subject by systemic administration, and/or at least one other therapeutic drug is administered to the subject by topical, local and/or systemic administration before, simultaneously, and/or after the topical or local administration of the recombinant interferon.
  • (23) The method of (22), wherein the recombinant interferon is further administered to the subject by systemic administration, and/or at least one other therapeutic drug is administered to the subject by topical, local and/or systemic administration simultaneously and/or after the topical or local administration of the recombinant interferon.
  • (24) The method of (22) or (23), wherein the at least one other therapeutic drug comprises at least one antitumor drug.
  • (25) The method of (24), wherein the at least one antitumor drug comprises one or more chemotherapeutic drugs, targeted drugs, and/or biological drugs.
  • (26) The method of (25), wherein the one or more chemotherapeutic drugs comprise platinum compounds, such as Cisplatin.
  • (27) The method of (25), wherein one or more targeted drugs comprise Gefitinib, Erlotinib, and/or recombinant human endostatin.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for eliminating or reducing the pleural effusion, ascites, and/or pericardial effusion in a subject with tumor, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • (2) The method of (1), wherein the tumor is a cancer or a solid tumor that is indicated or is appropriate for surgery.
  • (3) The method of (1), wherein the tumor is a cancer or a solid tumor that is not indicated nor appropriate for surgery.
  • (4) The method of (1), wherein the tumor is a tumor that is capable of being resected.
  • (5) The method of (1), wherein the tumor is a tumor that is not capable of being resected.
  • (6) The method of (4) or (5), wherein the tumor is resected by a surgical resection.
  • (7) The method of any one of (1)-(6), wherein the subject is an early, medium-term, or advanced cancer patient, optionally, the subject is a medium-term, or advanced cancer patient, or further optionally, the subject is an advanced cancer patient.
  • (8) The method of any one of (1)-(6), wherein the subject is a stage 0, I, II, III, or IV cancer patient, optionally, the subject is a stage III or stage IV cancer patient.
  • (9) The method of any one of (1)-(8), wherein the subject is a medium-term, or advanced cancer patient, or stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • (10) The method of any one of (1)-(9), wherein the tumor is a solid tumor.
  • (11) The method of (10), wherein the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • (12) The method of (11), wherein the solid tumor comprises lung cancer, optionally, the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • (13) The method of any one of (1)-(12), wherein the pleural effusion is a malignant pleural effusion, the ascites is a malignant ascites, and/or the pericardial effusion is a malignant pericardial effusion.
  • (14) The method of any one of (1)-(13), wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, local administration, and topical administration, optionally, by topical and local administration, further optionally, by local administration.
  • (15) The method of any one of (1)-(14), wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises one or more of: infiltration administration, intrapleural administration, abdominal administration, and pericardial administration.
  • (16) The method of any one of (1)-(15), wherein the administration is conducted by perfusion.
  • (17) The method of any one of (14)-(16), wherein the recombinant interferon is administered in an amount in a range of about 30 μg to about 2000 μg, optionally, about 100 μg to about 1500 μg, further optionally, about 150 μg to about 1000 μg, still further optionally, about 200 μg to about 800 μg, still optionally, about 200 μg to about 400 μg by one topical or local administration.
  • (18) The method of any one of (14)-(17), wherein the recombinant interferon is administered by topical or local administration once every about 1 to about 10 days, optionally every about 1 to about 7 days, such as every about 1, 2, 3, 4, 5, 6, or 7 days.
  • (19) The method of any one of (14)-(18), wherein the recombinant interferon is further administered to the subject by systemic administration, and at least one other therapeutic drug is administered to the subject by topical, local and/or systemic administration before, simultaneously, and/or after the topical or local administration of the recombinant interferon.
  • (20) The method of (19), wherein the recombinant interferon is further administered to the subject by systemic administration, and at least one other therapeutic drug is administered to the subject by topical, local and/or systemic administration simultaneously and/or after the topical or local administration of the recombinant interferon.
  • (21) The method of (19) or (20), wherein the at least one other therapeutic drug comprises an antitumor drug.
  • (22) The method of (21), wherein the antitumor drug comprises at least one of: chemotherapeutic drug, targeted drug, and biological drug.
  • (23) The method of (22), wherein the at least one chemotherapeutic drug comprises at least one platinum compounds, such as Cisplatin.
  • (24) The method of (22), wherein at least one targeted drug comprises at least one of: Gefitinib, Erlotinib, and recombinant human endostatin.
  • (25) The method of any one of (1)-(24), wherein the therapies eliminate the tumor or reduce the size of the tumor compared to the tumor before treatment.
  • (26) The method of any one of (1)-(25), wherein the therapies are the non-surgical therapies.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for treating tumor in a subject, comprising topically or locally administering to the tumor lesions of the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • (2) The method of (1), wherein the tumor lesions comprise metastatic tumor lesions.
  • (3) A method for eliminating or reducing metastatic tumor lesions in a subject, comprising topically or locally administering to the metastatic tumor lesions of the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • (4) The method of any one of (1)-(3), wherein the tumor lesions comprise at least one of: bone lesions, muscular lesions, subcutaneous tissue lesions, prostatic lesions and lymph node lesions, and the tumor metastatic lesions comprise at least one of: bone metastatic lesions, muscular metastatic lesions, subcutaneous tissue metastatic lesions, prostatic metastatic lesions, and lymph node metastatic lesions, optionally, the tumor metastatic lesions comprise bone metastatic lesions.
  • (5) The method of any one of (1)-(4), wherein the subject is a medium-term, advanced, or stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • (6) The method of any one of (1)-(4), wherein the tumor or the metastatic tumor lesions comprise a cancer or a solid tumor that is not indicated nor appropriate for surgery.
  • (7) The method of any one of (1)-(6), wherein the topical or local administration comprises at least one of: infiltration administration, percutaneous administration, transdermal administration, epidermal administration and transmucosal administration, optionally, the topical and local administration comprises transdermal administration, or infiltration administration.
  • (8) The method of (7), wherein the infiltration administration comprises one or more of: percutaneous infiltration administration, epidermal infiltration administration, transdermal infiltration administration, and transmucosal infiltration administration.
  • (9) The method of (7), wherein the percutaneous administration, transdermal administration, epidermal administration, or transmucosal administration comprises percutaneous spray administration, transdermal spray administration, epidermal spray administration, or transmucosal spray administration, respectively.
  • (10) The method of any one of (1)-(9), wherein the recombinant interferon is administered in an amount in a range of about 2 μg to about 2000 μg, optionally about 4 μg to about 1500 μg, further optionally about 9 μg to about 1000 μg by one topical or local administration.
  • (11) The method of any one of (1)-(10), wherein the recombinant interferon is administered to the subject by topical or local administration about 1, 2, 3, 4, 5, 6, 7, 8, or more times per day, or the recombinant interferon is administered to the subject by topical or local administration once at the time interval of every about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days, every month, every 2 months, or a longer time.
  • (12) The method of any one of (7)-(11), wherein the recombinant interferon is administered in an amount in a range of about 6 μg to about 100 μg, optionally about 10 μg to about 40 μg, further optionally about 20 μg to about 40 μg by one spray administration when the topical or local administration is conducted by spray administration.
  • (13) The method of (12), wherein the recombinant interferon is administered by spray administration about 1 to about 6 times, such as about 1, 2, 3, 4, 5, or 6 times, per day.
  • (14) The method of any one of (1)-(13), wherein the recombinant interferon and/or one or more other therapeutic drugs are administered to the subject by systemic administration before, simultaneously, and/or after the topical or local administration of the recombinant interferon.
  • (15) The method of (14), wherein the systemic administration comprises subcutaneous and/or intramuscular administration.
  • (16) The method of (15), wherein the subcutaneous administration comprises subcutaneous injection.
  • (17) The method of (15), wherein the intramuscular administration comprises intramuscular injection.
  • (18) The method of any one of (15)-(17), wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in the range of about 2 μg to about 10 μg each time, optionally, about 4 μg to about 10 μg each time, more optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 μg to about 70 μg each time, optionally about 12 μg to about 50 μg each time, more optionally about 12 μg to about 30 μg each time.
  • (19) The method of (18), wherein the time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • (20) The method of (18) or (19), wherein the recombinant interferon is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days when the recombinant interferon is administered more times at an induction dose.
  • (21) The method of any one of (18)-(20), wherein the recombinant interferon is administered at a therapeutic dose once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
  • (22) The method of any one of (18)-(21), wherein the duration of administration of induction dose and therapeutic dose is at least: about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • (23) The method of any one of (1)-(22), wherein the recombinant interferon is administered to the subject as monotherapy.
  • (24) The method of any one of (1)-(22), further comprising at least one other anti-cancer therapy administered to the subject, optionally, the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • (25) The method of (24), wherein the at least one other anti-cancer therapy comprises one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • (26) The method of any one of (1)-(25), wherein the recombinant interferon therapy and/or at least one other anti-cancer therapy eliminate the tumor or tumor metastatic lesions or reduce the size of the tumor or tumor metastatic lesions compared to the tumor or tumor metastatic lesions before treatment.
  • (27) A method for eliminating or reducing the bone metastatic lesions of tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by topical or local administration, wherein the topical or local administration comprises transdermal administration and/or infiltration administration, optionally, the recombinant interferon is administered to the bone metastatic lesions of tumor of the subject.
  • (28) A method for eliminating or reducing the bone lesions of tumor such as bone metastatic lesions of tumor, muscular lesions of tumor such as muscular metastatic lesions of tumor, subcutaneous tissue lesions of tumor such as subcutaneous tissue metastatic lesions of tumor, prostatic lesions of tumor such as prostatic metastatic lesions of tumor, and/or lymph node lesions of tumor such as lymph node metastatic lesions of tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by any administration route through the skin, so that eliminating or reducing the bone lesions of tumor such as bone metastatic lesions of tumor, muscular lesions of tumor such as muscular metastatic lesions of tumor, subcutaneous tissue lesions of tumor such as subcutaneous tissue metastatic lesions of tumor, prostatic lesions of tumor such as prostatic metastatic lesions of tumor, and/or lymph node lesions of tumor such as lymph node metastatic lesions of tumor, optionally, the recombinant interferon is administered to the metastatic lesions of tumor of the subject.
  • (29) The method of any one of (1)-(28), wherein the therapies are non-surgical therapies.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • (2) The method of (1), wherein the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • (3) The method of (1) or (2), wherein the lung cancer in the subject comprises a metastasized tumor.
  • (4) The method of any one of (1)-(3), wherein the subject is an early, medium-term, or advanced cancer patient, optionally, the subject is a medium-term, or advanced cancer patient, further optionally, the subject is an advanced cancer patient.
  • (5) The method of any one of (1)-(3), wherein the subject is a stage 0, I, II, III, or IV cancer patient, optionally, the subject is an stage III or stage IV cancer patient.
  • (6) The method of any one of (1)-(5), wherein the lung cancer comprises a lung cancer that is indicated or appropriate for surgery.
  • (7) The method of any one of (1)-(5), wherein the lung cancer comprises a lung cancer that is not indicated nor appropriate for surgery.
  • (8) The method of any one of (1)-(5), wherein the lung cancer comprises a lung cancer that is capable of being resected.
  • (9) The method of any one of (1)-(5), wherein the lung cancer comprises a lung cancer that is not capable of being resected.
  • (10) The method of (8) or (9), wherein the lung cancer is resected by a surgical resection.
  • (11) The method of any one of (1)-(10), wherein an effective amount of recombinant interferon encoded by the nucleotide sequence of SEQ ID NO: 2 is administered to the subject, optionally, the effective amount is a therapeutically effective amount.
  • (12) The method of any one of (1)-(11), wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, topical administration, and local administration.
  • (13) The method of any one of (1)-(12), wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises one or more of: oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, and intravesical administration.
  • (14) The method of any one of (1)-(13), wherein the recombinant interferon is administered to the subject by subcutaneous administration and/or intramuscular administration.
  • (15) The method of (14), wherein the subcutaneous administration comprises subcutaneous injection.
  • (16) The method of (14), wherein the intramuscular administration comprises intramuscular injection.
  • (17) The method of any one of (14)-(16), wherein the recombinant interferon is administered in an amount in a range of about 2 μg to about 70 μg by one subcutaneous and/or intramuscular administration.
  • (18) The method of (17), wherein the recombinant interferon is administered in an amount in a range of about 4 μg to about 50 μg by one subcutaneous and/or intramuscular administration.
  • (19) The method of (18), wherein the recombinant interferon is administered in an amount in a range of about 4 μg to about 30 μg by one subcutaneous and/or intramuscular administration.
  • (20) The method of any one of (14)-(19), wherein the recombinant interferon is administered by subcutaneous and/or intramuscular administration once every about 1 to about 7 days.
  • (21) The method of (20), wherein the recombinant interferon is administered by subcutaneous and/or intramuscular administration once every about 1 to about 2 days.
  • (22) The method of any one of (1)-(21), wherein the recombinant interferon is administered to the subject by inhalation administration.
  • (23) The method of (22), wherein the recombinant interferon is administered by pulmonary and/or nasal inhalation.
  • (24) The method of (22) or (23), wherein the inhalation administration comprises dry powder inhalation and/or aerosol inhalation.
  • (25) The method of any one of (22)-(24), wherein the recombinant interferon is administered in an amount in a range of about 100 μg to about 2000 μg, optionally about 100 μg to about 1500 μg by one inhalation administration.
  • (26) The method of (25), wherein the recombinant interferon is administered in an amount in a range of about 150 μg to about 800 μg by one inhalation administration.
  • (27) The method of (26), wherein the recombinant interferon is administered in an amount in a range of about 200 μg to about 600 μg by one inhalation administration.
  • (28) The method of any one of (22)-(27), wherein the recombinant interferon is administered by inhalation administration once every about 1 to about 3 days.
  • (29) The method of (28), wherein the recombinant interferon is administered by inhalation administration once every about 1 day.
  • (30) The method of any one of (1)-(29), wherein the subject has the pleural effusion, ascites, and/or pericardial effusion.
  • (31) The method of (30), wherein the pleural effusion comprises a malignant pleural effusion, the ascites comprises a malignant ascites, and/or the pericardial effusion comprises a malignant pericardial effusion.
  • (32) The method of (30) or (31), wherein the recombinant interferon is administered to the subject by intrapleural administration, abdominal administration, and/or pericardial administration.
  • (33) The method of (32), wherein the intrapleural administration comprises intrapleural perfusion.
  • (34) The method of (32), wherein the abdominal administration comprises abdominal perfusion.
  • (35) The method of (32), wherein the pericardial administration comprises pericardial perfusion.
  • (36) The method of any one of (32)-(35), wherein the recombinant interferon is administered in an amount in a range of about 30 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 1000 μg, still optionally about 200 μg to about 800 μg by one intrapleural, abdominal, and/or pericardial administration.
  • (37) The method of (36), wherein the recombinant interferon is administered in an amount in a range of about 200 μg to about 400 μg by one intrapleural, abdominal, and/or pericardial administration.
  • (38) The method of any one of (32)-(37), wherein the recombinant interferon is administered by intrapleural, abdominal, and/or pericardial administration once every about 1 to about 10 days, optionally every about 1 to about 7 days, such as every about 1, 2, 3, 4, 5, 6, or 7 days.
  • (39) The method of any one of (1)-(13), wherein the recombinant interferon is administered to the subject by intratumoral administration.
  • (40) The method of (39), wherein the intratumoral administration comprises intratumoral injection.
  • (41) The method of (39) or (40), wherein the recombinant interferon is administered in an amount in a range of about 60 μg to about 600 μg, optionally about 60 μg to about 500 μg by one intratumoral administration.
  • (42) The method of (41), wherein the recombinant interferon is administered in an amount in a range of about 80 μg to about 400 μg by one intratumoral administration.
  • (43) The method of (42), wherein the recombinant interferon is administered in an amount in a range of about 100 μg to about 250 μg by one intratumoral administration.
  • (44) The method of any one of (39)-(43), wherein the recombinant interferon is administered by intratumoral administration once every about 1 day to about 10 days, optionally every about 1 day to about 7 days such as every about 1, 2, 3, 4, 5, 6, or 7 days.
  • (45) The method of any one of (39)-(44), wherein the protocol of intratumoral administration is as follow: the recombinant interferon is administered by intratumoral injection once every about 1 day for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 3 days to about 5 days for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 7 days, the intratumoral administration is stopped when the tumor disappears or becomes too small to conduct the intratumoral injection.
  • (46) The method of any one of (1)-(45), wherein the lung cancer in the subject comprises tumor metastasis in at least one of: skin, mucosa, superficial lymph nodes, and subcutaneous tissue.
  • (47) The method of (46), wherein the recombinant interferon is administered to the subject by spray administration.
  • (48) The method of (47), wherein the spray administration comprises at least one of: percutaneous spray administration, transdermal spray administration, epidermal spray administration, and transmucosal spray administration.
  • (49) The method of (47) or (48), wherein the recombinant interferon is administered in an amount in a range of about 6 μg to about 100 μg by one spray administration.
  • (50) The method of (49), wherein the recombinant interferon is administered in an amount in a range of about 10 μg to about 40 μg, optionally about 20 μg to about 40 μg by one spray administration.
  • (51) The method of any one of (47)-(50), wherein the recombinant interferon is administered by spray administration about 1 to about 6 times such as about 1, 2, 3, 4, 5, or 6 times per day.
  • (52) The method of any one of (1)-(51), wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises at least one of: subcutaneous administration, intramuscular administration, inhalation administration, infiltration administration, intrapleural administration, abdominal administration, pericardial administration, intratumoral administration, and spray administration.
  • (53) The method of any one of (1)-(52), wherein the recombinant interferon is administered to the subject as monotherapy.
  • (54) The method of any one of (1)-(52), further comprising at least one other anti-cancer therapy administered to the subject, optionally, the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • (55) The method of (54), wherein the at least one other anti-cancer therapy comprises at least one of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • (56) The method of (55), wherein the at least one other anti-cancer therapy comprises chemotherapy.
  • (57) The method of (56), wherein the chemotherapy is the first-line chemotherapy.
  • (58) The method of (57), wherein at least one chemotherapeutic drugs used for the first-line chemotherapy comprise platinum compounds, such as Cisplatin.
  • (59) The method of (55), wherein the at least one other anti-cancer therapy comprises radiotherapy.
  • (60) The method of (59), wherein the radiotherapy comprises head gamma knife therapy when the lung cancer metastasizes to brain.
  • (61) The method of (55), wherein the at least one other anti-cancer therapy comprises surgical therapy.
  • (62) The method of (55), wherein the at least one other anti-cancer therapy comprises targeted therapy.
  • (63) The method of (62), wherein the targeted therapy comprises administering Gefitinib, Erlotinib, and/or recombinant human endostatin.
  • (64) The method of (55), wherein the at least one other anti-cancer therapy comprises biotherapy.
  • (65) The method of any one of (1)-(64), wherein the recombinant interferon is administered in at least one treatment cycle, optionally, the at least one treatment cycle comprises 2, 3, 4, 5, 6, 7, 8, 9, or 10 treatment cycles, or optionally, more than 10 treatment cycles.
  • (66) The method of (65), wherein the duration of the treatment cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (67) The method of (65) or (66), wherein the time interval between any two adjacent treatment cycles of the more treatment cycles is at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like; or the time interval can also be about 2 days to about 6 years, about 4 days to about 3 years, about 1 week to about 1 year, about 2 months to about 9 months, or about 3 months to about 6 months and the like.
  • (68) The method of any one of (1)-(67), wherein the therapies eliminate the tumor of the lung or reduce the size of the tumor of the lung compared to the tumor size before treatment.
  • (69) A method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 and one or more chemotherapeutic drugs in two or more treatment cycles, and then administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 and one or more targeted drugs in one or more treatment cycles.
  • (70) The method of (69), wherein the therapies eliminate the tumor of the lung or reduce the size of the tumor of the lung compared to the tumor size before treatment.
  • (71) The method of (69) or (70), wherein the one or more chemotherapeutic drugs comprise platinum compounds, such as Cisplatin.
  • (72) The method of any one of (69)-(71), wherein the one or more targeted drugs comprise Gefitinib, Erlotinib, and/or recombinant human endostatin.
  • (73) The method of any one of (69)-(72), wherein an effective amount of recombinant interferon, encoded by the nucleotide sequence of SEQ ID NO: 2, is administered to the subject, optionally, the effective amount is a therapeutically effective amount.
  • (74) The method of any one of (1)-(73), wherein the therapies are the non-surgical therapies.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by subcutaneous administration and/or intramuscular administration, wherein the recombinant interferon is administered in an amount in a range of about 2 μg to about 70 μg, optionally about 4 μg to about 50 μg, further optionally about 4 μg to about 30 μg by one subcutaneous administration and/or intramuscular administration, the recombinant interferon is administered by subcutaneous administration and/or intramuscular administration once every about 1 to about 7 days, optionally every about 1 to about 2 days, lasting at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (2) The method of (1), wherein the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • (3) The method of (1) or (2), wherein the lung cancer in the subject comprises a metastasized tumor.
  • (4) The method of any one of (1)-(3), wherein the subject is an early, medium-term, or advanced cancer patient, optionally, the subject is a medium-term, or advanced cancer patient, further optionally, the subject is an advanced cancer patient.
  • (5) The method of any one of (1)-(3), wherein the subject is a stage 0, I, II, III, or IV cancer patient, optionally, the subject is a stage III or IV cancer patient.
  • (6) The method of any one of (1)-(5), wherein the lung cancer is a lung cancer that is indicated or appropriate for surgery.
  • (7) The method of any one of (1)-(5), wherein the lung cancer is a lung cancer that is not indicated nor appropriate for surgery.
  • (8) The method of any one of (1)-(5), wherein the lung cancer is a lung cancer that is capable of being resected.
  • (9) The method of any one of (1)-(5), wherein the lung cancer is a lung cancer that is not capable of being resected.
  • (10) The method of (8) or (9), wherein the lung cancer is resected by a surgical resection.
  • (11) The method of any one of (1)-(10), wherein the subcutaneous administration comprises subcutaneous injection.
  • (12) The method of any one of (1)-(10), wherein the intramuscular administration comprises intramuscular injection.
  • (13) The method of any one of (1)-(12), further comprising administering to the subject the recombinant interferon by inhalation administration.
  • (14) The method of (13), wherein the inhalation administration is conducted before, simultaneously, and/or after the subcutaneous administration and/or intramuscular administration.
  • (15) The method of (13) or (14), wherein the inhalation administration comprises pulmonary and/or nasal inhalation administration.
  • (16) The method of any one of (13)-(15), wherein the inhalation administration comprises aerosol inhalation.
  • (17) The method of any one of (13)-(16), wherein the recombinant interferon is administered in an amount in a range of about 100 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 800 μg, still optionally about 200 μg to about 600 μg by one inhalation administration, the recombinant interferon is administered by inhalation administration once every about 1 day to about 3 days, optionally every about 1 day, lasting at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (18) The method of any one of (1)-(17), further comprising administering to the subject the recombinant interferon by intratumoral administration.
  • (19) The method of (18), wherein the intratumoral administration is conducted before, simultaneously, and/or after the subcutaneous administration and/or intramuscular administration.
  • (20) The method of (18), wherein the intratumoral administration is conducted before, simultaneously, and/or after the inhalation administration.
  • (21) The method of any one of (18)-(20), wherein the intratumoral administration comprises intratumoral injection.
  • (22) The method of any one of (18)-(21), wherein the recombinant interferon is administered in an amount in a range of about 60 μg to about 600 μg, optionally about 60 μg to about 500 μg, further optionally about 80 μg to about 400 μg, still further optionally about 100 μg to about 250 μg by one intratumoral administration, and the recombinant interferon is administered by intratumoral administration once every about 1 day to about 10 days, optionally every about 1 day to about 7 days such as every about 1, 2, 3, 4, 5, 6, or 7 days, the duration of the intratumoral administration is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (23) The method of any one of (18)-(22), wherein the protocol of intratumoral administration is as follows: the recombinant interferon is administered by intratumoral injection once every about 1 day for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 3 days to about 5 days for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 7 days, the intratumoral administration is stopped when the tumor disappears or becomes too small to conduct the intratumoral injection.
  • (24) The method of any one of (1)-(23), wherein the subject has the pleural effusion, ascites, and/or pericardial effusion.
  • (25) The method of (24), wherein the pleural effusion is a malignant pleural effusion, the ascites is a malignant ascites, and/or the pericardial effusion is a malignant pericardial effusion.
  • (26) The method of (24) or (25), wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises at least one of: intrapleural administration, abdominal administration, and pericardial administration.
  • (27) The method of (26), wherein the intrapleural administration comprises intrapleural perfusion.
  • (28) The method of (26), wherein the abdominal administration comprises abdominal perfusion.
  • (29) The method of (26), wherein the pericardial administration comprises pericardial perfusion.
  • (30) The method of any one of (26)-(29), wherein the recombinant interferon is administered in an amount in a range of about 30 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 1000 μg, still optionally about 200 μg to about 800 μg by one intrapleural, abdominal, and/or pericardial administration.
  • (31) The method of (30), wherein the recombinant interferon is administered in an amount in a range of about 200 μg to about 400 μg by one intrapleural, abdominal, and/or pericardial administration.
  • (32) The method of any one of (26)-(31), wherein the recombinant interferon is administered by intrapleural, abdominal, and/or pericardial administration once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, such as every about 1, 2, 3, 4, 5, 6, or 7 days.
  • (33) The method of any one of (1)-(32), wherein the lung cancer in the subject comprises tumor metastasis in at least one of: skin, mucosa, superficial lymph nodes, and subcutaneous tissue.
  • (34) The method of (33), wherein the recombinant interferon is administered to the subject by spray administration.
  • (35) The method of (34), wherein the spray administration comprises at least one of: percutaneous spray administration, transdermal spray administration, epidermal spray administration, and transmucosal spray administration.
  • (36) The method of (34) or (35), wherein the recombinant interferon is administered in an amount in a range of about 6 μg to about 100 μg by one spray administration.
  • (37) The method of (36), wherein the recombinant interferon is administered in an amount of about 10 μg to about 40 μg, optionally about 20 μg to about 40 μg by one spray administration.
  • (38) The method of any one of (34)-(37), wherein the recombinant interferon is administered by spray administration about 1 to about 6 times per day, such as about 1, 2, 3, 4, 5, or 6 times per day.
  • (39) The method of any one of (1)-(38), wherein the recombinant interferon is administered to the subject as monotherapy.
  • (40) The method of any one of (1)-(38), further comprising at least one other anti-cancer therapy administered to the subject, optionally, the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • (41) The method of (40), wherein the at least one other anti-cancer therapy comprises one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • (42) The method of (41), wherein the at least one other anti-cancer therapy comprises chemotherapy.
  • (43) The method of (42), wherein the chemotherapy is the first-line chemotherapy.
  • (44) The method of (43), wherein one or more chemotherapeutic drugs used for the first-line chemotherapy comprise platinum compounds, such as Cisplatin.
  • (45) The method of (41), wherein the at least one other anti-cancer therapy comprises radiotherapy.
  • (46) The method of (45), wherein the radiotherapy comprises head gamma knife therapy when the lung cancer metastasizes to brain.
  • (47) The method of (41), wherein the at least one other anti-cancer therapy comprises surgical therapy.
  • (48) The method of (41), wherein the at least one other anti-cancer therapy comprises targeted therapy.
  • (49) The method of (48), wherein the targeted therapy comprises administering Gefitinib, Erlotinib, and/or recombinant human endostatin.
  • (50) The method of (41), wherein the at least one other anti-cancer therapy comprises biotherapy.
  • (51) The method of any one of (1)-(50), wherein the therapies eliminate the tumor or reduce the size of the tumor or the number of tumor metastasis compared to the tumor before treatment.
  • (52) The method of any one of (1)-(51), wherein the therapies are the non-surgical therapies.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by subcutaneous administration and/or intramuscular administration, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose in a range of about 10 μg to about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time.
  • (2) The method of (1), wherein the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • (3) The method of (1) or (2), wherein the tumor in the subject comprises a metastasized tumor.
  • (4) The method of any one of (1)-(3), wherein the subject is an early, medium-term, or advanced cancer patient, optionally, the subject is a medium-term, or advanced cancer patient, further optionally, the subject is an advanced cancer patient.
  • (5) The method of any one of (1)-(3), wherein the subject is a stage 0, I, II, III, or IV cancer patient, optionally, the subject is a stage III or IV cancer patient.
  • (6) The method of any one of (1)-(5), wherein the lung cancer is a lung cancer that is indicated or appropriate for surgery.
  • (7) The method of any one of (1)-(5), wherein the lung cancer is a lung cancer that is not indicated nor appropriate for surgery.
  • (8) The method of any one of (1)-(5), wherein the lung cancer is a lung cancer that is capable of being resected.
  • (9) The method of any one of (1)-(5), wherein the lung cancer is a lung cancer that is not capable of being resected.
  • (10) The method of (8) or (9), wherein the lung cancer is resected by a surgical resection.
  • (11) The method of any one of (1)-(10), wherein the subcutaneous administration comprises subcutaneous injection.
  • (12) The method of any one of (1)-(10), wherein the intramuscular administration comprises intramuscular injection.
  • (13) The method of any one of (1)-(12), wherein the time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • (14) The method of any one of (1)-(13), the recombinant interferon is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days when the recombinant interferon is administered more times at an induction dose.
  • (15) The method of any one of (1)-(14), wherein the recombinant interferon is administered at a therapeutic dose once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
  • (16) The method of any one of (1)-(15), wherein the duration of administration of induction dose and therapeutic dose is at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • (17) The method of any one of (1)-(16), further comprising administering to the subject the recombinant interferon by inhalation administration.
  • (18) The method of (17), wherein the inhalation administration is conducted before, simultaneously, and/or after the subcutaneous administration and/or intramuscular administration.
  • (19) The method of (17) or (18), wherein the inhalation administration comprises pulmonary and/or nasal inhalation administration.
  • (20) The method of any one of (17)-(19), wherein the inhalation administration comprises aerosol inhalation.
  • (21) The method of any one of (17)-(20), wherein the recombinant interferon is administered in an amount in a range of about 100 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 800 μg, still further optionally about 200 μg to about 600 μg by one inhalation administration, the recombinant interferon is administered by inhalation administration once every about 1 day to about 3 days, optionally every about 1 day, lasting at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (22) The method of any one of (1)-(21), further comprising administering to the subject the recombinant interferon by intratumoral administration.
  • (23) The method of (22), wherein the intratumoral administration is conducted before, simultaneously, and/or after the subcutaneous administration and/or intramuscular administration.
  • (24) The method of (22), wherein the intratumoral administration is conducted before, simultaneously, and/or after the inhalation administration.
  • (25) The method of any one of (22)-(24), wherein the intratumoral administration comprises intratumoral injection.
  • (26) The method of any one of (22)-(25), wherein the recombinant interferon is administered in an amount in a range of about 60 μg to about 600 μg, optionally about 60 μg to about 500 μg, further optionally about 80 μg to about 400 μg, still further optionally about 100 μg to about 250 μg by one intratumoral administration, and the recombinant interferon is administered by intratumoral administration once every about 1 day to about 10 days, optionally every about 1 day to about 7 days such as every about 1, 2, 3, 4, 5, 6, or 7 days, the duration of the intratumoral administration is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (27) The method of any one of (22)-(26), wherein the protocol of intratumoral administration is as follows: the recombinant interferon is administered by intratumoral injection once every about 1 day for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 3 days to about 5 days for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 7 days, the intratumoral administration is stopped when the tumor disappears or becomes too small to conduct the intratumoral injection.
  • (28) The method of any one of (1)-(27), wherein the subject has the pleural effusion, ascites, and/or pericardial effusion.
  • (29) The method of (28), wherein the pleural effusion is a malignant pleural effusion, the ascites is a malignant ascites, and/or the pericardial effusion is a malignant pericardial effusion.
  • (30) The method of (28) or (29), wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises at least one of: intrapleural administration, abdominal administration, and pericardial administration.
  • (31) The method of (30), wherein the intrapleural administration comprises intrapleural perfusion.
  • (32) The method of (30), wherein the abdominal administration comprises abdominal perfusion.
  • (33) The method of (30), wherein the pericardial administration comprises pericardial perfusion.
  • (34) The method of any one of (30)-(33), wherein the recombinant interferon is administered in an amount in a range of about 30 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 1000 μg, still optionally about 200 μg to about 800 μg by one intrapleural administration, abdominal administration, and/or pericardial administration.
  • (35) The method of (34), wherein the recombinant interferon is administered in an amount in a range of about 200 μg to about 400 μg by one intrapleural administration, abdominal administration, and/or pericardial administration.
  • (36) The method of any one of (30)-(35), wherein the recombinant interferon is administered by intrapleural administration, abdominal administration, and/or pericardial administration once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, such as every about 1, 2, 3, 4, 5, 6, or 7 days.
  • (37) The method of any one of (1)-(36), wherein the lung cancer in the subject comprises tumor metastasis in at least one of: skin, mucosa, superficial lymph nodes, and subcutaneous tissue.
  • (38) The method of (37), wherein the recombinant interferon is administered to the subject by spray administration.
  • (39) The method of (38), wherein the spray administration comprises at least one of: percutaneous spray administration, transdermal spray administration, epidermal spray administration, and transmucosal spray administration.
  • (40) The method of (38) or (39), wherein the recombinant interferon is administered in an amount in a range of about 6 μg to about 100 μg by one spray administration.
  • (41) The method of (40), wherein the recombinant interferon is administered in an amount in a range of about 10 μg to about 40 μg, optionally about 20 μg to about 40 μg by one spray administration.
  • (42) The method of any one of (38)-(41), wherein the recombinant interferon is administered by spray administration about 1 to about 6 times per day, such as about 1, 2, 3, 4, 5, or 6 times per day.
  • (43) The method of any one of (1)-(42), wherein the recombinant interferon is administered to the subject as monotherapy.
  • (44) The method of any one of (1)-(42), further comprising at least one other anti-cancer therapy administered to the subject, optionally, the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • (45) The method of (44), wherein the at least one other anti-cancer therapy comprises one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • (46) The method of (45), wherein the at least one other anti-cancer therapy comprises chemotherapy.
  • (47) The method of (46), wherein the chemotherapy is the first-line chemotherapy.
  • (48) The method of (47), wherein one or more chemotherapeutic drugs are used for the first-line chemotherapy and comprise platinum compounds, such as Cisplatin.
  • (49) The method of (45), wherein the at least one other anti-cancer therapy comprises radiotherapy.
  • (50) The method of (49), wherein the radiotherapy comprises head gamma knife therapy when the lung cancer metastasizes to brain.
  • (51) The method of (45), wherein the at least one other anti-cancer therapy comprises surgical therapy.
  • (52) The method of (45), wherein the at least one other anti-cancer therapy comprises targeted therapy.
  • (53) The method of (52), wherein the targeted therapy comprises administering Gefitinib, Erlotinib, and/or recombinant human endostatin.
  • (54) The method of (45), wherein the at least one other anti-cancer therapy comprises biotherapy.
  • (55) The method of any one of (1)-(54), wherein the therapies eliminate the tumor of the lung or reduce the size of the tumor of the lung compared to the tumor size before treatment.
  • (56) The method of any one of (1)-(55), wherein the therapies are the non-surgical therapies.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to brain, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose in a range of about 10 μg to about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time, and the recombinant interferon is administered to the subject by inhalation administration before, simultaneously, and/or after the subcutaneous administration and/or intramuscular administration, the recombinant interferon is administered in an amount in a range of about 100 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 800 μg, still further optionally about 200 μg to about 600 μg by one inhalation administration, and the recombinant interferon is administered by inhalation administration once every about 1 day to about 3 days, optionally every about 1 day.
  • (2) The method of (1), wherein the subject is a medium-term, advanced, or stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • (3) The method of (1) or (2), wherein the cancer is a cancer that is not indicated nor appropriate for surgery.
  • (4) The method of (1) or (2), wherein the tumor is a tumor that is not capable of being resected.
  • (5) The method of (4), wherein the tumor is resected by a surgical resection.
  • (6) The method of any one of (1)-(5), wherein the subcutaneous administration comprises subcutaneous injection.
  • (7) The method of any one of (1)-(5), wherein the intramuscular administration comprises intramuscular injection.
  • (8) The method of any one of (1)-(7), wherein the inhalation administration comprises pulmonary and/or nasal inhalation administration.
  • (9) The method of any one of (1)-(8), wherein the inhalation administration comprises aerosol inhalation.
  • (10) The method of any one of (1)-(9), wherein the time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • (11) The method of any one of (1)-(10), wherein the recombinant interferon is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days when the recombinant interferon is administered more times at an induction dose.
  • (12) The method of any one of (1)-(11), wherein the recombinant interferon is administered at a therapeutic dose once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
  • (13) The method of any one of (1)-(12), wherein the duration of administration of induction dose and therapeutic dose is at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • (14) The method of any one of (1)-(13), wherein the duration of the inhalation administration is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (15) The method of any one of (1)-(14), wherein the recombinant interferon is administered to the subject as monotherapy.
  • (16) The method of any one of (1)-(15), further comprising at least one other anti-cancer therapy administered to the subject, optionally, the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • (17) The method of (16), wherein the at least one other anti-cancer therapy comprises one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • (18) The method of (17), wherein the chemotherapy is the first-line chemotherapy, optionally, one or more chemotherapeutic drugs are used for the first-line chemotherapy and comprise platinum compounds, such as Cisplatin.
  • (19) The method of (17), wherein the targeted therapy comprises administering Gefitinib, Erlotinib, and/or recombinant human endostatin.
  • (20) The method of (17), wherein the at least one other anti-cancer therapy comprises radiotherapy.
  • (21) The method of (20), wherein the radiotherapy comprises gamma knife therapy.
  • (22) The method of (21), wherein the gamma knife therapy comprises head gamma knife therapy.
  • (23) The method of any one of (1)-(22), wherein the therapies eliminate the tumor or reduce the size of the tumor compared to the tumor before treatment.
  • (24) The method of any one of (1)-(23), wherein the therapies are the non-surgical therapies.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to bone or liver, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 μg-about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time.
  • (2) The method of (1), wherein the subject is a medium-term, advanced, or stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • (3) The method of (1) or (2), wherein the cancer is a cancer that is not indicated nor appropriate for surgery.
  • (4) The method of (1) or (2), wherein the tumor is a tumor that is not capable of being resected.
  • (5) The method of (4), wherein the tumor is resected by a surgical resection.
  • (6) The method of any one of (1)-(5), wherein the subcutaneous administration comprises subcutaneous injection.
  • (7) The method of any one of (1)-(5), wherein the intramuscular administration comprises intramuscular injection.
  • (8) The method of any one of (1)-(7), wherein the time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • (9) The method of any one of (1)-(8), wherein the recombinant interferon is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days when the recombinant interferon is administered more times at an induction dose.
  • (10) The method of any one of (1)-(9), wherein the recombinant interferon is administered at a therapeutic dose once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
  • (11) The method of any one of (1)-(10), wherein the duration of administration of induction dose and therapeutic dose is at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • (12) The method of any one of (1)-(11), further comprising administering to the subject the recombinant interferon by inhalation administration.
  • (13) The method of (12), wherein the inhalation administration is conducted before, simultaneously, and/or after the subcutaneous administration and/or intramuscular administration.
  • (14) The method of (12) or (13), wherein the inhalation administration comprises pulmonary and/or nasal inhalation administration.
  • (15) The method of any one of (12)-(14), wherein the inhalation administration comprises aerosol inhalation.
  • (16) The method of any one of (12)-(15), wherein the recombinant interferon is administered in an amount in a range of about 100 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 800 μg, still further optionally about 200 μg to about 600 μg by one inhalation administration, the recombinant interferon is administered by inhalation administration once every about 1 day to about 3 days, optionally every about 1 day, and the duration of the inhalation administration is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (17) The method of any one of (1)-(16), wherein the recombinant interferon is administered to the subject as monotherapy.
  • (18) The method of any one of (1)-(16), further comprising at least one other anti-cancer therapy administered to the subject, optionally, the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • (19) The method of (18), wherein the at least one other anti-cancer therapy comprises one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • (20) The method of (19), wherein the at least one other anti-cancer therapy comprises chemotherapy.
  • (21) The method of (20), wherein the chemotherapy is first-line chemotherapy.
  • (22) The method of (21), wherein one or more chemotherapeutic drugs are used for the first-line chemotherapy and comprise platinum compounds, such as Cisplatin.
  • (23) The method of (19), wherein the at least one other anti-cancer therapy comprises targeted therapy.
  • (24) The method of (23), wherein the targeted therapy comprises administering Gefitinib, Erlotinib, and/or recombinant human endostatin.
  • (25) The method of (19), wherein the at least one other anti-cancer therapy comprises biotherapy.
  • (26) The method of any one of (1)-(25), wherein the therapies eliminate the tumor or reduce the size of the tumor compared to the tumor before treatment.
  • (27) The method of any one of (1)-(26), wherein the therapies are the non-surgical therapies.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to lymph nodes, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 μg to about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time, and the recombinant interferon is administered to the tumor and/or the lymph nodes metastases by topical or local administration before, simultaneously, and/or after the subcutaneous administration and/or intramuscular administration.
  • (2) The method of (1), wherein the subject is a medium-term, advanced, or stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • (3) The method of (1) or (2), wherein the cancer is a cancer that is not indicated nor appropriate for surgery.
  • (4) The method of (1) or (2), wherein the tumor is a tumor that is not capable of being resected.
  • (5) The method of (4), wherein the tumor is resected by a surgical resection.
  • (6) The method of any one of (1)-(5), wherein the subcutaneous administration comprises subcutaneous injection.
  • (7) The method of any one of (1)-(5), wherein the intramuscular administration comprises intramuscular injection.
  • (8) The method of any one of (1)-(7), wherein the time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • (9) The method of any one of (1)-(8), wherein the recombinant interferon is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days when the recombinant interferon is administered more times at an induction dose.
  • (10) The method of any one of (1)-(9), wherein the recombinant interferon is administered at a therapeutic dose once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
  • (11) The method of any one of (1)-(10), wherein the duration of administration of induction dose and therapeutic dose is at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • (12) The method of any one of (1)-(11), wherein the local administration comprises intratumoral administration when the lymph nodes are the deep lymph nodes.
  • (13) The method of (12), wherein the intratumoral administration comprises intratumoral injection.
  • (14) The method of (12) or (13), wherein the recombinant interferon is administered in an amount in a range of about 60 μg to about 600 μg, optionally about 60 μg to about 500 μg, further optionally about 80 μg to about 400 μg, still further optionally about 100 μg to about 250 μg by one intratumoral administration, and the recombinant interferon is administered by intratumoral administration once every about 1 day to about 10 days, optionally every about 1 day to about 7 days such as every about 1, 2, 3, 4, 5, 6, or 7 days, the duration of the intratumoral administration is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • (15) The method of any one of (12)-(14), wherein the protocol of intratumoral administration is as follow: the recombinant interferon is administered by intratumoral injection once every about 1 day for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 3 days to about 5 days for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 7 days, the intratumoral administration is stopped when the tumor and/or metastasized lymph nodes are disappeared or become too small to conduct the intratumoral injection.
  • (16) The method of any one of (1)-(11), wherein the topical or local administration comprises at least one of: infiltration administration, percutaneous administration, transdermal administration, epidermal administration, and transmucosal administration when the lymph nodes are superficial lymph nodes.
  • (17) The method of (16), wherein the local administration comprises infiltration administration.
  • (18) The method of (17), wherein the infiltration administration is conducted by perfusion.
  • (19) The method of (16), wherein the percutaneous administration, transdermal administration, epidermal administration, or transmucosal administration comprises percutaneous spray administration, transdermal spray administration, epidermal spray administration, or transmucosal spray administration, respectively.
  • (20) The method of (19), wherein the recombinant interferon is administered in an amount in a range of about 6 μg to about 100 μg by one spray administration.
  • (21) The method of (20), wherein the recombinant interferon is administered in an amount of about 10 μg to about 40 μg, optionally about 20 μg to about 40 μg by one spray administration.
  • (22) The method of any one of (19)-(21), wherein the recombinant interferon is administered by spray administration about 1 to about 6 times such as about 1, 2, 3, 4, 5, or 6 times per day.
  • (23) The method of any one of (1)-(22), wherein the recombinant interferon is administered to the subject as monotherapy.
  • (24) The method of any one of (1)-(22), further comprising at least one other anti-cancer therapy administered to the subject, optionally, the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • (25) The method of (24), wherein the at least one other anti-cancer therapy comprises one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • (26) The method of (25), wherein the at least one other anti-cancer therapy comprises chemotherapy.
  • (27) The method of (26), wherein the chemotherapy is first-line chemotherapy.
  • (28) The method of (27), wherein one or more chemotherapeutic drugs are used for the first-line chemotherapy and comprise platinum compounds, such as Cisplatin.
  • (29) The method of (25), wherein the at least one other anti-cancer therapy comprises targeted therapy.
  • (30) The method of (29), wherein the targeted therapy comprises administering Gefitinib, Erlotinib, and/or recombinant human endostatin.
  • (31) The method of (25), wherein the at least one other anti-cancer therapy comprises biotherapy.
  • (32) The method of any one of (1)-(31), wherein the therapies eliminate the tumor or reduce the size of the tumor compared to the tumor before treatment.
  • (33) The method of any one of (1)-(32), wherein the therapies are the non-surgical therapies.
  • In another aspect, another embodiment of the present invention provides:
  • (1) A method for treating lung cancer in a subject, wherein the subject has pleural effusion, ascites and/or pericardial effusion, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by topical or local administration.
  • (2) The method of (1), wherein the subject is a medium-term, advanced, or stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • (3) The method of (1) or (2), wherein the lung cancer is a lung cancer that is not indicated nor appropriate for surgery.
  • (4) The method of (1) or (2), wherein the lung cancer is a lung cancer that is not capable of being resected.
  • (5) The method of (4), wherein the tumor is resected by a surgical resection.
  • (6) The method of any one of (1)-(5), wherein the pleural effusion is a malignant pleural effusion, the ascites is a malignant ascites, and/or the pericardial effusion is a malignant pericardial effusion.
  • (7) The method of any one of (1)-(6), wherein the local administration comprises at least one of: infiltration administration, intrapleural administration, abdominal administration, and pericardial administration.
  • (8) The method of (7), wherein the local administration is conducted by perfusion.
  • (9) The method of (8), wherein the recombinant interferon is administered in an amount in a range of about 30 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 1000 μg, still optionally about 200 μg to about 800 μg, still further optionally about 200 μg to about 400 μg by one perfusion administration.
  • (10) The method of (8) or (9), wherein the recombinant interferon is administered by perfusion administration once every about 1 to about 10 days, optionally every about 1 to about 7 days, such as every about 1, 2, 3, 4, 5, 6, or 7 days.
  • (11) The method of (10), wherein the recombinant interferon is administered by perfusion administration once every about 1 day, lasting about 4 to about 6 times.
  • (12) The method of any one of (1)-(11), wherein the recombinant interferon is administered to the subject by systemic administration before, simultaneously, and/or after the topical or local administration.
  • (13) The method of (12), wherein the systemic administration comprises subcutaneous and/or intramuscular administration.
  • (14) The method of (13), wherein the subcutaneous administration comprises subcutaneous injection.
  • (15) The method of (13), wherein the intramuscular administration comprises intramuscular injection.
  • (16) The method of any one of (13)-(15), wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 μg to about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time.
  • (17) The method of (16), wherein the time interval between administration of induction dose and administration of therapeutic dose is about 1 day to about 1 month, optionally about 1 day to about 1 week, further optionally about 1 day to about 3 days, comprising such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, or about 1 month.
  • (18) The method of (16) or (17), wherein the recombinant interferon is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days when the recombinant interferon is administered more times at an induction dose.
  • (19) The method of any one of (16)-(18), wherein the recombinant interferon is administered at a therapeutic dose once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 to about 2 days, comprising such as every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.
  • (20) The method of any one of (16)-(19), wherein the duration of administration of induction dose and therapeutic dose is at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • (21) The method of any one of (1)-(20), wherein other therapeutic drugs are further administered by topical, local and/or systemic administration
  • (22) The method of (21), wherein the other therapeutic drugs comprise antitumor drugs.
  • (23) The method of (22), wherein the antitumor drugs comprise one or more chemotherapeutic drugs, targeted drugs, or biological drugs.
  • (24) The method of (23), wherein one or more chemotherapeutic drugs comprise platinum compounds, such as Cisplatin.
  • (25) The method of (23), wherein one or more targeted drugs comprise Gefitinib, Erlotinib, and/or recombinant human endostatin
  • (26) The method of any one of (1)-(25), wherein the therapies eliminate the tumor or reduce the size of the tumor compared to the tumor size before treatment.
  • (27) The method of any one of (1)-(26), wherein the therapies are the non-surgical therapies.
  • More specifically, in one embodiment, in any one of the methods of the present invention mentioned above, the tumor is a solid tumor; optionally, the solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • In any one of methods of the present invention mentioned above, the tumor is a tumor such as cancer or solid tumor without indications for surgery or not indicated or appropriate for surgery; and/or the subject is a medium-term, advanced cancer patient, or III or IV stage cancer patient, optionally, the subject is an advanced, or III or IV stage cancer patient.
  • In any one of methods of the present invention mentioned above, the recombinant interferon is administered to the subject as monotherapy; or, further comprising one or more other anti-cancer therapies administered to the subject, optionally, other anti-cancer therapies are administered to the subject before, simultaneously, and/or after administration of the recombinant interferon. Optionally, the other anti-cancer therapies comprise one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
  • And, in another aspect, another embodiment of the present invention also provides:
  • (1) A method of treating a tumor in a subject comprising administering to the subject a recombinant interferon that comprises an anti-tumor effect as a first line monotherapy.
  • (2) The method of (1), wherein the tumor comprises one of: lung cancer, uterine cancer, cervical cancer, and pancreatic cancer.
  • (3) The method of (2), wherein the lung cancer comprises non-small cell lung cancer.
  • (4) The method of (1), wherein the tumor is not a kidney cancer.
  • (5) A method of treating a tumor in a subject comprising administering to the subject a recombinant interferon that comprises an antitumor effect as a second line monotherapy.
  • (6) The method of (5), wherein the tumor comprises one of: lung cancer, colorectal cancer, malignant melanoma, ovarian cancer, cervical cancer, liver cancer, breast cancer, gastrointestinal cancer, prostate cancer, neuroma, and squamous cell carcinoma.
  • (7) The method of (6), wherein the colorectal cancer comprises colon cancer.
  • (8) The method of (6), wherein the colorectal cancer comprises rectal cancer.
  • (9) The method of (6), wherein the lung cancer comprises non-small cell lung cancer.
  • (10) The method of (6), wherein the liver cancer comprises HCC.
  • (11) The method of (6), wherein the gastrointestinal cancer comprises gastric cancer.
  • (12) A method of treating a tumor in a subject comprising administering to the subject a recombinant interferon that comprises an anti-tumor effect as a first line therapy in combination with one or more other anti-cancer therapy.
  • (13) The method of (12), wherein the tumor comprises one of: lung cancer, prostate cancer, and lymphoma.
  • (14) The method of (13), wherein the lung cancer comprises at least one of non-small cell lung cancer and small cell lung cancer.
  • (15) The method of (12), wherein the tumor is not an ovarian cancer.
  • (16) A method of treating a tumor in a subject comprising administering to the subject a recombinant interferon that comprises an anti-tumor effect as a second line therapy in combination with one or more other anti-cancer therapies.
  • (17) The method of (16), wherein the tumor comprises one of: lung cancer, lymphoma, cervical cancer, and cholangioadenocarcinoma.
  • (18) The method of (17), wherein the lung cancer comprises at least one of non-small cell lung cancer and small cell lung cancer.
  • (19) The method of (17), wherein the lymphoma is non-Hodgkins lymphoma.
  • (20) The method of any of (12), (13), (14), (15), (16), (17), (18), or (19), wherein the one or more other anti-cancer therapies comprise at least one of: radiotherapy, small molecule therapy, chemotherapy, biologics therapy, TCM, and surgery.
  • (21) The method of (20), wherein the small molecule in the small molecule therapy comprises Getifinib.
  • (22) The method of (20), wherein the biologics therapy comprises treatment with at least one of: a recombinant protein and isolated cells.
  • (23) The method of (22), wherein the recombinant protein comprises Endostar.
  • (24) The method of (22), wherein the isolated cells comprises at least one of: stem cells and NK cells.
  • (25) The method of (20), wherein the recombinant interferon is administered after surgical treatment of cancer.
  • (26) The method of any of (20)-(24), wherein the recombinant interferon is administered prior to surgical treatment of cancer.
  • (27) The method of any of (1)-(26), wherein the recombinant interferon is administered by at least one of the following routes: systemically and locally.
  • (28) The method of any of (1)-(26), wherein the recombinant interferon is administered by at least one of the following routes: intramuscularly, intraperitoneally, intravenously, intra-arterially, intratumorally, by injection into lymph nodes, topically, locally on the tumor, intranasally, subcutaneously, by spraying, by inhalation, by perfusion, and by infusion.
  • (29) The method of any of (1)-(28), wherein the recombinant interferon comprises rSIFN-co.
  • (30) The method of (29), wherein the recombinant interferon is administered at a dose in a range of about 2 μg to about 2500 μg per treatment.
  • (31) The method of (29), wherein recombinant interferon is administered at a dose in a range of about 9 μg to about 2100 μg per treatment.
  • (32) The method of (29), wherein recombinant interferon is administered at a dose of one or more of the following doses: 2 μg, 4 μg, 9 μg, 13.5 μg, 15 μg, 18 μg, 21 μg, 24 μg, 25.5 μg, 30 μg, 36 μg, 45 μg, 70 μg, 84 μg, 90 μg, 100 μg, 105 μg, 120 μg, 126 μg, 139 μg, 150 μg, 168 μg, 180 μg, 189 μg, 198 μg, 200 μg, 207 μg, 210 μg, 240 μg, 252 μg, 273 μg, 300 μg, 315 μg, 400 μg, 500 μg, 600 μg, 1000 μg, 2000 μg, 2100 μg.
  • (33) The method of any of (1)-(32), wherein the recombinant interferon comprises a specified activity.
  • (34) The method of (33), wherein the recombinant interferon comprises an activity in the range of about 4.4×108 IU/mg to about 1.0×109 IU/mg, and optionally greater than 5.5×108 IU/mg.
  • (35) A method of preventing tumor recurrence in a subject comprising administering an amount of a recombinant interferon that comprises an amino acid sequence that is encoded by a nucleic acid sequence comprising the sequence of SEQ ID NO: 2 after surgery, chemotherapy, radiotherapy, cryoablation, radiofrequency ablation, biologics therapy, intervention therapy, and/or rSIFN-co therapy, whereby the recombinant interferon is administered after tumor bulk in the subject has been reduced.
  • (36) A method of prolonging tumor-free survival in a subject comprising administering an amount of a recombinant interferon that comprises an amino acid sequence that is encoded by a nucleic acid sequence comprising the sequence of SEQ ID NO: 2 after surgery, chemotherapy, radiotherapy, cryoablation, radiofrequency ablation, biologics therapy, intervention therapy, and/or rSIFN-co therapy, whereby the recombinant interferon is administered after tumor bulk in the subject has been reduced.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the comparative difference in the structures of the present recombinant interferon (rSIFN-co) and IFN-α2b, wherein in a side view and a top view in the FIG. 1, the red shows rSIFN-co, the green shows IFN-α2b, the red is black in a black and white print drawing, and the green is grey in the black and white print drawing.
  • FIG. 2 shows the comparative difference of the three-dimensional structure of the recombinant interferon rSIFN-co of the present invention and the computation model structure of INFERGEN® (being indicated as am-Infergen or Infergen) of the US Amgen, wherein in a circle in the right drawing, a thin line in yellow is rSIFN-co, and a thick spiral in blue is am-Infergen. Meanwhile, in the right drawing, the red shows rSIFN-co, and the green shows am-Infergen, wherein the red is black in the black and white print drawing, and the green is grey in the black and white print drawing.
  • FIGS. 3 a-3 b shows the treatment situation of patient 1, wherein an arrow in FIG. 3 a shows state of the original lesion observed in a CT image on 8th November, Year 2, after 12 months of medication; and an arrow in FIG. 3 b shows state of the original lesion observed in a CT image on 1st February, Year 3, after 15 months of medication, the year of the start of treatment being Year 1.
  • FIGS. 4 a-4 b shows the treatment situation of patient 2, wherein FIG. 4 a shows a PET/CT imaging diagnosis before rSIFN-co medication, and an arrow indicates the lesion; and FIG. 4 b shows a PET/CT imaging diagnosis after rSIFN-co medication, and an arrow indicates the state of the original lesion after treatment.
  • FIGS. 5 a-5 b and 6 a-6 b show the treatment situation of patient 3, wherein FIG. 5 a shows a lung CT image before rSIFN-co medication, and an arrow indicates the lesion; FIG. 5 b shows head and chest CT imaging diagnoses after rSIFN-co medication, and an arrow indicates the state of the original lesion after treatment; FIG. 6 a shows a brain CT image before rSIFN-co medication, and an arrow indicates the lesion; and FIG. 6 b shows head and chest imaging diagnoses after rSIFN-co medication, and an arrow indicates the state of the original lesion after treatment.
  • FIGS. 7 a-7 b and FIGS. 8 a-8 b show the treatment situation of patient 4, wherein FIGS. 7 a and 8 a show imaging diagnoses before rSIFN-co medication: as shown in PET/CT after chemotherapy, arrows in the FIGS. 7 a and 8 a indicate the lesions; and FIGS. 7 b and 8 b show imaging diagnoses after rSIFN-co medication: as shown in PET/CT, an arrow indicates the state of the original lesion after treatment.
  • FIGS. 9 a-9 b, 10 a-10 b and 11 a-11 b show the treatment situation of patient 5, wherein FIGS. 9 a, 10 a and 11 a show imaging diagnoses before rSIFN-co medication: as shown in PET/CT, and arrows in the FIGS. 9 a, 10 a and 11 a show the lesions; and FIGS. 9 b, 10 b and 11 b show imaging diagnoses after rSIFN-co medication: as shown in PET/CT, and arrows in the FIGS. 9 b, 10 b and 11 b show the states of the original lesions after treatment.
  • FIGS. 12 a-12 b shows the treatment situation of patient 6, wherein FIG. 12 a shows a chest CT imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion; and FIG. 12 b shows a CT imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 13 a-13 b and 14 a-14 b show the treatment situation of patient 7, wherein FIGS. 13 a and 14 a show CT imaging diagnoses before rSIFN-co medication, and arrows show the original lesions; and FIGS. 13 b and 14 b show CT imaging diagnoses after rSIFN-co medication, and arrows show the states of the original lesions after treatment.
  • FIGS. 15 a-15 b and 16 a-16 b show the treatment situation of patient 8, wherein FIGS. 15 a and 16 a show CT imaging diagnoses before rSIFN-co medication, and arrows show the original lesions; and FIGS. 15 b and 16 b show CT imaging diagnoses after rSIFN-co medication, and arrows show the states of the original lesions after treatment.
  • FIGS. 171-17 b shows the treatment situation of patient 9, wherein FIG. 17 a shows a CT imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion; and FIG. 17 b shows a CT imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 18 and 19 a-19 b show the treatment situation of patient 10, wherein the FIG. 18 shows pleural effusion change before and after the treatment; FIG. 19 a shows a chest CT imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion; and FIG. 19 b shows a chest CT imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 20, 21 a-21 b, 22 a-22 b and 23 a-23 b show the treatment situation of patient 11, wherein FIG. 20 shows the biopsy of patient before treatment, FIGS. 21 a, 22 a and 23 a show PET/CT imaging diagnoses before rSIFN-co medication, and arrows show the original lesions; and FIGS. 21 b, 22 b and 23 b show PET/CT imaging diagnoses after rSIFN-co medication, and arrows show the states of the original lesions after treatment.
  • FIGS. 24 a-24 b shows the treatment situation of patient 12, wherein FIG. 24 a shows a CT image at the beginning of the medicine administration, and an arrow shows the original lesion; and FIG. 24 b shows an imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 25 a-25 b shows the treatment situation of patient 13, wherein FIG. 25 a shows a CT image at the early stage of the treatment, and an arrow shows suspicious lesions of inferior lobe of right lung; and FIG. 25 b shows a chest CT image at the later stage of the treatment, and an arrow shows the state of original suspicious lesions of inferior lobe of right lung after treatment.
  • FIGS. 26 a-26 b shows the treatment situation of patient 14, wherein FIG. 26 a shows a CT image at the beginning of the medicine administration (after surgery), and an arrow shows the original lesion; and FIG. 26 b shows a CT image at the later stage of the treatment, and an arrow shows the state of the original lesion after treatment.
  • FIGS. 27 a-27 b shows the treatment situation of patient 15, wherein FIG. 27 a shows a pelvic cavity MRI imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion; and FIG. 27 b shows a pelvic cavity MRI imaging diagnosis after rSIFN-co medication, and an arrow shows the state of the original lesion after treatment.
  • FIG. 28 shows a pathological diagnosis of patient 16, and an arrow shows adenocarcinoma cells.
  • FIGS. 29 a-29 b shows the treatment situation of the patient 16, wherein FIG. 29 a shows a PEC/CT imaging diagnosis before rSIFN-co medication, and an arrow shows the original lesion; and FIG. 29 b shows a PEC/CT imaging diagnosis after rSIFN-co medication, and an arrow show the state of the original lesion after treatment.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The inventor found that rSIFN-co can be advantageously used to control cancer, either alone or in combination with other anti-cancer therapies, as a first line or second line monotherapy or in combination with other treatment modalities. The advantages are: Firstly, the recombinant interferon (rSIFN-co) has broad-spectrum anti-tumor effects, which is effective to treat both solid tumors and non-solid tumors. At the same time, rSIFN-co has good synergetic effect with existing treatment means such as surgical therapy, chemotherapy, radiotherapy, other biotherapies and other anti-tumor drugs. Secondly, rSIFN-co has low toxicity, which means that little or no harm to normal cells has been observed when rSIFN-co is used in large doses. Thirdly, rSIFN-co is convenient to use and can be directly applied to tumors located in any part of the body. Thus, rSIFN-co can be used by subcutaneous or intramuscular injection to control systemic progression of tumor, by intrapleural or abdominal perfusion to eliminate effusion and intrapleural or abdominal tumors, by topical or local injection to eliminate primary or metastatic tumors, and by infiltration (transdermal) administration to treat tumor lesions in bone, skin, muscle, prostate and the like. Also, rSIFN-co can be administered by aerosol inhalation or by nasal spray.
  • According to the above advantages of rSIFN-co, its effective rate on tumors, as a monotherapy and as one element of a combination therapy, is not lower than 90%. With regard to early or medium-term cancer cases, rSIFN-co can be used after surgery in place of chemotherapy and effectively prevent recurrence and tumor metastasis or prolong the period of disease-free survival; with regard to advanced cancer cases or cancer cases that are not indicated for surgery, rSIFN-co can be used to eliminate or reduce the size of tumors without surgery; with regard to tumors that are not indicated for surgery, rSIFN-co can be used to transform the tumors into ones for which surgery is possible, that is, turning a non-resectable tumor into a resectable tumor, thereby creating conditions appropriate for surgery. Therefore, rSIFN-co, alone or in combination with other one or more anti-tumor therapy, is capable of controlling cancer in a large number of instances.
  • 1. The Recombinant Interferon (rSIFN-Co) and Preparation Method Thereof
  • In one aspect, the amino acid sequence of the present recombinant interferon, as well as the nucleotide sequence encoding the same (together with a termination codon), are shown below as SEQ ID NO:1 and SEQ ID NO:2, respectively. These sequences are also referenced in U.S. Pat. Nos. 7,585,647; 7,364,724; 8,114,395 and 8,287,852:
  •  M  C  D  L  P  Q  T  H  S  L  G  N  R  R  A  L  I  L  L  A
    1 ATGTGCGACC TGCCGCAGAC CCACTCCCTG GGTAACCGTC GTGCTCTGAT CCTGCTGGCT
    TACACGCTGG ACGGCGTCTG GGTGAGGGAC CCATTGGCAG CACGAGACTA GGACGACCGA
     Q  M  R  R  I  S  P  F  S  C  L  K  D  R  H  D  F  G  F  P 
    61 CAGATGCGTC GTATCTCCCC GTTCTCCTGC CTGAAAGACC GTCACGACTT CGGTTTCCCG
    GTCTACGCAG CATAGAGGGG CAAGAGGACG GACTTTCTGG CAGTGCTGAA GCCAAAGGGC
     Q  E  E  F  D  G  N  Q  F  Q  K  A  Q  A  I  S  V  L  H  E 
    121 CAGGAAGAAT TCGACGGTAA CCAGTTCCAG AAAGCTCAGG CTATCTCCGT TCTGCACGAA
    GTCCTTCTTA AGCTGCCATT GGTCAAGGTC TTTCGAGTCC GATAGAGGCA AGACGTGCTT
     M  I  Q  Q  T  F  N  L  F  S  T  K  D  S  S  A  A  W  D  E 
    181 ATGATCCAGC AGACCTTCAA CCTGTTCTCC ACCAAAGACT CCTCCGCTGC TTGGGACGAA
    TACTAGGTCG TCTGGAAGTT GGACAAGAGG TGGTTTCTGA GGAGGCGACG AACCCTGCTT
     S  L  L  E  K  F  Y  T  E  L  Y  Q  Q  L  N  D  L  E  A  C
    241 TCCCTGCTGG AAAAATTCTA CACCGAACTG TACCAGCAGC TGAACGACCT GGAAGCTTGC
    AGGGACGACC TTTTTAAGAT GTGGCTTGAC ATGGTCGTCG ACTTGCTGGA CCTTCGAACG
     V  I  Q  E  V  G  Y  E  E  T  P  L  M  N  V  D  S  I  L  A
    301 GTTATCCAGG AAGTTGGTGT TGAAGAAACC CCGCTGATGA ACGTTGACTC CATCCTGGCT
    CAATAGGTCC TTCAACCACA ACTTCTTTGG GGCGACTACT TGCAACTGAG GTAGGACCGA
     V  K  K  Y  F  Q  R  I  T  L  Y  L  T  E  K  K  Y  S  P  C
    361 GTTAAAAAAT ACTTCCAGCG TATCACCCTG TACCTGACCG AAAAAAAATA CTCCCCGTGC
    CAATTTTTTA TGAAGGTCGC ATAGTGGGAC ATGGACTGGC TTTTTTTTAT GAGGGGCACG
     A  W  E  V  V  R  A  E  I  M  R  S  F  S  L  S  T  N  L  Q 
    421 GCTTGGGAAG TTGTTCGTGC TGAAATCATG CGTTCCTTCT CCCTGTCCAC CAACCTGCAG
    CGAACCCTTC AACAAGCACG ACTTTAGTAC GCAAGGAAGA GGGACAGGTG GTTGGACGTC
     E  R  L  R  R  K  E      (SEQ ID NO: 1) 
    481 GAACGTCTGC GTCGTAAAGAATAA (SEQ ID NO: 2) 
    CTTGCAGACG CAGCATTTCTTAIT (SEQ ID NO: 3) 
  • Compared with the IFN-α2b as published and the interferon such as interferon alfacon-1 (INFERGEN®), which has the amino acid sequence of SEQ ID NO: 1, but is not encoded by the nucleotide sequence of SEQ ID NO: 2, the three-dimensional structure of the present recombinant interferon (rSIFN-co) is different from the three-dimensional structure of IFN-α2b (see FIG. 1, wherein in the side view and the top view in the FIG. 1, the red represents rSIFN-co, the green represents IFN-α2b, the red is black in the black-and-white print drawing, and the green is grey in the black-and-white print drawing) and the computation model structure of the interferon alfacon-1 (see KORN, A P, Journal of Interferon Research 1994, 14:1-9). According to the comparison result between the present recombinant interferon and the interferon alfacon-1, there are obvious differences between the AB loops of the two, and their BC loops also cannot overlap completely (see FIG. 2).
  • In addition, after intramuscular injection of the present recombinant interferon into subjects whose BMI ranged from about 18 to about 23, the time of blood sample collection was plotted against the concentration of 2-5 A oligonucleotidase (also referred to as 2′,5′-OAS) in the serum of the subjects. The chart generally shows a two-peak pattern, and the resulting area under the curve of this chart is significantly greater than that of interferon alfacon-1 (INFERGEN®) after injection under the same conditions. Furthermore, the half-life period of this recombinant interferon is longer than that of interferon alfacon-1 (INFERGEN®) after injection into the body (see CN 1740197A; Zeng, J. P. et al. Modern Preventive Medicine, 2008, 35(5), 982-984).
  • The experimental results have also confirmed that the present recombinant interferon is more effective than any interferon used clinically at present (including interferon alfacon-1 (INFERGEN®)). For example, for HBV, the present recombinant interferon is capable of not only inhibiting DNA replication of HBV, but also inhibiting secretion of both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). The efficiency of inhibiting DNA replication of hepatitis B core antigen (HBcAg) by this interferon is about twice that of interferon alfacon-1 (INFERGEN®). The in vitro pharmacodynamics of the present recombinant interferon shows that it is capable of not only inhibiting the DNA replication of HBV, but also inhibiting secretion of both hepatitis B surface antigen and hepatitis B e antigen. The cytotoxicity of the present recombinant interferon is only ⅛ that of the current clinically used interferons, but its antiviral activity is as much as 5-20 times greater; meanwhile, the biological responses of the present recombinant interferon is more effective, more broad-spectrum and longer lasting in the human body (see CN 1740197A).
  • Furthermore, with respect to prevention of viral diseases or treatment of tumor, the present recombinant interferon shows higher antiviral activity and less side effects compared with any other interferons (including interferon alfacon-1 (INFERGEN®)). For example, this recombinant interferon possesses not only an antiviral activity 20 times as great as that of the interferons currently in clinical use, but also a more effective inhibiting tumor cell growth or promoting apoptosis function compared with recombinant human interferon α.
  • Thus, the present recombinant interferon has a different spatial configuration, enhanced biologic activities and/or different pharmacokinetics characteristics as compared with the interferon such as interferon alfacon-1 (INFERGEN®), which has the amino acid sequence of SEQ ID NO: 1, but is not encoded by the nucleotide sequence of SEQ ID NO: 2.
  • Therefore, in some embodiments, the present recombinant interferon has the amino acid sequence of SEQ ID NO: 1, such as consisting of the amino acid sequence of SEQ ID NO: 1. In some embodiments, the present recombinant interferon is encoded by the nucleotide sequence of SEQ ID NO: 2. In some embodiments, the present recombinant interferon has the amino acid sequence of SEQ ID NO: 1, and is encoded by the nucleotide sequence of SEQ ID NO: 2. Further, the recombinant interferon comprises the amino acid sequence of SEQ ID NO: 1, and is encoded by the nucleotide sequence of SEQ ID NO: 2. Still further, the recombinant interferon is consisted of the amino acid sequence of SEQ ID NO: 1, and is encoded by the nucleotide sequence of SEQ ID NO: 2.
  • In some embodiments, in comparison with interferon such as interferon alfacon-1 (INFERGEN®), which has the amino acid sequence of SEQ ID NO: 1, but is not encoded by the nucleotide sequence of SEQ ID NO: 2, the present recombinant interferon has a changed spatial configuration and/or enhanced biologic activities and/or different pharmacokinetics characteristics. For example, the present recombinant interferon has a changed spatial configuration and enhanced biologic activities, changed spatial configuration and different pharmacokinetics characteristics, or changed spatial configuration, enhanced biologic activities and different pharmacokinetics characteristics. The enhanced biological activities include: enhanced antiviral activity, enhanced tumor cell growth inhibition or proapoptotic effect, less side effects and/or could be used in large dose (e.g. each dose >10 million IU). For example, the enhanced biological activities can be enhanced antiviral activity and/or enhanced tumor cell (such as breast cancer cell or cervical cancer cell) growth inhibition or proapoptotic effect (see Zheng, J. et al. J Sichuan Univ (Med Sci Edi), 2010, 41(1), 29-34; Chen, Y, et al. J Sichuan Univ (Med Sci Edi), 2008, 39(5), 715-718). The different pharmacokinetics characteristics include: after intramuscular injection of the recombinant interferon in subjects whose BMI ranged from about 18 to about 23, the time of blood sample collection was plotted against the concentration of 2-5 A oligonucleotidase in the serum of the subjects, and the resulting area under the curve of this chart is significantly greater and/or the half-life of this recombinant interferon in the body is longer than those of the interferon such as interferon alfacon-1 (INFERGEN®), which has the amino acid sequence of SEQ ID NO: 1, but is not encoded by the nucleotide sequence of SEQ ID NO: 2 after injection under the same conditions.
  • In some embodiments, the present recombinant interferon has the amino acid sequence of SEQ ID NO: 1, and is encoded by the nucleotide sequence of SEQ ID NO: 2, wherein the recombinant interferon has increased inhibitory activities on the expression of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) of Hepatitis B Virus as compared to an interferon interferon such as interferon alfacon-1 (INFERGEN®), which has the amino acid sequence of SEQ ID NO: 1, but is not encoded by the nucleotide sequence of SEQ ID NO: 2.
  • In another aspect, the recombinant interferon (rSIFN-co) used in the present invention can be produced by the methods disclosed in, for example, U.S. Pat. No. 7,364,724, U.S. Pat. No. 7,585,647, U.S. Pat. No. 8,114,395, CN 1740197 A, CN 101001644 A, US 2009/0123417, US 2011/0158941 and WO 2011072487A1. In a specific embodiment, the present recombinant interferon can be produced by the method comprising the following steps: introducing a nucleotide sequence comprising SEQ ID NO: 2 that encodes the recombinant interferon into an isolated host cell; culturing the host cell under appropriate condition for expression of the recombinant interferon; and harvesting the recombinant interferon, wherein the recombinant interferon has an amino acid sequence of SEQ ID NO: 1, and the recombinant interferon inhibits secretion of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) of Hepatitis B Virus. Further, the host cell is Escherichia coli, such as Escherichia coli LGM 194. Further, the nucleotide sequence comprising SEQ ID NO: 2 is under the control of the promoter PBAD. Further, the harvesting step comprises extraction of the interferon from the fermentation broth, collection of the inclusion bodies, denaturation and renaturation of the harvested interferon. Still further, the harvesting step also comprises separation and purification of the recombinant interferon.
  • The person skilled in the art can prepare intramuscular injection dosage form, spray dosage form, or inhalation dosage form and the like of the present recombinant interferon with reference to the contents of the following part D with title of Pharmaceutical composition and administration route.
  • The specific activity of the present recombinant interferon is in a range of about 4.4×108 IU/mg to about 1.0×109 IU/mg, and optionally greater than 5.5×108 IU/mg. Such specific activity is the ratio of the biological activity and the content of protein. The biological activity is measured by a method well-known by the person skilled in the art such as the biological activity measurement method for the interferon (i.e. the cell lesion inhibition method) published in the Appendix X C in Chinese Pharmacopoeia (the third book), Edition 2010; and the content of the protein is measured by a method well-known by the person skilled in the art such as the second method (i.e. the Lowry method) of protein measurement method published in the Appendix VI B in Chinese Pharmacopoeia (the third book), Edition 2010.
    • 2. Therapeutic Uses
  • The inventor has found that the present recombinant interferon (rSIFN-co) can be effectively used for treating tumors, in particular, solid tumors such as lung cancers and the like. Monotherapy using the present recombinant interferon, rSIFN-co, can suppress the growth of the tumors in patients, reduce the size of tumors in the patients effectively, even non-surgically directly eliminate tumors in the patients, reduce and even eliminate malignant pleural effusion, malignant ascites and/or malignant pericardial effusion, reduce tumor markers, effectively prolong the survival and/or tumor-free survival of the tumor patients and prevent postoperative cancer recurrence and/or metastasis of the tumor in the patients, and effectively treat advanced cancer patients and the cancer patients that are not indicated or appropriate for surgery. Combining other anti-cancer therapies such as one or more of chemotherapy, radiotherapy, surgical therapy, or targeted therapy, the present recombinant interferon can effectively eliminate the tumors of the patients so as to achieve the effect of cure in some embodiments. In addition, compared with existing interferons such as INFERGEN®, the present recombinant interferon has less side effects, so that it can be used in larger doses.
    • A. Diseases and Conditions
  • The diseases and conditions suitable for the treatment and/or prevention method of the invention include tumors. As used herein, the term “tumor” refers to all uncontrolled and malignant neoplastic cell growth and proliferation as well as all cancerous cells and tissues, and abnormally or aberrantly proliferative cells. In some embodiments, the tumors include malignant tumors. As used herein, the term “cancer” refers to physiological conditions of mammal generally characterized by unregulated cell growth and/or proliferation. In the context, the terms “cancer” and “malignant tumor” can be used interchangeably.
  • In some embodiments, the tumors include solid tumors and non-solid tumors, optionally, the solid tumors. As used herein, the term “solid tumor” refers to the abnormal growth or caking of tissues, and generally does not include cyst or liquid areas. As used herein, the term “non-solid tumor” refers to neoplasia of the hemopoietic system, such as lymphoma, myeloma and leukemia, or neoplasia without solid formation generally and with spread substantially.
  • In some embodiment, the solid tumors include but not limited to lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma.
  • In some embodiments, the non-solid tumors include but not limited to leukemia, acute leukemia, chronic leukemia, chronic myelocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T-cell leukemia, hairy cell leukemia, polycythemia, myelodysplastic syndrome, multiple myeloma, lymphadenoma, Hodgkin's lymphoma, and Non-Hodgkin's lymphoma.
  • In some embodiments, the tumors are lung tumors, and include but not limited to abnormally proliferative or aberrantly proliferative lung cells and/or malignant lung tumor. As used herein, the term “lung tumor” refers to any lung tumors, therefore, such tumors can be primary lung tumors and/or metastatic lung tumors, for example, the tumors are formed in a way that tumors at other positions are metastasized to the lung through various metastasis modes. The lung tumors can be benign (non-carcinous), preinvasive lesion (precancerous lesion), or malignant (carcinous) lung tumors, such as lung cancers.
  • In a specific embodiment, the lung tumors are the lung cancers, and include but not limited to small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). As used herein, the term “lung cancer” refers to all types of lung cancers, and include but not limited to small cell lung cancer (SCLC) and the non-small cell lung cancer (NSCLC, including but not limited to adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma and sarcomatoid carcinoma). Further, the SCLC includes but not limited to complex small cell lung cancer; and the NSCLC includes but not limited to adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma, sarcomatoid carcinoma, carcinoid and salivary gland cancer. As used herein, the term “complex small cell lung cancer” refers to one lung cancer, wherein the ingredients of the non-small cell lung cancer, such as large cell carcinoma, are mixed in the small cell lung cancer.
  • In an embodiment, the lung tumors are preinvasive lesion (precancerous lesion), and include but not limited to squamous epithelial dysplasia of the lung, lung carcinoma in situ, atypical adenomatous hyperplasia of the lung, and diffuse and idiopathic neuroendocrine cell proliferation of the lung. In one embodiment, the metastatic lung tumors are the tumors formed in a way that breast cancer, colorectal cancer, stomach cancer, pancreatic cancer, renal cancer, malignant melanoma, prostate cancer, liver cancer, thyroid cancer and adrenal tumors and the like are metastasized to the lung.
  • In some embodiments, the tumors are metastasized, and such metastasis can be in situ and in the distance. As used herein and related to cancers or malignant tumors, the term “metastasis” refers to the spread of cancers or malignant tumors from the in-situ position to other in-vivo positions. Cancer cells can separate from in-situ tumors, penetrate into lymphatic vessels and blood vessels, and then grow in distant lesions in normal tissues at other in-vivo positions through blood circulation. The metastasis can be in situ or at the distance. The lung tumors such as lung cancers can metastasize to lymph nodes, brain, central nervous system, bone, liver, adrenal, skin, intestine, thyroid, ovary, prostate and the like. Therefore, the present recombinant interferon can be used for treating these metastasized tumors such as metastasized lung cancers; particularly, the present recombinant interferon can relieve the symptoms caused by partial stress and invasion of the lung cancers to adjacent tissues, and treat the distant metastasis of the lung cancers. The symptoms caused by the partial stress and invasion of the lung cancers include but not limited to dyscatabrosis caused by the metastasis and hyperplasia of lymph node around esophagus as well as dyspnea caused by the spread of tumors through the lung parenchyma lymphatic vessels. The distant metastases of the lung cancers include but not limited to brain metastases of the lung cancers, central nervous system metastases of the lung cancers, bone metastases of the lung cancers, liver metastases of the lung cancers, adrenal metastases of the lung cancers, and other metastases such as skin metastases, thyroid metastases, ovary metastases, prostate metastases and the like of the lung cancers.
  • In some embodiments, the tumors can be multiple primary cancers, for example, in the condition that the tumors are the lung cancers, such lung cancers can be multiple primary lung cancers such as the multiple primary lung cancers at different pulmonary segments or pulmonary lobes. As used herein, the term “multiple primary cancers” refers to more than two kinds of multiple primary malignant tumors that are formed at the same time or successively on a same body. Such multiple primary malignant tumors must be confirmed to be malignant and non-external metastasis tumors by histology. As used herein, the term “multiple primary lung cancers” refers to more than two multiple primary malignant tumors which are identical in histology and independent in existence, do not have metastasis between each other, and are generated at different pulmonary segments or pulmonary lobes.
  • The disease suitable for the treatment and/or prevention method of the invention also includes cancer emergencies, for example advanced cancer emergencies such as pleural effusion, ascites and/or pericardial effusion. In some embodiments, the pleural effusion, ascites and/or pericardial effusion are malignant pleural effusion, malignant ascites and/or malignant pericardial effusion. In some embodiments, the malignant pleural effusion can be caused by pleural primary tumors or pleural metastasized tumors, and is the common emergencies in the advanced lung cancers. The pleural primary tumors include malignant and diffuse mesothelioma, and the pleural metastasized tumors are originated from lung cancer, breast cancer, lymphoma, ovarian cancer, endometrial cancer, cervical cancer, stomach cancer, colorectal cancer, pancreatic cancer, bladder cancer, liver cancer and the like. In some embodiments, the malignant pericardial effusion can be caused by lung cancer, breast cancer and the like. For example, the malignant pericardial effusion can be caused in a way that the lung cancer can be metastasized or can directly invade pericardium, which is also the common expression of the advanced lung cancers. In some embodiments, the malignant ascites can be caused by malignant tumors, wherein excessive liquid is accumulated in enterocoelia, and the malignant ascites is one of the advanced emergencies of cancers, and the malignant ascites are generally caused by ovarian cancer, cervical cancer, endometrial cancer, digestive tract tumor, lymphoma, breast cancer, peritoneal mesothelioma and the like.
    • B. Subjects
  • The subject suitable for the treatment and/or prevention method of the invention includes mammal, which comprises but not limited to human and non-human mammal, optionally, the subject is human. In the context, the terms “subject” and “patient” can be used interchangeably. In some embodiments, the subject with tumors is the subject previously diagnosed with tumors such as malignant tumors.
  • In some embodiments, the subjects include but not limited to a subject with tumors such as malignant tumors that are not capable of being resected, a subject with tumors such as malignant tumors that are capable of being resected, a subject with cancers, a subject with metastasized tumors such as metastasized malignant tumors, and/or a subject with pleural effusion, ascites and/or pericardial effusion such as malignant pleural effusion, malignant ascites and/or malignant pericardial effusion. In some embodiments, the tumor is optionally resected by a surgical resection. In some embodiments, the subjects suffered from solid tumors. In some embodiments, the solid tumors are capable of being resected or are not capable of being resected, such as solid tumors that are capable of being resected or are not capable of being resected surgically. In some embodiments, the solid tumors that are capable of being resected or are not capable of being resected, such as solid tumors that are capable of being resected or are not capable of being resected surgically, are advanced, or stage III or stage IV solid tumors. In some embodiments, the subjects are the subjects with or without indications for cancers or tumors surgery such as lung cancers surgery. In some embodiments, the solid tumors are solid tumors with or without indications for surgery such as indications for tumor surgery. In some embodiments, the solid tumors with or without indications for surgery such as indications for tumor surgery, are advanced, or stage III or stage IV solid tumors. In some embodiments, the solid tumors are lung cancers.
  • As used herein, the term “indication for surgery” or “indicated for surgery” or “appropriate for surgery” refers to a surgical method which is employed when a disease is in accordance with the standard specified by treatment routine and cannot be cured by a non-surgical method and the surgical method can be employed for being helpful for the treatment of the disease. In some embodiments, the cancers without indications or not indicated for surgery include: (1) non-solid tumors or systematic tumors, such as leukemia, malignant lymphoma, bone tumor and the like; (2) cancers with extensive systematic metastases for which surgical treatment is of no value; (3) cancers at a position which is difficult for surgical resection, such as nasopharyngeal carcinoma, upper esophageal carcinoma, radix linguae carcinoma and the like; (4) cancers which easily metastasize at a very early stage, such as undifferentiated small cell lung cancer, so that surgical resection is generally not suggested; and (5) cancers with carcinoma cells which infiltrate into surrounding tissues while growing, have unclear boundary and cannot be completely resected by surgery, such as tonsil carcinoma, pancreas carcinoma and the like. In some embodiments, the solid tumors without indications or not indicated for surgery include: (1) systematic solid tumors such as bone tumor and the like; (2) solid tumors with extensive systematic metastases for which surgical treatment is of no value; (3) solid tumors at a position which is difficult for surgical resection, such as nasopharyngeal carcinoma, upper esophageal carcinoma, radix linguae carcinoma and the like; (4) solid tumors which easily metastasize at a very early stage, such as undifferentiated small cell lung cancer; and (5) solid tumors with carcinoma cells which infiltrate into surrounding tissues while growing, have unclear boundary and cannot be completely resected by surgery, such as tonsil carcinoma, pancreas carcinoma and the like.
  • As used herein, the term “tumors that are capable of being resected” are tumors which are limited to primary organs and are suitable for surgical therapy, such as malignant tumors. A subject with tumors such as malignant tumors that are not capable of being resected also includes a subject with tumors such as malignant tumors that are not capable of being resected surgically. Such surgery can include surgical procedures, minimally invasive operation and the like. In a specific embodiment, the subject with tumors such as malignant tumors that are capable of being resected includes a subject with tumors such as malignant tumors which can be resected surgically.
  • In some embodiments, the subjects include but not limited to early cancer patients, medium-term and advanced cancer patients, optionally medium-term or advanced cancer patients. As used herein, the term “early cancer” includes cancer in situ and stage I cancer, the term “medium-term cancer” includes stage II and stage III cancers, and the term “advanced cancer” refers to metastatic cancers with extensive infiltration in situ or with metastises at remote organs, such as stage IV cancer. In some embodiments, the subjects include but not limited to stage 0, I, II, III or IV cancer patients, optionally stage III or stage IV cancer patients; and the subjects with metastasized tumors such as metastasized malignant tumors includes but not limited to subjects with tumors such as malignant tumors which are metastasized in situ or in the distance. It should be understood that when the tumor or cancer is referred to as stage 0, I, II, III, or IV tumor or cancer, the stages of the tumor or cancer is defined by the TNM staging method well known in the art (see AJCC Cancer Staging Manual (Sixth Edition), Greene, F. L. et al. editor. LIAONING SCIENCE AND TECHNOLOGY PUBLISHING HOUSE, August 2005). For example, in the TNM staging method, the Stage 0 means T0N0M0; the Stage Ia means T1N0M0; the Stage Ib means T2N0M0; the Stage IIa means T1N1M0; the Stage IIb means T2N1M0 and T3N0M0; the Stage IIIa stage means T3N1M0 and T1-3N2M0; the Stage IIIb means any T, N3 and M0, T4, and any N and M0; and Stage IV means any T, and any N and M1. In some embodiments, the subjects are medium-term, advanced, or Stage III or Stage IV cancer patients. In some embodiments, the subjects are advanced, or Stage III or Stage IV cancer patients.
  • In some embodiments, the subjects with malignant pleural effusion, malignant ascites and/or malignant pericardial effusion include the subjects with malignant pleural effusion, malignant ascites and/or malignant pericardial effusion caused by cancers such as advanced, or Stage III or Stage IV cancers. In one embodiment, the cancers are lung cancers.
  • In some embodiments, the subjects suffered from tumors which can be lung tumors, such as lung cancers. In one embodiment, the subjects can be lung cancer patients, such as patients of lung cancer that is not capable of being resected surgically, the medium-term and advanced lung cancer patients, the Stage 0, I or II lung cancer patients, or Stage III or IV lung cancer patients, and the metastasized lung cancer patients or the lung cancer patients with malignant pleural effusion, malignant ascites and/or malignant pericardial effusion. In one embodiment, the lung cancer patients include but not limited to small cell lung cancer patients and non-small cell lung cancer patients.
    • C. Combination Therapy
  • In some embodiments of the method of the invention, other therapies or drugs can be administered to the subject before, simultaneously, and/or after administration of the present recombinant interferon. In some embodiments, the therapies are optionally anti-cancer therapies, and the drugs are optionally anti-tumor drugs. As used herein, the term “administration” refers to giving a substance to achieve the therapeutic purposes. As used herein, the term “combination therapy” refers to employing two or more treatment means for the subjects in the process of the treatment period, such as employing the present recombinant interferon and extra treatment means. The extra treatment means can be employed for the subjects before, simultaneously, and/or after administration of the present recombinant interferon. As used herein, the term “anti-cancer therapy” refers to a useful therapy in the cancer treatment.
  • In some embodiments, the other anti-cancer therapies include but not limited to chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immune therapy, targeted therapy, traditional Chinese medicine therapy and any combination thereof. The other anti-cancer therapies can be easily determined by the person skilled in the art. In some embodiments, the other anti-cancer therapies are optionally chemotherapy, radiotherapy, surgical therapy, targeted therapy and/or biotherapy. In some embodiments, the other anti-cancer therapies are optionally chemotherapy and/or radiotherapy.
  • As used herein, the term “chemotherapy” refers to a drug therapy affecting cell growth and cell division, namely, the drug therapy is taken as a cell proliferation inhibitor or is used for inducing cell death (cell apoptosis). Compared with normal cells, cancer cells grow and divide uncontrollably so that the chemotherapy should be more effective to the cancer cells. In a specific embodiment, chemotherapy includes arterial infusion chemotherapy and embolism-form chemotherapy. In a specific embodiment, for different cancers, the chemotherapy can be the common first-line chemotherapy for the cancers. For example, chemotherapeutic drugs used in the first-line chemotherapy for treating lung cancer include but not limited to platinum compounds such as Cisplatin.
  • The chemotherapeutic drugs used in the chemotherapy for the cancers in the invention include but not limited to alkylating agents such as nitrogen mustards including but not limited to chlormethine hydrochloride, chlorambucil, phenylalanine mustard, chlornaphazine, estramustine, cyclophosphamide, ifosfamide, Mechlorethamine, mustron, Melphalan, novembichin, phenesterin, Prednimustine, Trofosfamide and Uramustine; ethyleneimines and methyl melamines including but not limited triethylenemelamine, Thiotepa, MST-16, altretamine, triethylene melamine, triethylene phosphamide, triethylene Thiophosphoramide and trimethylol melamine; sulfoacid alkyl esters including but not limited to busulfan, improsulfan and piposulfan; and nitrosoureas including but not limited to carmustine, Semustine, Streptozotocin, chlorozotocin, Fotemustine, Lomustine, Nimustine and Ranimustine; antimetabolites such as anti-folate antimetabolite including but not limited to methopterin (MTX), trimethyl-oxy quinazoline, dimethyl folate, pteropterin, trimetrexate, leucovorin and Pemetrexed (Alimta); pyrimidine antimetabolites including 5-fluorouracil (5-FU), floxuridine, ftorafur (Tegafur), Capecitabine (Xeloda), Ancitabine, Carmofur, di-deoxyuridine, Doxifluridine and enocitabine; cytidines antimetabolites including but not limited to cytarabine, Azacytidine, ancitabine and Gemcitabine (Gemzar); purines antimetabolites including but not limited to 6-mercaptopurine, 6-thioguanine, deoxycoformycin, Fludarabine and thiamiprine; plant-origin anti-tumor drugs such as Vinca Alkaloids including but not limited to vinblastine, vindesine, vincristine, vindesine, Vinorelbine, vinblastine sulfate, vincristine sulfate, Vinorelbine Tartrate and Vinflunine; Harringtonine and Homoharringtonine; Indirubin and analogue thereof including but not limited to N-methyllisoinidog-tin; etoposide drugs including but not limited to Teniposide (VM-26) and Etoposide (VP-16); Camptotheca and Camptothecin compounds including but not limited to Camptothecin, Topotecan (TPT) and Irinotecan (CPT-11); Paclitaxel compound including but not limited to Paclitaxel (Paclitaxel Liposome For Injection), Docetaxel (Docetaxel Injection, Taxotere) and paclitaxel liposome; antitumor antibiotics such as anthracyclines including but not limited to daunorubicin, adriamycin, aclacinomycin A, Epirubicin, mitoxantrone and marcellomycin; Glycopeptides including but not limited to bleomycin, tallysomycine, Leroymycin, pepreomycin and Pingyangmycin; actinomycins including but not limited to actinomycin C, actinomycin D, aurantin and dactinomycin; glucosides including but not limited to mithramycin, chromomycin A3 and Olivomycin; mitomycins including but not limited to mitomycin C; and Streptozotocin; the platinum compounds include but not limited to Spiroplatin, Cisplatin, Carboplatin, Nedaplatin, oxaliplatin, Lobaplatin, JM-216, Ring Platinum, SKI2053R, L-NDDP and TRK-710; retinoid compounds include but not limited to all-trans retinoic acid and 13-cis-retinoic acid; hormones include androgens including but not limited to Testosterone Propionate, Methyltestosterone, Fluoxymesterone, durabolin, calusterone, propionic-acid methyl androstane pregnanolone, epithioandrostanol, mepitiostane and testolactone; antiandrogens including but not limited to flutamide, Nilutamide, Bicalutamide (Casodex), Goserelin, Leuprorelin and Androcur; estrogens including but not limited to diethylstilbestrol, estradiol and ethinyloestradiol; estrogen receptor blocker and composite drug formed by transplanting estrogen, including but not limited to Tamoxifen, Toremifene, Anastrozole and Exemestane; progesterones including but not limited to Methylhydroxyprogesterone and Megestrol Acetate; Gonadotropin releasing hormone analogues including but not limited to Leuprorelin, Gonadorelin and Dingsi-relin and naphthoxy-propyl-relin; adrenocortical hormone including but not limited to metacortandracin (prednisone) and dexamethasone (DXM); adrenal-cortex selective damaging agent including but not limited to Mitotane; thyroid hormones including but not limited to thyroxine; and others including but not limited to Bacillus Calmette Guerin (BCG), Asparaginase, hydroxycarbamide, Ibenzmethyzin and Dacarbazine (DTIC); and pharmaceutically acceptable salts, acids or derivatives of any above substance.
  • In some embodiments, chemotherapy protocols used for treating cancers such as lung cancers in the invention include but not limited to a CMC protocol (cyclohexyl nitrosourea, cyclophosphamide and Methotrexate), an EP protocol (etoposide and Cisplatin), an IVP protocol (ifosfamide, vindesine and Cisplatin), an ICE protocol (ifosfamide, Cisplatin and etoposide), a NIP protocol (Navelbine, ifosfamide and Cisplatin), a Paclitaxel+DDP/CBP protocol (Paclitaxel and Cisplatin/carboplatin), a docetaxel+DDP/CBP protocol (docetaxel and Cisplatin/carboplatin), a topotecan+DDP protocol (topotecan and Cisplatin), an IP protocol (Irinotecan and carboplatin), a MVP protocol (mitomycin, vindesine and Cisplatin), a NP protocol (Navelbine and Cisplatin), a docetaxel protocol, a GEM+DDP (GP) protocol or GEM+CBP protocol (Gemzar and Cisplatin/carboplatin) and the like (see Lung Oncology Phymatology, First Edition, September 2008, Liao, M. L. editor, Shanghai Scientific and Technical Publisher, pages 323-326).
  • In addition, other chemotherapy protocols used for treating tumors such as cancers in the invention include but not limited to an FOLFOX protocol (see Newest Chemotherapy Development of Malignant Tumors, July, 2009, chief editor: Zheng Cuiping, Beijing: People's Military Medical Press, 1031), a DP protocol (see Newest Chemotherapy Development of Malignant Tumors, July, 2009, chief editor: Zheng Cuiping, Beijing: People's Military Medical Press, 232), a CHOPE protocol, a MTX protocol, a GCE protocol, an ESAP protocol, a CMOP protocol, a CHOP protocol (see Practical Anti-tumor Pharmacotherapeutics, 2002, chief editor: Liu Xinchun etc., Beijing: People's Medical Publishing House, 1031), a bleomycin+CHOP+Methotrexate protocol, a GP+Endostar protocol, a GP-T2 protocol, a TP protocol (see Practical Anti-tumor Pharmacotherapeutics, 2002, chief editor: Liu Xinchun etc., Beijing: People's Medical Publishing House, 668 and 744), a Cisplatin+mitomycin protocol and the like.
  • As used herein, the term “radiotherapy” refers to employing high-energy radiation for treating tumors such as cancers. The radiotherapy includes external radiation such as external radiotherapy from a linear accelerator, and brachytherapy for which radioactive sources are placed near the surface of the human body or in the body cavity. In the radiotherapy of the invention, the radioactive sources include but not limited to α, β and γ rays generated by radioactive nuclides, and electron beams, proton beams. Neutron beams, −π meson beams and other heavy particle beams generated by various accelerators. The radioactive nuclides include but not limited to 137Cs, 60Co, 131I, 125I, 32P, 198Au, 192Ir, 90Y, 186Re and 109Pd. Such radioactive sources can perform radiation in vitro and/or in vivo.
  • It should be understood that many methods known in the art can be used for determining the accumulation and duration of the radiotherapy. The typical radiotherapy is employed as one-time administration, and the usual dose is in the range of about 1 to about 200 grays/day, such as about 2 to about 150 grays/day, about 5 to about 100 grays/day, about 10 to about 70 grays/day, about 10 to about 50 grays/day and the like. In one embodiment, the radiotherapy used in the invention includes but not limited to two-dimensional conventional radiotherapy, three-dimensional conformal radiotherapy (3D-CRT), proton radiotherapy, brachytherapy, intensity modulated radiotherapy (IMRT), stereotactic radiotherapy (SRT), respiratory gating four-dimensional radiotherapy (4DRT) and gamma knife therapy, such as systematic gamma knife therapy and head gamma knife therapy.
  • As used herein, the term “targeted therapy” refers to a therapy aiming at identifying specific target molecules which can be, for example, play a role in tumorigenesis or tumor proliferation or cell repairing. Such identification may be, for example, lead to the combination between the targeted therapy and the target molecules, and can enhance or reduce the activity of the target molecules. Drugs used for the targeted therapy includes antibodies, in particular to monoclonal antibodies and small molecule drugs. Potential targets include EGFR receptors, which playing a role in vasculogenesis, VEGFA ligands, which being important in vasculogenesis, or PARP1, which being important in cell repairing, because the tumors with cancer gene defect can be more sensitive to the chemical therapy due to the suppression to the PARP1.
  • In the targeted therapy of the present invention, the targeted drug includes but not limited to an anti-angiogenesis drug, Kinase inhibitor, pan Kinase inhibitor or growth factor inhibitor. The anti-angiogenesis drug includes but not limited to EGF inhibitor, EGFR inhibitor, VEGF inhibitor, VEGFR inhibitor, TIE2 inhibitor, IGF1R inhibitor, COX-II (cyclo-oxygenase-II) inhibitor, MMP-2 (matrix metalloproteinase-2) inhibitor and MMP-9 (matrix metalloproteinase-9) inhibitor. A targeted drug that can be used herein includes but not limited to at least one of: Gefitinib (Iressa), Erlotinib (TARCEVA®), Lapatinib (GSK572016), Vatalanib (PTK787), Imatinib (GLEEEVEC®), Dasatinib (Sprycel), Sunitinib (SUTENT®), Nilotinib (Tasigna), Semaxanib (SU5416), Pazopanib (GW-786034), Erbitux (IMC-C225), Panitumumab (Vectibix), Trastuzumab (Herceptin), Recombinant Human Endostatin (Endostar), Sorafenib (NEXAVAR®), Bevacizumab (Avastin), Alemtuzumab (Campath), Gemtuzumab (Mylotarg), ibritumomab tiuxetan (Zevalin), tositumomab (Bexxar), Affinitak (LY90003/ISI3521), Farnesyltransferase inhibitors, Tipifanib, Lonafanib, BMS214-662, R115777 (Zarnestra), SCH-66336 (Sarasar), L-778,123, ZD6474 (ZACTIMA®), AZD2171, OSI-7904, ZD6126 (ANG453), ZD1839, AMG706, AG013736, MLN-518, CEP-701, PKC-412, VELCADE®, XL880 and CHIR-265. In some embodiments, the targeted drug in the targeted therapy used for treating cancers such as lung cancers in the invention includes but not limited to Gefitinib (Iressa), Erlotinib (TARCEVA®), and Recombinant Human Endostatin (Endostar).
  • The dose and duration of the drugs and/or the radioactive sources used in the chemical therapy, radiotherapy and/or targeted therapy can be easily determined by skilled physicians according to the experience and the practical situations of patients such as age, weight, general health state, gender, diet, administration time, drug interaction and illness severity.
  • As used herein, the term “surgical therapy” refers to an invasive cancer therapy aiming at physically eliminating cancer cells. The surgical therapy includes, for example, tumor resection and lymph node dissection.
  • As used herein, the term “gene therapy” refers to a therapy by delivering recombinant genetic materials by virus or non-virus carriers ex vivo or in vivo so as to treat or prevent diseases or medical conditions, such as cancers.
  • As used herein, the term “ablation therapy” refers to a well known tissue damage method, such as high-temperature ablation such as radio frequency, microwave and laser ablation, low-temperature ablation such as cryocare knife cryotherapy, chemical ablation, radioactive ablation and the like.
  • As used herein, the term “immunotherapy” refers to a treatment strategy which is employed for regulating the immune system so as to prevent and/or treat specific diseases such as cancers. For example, vaccination is one immunotherapy. The vaccine used in the present immunotherapy includes but limited to ALLOVECTIN® vaccine, LEUVECTIN® vaccine, VAXID® vaccine and the like.
  • As used herein, the term “interventional therapy” refers to a treatment method with smallest trauma for performing local treatment to the lesion under the condition that the lesion is not operated through tiny channels made on the skin or original channels of the human body under the guidance of imaging equipment (such as a Digital Subtraction Angiography, a perspective machine, CT, MR and B ultrasonic). When being used for treating the tumors, the interventional therapy includes but not limited to transcatheter arterial chemoembolization, arterial infusion chemotherapy, high-temperature ablation such as radio frequency, microwave and laser ablation, low-temperature ablation such as cryocare knife cryotherapy, chemical ablation, radioactive ablation, gene drug arterial infusion, stent implantation and the like.
  • As used herein, the term “biotherapy” refers to all treatment methods employing modern biotechnologies and the products (small molecule compounds, polypeptide, polysaccharide, protein, cells, tissues, genes, RNAs and the like) thereof. When being used for treating the tumors, the biotherapy can directly or indirectly mediate anti-tumor and tumor-killing effects. The biotherapy used for treating the tumors includes but not limited to the application of non-specific immunologic stimulant, Biological Response Modifier (BRM), a tumor cell factor treatment and immunological effect cell treatments such as NK cell anti-tumor therapy, biology supporting therapy, tissue and cell transplanting therapy and the like.
  • As used herein, the term “traditional Chinese medicine therapy” refers to all methods employing the traditional Chinese medicine and drugs guided by Chinese medicine theories for treating diseases such as cancers.
  • In addition, other anti-tumor drugs which can be administered together with the present recombinant interferon include but not limited to biological agents used in the biotherapy such as tumor necrosis factors including TNF-α or TNF-β and the like; interferon such as interferon α including interferon α-1a, interferon α-1b, interferon α-2a, interferon α-2b and the like, interferon β including interferon β-1a, interferon β-1b and the like, interferon γ including interferon γ-1b and the like, consensus interferon such as interferonα-con1, long-acting interferon such as PEGylation interferon, fusion protein of interferon and albumin, and fusion protein of interferon and IgG Fc fragment; colony stimulating factors (CSF) such as macrophage-colony stimulating factor (M-CSF), granulocyte-macrophage (GM-CSF) and granulocyte-colony stimulating factor (G-CSF); interleukin (IL) such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, and Thymosin; antisense oligonucleotide, especially those for inhibition of the expression of genes (such as PKC-α, Raf and H-Ras) in signaling pathway involved in the proliferation of adherent cells; siRNA and the like.
    • D. Pharmaceutical Composition and Administration Route
  • The present recombinant interferon can be incorporated into pharmaceutical compositions, so as to be administered to subjects. Generally, the pharmaceutical composition comprises the present recombinant interferon and pharmaceutically acceptable carriers. The “pharmaceutically acceptable carrier” herein includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the present recombinant interferon.
  • The pharmaceutical compositions of the invention may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, aqueous solutions, tablets, capsules, oral solutions, patchs, sprays, suppositorys, powders and lyophilized powders. The form appropriate for use depends on the intended mode of administration and therapeutic application. Typical pharmaceutical compositions are in the form of injectables or infusible solutions, lyophilized powders, sprays, and aqueous solutions.
  • The pharmaceutical composition can be prepared by any well known method in the pharmaceutical field with reference to: Gilman, etc., (editor) 1990, The Pharmacological Bases of Therapeutics, the 8th version, Pergamon Press; A. Gennaro (editor), Remington's Pharmaceutical Sciences, the 18th version, 1990, Mack Publishing Co., Easton, Pa.; Avis, etc., (editor) 1993, Pharmaceutical Dosage Forms: Parenteral Medications Dekke, New York; Lieberman, etc., (editor) 1990, Pharmaceutical Dosage Forms: Tablets Dekker, New York; and Lieberman, etc., (editor) 1990, Pharmaceutical Dosage Forms: Disperse Systems Dekker, New York.
  • The present recombinant interferon can be administered to the subjects through at least one of: systemic administration, topical administration, and local administration. As used herein, the term “systemic administration” refers to a mode for administering compositions or drugs to a subject, in a manner that leads to systemic circulation of the drugs or compositions in the subject, such as the spreading or distribution of the administered compositions or drugs to all parts of the body. Examples of systemic administration include, but are not limited to: intravenous injection, intra-arterial injection, intramuscular injection, subcutaneous injection, intra-lymphatic injection, oral administration, and the like.
  • As used herein, the term “local administration” refers to administering a composition or drug into a limited or partial anatomy space. Examples of local administration include but are not limited to: intratumoral, intra-lymph node, intra-pleural space, intraperitoneal cavity and the like.
  • As used herein, the term “topical administration” refers to administering a drug or composition on the surface of skin or mucous membrane. For example, topical administration includes but is not limited to spraying the drug or composition onto the skin of a subject.
  • In some embodiments, the present recombinant interferon can be administered to the subject by at least one administration route, the administration route comprises but not limited to: oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, and intravesical administration. In some embodiments, the present recombinant interferon can be administered to the subject by injection route, such as subcutaneous, intramuscular, intravenous, intra-arterial, intracerebral, intraperitoneal and/or intratumoral injection. In some embodiments, the present recombinant interferon can be administered to the subject by inhalation, such as pulmonary inhalation and nasal inhalation. In some embodiments, the inhalation can be dry powder inhalation and/or aerosol inhalation. In some embodiments, the present recombinant interferon can be administered to the subject by perfusion, such as intrapleural perfusion, abdominal perfusion, pericardial perfusion, uterine perfusion and/or intravesical perfusion. In some embodiments, the present recombinant interferon can be administered to lesion (such as the surfaces of skin and mucosa, superficial lymph nodes and/or subcutaneous tissue) by spray, such as percutaneous, epidermal, transdermal and/or transmucosal spray administration. In some embodiments, the infiltration administration includes pulmonary infiltration administration, percutaneous infiltration administration, epidermal infiltration administration, transmucosal infiltration administration, intrapleural infiltration administration, abdominal infiltration administration, uterine infiltration administration, vaginal infiltration administration, intravesical infiltration administration, pericardial infiltration administration and the like.
    • Injection/Perfusion Administration
  • The pharmaceutical compositions suitable for injection/perfusion include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the composition must be sterile and should be fluid so as to be administered using a syringe. Such compositions should be stable during manufacture and storage and must be preserved against contamination from microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (such as glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures. Various antibacterial and antifungal agents; for example, parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal; isotonic agents; for example, sugars, polyalcohols such as manitol, sorbitol, and sodium chloride can be included in the composition. Compositions that can delay absorption include agents such as aluminum monostearate and gelatin.
  • Sterile injection/perfusion solutions can be prepared by incorporating the present recombinant interferon in the required amount in an appropriate solvent with one or a combination of ingredients as required, followed by sterilization. Generally, dispersions are prepared by incorporating the present recombinant interferon into a sterile vehicle that contains a basic dispersion medium, and the other required ingredients. Sterile powders for the preparation of sterile injection/perfusion solutions, methods of preparation include vacuum drying and freeze-drying that yield a powder containing the active ingredient and any desired ingredient from a sterile solutions.
    • Inhalation Administration
  • The present recombinant interferon can be delivered by any of a variety of inhalation devices know in the art for administration of a therapeutic agent by inhalation. These devices include metered dose inhalers, nebulizers, dry powder generators, sprayers, and the like. Other devices suitable for inhalation administration of the present recombinant interferon are also known in the art.
  • Metered dose inhalers like the Ventolin® metered dose inhaler, typically use a propellent gas and require actuation during inspiration (See, e.g., WO 94/16970, WO 98/35888). Dry powder inhalers like Turbuhaler™ (Astra), Rotahaler® (Glaxo), Diskus® (Glaxo), Spiros™ inhaler (Dura), devices marketed by Inhale Therapeutics, and the Spinhaler® powder inhaler (Fisons), use breath-actuation of a mixed powder (U.S. Pat. No. 4,668,218 Astra, EP 237507 Astra, WO 97/25086 Glaxo, WO 94/08552 Dura, U.S. Pat. No. 5,458,135 Inhale, WO 94/06498 Fisons). Nebulizers like AERx™ Aradigm, the Ultravent® nebulizer (Mallinckrodt), the Acorn II® nebulizer (Marquest Medical Products) (U.S. Pat. No. 5,404,871 Aradigm, WO 97/22376), and the AP-100200 type spray inhaler (Taiwan Albert incorporated company). Producing aerosols from solutions, while metered dose inhalers, dry powder inhalers, etc. generate small particle aerosols.
  • Optionally, the present recombinant interferon is delivered by a nebulizer. The inhalation devices for administering the present recombinant interferon have several desirable features. For example, delivery by the inhalation device is advantageously reliable, reproducible, and accurate. The inhalation device can optionally deliver small dry particles or aerosol, e.g., less than about 10 μm, for example about 0.5 μm to about 5 μm, for good respirability.
    • Spray Administration
  • A spray including the present recombinant interferon can be produced by forcing a suspension or solution of the recombinant interferon through a nozzle under pressure. The nozzle size and configuration, the applied pressure, and the liquid feed rate can be chosen to achieve the desired output and particle size. An electrospray can be produced, for example, by an electric field in connection with a capillary or nozzle feed. Advantageously, particles delivered by a sprayer have a particle size less than about 10 μm, optionally, in the range of about 0.5 μm to about 5 μm.
  • Formulations of the present recombinant interferon suitable for use with a sprayer typically include ones at a concentration in a range of about 0.01 mg to about 5 mg, such as about 0.03 mg to about 2 mg, about 0.05 mg to about 1 mg, and about 0.1 mg to about 0.5 mg of the recombinant interferon per ml of solution. The formulation can include an excipient or agent for stabilization of the present recombinant interferon, such as a buffer, a reducing agent, a bulk protein, or a carbohydrate. Bulk proteins useful in formulating the recombinant interferon include albumin, protamine, or the like. Typical carbohydrates useful in formulating the recombinant interferon include sucrose, mannitol, lactose, trehalose, glucose, or the like. The present recombinant interferon formulation can also include a surfactant, which can reduce or prevent surface-induced aggregation of the recombinant interferon caused by atomization of the solution in forming an aerosol.
    • E. Administration Dosage and Administration Protocol
  • Effective amount of the present recombinant interferon can be administered to the subjects such as cancer subjects, and such effective amount can be a therapeutically effective amount or a prophylactically effective amount according to the method of the invention. As used herein, the term “effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. A therapeutically effective amount of the present recombinant interferon may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the recombinant interferon to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the recombinant interferon are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically but no surely, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
  • The present recombinant interferon can be administered to the subjects such as the cancer subjects in different amounts of single doses. For example, the single doses of the present recombinant interferon can be in the range of about 2 μg to about 2000 μg, optionally about 4 μg to about 1500 μg, and further optionally about 9 μg to about 1000 μg. As used herein, the term “single dose” refers to an amount of drug which can be at administered one time, that can be therapeutically or prophylactically effective by itself or cumulatively with other single doses. Such administration includes systemic administration, local administration and/or topical administration.
  • When the present recombinant interferon is systemically administered via injection administration (such as subcutaneous injection, intramuscular injection, intravenous injection, intra-arterial injection, intracerebral injection and/or intraperitoneal injection), the single dose of the recombinant interferon can be in the range of about 4 μg to about 70 μg, optionally, about 4 μg to about 50 μg, and further optionally, about 4 μg to about 30 μg, wherein the single dose can be about 4 μg, about 4.5 μg, about 5 μg, about 6 μg, about 7 μg, about 8 μg, about 9 μg, about 10 μg, about 11 μg, about 12 μg, about 13 μg, about 13.5 μg, about 14 μg, about 15 μg, about 16 μg, about 17 μg, about 18 μg, about 19 μg, about 20 μg, about 21 μg, about 22 μg, about 23 μg, about 24 μg, about 25 μg, about 25.5 μg, about 26 μg, about 27 μg, about 28 μg, about 29 μg, about 30 μg, about 31 μg, about 32 μg, about 33 μg, about 34 μg, about 35 μg, about 36 μg, about 37 μg, about 38 μg, about 39 μg, about 40 μg, about 41 μg, about 42 μg, about 43 μg, about 44 μg, about 45 μg, about 46 μg, about 47 μg, about 48 μg, about 49 μg, about 50 μg, about 51 μg, about 52 μg, about 53 μg, about 54 μg, about 55 μg, about 56 μg, about 57 μg, about 58 μg, about 59 μg, about 60 μg, about 61 μg, about 62 μg, about 63 μg, about 64 μg, about 65 μg, about 66 μg, about 67 μg, about 68 μg, about 69 μg, and about 70 μg.
  • When the present recombinant interferon is locally administered via injection administration (such as the intratumoral injection), the single dose of the recombinant interferon can be in a range of about 60 μg to about 600 μg, optionally, about 60 μg to about 500 μg, further optionally, about 80 μg to about 400 μg, and still further optionally, about 100 μg to about 250 μg, wherein the single dose can be about 60 μg, about 70 μg, about 80 μg, about 90 μg, about 100 μg, about 110 μg, about 120 μg, about 130 μg, about 140 μg, about 150 μg, about 160 μg, about 170 μg, about 180 μg, about 190 μg, about 200 μg, about 210 μg, about 220 μg, about 230 μg, about 240 μg, about 250 μg, about 260 μg, about 270 μg, about 280 μg, about 290 μg, about 300 μg, about 310 μg, about 320 μg, about 330 μg, about 340 μg, about 350 μg, about 360 μg, about 370 μg, about 380 μg, about 390 μg, about 400 μg, about 410 μg, about 420 μg, about 430 μg, about 440 μg, about 450 μg, about 460 μg, about 470 μg, about 480 μg, about 490 μg, about 500 μg, about 510 μg, about 520 μg, about 530 μg, about 540 μg, about 550 μg, about 560 μg, about 570 μg, about 580 μg, about 590 μg, and about 600 μg.
  • When the present recombinant interferon is administered through inhalation administration (such as pulmonary inhalation and nasal inhalation, including dry powder inhalation and aerosol inhalation), the single dose of the recombinant interferon can be in a range of about 100 μg to about 2000 μg, optionally, about 100 μg to about 1500 μg, further optionally, about 150 μg to about 800 μg, and still further optionally, about 200 μg to about 600 μg, wherein the single dose can be about 100 μg, about 110 μg, about 120 μg, about 130 μg, about 140 μg, about 150 μg, about 160 μg, about 170 μg, about 180 μg, about 190 μg, about 200 μg, about 210 μg, about 220 μg, about 230 μg, about 240 μg, about 250 μg, about 260 μg, about 270 μg, about 280 μg, about 290 μg, about 300 μg, about 310 μg, about 320 μg, about 330 μg, about 340 μg, about 350 μg, about 360 μg, about 370 μg, about 380 μg, about 390 μg, about 400 μg, about 410 μg, about 420 μg, about 430 μg, about 440 μg, about 450 μg, about 460 μg, about 470 μg, about 480 μg, about 490 μg, about 500 μg, about 510 μg, about 520 μg, about 530 μg, about 540 μg, about 550 μg, about 560 μg, about 570 μg, about 580 μg, about 590 μg, about 600 μg, about 610 μg, about 620 μg, about 630 μg, about 640 μg, about 650 μg, about 660 μg, about 670 μg, about 680 μg, about 690 μg, about 700 μg, about 710 μg, about 720 μg, about 730 μg, about 740 μg, about 750 μg, about 760 μg, about 770 μg, about 780 μg, about 790 μg, about 800 μg, about 810 μg, about 820 μg, about 830 μg, about 840 μg, about 850 μg, about 860 μg, about 870 μg, about 880 μg, about 890 μg, about 900 μg, about 910 μg, about 920 μg, about 930 μg, about 940 μg, about 950 μg, about 960 μg, about 970 μg, about 980 μg, about 990 μg, about 1000 μg, about 1100 μg, about 1200 μg, about 1300 μg, about 1400 μg, about 1500 μg, about 1600 μg, about 1700 μg, about 1800 μg, about 1900 μg, and about 2000 μg.
  • When the present recombinant interferon is administered through perfusion or infiltration administration (such as intrapleural perfusion, abdominal perfusion, pericardial perfusion, uterine perfusion and intravesical perfusion), the single dose of the recombinant interferon can be in a range of about 30 μg to about 2000 μg, optionally, about 100 μg to about 1500 μg, further optionally, about 150 μg to about 1000 μg, still optionally, about 200 μg to about 800 μg, and still further optionally, about 200 μg to about 400 μg, wherein the single dose can be about 30 μg, about 40 μg, about 50 μg, about 60 μg, about 70 μg, about 80 μg, about 90 μg, about 100 μg, about 110 μg, about 120 μg, about 130 μg, about 140 μg, about 150 μg, about 160 μg, about 170 μg, about 180 μg, about 190 μg, about 200 μg, about 210 μg, about 220 μg, about 230 μg, about 240 μg, about 250 μg, about 260 μg, about 270 μg, about 280 μg, about 290 μg, about 300 μg, about 310 μg, about 320 μg, about 330 μg, about 340 μg, about 350 μg, about 360 μg, about 370 μg, about 380 μg, about 390 μg, about 400 μg, about 410 μg, about 420 μg, about 430 μg, about 440 μg, about 450 μg, about 460 μg, about 470 μg, about 480 μg, about 490 μg, about 500 μg, about 510 μg, about 520 μg, about 530 μg, about 540 μg, about 550 μg, about 560 μg, about 570 μg, about 580 μg, about 590 μg, about 600 μg, about 610 μg, about 620 μg, about 630 μg, about 640 μg, about 650 μg, about 660 μg, about 670 μg, about 680 μg, about 690 μg, about 700 μg, about 710 μg, about 720 μg, about 730 μg, about 740 μg, about 750 μg, about 760 μg, about 770 μg, about 780 μg, about 790 μg, about 800 μg, about 810 μg, about 820 μg, about 830 μg, about 840 μg, about 850 μg, about 860 μg, about 870 μg, about 880 μg, about 890 μg, about 900 μg, about 910 μg, about 920 μg, about 930 μg, about 940 μg, about 950 μg, about 960 μg, about 970 μg, about 980 μg, about 990 μg, about 1000 μg, about 1100 μg, about 1200 μg, about 1300 μg, about 1400, about 1500 μg, about 1600 μg, about 1700 μg, about 1800 μg, about 1900 μg, and about 2000 μg.
  • When the present recombinant interferon is administered to the lesions (such as surfaces of the skin and the mucosa, superficial lymph nodes and/or subcutaneous tissue) by spray administration such as percutaneous spray, epidermal spray, transdermal spray, transmucosal spray, the single dose of the recombinant interferon can be in a range of about 6 μg to about 100 μg, optionally, about 10 μg to about 40 μg, and further optionally, about 20 μg to about 40 μg, wherein the single dose can be about 6 μg, about 7 μg, about 8 μg, about 9 μg, about 10 μg, about 11 μg, about 12 μg, about 13 μg, about 14 μg, about 15 μg, about 16 μg, about 17 μg, about 18 μg, about 19 μg, about 20 μg, about 21 μg, about 22 μg, about 23 μg, about 24 μg, about 25 μg, about 26 μg, about 27 μg, about 28 μg, about 29 μg, about 30 μg, about 31 μg, about 32 μg, about 33 μg, about 34 μg, about 35 μg, about 36 μg, about 37 μg, about 38 μg, about 39 μg, about 40 μg, about 41 μg, about 42 μg, about 43 μg, about 44 μg, about 45 μg, about 46 μg, about 47 μg, about 48 μg, about 49 μg, about 50 μg, about 51 μg, about 52 μg, about 53 μg, about 54 μg, about 55 μg, about 56 μg, about 57 μg, about 58 μg, about 59 μg, about 60 μg, about 61 μg, about 62 μg, about 63 μg, about 64 μg, about 65 μg, about 66 μg, about 67 μg, about 68 μg, about 69 μg, about 70 μg, about 71 μg, about 72 μg, about 73 μg, about 74 μg, about 75 μg, about 76 μg, about 77 μg, about 78 μg, about 79 μg, about 80 μg, about 81 μg, about 82 μg, about 83 μg, about 84 μg, about 85 μg, about 86 μg, about 87 μg, about 88 μg, about 89 μg, about 90 μg, about 91 μg, about 92 μg, about 93 μg, about 94 μg, about 95 μg, about 96 μg, about 97 μg, about 98 μg, about 99 μg, and about 100 μg.
  • The present recombinant interferon can be administered to the subjects through different administration protocols. For example, for the purpose of treatment, the present recombinant interferon can be administered to the subject about 1, 2, 3, 4, 5, 6, 7, 8, or more times per day, or the present recombinant interferon can be administered to the subject once at the time interval of every about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days, every month, every 2 months, or longer time. For the purpose of prevention, the present recombinant interferon can be administered to the subject once at the time interval of every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, every 2 weeks, every 3 weeks, every month, every 2 months, every 3 months, every half year, every 1 year, or a longer time.
  • The present recombinant interferon can be administered to the subjects in one or more treatment cycles. As used herein, the term “treatment cycle” refers to a biological or medical response time length reached by the present recombinant interferon or the pharmaceutical composition comprising the recombinant interferon, and explored for researchers, veterinarians, medical practitioners or other clinicians observed in tissues, systems, animals, individuals or human beings. The duration of such one treatment cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like. The present recombinant interferon can be administered for a long time, namely, namely, the lasting prolonged time in one treatment cycle includes over the life time of the subject so as to improve or control or limit the symptom of the subjects. In one treatment cycle, the present recombinant interferon can be administered to the subjects one or more times.
  • Alternatively, the present recombinant interferon can be administered to the subjects in more treatment cycles. For example, such treatment cycles can be 2, 3, 4, 5, 6, 7, 8, 9, 10, or more treatment cycles; and the duration of the treatment cycles can include over the life time of the subject. The time intervals (i.e. withdrawal period) of any two adjacent treatment cycles in all the treatment cycles can be the same or different, for example, the time interval can be at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like; and such time interval can also be about 2 days to about 6 years, about 4 days to about 3 years, about 1 week to about 1 year, about 2 months to about 9 months, or about 3 months to about 6 months and the like.
  • When the present recombinant interferon is administered for more times in one treatment cycle, the dose in every administration can be the same or different, for example, the present recombinant interferon is administered for one or more times in a lower dose, and then the present recombinant interferon is administered for one or more times in an increased or gradually-increased dose; or, the present recombinant interferon is administered for one or more times in a smaller dose, then the present recombinant interferon is administered for one or more times in an increased or gradually-increased dose, and the present recombinant interferon is administered for one or more times in a decreased or gradually-decreased dose; or, the present recombinant interferon is administered for one or more times in a larger dose, and then the present recombinant interferon is administered for one or more times in a decreased or gradually-decreased dose; or, the present recombinant interferon is administered for one or more times in a larger dose, then the present recombinant interferon is administered for one or more times in a decreased or gradually-decreased dose, and the present recombinant interferon is administered for one or more times in an increased or gradually-increased dose. In some embodiments, the smaller dose can be the induction dose.
  • Compared with the previously administered dose, the later increasingly administered dose can be about 110% to about 500%, including, for example about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 220%, about 240%, about 260%, about 280%, about 300%, about 350%, about 400%, about 450% and about 500%, of the previously administered dose. Compared with the previously administered dose, the later gradually-increased administered dose can be about 110% to about 500% including, for example about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 220%, about 240%, about 260%, about 280%, about 300%, about 350%, about 400%, about 450% and about 500%, of the previously administered dose sequentially. The gradually-increased dose can be increased by 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, or more times, and then the last dose can be kept till the end of the treatment cycle.
  • Compared with the previously administered dose, the later decreasingly administered dose can be about 5% to about 99% including, for example, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% and about 99%, of the previously administered dose. Compared with the previously administered dose, the later gradually-decreased administered dose can be about 5% to about 99% including, for example, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% and 99%, of the previously administered dose sequentially. The gradually-decreased dose can be decreased by 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, or more times, and then the last dose can be kept till the end of the treatment cycle.
  • In addition, when the present recombinant interferon is administered for one or more times in the same single dose in each of the treatment cycles, the single doses of the present recombinant interferon in two different treatment cycles can be the same or different. For example, the single dose can be gradually increased or decreased. Compared with the previously administered dose, the increasing or decreasing degree is as mentioned above.
  • In some embodiments, the gradually increasing or the gradually decreasing can be linear increasing or decreasing, for example, the first administered drug is 9 μg, then the later increased dose is 18 μg, 36 μg, 72 μg and the like sequentially, namely, the sequential increasing rate is 100%; or, the gradually increasing or the gradually decreasing can be non-linear increasing or decreasing, for example, the first administered drug is 9 μg, then the later increased dose can be 15 μg, 18 μg, 21 μg and the like, namely, compared with the previous administered drug, the drug increasing degree at every time can be different.
  • It should be noted that the administration dosage and the administration protocol can be changed reasonably by the person skilled in the art based on the teaching of the invention, with the type and severity of the disorder to be released, the subject, the administration methods and the like.
    • F. Specific Treatment Methods and Pharmaceutical Applications.
  • Specific treatment methods and pharmaceutical applications with use of the present recombinant interferon are provided herein.
  • In one aspect, the present invention provides a method for treating a tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • In one embodiment, the present invention provides a method for treating tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, and at least one other anti-cancer therapy, wherein the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon, and wherein the tumor is a cancer or solid tumor that is not indicated nor appropriate for surgery, or the tumor is a solid tumor that cannot be resected, and the combination of the recombinant interferon and the at least one other anti-cancer therapy eliminate the tumor or reduce the size of the tumor compared to the tumor before treatment.
  • In one embodiment, the present invention provides a method for preventing tumor recurrence and/or metastasis or prolonging or maintaining a tumor-free status in a subject with a tumor after at least one anti-cancer therapy, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • In one embodiment, the present invention provides a non-surgical method for eliminating a tumor in a subject or reducing the size of a tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • In one embodiment, the present invention provides a method for eliminating or reducing the pleural effusion, ascites, and/or pericardial effusion in a subject with tumor, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • In one embodiment, the present invention provides a method for treating tumor in a subject, comprising topically or locally administering to the tumor lesions of the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • In one embodiment, the present invention provides a method for eliminating or reducing metastatic tumor lesions in a subject, comprising topically or locally administering to the metastatic tumor lesions of the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • In one embodiment, the present invention provides a method for eliminating or reducing the bone metastatic lesions of tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by topical or local administration, wherein the topical or local administration comprises transdermal administration and/or infiltration administration, optionally, the recombinant interferon is administered to the bone metastatic lesions of tumor of the subject.
  • In one embodiment, the present invention provides a method for eliminating or reducing the bone lesions of tumor such as bone metastatic lesions of tumor, muscular lesions of tumor such as muscular metastatic lesions of tumor, subcutaneous tissue lesions of tumor such as subcutaneous tissue metastatic lesions of tumor, prostatic lesions of tumor such as prostatic metastatic lesions of tumor, and/or lymph node lesions of tumor such as lymph node metastatic lesions of tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by any administration route through the skin, so that eliminating or reducing the bone lesions of tumor such as bone metastatic lesions of tumor, muscular lesions of tumor such as muscular metastatic lesions of tumor, subcutaneous tissue lesions of tumor such as subcutaneous tissue metastatic lesions of tumor, prostatic lesions of tumor such as prostatic metastatic lesions of tumor, and/or lymph node lesions of tumor such as lymph node metastatic lesions of tumor, optionally, the recombinant interferon is administered to the metastatic lesions of tumor of the subject.
  • In another aspect, the present invention provides a method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
  • In one embodiment, the present invention provides a method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 and one or more chemotherapeutic drugs in two or more treatment cycles, and then administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 and one or more targeted drugs in one or more treatment cycles.
  • In one embodiment, the present invention provides a method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by subcutaneous administration and/or intramuscular administration, wherein the recombinant interferon is administered in an amount in a range of about 2 μg to about 70 μg, optionally about 4 μg to about 50 μg, further optionally about 4 μg to about 30 μg by one subcutaneous administration and/or intramuscular administration, the recombinant interferon is administered by subcutaneous administration and/or intramuscular administration once every about 1 to about 7 days, optionally every about 1 to about 2 days, lasting at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • In one embodiment, the present invention provides a method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by subcutaneous administration and/or intramuscular administration, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose in a range of about 10 μg to about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time.
  • In one embodiment, the present invention provides a method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to brain, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose in a range of about 10 μg to about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time, and the recombinant interferon is administered to the subject by inhalation administration before, simultaneously, and/or after the subcutaneous administration and/or intramuscular administration, the recombinant interferon is administered in an amount in a range of about 100 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 800 μg, still further optionally about 200 μg to about 600 μg by one inhalation administration, and the recombinant interferon is administered by inhalation administration once every about 1 day to about 3 days, optionally every about 1 day.
  • In one embodiment, the present invention provides a method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to bone or liver, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 μg-about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time.
  • In one embodiment, the present invention provides a method for treating cancer in a subject, wherein the cancer originates from lung cancer in the subject and metastasizes to lymph nodes, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered one or more times by subcutaneous administration and/or intramuscular administration at an induction dose in a range of about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to about 9 μg each time, such as about 4.5 μg each time or about 9 μg each time, and then the recombinant interferon is administered more times by subcutaneous administration and/or intramuscular administration at a therapeutic dose of about 10 μg to about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time, and the recombinant interferon is administered to the tumor and/or the lymph nodes metastases by topical or local administration before, simultaneously, and/or after the subcutaneous administration and/or intramuscular administration.
  • In one embodiment, the present invention provides a method for treating lung cancer in a subject, wherein the subject has pleural effusion, ascites and/or pericardial effusion, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2 by topical or local administration.
  • In another aspect, the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for treating tumors in a subject.
  • In one embodiment, the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 and other anti-tumor drugs in preparation of drugs for treating tumors in a subject.
  • In one embodiment, the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for preventing tumor recurrence and/or metastasis after anti-tumor therapies in a subject.
  • In one embodiment, the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for eliminating a tumor or reducing the size of a tumor in a subject by non-surgical method.
  • In one embodiment, the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for eliminating or reducing pleural effusion, ascites, and/or pericardial effusion in a subject with tumor.
  • In one embodiment, the present invention provides a uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for treating lung cancer in a subject.
  • In one embodiment, the present invention provides uses of a recombinant interferon encoded by SEQ ID NO: 2 in preparation of drugs for treating lung cancer in a subject in combination with chemotherapeutic drugs, targeted drugs.
  • In some embodiments, the subject is an early, medium-term, or advanced cancer patient, optionally, the subject is a medium-term, or advanced cancer patient, further optionally, the subject is an advanced cancer patient, such as an advanced lung cancer patient.
  • In some embodiments, the subject can be a stage 0, I, II, III, or IV cancer patient, optionally, the subject is an stage III or stage IV cancer patient, such as an stage III or stage IV lung cancer patient. Such cancer patient can be a patient with metastasized tumors, such as the tumors which are metastasized in situ or in the distance.
  • In some embodiments, the subject is a medium-term, advanced cancer patient, or stage III or stage IV cancer patient, optionally, the subject is an advanced, or stage III or stage IV cancer patient.
  • In some embodiments, the tumor is a cancer or a solid tumor with or without indications for surgery.
  • In some embodiments, the tumor in a subject is a tumor that is capable of being resected. In some embodiments, the tumor in a subject is a tumor that is not capable of being resected. In some embodiments, the surgeries include but not limited to surgical procedures.
  • In some embodiments, the subject is a subject with solid tumors.
  • In some embodiments, the solid tumor is a solid tumor that is capable of or is not capable of being resected.
  • In some embodiments, the solid tumor that is capable of or is not capable of being resected is an advanced solid tumor.
  • In some embodiments, the solid tumor is a solid tumor with or without indications for surgery, such as indications for tumor surgery.
  • In some embodiments, the solid tumor with or without indications for surgery such as indications for tumor surgery is an advanced, or stage III or stage IV solid tumor.
  • In some embodiments, the tumor is a solid tumor. The solid tumor comprises one or more of: lung cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, cholangiocarcinoma, gallbladder carcinoma, stomach cancer, abdominal cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, renal cancer, bone cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, bladder cancer, superficial bladder cancer, prostate cancer, adrenal tumors, squamous cell carcinoma, neuroma, malignant neuroma, myoepithelial carcinoma, synovial sarcoma, rhabdomyosarcoma, gastrointestinal interstitial cell tumor, skin cancer, basal cell carcinoma, malignant melanoma, thyroid cancer, nasopharyngeal carcinoma, hemangioma, epidermoid carcinoma, head and neck cancer, glioma, or Kaposi's sarcoma; optionally, lung cancer; further optionally, the lung cancer comprises small cell lung cancer (SCLC), non small cell lung cancer (NSCLC), or both.
  • In some embodiments, the tumor is a non-solid tumor. The non-solid tumor comprises one or more of leukemia, acute leukemia, chronic leukemia, chronic myelocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T-cell leukemia, hairy cell leukemia, polycythemia, myelodysplastic syndrome, multiple myeloma, lymphadenoma, Hodgkin's lymphoma, or Non-Hodgkin's lymphoma.
  • In some embodiments, the effective amount is a therapeutically effective amount or a prophylactically effective amount. In some embodiments, the present recombinant interferon can be administered to the subject in single dose of about 2 μg to about 2000 μg, optionally, about 4 μg to about 1500 μg, further optionally, about 9 μg to about 1000 μg, and still further optionally, about 9 μg to about 600 μg. In certain embodiments, when the present recombinant interferon is administered by systemic administration, the therapeutically effective amount is about 2 μg to about 70 μg, optionally about 4 μg to about 50 μg, further optionally about 4 μg to about 30 μg, and still further optionally, about 9 μg to about 30 μg. In specific embodiments, when the present recombinant interferon is administered by systemic administration, the prophylactically effective amount is about 2 μg to about 70 μg, optionally about 4 μg to about 50 μg, further optionally about 4 μg to about 30 μg, and still further optionally, about 9 μg to about 30 μg.
  • In some embodiments, the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by at least one of: systemic administration, topical administration, and local administration. In some embodiments, the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by an administration route, the administration route comprises one or more of oral, rectal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intra-bone, intracutaneous, intra-articular, intraperitoneal, intrathecal, intracerebral, vaginal, percutaneous, transdermal, epidermal, transmucosal, transocular, pulmonary, nasal, abdominal, intrapleural, intraventricular, pericardial, inhalation, intratumoral, uterine, infiltration, or intravesical administration. In some specific embodiments, the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by subcutaneous, intramuscular, inhalation, infiltration, intrapleural, abdominal, pericardial, intratumoral, spary administration or any combination thereof. In some embodiments, the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by intramuscular and/or subcutaneous administration. In some embodiments, when the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant are administered to the operative site, which can be administered to the subject by topical or local administration, such as infiltration, intrapleural, abdominal, pericardial, uterine, intravesical, intratumoral, pulmonary, nasal, percutaneous, transdermal, epidermal, and/or transmucosal administration.
  • In some embodiments, the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be administered to the subject by injection, such as subcutaneous, intramuscular, intravenous, intra-arterial, intracerebral, intraperitoneal, intratumoral, intra-articular, intrathecal and intra-bone injection and the like. In some embodiments, when administering by inhalation, the inhalation can be pulmonary and/or nasal inhalation. In some specific embodiments, the inhalation administration can be dry powder inhalation or aerosol inhalation. In some embodiments, when administering by intrapleural, abdominal, uterine, intravesical, pericardial administration, the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be further administered to the subject by perfusion, such as intrapleural, abdominal, uterine, intravesical, and/or pericardial perfusion. In some embodiments, when administering by percutaneous, transdermal, epidermal or transmucosal administration, the present recombinant interferon and/or chemotherapeutic drugs, targeted drugs, biological drugs and the like combined with the present recombinant interferon can be further administered to the subject by spray, such as percutaneous, epidermal, transdermal and/or transmucosal spray.
  • When the present recombinant interferon is systemically administered via injection administration (such as subcutaneous injection, intramuscular injection), the single dose can be about 2 μg to about 70 μg, optionally about 4 μg to about 50 μg, and further optionally about 4 μg to about 30 μg, including but not limited to about 2 μg, about 3 μg, about 4 μg, about 4.5 μg, about 9 μg, about 13.5 μg, about 15 μg, about 18 μg, about 21 μg, about 25.5 μg, about 30 μg, about 40 μg, about 50 μg, about 60 μg, and about 70 μg. In some embodiments, the present recombinant interferon is administered by subcutaneous and/or intramuscular administration once every about 1 day to about 7 days, optionally once every about 1 day to about 2 days. In some embodiments, the injection lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • When the present recombinant interferon is locally administered via injection administration (such as the intratumoral injection), the single dose of the recombinant interferon can be in the range of about 60 μg to about 600 μg, optionally about 60 μg to about 500 μg, further optionally about 80 μg to about 400 μg, and still further optionally about 100 μg to about 250 μg. In some embodiments, the present recombinant interferon is administered via intratumoral administration once every about 1 day to about 10 days, optionally once every about 1 day to about 7 days such as every about 1, 2, 3, 4, 5, 6 or 7 days. In some embodiments, the intratumoral administration such as intratumoral injection lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like. In specific embodiments, when the present recombinant interferon is administered via intratumoral administration, the protocol of intratumoral administration is as follow: the recombinant interferon is administered by intratumoral injection once every about 1 day for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 3 days to about 5 days for about 4 to about 8 times, and then the recombinant interferon is administered by intratumoral injection once every about 7 days, the intratumoral administration is stopped when the tumor disappears or becomes too small to conduct the intratumoral injection, wherein the recombinant interferon is administered in an amount of about 60 μg to about 600 μg, optionally about 60 μg to about 500 μg, further optionally about 80 μg to about 400 μg, still further optionally about 100 μg to about 250 μg by once intratumoral injection.
  • When the present recombinant interferon is administered via inhalation (such as pulmonary and nasal inhalation, including dry powder inhalation and aerosol inhalation), the single dose of the recombinant interferon can be about 100 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 μg to about 800 μg, and still further optionally about 200 μg to about 600 μg, including but not limited to about 100 μg, about 200 μg, about 300 μg, about 400 μg, about 500 μg, about 600 μg, about 700 μg, about 800 μg, about 900 μg and about 1000 μg. In some embodiments, the present recombinant interferon is administered via inhalation once every about 1 day to about 3 days, optionally every about 1 day. In some embodiments, the inhalation lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • When the present recombinant interferon is administered via perfusion (such as intrapleural, abdominal, uterine, intravesical, pericardial perfusion), the single dose of the recombinant interferon can be about 30 μg to about 2000 μg, optionally about 100 μg to about 1500 μg, further optionally about 150 to about 1000 μg, still optionally about 200 to about 800 μg, and still further optionally about 200 to about 400 μg. In some embodiments, the present recombinant interferon is administered via intrapleural, abdominal and/or pericardial administration once every about 1 day to about 10 days, optionally once every about 1 day to about 7 days such as every about 1, 2, 3, 4, 5, 6, or 7 days. In some embodiments, the perfusion lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • When the present recombinant interferon is administered to the lesions (such as the surfaces of skin and mucosa) by spray, such as percutaneous, epidermal, transdermal, transmucosal spray, the single dose of the recombinant interferon can be about 6 μg to about 100 μg, optionally about 10 μg to about 40 μg, and further optionally about 20 μg to about 40 μg. In some embodiments, the present recombinant interferon is administered by spray administration about 1 to about 6 times such as about 1, 2, 3, 4, 5, or 6 times per day. In some embodiments, the spray lasts at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the recombinant interferon can be administered for a long time, including over the life time of the subject; or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like.
  • In some embodiments, for the purpose of treatment, the present recombinant interferon can be administered to the subject about 1, 2, 3, 4, 5, 6, 7, 8, or more times per day, or the present recombinant interferon can be administered to the subject once at the time interval of every about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days, every month, every 2 months, or a longer time. In some embodiments, for the purpose of prevention, the present recombinant interferon can be administered to the subject once at the time interval of every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, every 2 weeks, every 3 weeks, every month, every 2 months, every 3 months, every half year, every 1 year, or a longer time.
  • In some embodiments, the present recombinant interferon is administered in one or more treatment cycles. Optionally, the more cycles can be 2, 3, 4, 5, 6, 7, 8, 9, 10, or more treatment cycles. In specific embodiments, duration of the one treatment cycle is at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, or the duration can also be about 1 day to about 6 years, about 1 week to about 4 years, about 2 weeks to about 3 years, about 1 month to about 1 year, or about 2 months to about 9 months and the like. In specific embodiments, the present recombinant interferon can be administered for a long time, including over the life time of the subject, so as to improve or control or limit the symptom of the subjects.
  • In some embodiments, the present recombinant interferon could be administered in more treatment cycles. In certain embodiments, the treatment cycles are 2 or more treatment cycles. In specific embodiments, the duration of the multiple treatment cycles may include over the life time of the subject. In some embodiments, the time intervals of any two adjacent treatment cycles in all the treatment cycles can be the same or different. In specific embodiments, the time intervals can be at least about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like; or the time intervals can be about 2 days to about 6 years, about 4 days to about 3 years, about 1 weeks to about 1 years, about 2 months to about months, about 3 months to about 6 months and the like.
  • In some embodiments, when the present recombinant interferon is administered more times in one treatment cycle, the present recombinant interferon can be administered for one or more times in a smaller dose, then the present recombinant interferon is administered for one or more times in an increased or gradually-increased dose. In specific embodiments, when the present recombinant interferon is systemically administered via subcutaneous, intramuscular administration (such as subcutaneous, intramuscular injection), the present recombinant interferon can be administered once at a smaller dose such as about 4.5 μg or 9 μg, then the recombinant interferon can be administered for more times in an increased (such as to be about 15 μg, about 18 μg, about 21 μg) or gradually-increased dose. In embodiments, the present recombinant interferon is administered once every about 1 day to abut 2 days. In embodiments, the duration for administration of the present recombinant interferon is about 1 week to about 2 years, optionally about 2 weeks to about 1 year, or further optionally about 1 month to about 9 months, including about 2 months to about 6 months, or over the life time of the subject. In embodiments, the gradually-increased administered dose can be about 110% to about 500% of the previously administered dose sequentially. In embodiments, a smaller dose of the present recombinant interferon (such as about 4.5 μg or about 9 μg) can be administered, followed by about 12 μg to about 18 μg (such as about 13.5 μg, about 15 μg, about 18 μg), and then about 15 μg to about 30 μg (such as about 18 μg, about 21 μg, about 25.5 μg, about 30 μg), once every about 2 days, and for about 2 months to about 3 years, or over the life time of the subject.
  • In some embodiments, the recombinant interferon can be administered one or more times at an induction dose, and then one or more times at a therapeutic dose. In some embodiments, the induction dose is about 2 μg to about 10 μg each time, optionally about 4 μg to about 10 μg each time, further optionally about 4.5 μg to 9 μg each time, for example, about 4.5 μg each time or about 9 μg each time. In some embodiments, the therapeutic dose is about 10 μg to about 70 μg each time, optionally about 12 μg to about 50 μg each time, further optionally about 12 μg to about 30 μg each time. In some embodiments, the induction dose is about 4 μg to about 10 μg each time, and the therapeutic dose is about 12 μg to about 50 μg each time. In some embodiments, the induction dose is usually lower than the therapeutic dose. In some embodiments, the time interval between administration of the induction dose and the therapeutic dose is about 1 day to about 1 month, optionally about 1 day to 1 week, further optionally about 1 day to about 3 days, including, for example, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 1 week, about 2 weeks, about 3 weeks and about 1 month. In some embodiments, when the induction dose is administered more times, it is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 day to about 2 days, including, for example every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days. In some embodiments, when the therapeutic dose is administered more times, it is administered once every about 1 day to about 10 days, optionally every about 1 day to about 7 days, further optionally every about 1 day to about 2 days, including, for example, every about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days. In some embodiments, the total administration time of the induction and therapeutic dose should last at least about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years and the like, o or the recombinant interferon can be administered for a long time, including over the life time of the subject.
  • In some embodiments, the treatment has reduced the tumor size of the subject, for example, by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 100% or more, or even completely eliminate the tumor, according to the tumor size at the beginning of treatment. In some embodiments, the treatment has reduced the number of cancer cells in tumor, malignant pleural effusion, malignant ascites and/or malignant pericardial effusion of the subjects, for example, by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 100% or more, or even the number of cancer cells is zero, according to the number of cancer cells at the beginning of treatment. In some embodiments, the treatment has inhibited (including reduced to some degree and/or terminated) the infiltration of tumor cells into peripheral organs; inhibited or prevented tumor metastasis, such as the in-situ or distant metastasis of tumors, or micrometastasis of tumors; reduced the size of the lesions; brought about downstaging of tumor; and also inhibited or killed micrometastasis in the blood and lymphatic channels; thereby allowing complete resection of initially unresectable tumors or helping to resect tumor which is capable of being resected, such resection is for example a surgical resection. As for the method, it can be a “neoadjuvant method” or an “introducing method”. As used herein, term “neoadjuvant method” or “introducing method” refers to a therapy given prior to surgery, the goal of the therapy is to reduce the size of the lesions, bring about downstaging of tumor, inhibit or kill micrometastases in the blood and lymphatic channels, reduce the tumor size thereby allowing more conveniently resect tumors or completely resect of initially unresectable tumors. In addition, the present recombinant interferon can be further administered to the subject to prevent recurrence and/or metastasis of the tumors after resection of the tumors.
  • In some embodiments, the method has reduced or eliminated malignant pleural effusion, malignant ascites and/or malignant pericardial effusion, for example, by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 100% or more, or even completely eliminated malignant pleural effusion, malignant ascites and/or malignant pericardial effusion, according to the volume of malignant pleural effusion, malignant ascites and/or malignant pericardial effusion at the beginning of treatment.
  • In some embodiments, the method for preventing recurrence of tumor has reduced the possibility of tumor recurrence after the subject with tumors received treatment. In some embodiments, the subject with tumors has been identified and treated prior to administration of the present recombinant interferon (rSIFN-co); such treatments may be the method with the present recombinant interferon, or one or more other different anti-cancer therapies such as chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, traditional Chinese medicine therapy or any combination thereof. The treatment results can be clinical or basic healing. In some embodiments, such preventive therapies can inhibit or eliminate possible micrometastasis in the blood channel and lymphatic channel, so as to prevent recurrence and/or metastasis of the tumor, such micrometastasis can or cannot be clinically detected.
  • In some embodiments, the present recombinant interferon could delay the growth of tumor in the subject, for example, by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or more, according to the tumor growth speed at the beginning of the treatment.
  • In some embodiments, the present recombinant interferon is administered to the subject as monotherapy. In some embodiments, further comprising one or more other anti-cancer therapies administered to the subject, optionally, other anti-cancer therapies are administered to the subject before, simultaneously, and/or after administration of the recombinant interferon. In some embodiments, the other anti-cancer therapies comprise one or more of: chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy. In certain embodiments, the other anti-cancer therapies comprise one or more of chemotherapy, radiotherapy, surgical therapy, targeted therapy, and biotherapy. In some embodiments, the other anti-cancer therapies comprise chemotherapy, radiotherapy, or both. In some embodiments, the other anti-cancer therapies comprise chemotherapy such as first-line chemotherapy, for example, chemotherapeutic drugs and/or chemotherapeutic protocols comprising platinum compounds, such as Cisplatin.
  • In some embodiments, when in the treatment for lung cancer, chemotherapeutic drugs used in the chemotherapy combined with the present recombinant interferon include but not limited to platinum compounds such as Cisplatin, Carboplatin, Eloxatin and the like; Paclitaxel compounds such as Docetaxel (Docetaxel Injection, Taxotere) and the like; cytidine antimetabolite such as Gemcitabine (Gemzar) and the like; antifolic antimetabolite such as Pemetrexed (Alimta) and the like; pyrimidine antimetabolite such as Capecitabine (Xeloda) and the like; as well as any combination of the chemotherapeutic agents. Or otherwise the following chemotherapy protocols are used, including but not limited to chemotherapy protocols containing platinum compounds, such as GP, TP, EP, GP-T2 protocols and the like. In specific embodiments, when in the treatment for the lung cancer, the chemotherapy protocol applied in conjunction with the present recombinant interferon includes Cisplatin nebulized inhalation, Cisplatin pericardial perfusion and the like.
  • In some embodiments, when in the treatment for lung cancer, the targeted drugs used in the targeted therapy combined with the present recombinant interferon include but not limited to Gefitinib, Erlotinib and/or recombinant human endostatin and the like.
  • In some embodiments, when in the treatment for the lung cancer, other anti-cancer therapies applied in combination with the present recombinant interferon include any combination of the chemotherapeutic drugs/chemotherapy protocols and targeted drugs.
  • In specific embodiments, when in the treatment for the lung cancer, other anti-cancer therapies applied in combination with the present recombinant interferon include GP protocol combined with recombinant human endostatin, EP protocol combined with Cisplatin nebulized inhalation and the like.
  • In some embodiments, the method of the present invention is a non-surgical therapy.
    • G. Evaluation Standard of Curative Effect and Adverse Effect
  • The curative effect evaluation on the present recombinant interferon in the aspect of clinical treatment for tumors such as solid tumors adopts the Response Evaluation Criteria in Solid Tumors standard (RECIST standard) published in 1999 (see James, K. et al. J Natl Cancer Inst, 1999, 91, 523-528).
  • The tumor lesions are divided into measurable lesions and un-measurable lesions, wherein the measurable lesions are defined as target lesions; the longest diameter represents the size of each lesion; at most 5 lesions can be selected in each involved organ, the sum of the measured lesions of all the involved organ is not more than 10, and the sum of the longest diameters of all the lesions is the overall diameter of the target lesion. The un-measurable lesions are defined as non-target lesions, only the existence of the lesions are recorded and tracked, but the sizes of the lesions are not measured.
  • The curative effect evaluation standard of the target lesion is divided into 4 grades, the curative effect evaluation standard of the non-target lesion is divided into 3 grades, and the overall curative effect evaluation is obtained by combining the curative effects of the two kinds of lesions. It is specifically described as follows:
  • The curative effect evaluation standard of the target lesions: (1) CR (complete remission): all the target lesions disappear; (2) PR (partial remission): the overall diameter of the target lesions is decreased by more than 30%; (3) NC or SD (no change or stable disease): the target lesions are neither decreased to “PR” nor increased to “PD”; and (4) PD (progression disease): the overall diameter of the target lesions is increased by more than 20%, or one or more new lesions appear.
  • The curative effect evaluation standard of the non-target lesion: (1) CR: all the non-target lesions disappear, and the tumor marker level is normal; (2) IR (incomplete response)/SD: one or more non-target lesions is/are not changed, and/or the tumor markers exceed the normal limit; and (3) PD: one or more new lesions appear, and/or the non-target lesions are obviously developed.
  • The overall curative effect evaluation standard of solid tumors.
  • TABLE 1
    The overall curative effect evaluation standard of solid tumors
    Non-target Overall curative
    Target lesion lesion New lesion effect
    CR CR No CR
    CR IR/SD No PR
    PR Non-PD No PR
    NC/SD Non-PD No NC/SD
    PD Any Yes or No PD
    Any PD Yes or No PD
    Any Any Yes PD
  • The adverse effect evaluation on the present recombinant interferon for clinical treatment for the tumors such as the solid tumors takes the reference to the “WHO” Toxicity Grading Standard.
  • Compared with the prior art, the recombinant interferon has the beneficial effects as follows:
  • The recombinant interferon rSIFN-co used in the present invention has obvious different structural features and physiological activities compared with the existing interferons such as INFERGEN® (interferon alfacon-1) of the US Amgen. On one hand, the recombinant interferon can be singly used and/or can be combined with radiotherapy, chemotherapy, biological agents, and/or targeted drugs and the like, so as to non-surgically eliminate or reduce the tumors of the solid tumor subjects, particularly advanced tumors; specifically, the recombinant interferon can eliminate or reduce the solid tumors without indications for surgery, particularly the advanced solid tumors without indications for surgery. On the other hand, the recombinant interferon can be singly administered through topical or local administration such as intratumoral injection/epidermal spray administration and the like, or through the combination of the topical or local administration together with the systemic administration (using the present recombinant interferon or radiotherapy/other anti-tumor drugs and the like), so as to non-surgically (namely, without surgery) eliminate or reduce the solid tumors. Further, the recombinant interferon has obvious effect in replacing the chemotherapy drugs for preventing post-surgery recurrence or metastasis of the tumors, particularly various metastatic lesions such as bone metastasis which cannot be eliminated by existing treatment means; however, drugs can be directly administered to the lesions by the present invention, especially by the topical or local administration, to obviously reduce or eliminate the tumors. In addition, the recombinant interferon can be singly administered through intrapleural or abdominal perfusion so as to for effectively eliminate or decrease malignant pleural effusion and/or malignant ascites.
  • Furthermore, cancer can be controlled by the rSIFN-co combination therapy. Firstly, the present recombinant interferon (rSIFN-co) has broad-spectrum anti-tumor effects, which is effective on both solid tumors and non-solid tumors while, at the same time, rSIFN-co has a good synergetic effect with existing treatment means such as surgical therapy, chemotherapy, radiotherapy, biotherapy and other anti-tumor drugs. Secondly, rSIFN-co has low toxicity which means no harm to normal cells has been observed when rSIFN-co is used in large doses. Thirdly, rSIFN-co is convenient to use and can be directly applied to tumors in any position. The rSIFN-co can be used by subcutaneous/intramuscular injection to control systemic progress of tumor, by intrapleural/abdominal perfusion to eliminate effusion and intrapleural/abdominal tumors, by topical or local injection to eliminate primary or metastatic tumors, and by infiltration (transdermal) administration to treat tumor lesions in bone, skin, muscle, prostate and the like; and rSIFN-co can also be administered by aerosol inhalation. According to above three advantages of rSIFN-co, effective rate of the combination therapy is no lower than 90%. With regard to early or medium-term cancer cases, rSIFN-co can be used after surgery to replace chemotherapy and effectively prevent recurrence and metastasis; with regard to advanced cancer cases or cancer cases without indications for therapy, rSIFN-co can be used to eliminate tumors without surgery; with regard to cases without indications for surgery, rSIFN-co can be used to transformed the cases into ones with indications for surgery, thereby creating surgical conditions. Therefore, we believe the rSIFN-co combination therapy is capable of curing cancer.
  • In one embodiment, the present invention provides a method for eliminating or reducing the malignant pleural effusion, malignant ascites, and/or malignant pericardial effusion in a subject with tumor, the method comprises administering to the subject a recombinant interferon encoded by SEQ ID NO: 2. In one embodiment, the tumor is a solid tumor.
  • In one embodiment, the recombinant interferon is administered to the subject by an administration route comprising one or more of: infiltration administration, intrapleural administration, abdominal administration, pericardial administration, thoracic administration and intraperitoneal administration. In one embodiment, the recombinant interferon is administered in an amount in a range of about 30 μg to about 2000 μg by one administration. In another embodiment, the recombinant interferon is additionally administered to the subject by systemic administration. In one embodiment, the subject is administered with at least one other anti-cancer drug. In another embodiment, the other anti-cancer drug is chemotherapeutic drug, targeted drug, or biological drug.
  • In one embodiment, the present invention provides a method for preventing tumor recurrence or metastasis, or prolonging or maintaining a tumor-free status in a subject with a tumor, the method comprises administering to the subject a recombinant interferon encoded by the nucleotide sequence SEQ ID NO: 2, and the subject has been treated with at least one anti-cancer therapy before the administration of said recombinant interferon.
  • In one embodiment, the anti-cancer therapy is chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, or traditional Chinese medicine therapy. In another embodiment, the recombinant interferon is administered to the subject in a single dose of the range of about 2 μg to about 2000 μg.
  • In one embodiment, the present invention provides a method for eliminating or reducing metastatic tumor lesion in a subject, the method comprises administering a recombinant interferon encoded by SEQ ID NO: 2 topically or locally to the tumor lesion. In one embodiment, the metastatic tumor lesion comprises at least one of a bone lesion, a muscular lesion, a subcutaneous tissue lesion, a prostatic lesion, and a lymph node lesion.
  • In one embodiment, the recombinant interferon is administered to the lesion by an administration route comprising at least one of infiltration administration, percutaneous administration, transdermal administration, epidermal administration and transmucosal administration. In another embodiment, the recombinant interferon is administered topically. In another embodiment, the recombinant interferon is further administered systemically.
  • In one embodiment, the present invention provides a non-surgical method for eliminating a tumor in a subject or reducing the size of a tumor in a subject, the method comprises administering to the subject a recombinant interferon encoded by SEQ ID NO: 2. In one embodiment, the tumor is a non-resectable tumor.
  • In one embodiment, the recombinant interferon is administered to the subject by at least one of systemic administration, local administration, and topical administration. In one embodiment, the local administration or topical administration comprises one or more of intratumoral administration and spray administration.
  • In one embodiment, the subject is administered at least one other anti-cancer therapy. In one embodiment, the anti-cancer therapy is chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, or traditional Chinese medicine therapy.
  • In one embodiment, the present invention provides a method for treating lung cancer in a subject, the method comprises administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, and the recombinant interferon is administered to the subject by at least one of systemic administration, topical administration, and local administration.
  • In one embodiment, the recombinant interferon is administered systemically and via inhalation. In one embodiment, the systemic administration comprises at least one of subcutaneous administration and intramuscular administration, and inhalation comprises at least one of: pulmonary inhalation and nasal inhalation. In another embodiment, the recombinant interferon is administered locally by perfusion.
  • In one embodiment, the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
  • The present invention will be specifically described in the following examples that are only used to elaborate the purpose but not to limit the scope of the present invention. The present invention can be modified without deviating from its scope. All publications, patents and patent applications that are referenced, the contents of which are hereby incorporated by reference into this application as every independent publication, patent and patent application are separately incorporated by reference into this application.
  • Informed Consent Forms have been signed by all patients involved in the following embodiments, and Confidentiality Agreements have been signed by and between the applicants and hospitals. At the same time, the test processes are conducted in accordance with the requirements set forth by Ethics Committee for Clinical Drug Trials.
    • Example 1 Preparation of the Composition of the Recombinant Interferon Ingredients of Recombinant Interferon Freeze-Dried Injection (Freeze-Dried Powder)
  • rSIFN-co stock solution solution of 34.5 μg/ml
    present invention
    pH 7.0 phosphate buffer (PB) 10 mmol/L
    Glycine 0.4 mol/L
  • Preparation procedures: raw materials were weighed by the ingredients and dissolved by sterile and pyrogen-free water for injected; then filtered by a membrane of 0.22 μm pore diameter for sterilization, and preserved at 6-10° C.; the materials were sampled for sterile and pyrogen inspections and then separately loaded in vials after qualified inspections, each with a single dose of 0.3-0.5. And then, the materials were put into freeze dryer for freezing and drying.
  • Ingredients of Recombinant Interferon Water Solution Injection
  •
    rSIFN-co stock solution of present 34.5 μg/ml
    invention
    pH 7.0 phosphate buffer (PB) 25 mmol/L
    sodium chloride 0.4 mol/L
  • Preparation procedures: raw materials were weighed by the ingredients and dissolved by sterile and pyrogen-free water for injection; then filtered by a membrane of 0.22 μm pore diameter for sterilization, and preserved at 6-10° C.; the materials were sampled for sterile and pyrogen inspections and then separately loaded in sealed containers after qualified inspections, each with a single dose of 0.3-0.5. And then, the finished product were preserved at 2-10° C. in dark places.
  • Ingredients of Recombinant Interferon Spray
  • The ingredient content percentages in the table below are based on weight percentages.
  •
    EDTA 0.01%
    Tween 80 0.05%
    Trisodium citrate
    10 mmol/L
    Glycerol 1.26%
    Sodium chloride 0.03%
    Benzyl alcohol  0.5%
    Human albumin  0.1%
    Recombinant super-compound interferon 10 μg/ml
  • The preparation method refers to conventional preparation method of spray.
  • Preparation of Recombinant Interferon Inhalant
  • Conventional preparation methods of interferon inhalant were adopted. The recombinant interferon inhalant of the present invention was prepared according to conventional preparation methods of interferon inhalant.
    • Example 2 Clinical Data of Patients Treated by the Present Recombinant Interferon (58 Cases)
  • Following is a summary clinical treatment table (table 2) of 58 patients of various cancer types who have been treated by the present recombinant interferon until Jul. 1, 2012.
  • Table 2: Summary of Clinical Treatment of Multiple Types of Cancers in 58 Patients
  • TABLE 2
    Summary of Clinical Treatment of Multiple Types of Cancers in 58 Patients
    Total
    Patient Diagnosed Treatment prior to drug Regimens for Treatment therapeutic
    No. Sex Age Condition(s) Stage administration Dosage regimens for Interferon Combined therapy results effectiveness
    1 Male 53 Non small cell IIIb DP Regimen{circle around (8)} was The rSIFN-co therapy started in Radiotherapy{circle around (3)} Primary CR
    lung cancer in provided from October 14, November, Year 1. Intramuscular (DT40Gy) on right lesions on
    right lung Year 1 to November 25, injection of rSIFN-co was done once lung and mediastinal right
    Year 1: 75 mg of Taxotere every other day: 9 μg for the 1st lymph nodes started pulmonary
    and 75 mg of Cisplatin on time, 15 μg for the 2nd time and on December 2, Year hilum
    Day
    1. Two cycles of 18 μg for the 3rd time and thereafter. 1 followed by disappeared
    chemotherapy were Therapy continued till February, X-knife therapy and cured.
    performed in total, each Year 3, during which rSIFN-co (DT20Gy)
    lasting for 21 days. treatment had been stopped for 1
    month in April, Year 2, leading to a
    total treatment duration of 15 months.
    2 Male 40 Non small cell IV Systematic chemotherapy The rSIFN-co therapy began on From April 20, Year The size of PR
    lung began at January, Year 1: April 14, Year 1. Intramuscular 1 to September 3, the primary
    adenocarcinoma Taxotere and Carboplatin. injection of rSIFN-co was done once Year 1, Endostar{circle around (5)} lesions on
    One cycle of 21 days was every other day: 9 μg for the 1st was administrated upper lobe of
    provided. time, 15 μg for the 2nd time, 18 μg every day: 7.5 mg/m2 right lung
    for the 3rd time and 21 μg for the 4th per dose, reduced from
    time and thereafter. Meanwhile, 1.2 × 105 U/m2. Four about
    aerosol inhalation of rSIFN-co was cycles were 10.2 × 8.2 × 7.7
    done once every day: 300 μg for the performed totally cm to
    1st time, 500 μg for the 2nd time, with each lasting for 1.2 × 1.4 cm.
    600 μg for the 3rd time and 14 days. Meanwhile, Metastatic
    thereafter. Administration of GP regimen was lesions in the
    rSIFN-co ended in April Year 2. combined: 1600 mg right liver and
    of Gemcitabine on multiple
    days
    1 and 8 and lymph nodes
    40 mg of Cisplatin on disappeared.
    days 1~3. Four cycles The
    were performed, each metastatic
    being 15 days. lesions on the
    One intrapericardial two lungs
    infusion with decreased in
    Cisplatin (30 mg) was size and the
    performed on July 19, Year 1. radioactive
    Aerosol inhalation of concentration/
    Cisplatin was added accumulation
    from December 23, decreased.
    Year 1 to January 14,
    Year 2: 10 mg/dose, 2
    doses per day.
    The second course of
    Endostar treatment
    was provided from
    January 18, Year 2 to
    January 30, Year 2
    with same dosage.
    Chemotherapy using
    Pemetrexed{circle around (6)}
    proceeded from
    December 25, Year 1
    to January 19, Year
    2: iv. 500 mg/m2,
    every 3 to 4 weeks.
    As none of the
    treatments had any
    obvious effect, the
    chemotherapy during
    February 15, Year 2
    to April 25, Year 2
    was replaced with DP
    regimen{circle around (8)} (75 mg/m2
    of Taxotere and
    75 mg/m2 of
    Cisplatin on day 1)
    in combination with
    administration with
    Tarceva (150 mg/day)
    for 4 cycles with 21
    days per cycle.
    A Gamma knife
    therapy was
    performed on head
    on June 29, Year 2.
    3 Female 51 Non small cell IV Treatment with rSIFN-co started on During this period, The primary CR
    lung cancer May 29, Year 1. Intramuscular Gamma knife lesion of
    injection of rSIFN-co was done once radiotherapy for the about
    every other day: 9 μg for the 1st brain lesions was 5.1 × 3.2 cm on
    time, 18 μg for the 2nd time and conducted. the upper lobe
    21 μg for the 3rd time and thereafter. of right lung
    Aerosol inhalation of rSIFN-co was disappeared.
    simultaneously performed: The enlarged
    200 μg/every other day. lymph nodes
    From July 14, Year 1, 18 μg of in the
    rSIFN-co was used in intramuscular mediastinum
    injection. Aerosol inhalation of and the
    400 μg of rSIFN-co was metastatic
    simultaneously performed every lesions in the
    other day. brain of about
    The administration continued for 3.7 × 2.6 cm
    more than 3 months till September basically
    16, Year 1. disappeared.
    4 Male 49 Small cell lung IV The first cycle of EP{circle around (7)} The treatment of rSIFN-co began on Five cycles of EP A primary CR
    cancer in right chemotherapy was April 12, Year 1. Intramuscular chemotherapy were lesion of about
    lung conducted from March 25, injection was done once every other conducted from 0.6 × 0.4 cm, on
    Year 1 to Apr 9, Year 1: day: 9 μg for the 1st time, 15 μg for March 25, Year 1 to the apex of
    100 mg of Etoposide and the 2nd time and 18 μg for the 3rd September 10, Year 1 right lung
    30 mg of Cisplatin. time and thereafter. Aerosol and the same regimen disappeared.
    inhalation of rSIFN-co was as mentioned above A lesion with
    performed once every other day: was used. a nodule of about
    0.5~2 ml/dose (200 μg/ml). An interventional 2.6 × 2.2 cm on
    From July 16, Year 1, 21 μg of cryoablation was the of right
    rSIFN-co was used in intramuscular conducted on the clavicle
    injection. Aerosol inhalation of supraclavicular disappeared.
    rSIFN-co continued but the amount lesions on September Mutilple nodules
    per dose was changed to 200 μg. 3, Year 2. appearing in
    The first cycle finished by the end of From October Year neighboring
    March Year 2 (lasting for almost 1 1, a 15-day regimen areas of the
    year). The administration of of aerosol inhalation mediastinal
    rSIFN-co was stopped for 1 month of Cisplatin was brachiocephal
    because Aerosol inhalation of added: 10 mg per ic trunk, right
    Cisplatin (one dose per day and dose, 1 dose per day. brachiocephal
    10 mg per dose) was performed Two cycles were ic veins,
    throughout September Year 1. done, each lasting for superior vena
    The 2nd cycle of treatment 15 days. cava, and
    proceeded from October 9, Year 2 to trachea, part
    January 26, Year 3 during which ofwhich fused and
    18 μg of rSIFN-co was lesions of about
    intramuscularly injected every other 5.5 cm × 4.9 cm
    day. in size disappeared.
    5 Female 42 Metastatic IV A surgical repair of right Treatment with rSIFN-co began on Aerosol inhalation of Radioactive CR
    moderately humerus was performed on April 15, Year 1. Intramuscular Cisplatin began on concentrations
    differentiated February 23, Year 1. injection was performed once every September 16, Year at the
    lung After that surgery, patient other day: 9 μg for the 1st time and 1: 10 mg per dose and primary
    adenocarcinoma was given 4 courses of DP{circle around (8)} 21 μg for the 2nd time and thereafter. 2 doses per day. lesion of right
    (in right chemotherapy: 75 mg of The treatment was provided for a Eight cycles were lung tumor,
    humerus) Taxotere and 75 mg of total of 3 months till September 15, conducted with each right humerus
    Cisplatin on day 1. Year 1, during which rSIFN-co cycle being 15 days. and the T6
    administration was suspended for 1 vertebra
    month due to chemotherapy (the evidently
    chemotherapy regimen shown below decreased.
    related to aerosol inhalation of Metastatic
    Cisplatin) and for 1 month because lesions on
    of the patient's physical condition. pelvis and
    Aerosol inhalation of rSIFN-co was lumbar
    added on September 16, Year 1: 1 ml vertebrae as
    (200 μg/ml) per day. Till February, well as
    Year 2, the co-administration enlarged
    regimen was provided for 5 months. paratracheal
    From September 15, Year 2, lymph nodes
    intramuscular injection of 15 μg was disappeared.
    provided every other day.
    6 Male 39 Moderately-poorly IV The first cycle of GP Treatment with rSIFN-co began on The second cycle of Primary CR
    differentiated Regimen{circle around (9)} began in October 12, Year 1 with aerosol GP Regimen{circle around (9)} started lesion of
    adenocarcinoma September Year 1 with each inhalation of 600 μg every day. on October 14, Year 1 about
    in left lung cycle lasting for 21 days: Intramuscular injection of rSIFN-co (the regimen was 9 × 3.5 cm in
    1000 mg/m2 of Gemcitabine started on December 12, Year 1, exactly the same as size at the left
    on day 1 and 8 and 75 mg/m2 once every other day: 9 μg for 1st mentioned above). lung almost
    of Cisplatin on day 1. time, 15 μg for 2nd time and 18 μg Gefinitib was taken disappeared.
    for 3rd time and thereafter. from November 24, Enlarged
    Local spraying on bone metastases Year 1: 1 pill/dose lymph nodes
    began on March 12, Year 2: (250 mg/pill), 1 of about
    70 μg~139 μg/does/site, 4~5 dose/day. 1.0 cm × 0.7 cm
    doses/day. at left
    segment of
    neck, nodules
    of about
    1.2 cm × 0.8 cm
    at left
    supraclavicular
    fossa and
    nodules of
    about
    1.4 cm × 1.1 cm
    at right and
    root segment
    of neck
    disappeared.
    Metastatic
    lesions on
    sternum
    disappeared;
    and metastatic
    lesions at
    right
    sternoclavicular
    joints, ribs
    and pelvis
    shrank and
    relieved to
    some extent.
    7 Female 53 Metastatic IV Treatment with rSIFN-co began on Meanwhile, Iressa Primary PR
    lung July 31, Year 1. Intramuscular (Gefinitib){circle around (10)} lesions in
    adenocarcinoma injection was done once every other produced in India right lung and
    (lymph nodes day: 9 μg for 1st time, 18 μg for 2nd was administered in metastatic
    at left clavicle) time and 21 μg for 3rd time and combination for 1 lesions in
    thereafter. year: 1 pill/dose both lungs
    Seventy-five times of intramuscular (250 mg/pill), 1 and several
    injection were done till January 2, dose/day. bones shrank
    Year 2 (totally 5 months). with
    radioactive
    concentration
    decreased;
    metastasis in
    liver
    disappeared.
    8 Female 68 Lung cancer in IV Treatment with rSIFN-co began on Administration of Lesions of CR
    right lung July 21, Year 1 Intramuscular Gefinitib (Iressa){circle around (10)} about
    injection was done once every other was added in 3.0 × 3.9 cm at
    day: 9 μg for 1st time, 15 μg for 2nd July Year 1: the lower lobe
    time and 18 μg for 3rd time and 250 mg/pill, 1 of right lung,
    thereafter. pill/dose, 1 and metastatic
    Meanwhile, aerosol inhalation of dose/day. lesions in left
    rSIFN-co of 600 μg was performed ilium
    once a day. Administration of disappeared
    rSIFN-co continued for 3 months till basically.
    October 31, Year 1.
    9 Male 55 Squamous cell IIb Treatment with rSIFN-co began on Four cycles of Primary CR
    carcinoma March 18, Year 1. Aerosol chemotherapy (GP lesions of
    inhalation of rSIFN-co of 600 μg was regimen{circle around (9)}) were about
    performed once a day. A course performed with the 3.3 × 2.4 × 2.0 cm
    completed till July 20, Year 1 (for 4 first one beginning at in right
    months) with 100 doses of aerosol April 12, Year 1 and lung
    inhalation done. each cycle lasting for basically
    21 days: 1600 mg of disappeared
    Gemcitabine on days and
    1 and 8 and 40 mg of enlarged
    Cisplatin on days 1 and 3. lymph nodes
    Meanwhile, 3 cycles in right hilum
    of Endostar{circle around (5)} of about
    administration were 2.0 × 2.2 cm
    performed with 14 disappeared.
    days as one cycle:
    7.5 mg/m2
    (1.2 × 105 U/m2) per
    dose, 1 dose/day.
    Second cycle of
    chemotherapy began
    on May 10, Year 1
    with the same
    regimen.
    Third cycle of
    chemotherapy began
    on June 7, Year 1
    with the same
    regimen.
    Fourth cycle of
    chemotherapy began
    on July 7, Year 1
    with the same
    regimen.
    Four cycles of
    chemotherapies were
    totally performed.
    10 Female 48 Non small cell IIIb Treatment with rSIFN-co began on Primary CR
    lung cancer in March 9, Year 1. Intramuscular lesions of
    left lung injection of rSIFN-co was about
    performed once every other day: 2.0 × 2.0 cm in
    18 μg for 1st time, 21 μg for 2nd time left lung
    and thereafter. Such administration basically
    continued for almost 1 year till disappeared
    March, Year 2. and malignant
    Intrapleural perfusion of rSIFN-co pleural
    was done once every 8 days from effusion
    April 29, Year 1: 9 μg × 4 vials for 1st disappeared.
    and 2nd time and 9 μg × 5 vials for
    3rd time. Three perfusions were
    provided totally.
    Four CT-guided interventional
    operations were performed in July
    and August Year 2. The rSIFN-co
    was injected into relatively large
    lesions in lungs and 21 μg × 10 vials
    were used each time.
    11 Male 40 Non-hodgkin IV Chemotherapy was Treatment with rSIFN-co began on Four cycles of Soft tissure PR
    lymphoma on performed for 7 times (five June 9, Year 3. An aerosol CHOP(11) around
    mesenteric times of CHOPE regimen preparation of rSIFN-co (72 μg/ml) chemotharepy were nasopharynx
    lymph nodes and two times of MTX was sprayed onto the nasopharynx provided from July and
    regimen) began on August, Year 1. and Oral Cavity 2~3 times every Year 3 to November oropharynx
    Autologous stem cell day. Administration continued till 28, Year 3 with each with the
    transplantation was done in August 27, Year 3 with 5 days of cycle lasting for thickest part
    March Year
    2. suspension because of 21 days. of 3.0 cm
    Chemotherapy were chemotherapy (see chemotherapy Radiotherapy began entirely
    provided for 4 times (1 time describebd below). on June 11, Year 3 disappeared,
    of GCE regimen and 3 Local injections on lymph nodes in (scheduled for 25 and the
    times of ESAP regimen) neck started on June 11, Year 3. times) and stopped largest fused
    began on August, Year 2. Injection was performed every other on July 5, Year 3 as lymph node
    The forth one ended on day by injection at multiple sites in a the patient was weak among those
    November 26, Year 2. quincunx: 15 μg × 10 vials per due to at
    Chemotherapy was treatment. Two times later, local myelosuppression. submaxillary
    administered 6 times (3 subcutaneous injection was region, neck
    times of large-dosed performed every other day: 30 μg per and clavicular
    CHOPE regimen, 2 times treatment. Till August 27, Year 3 region shrank
    of CMOP regimen and 1 (more than 2 months), for a total of from 7.4 cm ×
    time of a regimen of 10 times. 2.4 cm ×
    “bleomycin + CHOP(11) + 14.6 cm to
    Methotrexate”) began on 1.1 cm ×
    January, Year 3, in 1.5 cm.
    combination with stem cell
    therapy.
    12 Male 67 Non small cell IIb From August 16, Year 1, Treatment with rSIFN-co began The mass PR
    lung two cycles of GP regimen{circle around (9)} on November 10, Year 1. reduced from
    adenocarcinoma were provided: 1000 mg/m2 Intramuscular injection of rSIFN-co about 3.1 ×
    in right lung of Gemcitabine on day 1 was provided once every two days: 4.2 cm to 2.2 ×
    and 8 and 75 mg/m2 of 9 μg for 1st time, 18 μg for 2nd time 1.5 cm after
    Cisplatin on day 1. and 21 μg for 3rd time and thereafter. 2 months'
    Intrathoracic injection of Administration lasted for almost 1 treatment, and
    Cisplatin was also year till October 27, Year 2. the lesion
    performed for 5 times. 1 further reduced in
    dose every 7 days, 30- size after
    40 mg per dose. administration
    for 3 months.
    13 Male 63 Poorly IIIb On October 15, Year 1, Treatment with rSIFN-co began on After surgery CR
    differentiated resection of upper lobe of December 10, Year 1. Intramuscular on primary
    adenocarcinoma right lung and lymph node injection of rSIFN-co was provided lesions, no
    (upper lobe dissection were done as once every other days: 9 μg for 1st tumor
    of right lung) well as wedge resection of time, 21 μg for 2nd time and recurrence or
    nodules on lower lobe of thereafter). The first course was metastasis
    right lung. finished on April 9, Year 2. occurred.
    The second course was performed
    from December Year 2 to July Year
    3 during which intramuscular
    injection was done every other day
    with 21 μg per dose.
    The third course was performed
    from February 21, Year 4 to May 21,
    Year 4 during which intramuscular
    injection was done every other day
    with 18 μg per dose.
    14 Male 44 Non small cell IIIb Upper lobe of right lung Treatment of rSIFN-co began on After surgery, CR
    lung cancer was resected on October November 6, Year 1. Intramuscular no tumor
    (poorly 20, Year 1. injection of rSIFN-co was recurrence or
    differentiated administered once every other day: metastasis
    adenocarcinoma) 18 μg for 1st time, 21 μg for 2nd time was found at
    and thereafter. A first course of 6 primary
    months ended on May 10, Year 2. lesions.
    The second course started on March
    18, Year 3 and continued for the
    next following 3 months.
    Intramuscular injection of rSIFN-co
    was provided every other day with
    15 μg per dose.
    Intramuscular injection of rSIFN-co
    and Aerosol inhalation were
    administered for 3 months from
    November Year 4. Intramuscular
    injection was done once every other
    day with 15 μg per dose. Aerosol
    inhalation was performed every day
    and a total of 300 μg was used for
    one day.
    15 Male 68 Lung cancer IV Treatment with Gamma Treatment of rSIFN-co began on Mass of about PR
    with systemic Knife was done under local June 25, Year 3. The rSIFN-co was 11.3 × 4.9 cm in
    metastases anesthesia on April 27, Year injected into lymph nodes of groin pelvic cavity
    3. Intramuscularly every day: 15 μg × 6 reduced in
    Sr-89 therapy was done by vials for 1 st time, 15 μg × 8 vials for size to
    Nuclear Medicine 2nd time and 15 μg × 10 vials for 3rd 7.52 × 7.67 ×
    Department on April 30, time and thereafter. Eleven 6.72 cm
    Year 3. injections were done till July 20,
    Oral administration of Year 3 (Severe diarrhea occurred
    Gefitinib (Iressa) was after 3 injections and administration
    provided from December was stopped for 2 weeks; after that
    Year 1 to June Year 3: 1 injection was performed every day
    dose/day, 1 pill/dose, and 8 injections in total were
    250 mg/pill. continuasly provided).
    Discontinuous local injection in
    lymph nodes were performed for 6
    times from August 18, Year 3
    toSeptember 16, Year 3: 15 μg ×
    10 vials for each time.
    Local injection in lymph nodes were
    performed every 3 days from
    October 8, Year 3 to October 12,
    Year 3: 15 μg × 10 vials for each
    time.
    16 Female 63 Well to IIIb Laparoscopic-assisted Treatment of rSIFN-co began on After surgery, CR
    moderately abdominal perineal radical May 23, Year 1. Intramuscular no tumor
    differentiated resection of rectal cancer injection of rSIFN-co was provided recurrence or
    adenocarcinoma was done on May 16, Year 1. once every other day: 21 μg for each metastasis
    was found in time. The first course of 8 months occurred at
    rectum and ended on February Year 2. primary
    mucinous The second course was provided lesions.
    adenocarcinoma from January Year 3 to April Year 3.
    was found in Intramuscular injection of rSIFN-co
    part of rectum. was provided once every other day
    Cancer invaded with 9 μg each time and continued
    into deep for 3 months.
    muscularis of The third course was administered
    intestinal wall from December Year 3 to March
    and formed Year 4. Intramuscular injection was
    cancerous performed every other day with
    nodules in 15 μg each time.
    mesorectum.
    17 Female 25 cervical cancer Ib1 Treatment of rSIFN-co began on Malignant CR
    May 14, Year 1. Intramuscular cervical
    injection of rSIFN-co was provided lesion
    once every other day: 9 μg for 1st disappeared,
    time, 15 μg for 2nd time and 18 μg and test of
    for 3rd time and thereafter. high-risk
    Meanwhile, uterine perfusion was HPV became
    done once a day: at 1000 μg per negative.
    dose, for 2 hours. Uterine perfusion Also, no
    ended on June 28, Year 1 (lasted for tumor cells
    more than 1 month) and were found in
    intramuscular injection was stopped cervical
    on September 12, Year 1 (lasted for smear.
    4 months).
    18 Male 64 Prostatic IV Treatment of rSIFN-co began on Radiotherapy on Prostate of CR
    cancer November 15, Year 1. Intramuscular prostate (EBRT)(12) 4.7 × 3.5 × 5.6
    injection of rSIFN-co was provided was performed for 38 cm reduced
    once every other day: 9 μg for 1st times from December normal size;
    time, 15 μg for 2nd time, 18 μg for 5, Year 1 to February two lymph
    3rd time and 24 μg for 4th time and 26, Year 2. nodes in right
    thereafter. Meanwhile, the drug was ischiorectal
    locally applied by spraying to the fossa were
    skin surface where prostate biopsy eliminated;
    was done: 4~5 doses per day and at the posterior
    70 μg~139 μg per dose. wall of fundus
    The amount of rSIFN-co to be of urinary
    intramuscularly injected changed to bladder, bilateral
    21 μg from December 15, Year 1 to seminal
    July 1, Year 2. vesicles and
    anterior rectal
    wall infected
    by lesions
    recovered;
    and the level
    of specific
    antigen of
    Prostatic
    cancer (PSA)
    become normal.
    19 Female 43 Melanoma of IV Two cycles were provided Treatment of rSIFN-co began on Multiple CR
    nose (after a on October 30, Year 1 and December 21, Year 1. Intramuscular enlarged
    surgery) November 30, Year 1: injection of rSIFN-co was provided lymph nodes
    combined with 15 mg of Endostar on day once every other day: 9 μg for 1st at bilateral
    bone
    1~10 and 200 mg of time, 15 μg for 2nd time, 18 μg for shoulder
    metastases at temozolomide on day 1~5, 3rd time and thereafter. Meanwhile, joints and
    bilateral hip oral administration. the drug was locally applied by axillae
    joints, bilateral Targeted radiotherapy spraying onto the skin surface of the disappeared;
    femurs, (50Gy/25f) was done on right shouder: 70 μg- recurrence
    bilateral November 2, Year 1 and the 139 μg/dose/site, 4-5 doses/day. and metastatic
    humeri, ribs targets were right maxillary Spraying was provided to skin lesions at
    and bilateral sinus + ¼ of the left surface of the left shoulder and other residual right
    shoulder joints. maxillary sinus, bilateral sites with bone metastasis began on sinus and
    ethmoid sinus, frontal sinus February 27, Year 2: 70 μg- nasal cavity
    and the adjacent tissues of 139 μg/dose/site, 4-5 doses/day. after surgery
    the right eyeball. as well as
    Radiotherapy ended on multiple
    December 7, Year 1. abnormal
    signals at
    bilateral hip
    joints and
    upper parts of
    femora
    disappeared.
    20 Male 40 Lung cancer IV Treatment by administering Chemotherapy was Primary PR
    Recombinant super- compound conducted 3 times: lesions of the
    interferon (“rSIFN-co”) began on GP-T2 regimen right lower
    October 12, Year 1; (cisplatin day 1-4, lung was
    Intramuscular injection once every gemcitabine day 1) reduced;
    other day: 9 μg for the 1st time, 15 μg from October 25, swollen
    for the 2nd time and 21 μg for the Year 1 to November lymph nodes
    3rd time and thereafter; 7, Year 1; (no within the
    Aerosol inhalation of 1 ml “gemcitabine” was mediastinum
    (200 μg/ml) daily began from administered at day 8 were
    December 28, Year 1; due to the low white eliminated;
    Aerosol inhalation of 1 ml blood cell level of the pleural
    (300 μg/ml) daily began from patient). effusion was
    January 13, Year 2. DDP40 mg on day 1 subsided.
    and day 2 plus MMC
    10 mg chemotherapy
    1 time, beginning
    from November 26,
    Year 1.
    Administered DP
    regimen (Cisplatin
    40 mg on day 1-2 and
    30 mg on day 3,
    Docetaxel 120 mg day
    1) from December 6,
    Year 1 to December
    18, Year 1.
    21 Female 75 Lung cancer IIIb Self-medication with Treatment by administering Gefitinib. Primary CR
    with bone traditional Chinese rSIFN-co began on March 10, Year 1; lesions of the
    metastases medicine (“TCM”), Intramuscular injection once every right upper
    ganoderma lucidum extract, other day: lung and
    spore powder and Gefitinib. 9 μg for the 1st time, swollen
    15 μg for the 2nd time, and lymph nodes
    18 μg for the 3rd time and thereafter. within the
    From September 18, Year 1 to mediastinum
    November 17, Year 1, discontinuous were
    spray inhalation 1 ml each time eliminated
    (200 μg/ml).
    22 Male 50 Lung cancer IIIa 4 courses of “Paclitaxel + Intramuscular injection of 18 μg The 3rd Primary PR
    with hepatic Carboplatin” chemotherapy once every other day for two months radiofrequency lesions of the
    metastases began from October 3, Year 1. from January 19, Year 2 followed by ablation targeting left lung was
    Argon-helium cryoablation 21 μg every other day thereafter. liver metastases was eliminated,
    surgery of the lower left performed on March while no
    lung cancer was performed 17, Year 2. apparent
    on January 6, Year 2. Hepatic local change in
    Radiofrequency ablation of perfusion of liver
    the liver metastases was “Paclitaxel + metastases
    performed on January 13, Carboplatin” was was observed.
    Year 2. performed on April
    21, Year 2.
    23 Male 57 Lung IV One course of “PTX + Treatment by administering Primary CR
    adenocarcinoma DDP” chemotherapy began rSIFN-co began on December 6, lesions in the
    in the left on September 9, Year 1; Year 1; left lung and
    lung with drip infusion of 4 mg of Intramuscular injection once every systemic
    metastases to zoledronic acid to treat other day: 9 μg for the 1st time and multiple
    the left pleura, metastases to bone was 2nd time, and 21 μg for the 3rd time metastatic
    mediastinal administered on September and thereafter till February 15, Year 2. lesions were
    lymph nodes 9, Year 1. eliminated.
    and bone The 2nd course of TP
    chemotherapy began on
    October 6, Year 1;
    The 3rd course of
    chemotherapy of TP
    chemotherapy began on
    October 29, Year 1.
    24 Male 73 Lung cancer IIIb Treatment by administering Pleural PR
    rSIFN-co began on March 19, Year 1; effusion was
    Beginning from March 21, Year 1, reduced.
    intramuscular injection once every
    other day: 9 μg for the 1st time,
    13.5 μg for the 2nd time and 21 μg
    for the 3rd time and thereafter;
    Intrapleural perfusion of 21 μg × 6
    vials began from March 19, Year 1;
    Intrapleural perfusion of 21 μg × 8
    vials was performed on March 25, Year 1;
    Intrapleural perfusion of 21 μg × 10
    vials was performed on April 21, Year 1;
    Intrapleural perfusion of 21 μg × 10
    vials was performed on April 30, Year 1;
    Intrapleural injection of 21 μg × 10
    vials was performed on May 8, Year 1;
    Intrapleural perfusion of 21 μg × 12
    vials was performed on May 15, Year 1.
    25 Male 48 Lung cancer IIIa Treatment by administering Radiotherapy (time PD
    rSIFN-co began on November 19, Year 1; and regimen
    Intramuscular injection once every unknown).
    other day: 9 μg from November 19,
    Year 1 to November 25, Year 1, and
    21 μg from November 27, Year 1 to
    April 17, Year 2.
    26 Female 51 lung cancer IV “Self-medication with Treatment by administering Erlotmib Brain PR
    with brain Gefitinib” rSIFN-co began on December 18, hydrochloride. metastases
    metastases Year
    1; lesions were
    Discontinuous treatment by reduced,
    intramuscular injection once every while no
    other day: 21 μg, beginning apparent
    December 18, Year 1 change in
    From May 7, Year 3 to January Year primary
    4: intramuscular injection of 18 ug, lesions in the
    every other day. lungs was
    From May 17, Year 3 to September observed.
    18, Year 3: spray inhalation 100 ug/day.
    From September 19, Year 3 to
    December 28, Year 3: spray
    inhalation
    400 ug/day.
    From December 29, Year 3 to
    January, Year 4: spray inhalation
    300 ug/day.
    27 Male 46 Metastases to IIb Radical surgery of the Treatment by administering NC/SD
    both lungs after cancer in left lung in May rSIFN-co began on August 22, Year 2;
    surgery of the Year 1, followed by Intramuscular injection once every
    cancer in left chemotherapy and other day: 9 μg for the 1st time, and
    lung radiotherapy (details 21 μg for the 2nd time and thereafter.
    unknown).
    28 Male 53 Cancer in the IIb Wedge resection of the Treatment by administering NC/SD
    right upper right upper lung via video rSIFN-co began on March 13, Year 1;
    lung with assisted thoracoscopic Intramuscular injection once every
    intrapulmonary surgery (VATS), pleural other day: 9 μg for the 1st time, and
    metastasis and biopsy and pleural nodules 21 μg for the 2nd time and thereafter;
    metastases to burning were performed on nasal spray of aerosol, 3 times/day;
    the right January 20, Year 1. Aerosol inhalation of 0.2 ml
    thoracic cavity. After 3 days, intrapleural (1 mg/ml) once a day began July 27,
    perfusion of “Vivatuxin” to Year 1.
    the right thoracic cavity September 2, Year 1: intramuscular
    was performed. injection of 21 ug, every other day,
    spray inhalation 200 μg/day.
    October 15, Year 1: stopped using
    rSIFN-co.
    29 Male 76 Lung cancer IIIa The right upper lung was Treatment by administering Radiofrequency NC/SD
    resected on August 17, Year 1. rSIFN-co began on September 2 Year 1; ablation targeting
    Intramuscular injection once every lung was performed
    other day: on March 11, Year 3.
    9 μg for the 1st time,
    18 μg for the 2nd time and thereafter
    till September 20, Year 1,
    21 μg from November 22, Year 1 to
    April 27, Year 2;
    In combination with nasal spray of
    40 μg/ml aerosol, 3 times/day from
    April 29, Year 2.
    30 Male 47 Lung IV Whole brain radiotherapy Treatment by administering Pulmonary PR
    adenocarcinoma 30GY/10FX (10 times) was rSIFN-co began on July 18, Year 2; nodules
    with brain performed in December Intramuscular injection of 21 μg reduced (5
    metastases Year 1. once every other day in combination months later),
    4 courses of GP-T1 with aerosol inhalation of 1 ml brain lesions
    chemotherapy regimen (200 μg/ml) every day lasted for 8 basically
    (gemcitabine day 1 and day months. subsided (6
    8; DDP140 mg day 1) began months later).
    on January 3, Year 2.
    Gefitinib was taken in
    March Year 2.
    31 Male 71 Right lung IV Treatment by administering PD
    cancer with rSIFN-co began on June 29, Year 1;
    bone Intramuscular injection once every
    metastases other day: 9 μg for the 1st time,
    13.5 μg for the 2nd time, and 18 μg
    for the 3rd time and thereafter;
    Aerosol spray of 20 μg/ml rSIFN-co
    to lymph nodes at nasal cavity and
    neck began on August 20, Year 1;
    Injection of 21 μg rSIFN-co every
    other day began on September 16,
    Year 1.
    32 Female 69 Lung cancer IIb Three chemotherapy Treatment by administering Gefitinib. Lung tumor PR
    treatments were performed rSIFN-co began on July 9, Year 2; shrunk, and
    in March, April and May of Intramuscular injection once every swollen
    Year 1; Began taking other day: 9 μg for the 1st time, lymph nodes
    Gefitinib on June 10, Year 1. 13.5 μg for the 2nd time, and 18 μg disappeared.
    for the 3rd time and thereafter;
    Aerosol inhalation of 300 μg per day.
    33 Female 75 Lung cancer IIIb “Left lower lung lobectomy, Treatment by administering PD
    lymph node dissection, rSIFN-co began on September 22, Year 2;
    resection of part of thoracic Intramuscular injection once every
    aortic adventitia via VATS” other day:
    under general anesthesia 4.5 μg for the 1st time, 9 μg for the
    were performed on 2nd time,
    December 24, Year 1. 13.5 μg for the 3rd time, and 18 μg
    for the 4th time and thereafter;
    Injection of 9 μg every other day
    from September 29, Year 2. Later
    changed to 2 times of injection per
    week.
    Perfusion of rSIFN-co at 21 μg × 5
    vials once every 6-8 days began on
    September 22, Year 2, depending on
    the subject's pleural effusion level
    and tolerance..
    Perfusion of rSIFN-co at 21 μg × 6 to
    8 or 10 vials once every 4 days
    began on October 21, Year 2,
    depending on the subject's pleural
    effusion level and tolerance.
    34 Male 79 Lung cancer IV Treatment by administering Local brain NC/SD
    with multiple rSIFN-co began on October 12, Year 1; radiotherapy was
    metastases Intramuscular injection of 18 μg received 2 times in
    once every other day in combination November Year 1;
    with aerosol inhalation of 1 ml Treatment with
    (200 μg/ml) per day. anti-cancer TCM
    Stopped using rSIFN in December, began on
    Year 1. mid-December Year 1.
    35 Female 29 Lung IV Beginning on June 28, Year Treatment by administering From July 18, Year 1 Shrinkage of PR
    adenocarcinoma
    1, 1 course of rSIFN-co began on July 1, Year 1; to October 9, Year 1: the primary
    with bone chemotherapy Intramuscular injection once every 3 courses of lesion on the
    metastases (Gemcitabine 1.6 g on day 1 other day: chemotherapy. GP dorsal
    and day 8 + Cisplatin 60 mg 15 μg for the first time, chemotherapy segment of
    on day 1 and day 2). 18 μg for the second time and regimen: the lower lobe
    thereafter, and in combination with Gemcitabine + of the left
    aerosol inhalation at the same time, Cisplatin. lung was
    1 time a day, 600 μg each time. Radiofrequency evident.
    ablation targeting
    lung was performed
    on December 18, Year 1.
    Beginning in
    December, Year 1,
    began discontinuous
    use of Gefitinib.
    36 Female 73 Ovarian cancer IIIb “Hysterectomy, bilateral Treatment by administering The pleural PR
    Salpingo oophorectomy, rSIFN-co began on February 13, Year 2; effusion in
    omentectomy, superior end Intramuscular injection once every left thoracic
    rectum resection, other day: cavity was
    anastomosis, urinary 9 μg for the first time, disappeared;
    bladder rupture repair and 15 μg for the second time, the pleural
    cytoreductive surgery” were 18 μg for the third time and effusion right
    performed on May 19, Year 1. thereafter; thoracic
    Intramuscular injection of 21 μg cavity was
    every other day beginning from reduced.
    March 13, Year 2 until May 21, Year 2.
    37 Female 46 cervical cancer, IV Radiotherapy was Treatment by administering Size of PR
    after performed in Year 1: DT rSIFN-co began on November 30, cervical
    radiotherapy 5040Gy each time for 56 times; Year 2; lesions were
    and Treatment with PF regimen Intramuscular injection of 21 μg reduced from
    chemotherapy and radiotherapy were every other day. 64 × 58 mm to
    performed in August Year 2; 52 × 40 mm;
    Chemotherapy by arterial Swollen left
    infusion for cervical cancer inguinal
    was performed on August lymph nodes
    13, Year 2, primary drugs were
    administered: Paclitaxel disappeared.
    liposome + Carboplatin.
    38 Female 31 Uterine IV Treatment by administering NC/SD
    papillary rSIFN-co began on August 1, Year 1;
    serous Intramuscular injection of 18 μg
    carcinoma every other day in combination with
    (UPSC) mixed uterine drip once a day for a week
    with clear cell and once every 5 days thereafter at
    carcinoma 1 ml (200 μg/ml) each time.
    39 Female 41 Poorly Ib2 Laparoscopic extensive Treatment by administering NK cell therapy High-risk CR
    differentiated total hysterectomy + pelvic rSIFN-co began on November 26, Year 1; human
    cervical abdominal aortic Intramuscular injection once every papillomavirus
    squamous cell lymphadenectomy + other day: (HPV)
    carcinoma bilateral ovarian suspension 9 μg for the first time, changed from
    were performed on June 3, Year 1. 15 μg for the second time and positive to
    Following surgery, 1 course thereafter. negative.
    of PT chemotherapy Use of rSIFN for 6 months
    regimen was administered. altogether.
    40 Female 70 Cancer of IV Radical resection was Treatment by administering Radiofrequency PD
    hepatic flexure performed on May 4, Year 1. rSIFN-co began on March 17, Year ablation targeting
    of colon, with Six chemotherapy 4; right lung metastases
    lung treatments had been Intramuscular injection once every was performed on
    metastases performed from May Year other day: March 28, Year 4;
    after surgery 1 to September Year 1, with 9 μg for the first time, Argon-helium
    the regimen of XELOX, 21 μg for the second time and cryosurgery targeting
    capecitabine tablets thereafter. the right upper lung
    3000 mg, oral, d1-d14; metastases was
    oxaliplatin 200 mg, performed on April 9,
    intravenous drip, d1. Year 4; the right arm
    1 course of chemotherapy plexus was found
    treatment was performed damaged after the surgery;
    from October 26, Year 2. Radiofrequency
    Oxaliplatin 150 mg, ablations targeting
    intravenous drip, QD, d1; left lung metastases
    cetuximab 600 mg, were performed 2
    intravenous drip, QD, d1; times on May 5, Year
    irinotecan 240 mg, 4and June 13, Year 4,
    intravenous drip, QD, d2; respectively;
    fluorouracil 2500 mg, The right lower lung
    continuous intravenous drip metastases were
    for 48 hours; treated by ion
    TCM treatment had been implantation on May
    performed from November 27, Year 4.
    Year 2 to August Year 3. 2 courses of
    chemotherapy in
    December Year 4:
    capecitabine tablets
    3000 mg, oral, d1-d14.
    Systemic
    chemotherapy on
    March 9, Year 5,
    cetuximab + alimta.
    Avastin and NK cells
    were added for
    treatment on March
    23, Year 5.
    Radiotherapy of
    hepatic metastases
    from April 21, Year 5
    to May 19, Year 5.
    41 Male 57 Colon cancer IV Hepatic interventions were Treatment by administering NC/SD
    with hepatic performed 2 times in rSIFN-co began on September 30, Year 1;
    metastases August Year 1 and on Intramuscular injection once every
    September 12, Year 1, other day:
    respectively. 9 μg for the 1st time;
    21 μg from October 2, Year 1 to
    December 10, Year 1;
    21-25.5 μg from December 12, Year
    1 to January 9, Year 2;
    21 μg from January 11, Year 2 to
    July 17, Year 2;
    Injection into liver tumor: 21 μg × 5
    vials on January 15, Year 2;
    21 μg × 8 vials on January 22, Year 2
    21 μg × 10 vials on February 1, Year 2.
    42 Female 47 cholangiocarcinoma IV Diagnosed with intraheptic Treatment by administering Ovarian cancer The volume PR
    with biliary cystadenocarcinoma rSIFN-co began on November 21, Year 2; surgery was of multiple
    hepatic on May 31, Year 1 and Intramuscular injection once every performed on June space-occupying
    metastases radical surgery of other day: 18, Year 3. lesions of
    after surgery intraheptic biliary 9 μg for the 1st time; the right and
    cystadenocarcinoma was 18 μg for the 2nd time; left lobes of
    performed; 21 μg from February 27, Year 3 to liver is
    Resection of right hepatic July 5, Year 4; significantly
    posterior lobe and caudate Administration was stopped for 3 reduced and
    lobe mass + clearance of months from May Year 3 to August the number of
    abdominal lymph node + Year 3. the lesions is
    I125 ion implantation + Started using recombinant also reduced.
    abdominal drainage were super-compound interferon
    performed on November 23, Year 2. treatment again from June 5, Year 5.
    43 Female 50 Intrahepatic IV Right half liver resection + Treatment by administering PD
    cholangiocarcinoma cholecystectomy + rSIFN-co began on November 15,
    with abdominal Year 2;
    intrahepatic lymphadenectomy were Intramuscular injection of 9 μg once
    metastases performed on November 8, Year 1. every other day;
    Transcatheter arterial intramuscular injection of 21 μg
    chemoembolization every other day from November 21,
    (TACE) was performed on Year 2 to May 20, Year 3.
    December 22, Year 1.
    The 2nd TACE on liver was
    performed on June 4, Year 2.
    Chemotherapy by
    continuous hepatic arterial
    infusion (cisplatin +
    epirubicin + 5 FM) was
    performed on July 2, Year 2.
    The 3rd TACE was
    performed on August 2, Year 2.
    Argon-helium cryoablation
    targeting multiple
    intrahepatic lesions was
    performed in September Year 2.
    The 2nd argon-helium
    cryoablation was performed
    on November 7, Year 2.
    44 Male 58 Liver cancer IV Liver transplantation in Treatment by administering PD
    with lung Year 1. Wedge resection of rSIFN-co began on September 5, Year 4;
    metastases left lung superior lobe Intramuscular injection of 9 μg every
    masses was performed on other day from September 5, Year 4
    July 6, Year 4. to September 9, Year 4.
    Intramuscular injection of 18 μg
    every other day from September 11,
    Year 4 to October 23, Year 4.
    Intramuscular injection of 21 μg
    every other day from October 25,
    Year 4 to February 25, Year 5.
    45 Male 40 Liver cancer IV Hepatic arterial Treatment by administering The original PR
    with embolization was rSIFN-co began on August 21, Year massive primary
    intrahepatic performed on August 9, 1, 1 time every other day; space-occupying
    metastases Year 1. Intramuscular injection of 9 μg at the lesions of
    1st time; the left liver
    Intramuscular injection of 18 μg clearly shrunk;
    from the 2nd time and thereafter; the swollen
    Intramuscular injection of 21 μg retroperitoneal
    every other day from September 17, or abdominal
    Year
    1 to February 1, Year 2. para-aortic
    lymph nodes were
    disappeared.
    46 Female 37 breast cancer IIIc Breast-conserving cancer Treatment by administering PD
    with lymph surgery was performed on rSIFN-co began on May 18, Year 2.
    node June 3, Year 1, with 1/11 Intramuscular injection of 18 μg
    metastases axillary lymph nodes; every other day till September 16,
    after surgery 6 times of chemotherapy Year 2.
    were performed after
    surgery (main drug:
    perarubicin);
    33 times of radiotherapy
    were performed 1 month
    after the end of the
    chemotherapy.
    4 times of “docetaxel +
    xeloda” chemotherapy were
    performed after another
    metastatic lymph node
    resection in January Year 2.
    47 Female 58 breast cancer, IV Left mastectomy and Treatment by administering Oral administration PD
    recurrence after lymphadenectomy were rSIFN-co began on February 5, Year 3: oftamoxifen,
    surgery performed on December 26, Intrapleural injection of 21 μg × (5 or exemestane (Italy),
    Year 1 after 6 courses of 7 or 8 or 10 or 13 vials) each time anastrozole tablets.
    chemotherapy beginning in from February 5, Year 3 to May 23, Carboplatin
    July Year 1 (details unknow); Year 3; combined with
    Multiple courses of Local injection to points of the left thoracic perfusion of
    chemotherapy (details anterior chest wall 5 times from rSIFN-co.
    undknown) were performed May 30, Year 3 to July 11, Year 3, 1
    after the mastectomy; time/week, 21 μg × 8 vials each time;
    Left pleural effusion Intramuscular injection of 21 μg
    appeared in July Year 2and every other day from July 14, Year 3
    was improved after 2 to September 30, Year 3.
    courses of chemotherapy
    with “paclitaxel.”
    48 Female 45 Left breast IIa Left breast-conserving Treatment by administering 2 years after CR
    cancer, after surgery with clearance of rSIFN-co began on March 5, Year 2, left breast-
    surgery tumor cells plus right breast 1 time every other day: conserving
    lobectomy were performed intramuscular injection of 9 μg at the surgery,
    on August 22, Year 1. 1st time, intramuscular injection of subcutaneous
    15 μg at the 2nd time, layers of both
    intramuscular injection of 18 μg at breasts were
    the 3rd time, and clear without
    intramuscular injection of 21 μg any
    from the 4th time and thereafter; abnormalities;
    Intramuscular injection of 18 μg no defined
    every other day from April 23, Year 3. mass was
    Administration was stopped from detected in
    June 26, Year 2 to April 20, Year 3. both breasts.
    49 Female 39 Breast cancer, IV Radical surgery of right Treatment by administering NC/SD
    recurrence after breast with clearance of rSIFN-co began on November 29, Year 2:
    surgery cancer cells was performed Local injection, 4 times, 15 μg/× 6
    in November Year 1, vials each time, from November 29,
    followed by chemotherapy Year 2 to December 20, Year 2;
    (details unknown). Intramuscular injection of 9 ug,
    every other day, from December 11,
    Year 2 to December 20, Year 2.
    Intramuscular injection of 21 μg
    every other day from January 31,
    Year 3 to April 22, Year 3.
    50 Male 64 Gastric cancer, IV “Radical surgery of gastric Treatment by administering PD
    after radical cancer ” was performed on rSIFN-co began on April 14, Year 1,
    surgery March 15, Year 1. 1 time every other day:
    Intramuscular injection of 9 μg at the
    1st time, Intramuscular injection of
    18 μg from the 2nd time and thereafter.
    Intramuscular injection of 15 μg
    every other day from September 1,
    Year 1 to January 22, Year 2.
    Intramuscular injection of 21 μg
    every other day from January 24,
    Year 2 to August 29, Year 2.
    Administration was stopped for 2
    months from September Year 2 to
    November Year 2.
    Intraperitoneal injection of 21 μg ×
    (8-10 vials) each time to lesions in
    abdominal cavity under type-B
    ultrasound guidance from November
    28, Year 2 to December 24, Year 2.
    Intramuscular injection of 21 ug,
    every other day, from November 13,
    Year 2 to March 16, Year 3.
    51 Male 59 Gastric cancer, IV From October, Year 1 to Treatment by administering Ascites were PR
    with abdominal May, Year 3, rSIFN-co began on November 2, Year 3. significantly
    cavity Chemotherapy was Intraperitoneal perfusion, 1 time reduced;
    metastases administered for 9 times every other day: cancer cells in
    (regimen unknown). 15 μg × 8 vials at the 1st time, the ascites
    15 μg × 12 vials at the 2nd time, disappeared.
    15 μg × 14 vials at the 3rd time, and
    15 μg × 16 vials at the 4th time, total
    4 times until November 10, Year 3.
    52 Female 73 Pancreatic III Treatment by administering Lesions in the PR
    cancer rSIFN-co began on December 27, Year 1. portacaval
    Intramuscular injection of 9 μg every space shrank.
    other day.
    Intramuscular injection of 21 μg
    every other day from January 2,
    Year 2 to September 15, Year 2.
    53 Male 73 prostate cancer IV Oral Casodex, zoladex and Treatment by administering Casodex. Some of NC/SD
    with pelvic flutamide. rSIFN-co began on November 30, Three-dimensional pelvic
    metastases Androgen depreviation was Year 1, once every other day: conformal metastastic
    performed on January 16, Year 1. Intramuscular injection of 9 μg at the radiotherapy was lesions were
    Radiofrequency ablation 1st time; Intramuscular injection of performed 24 times, eliminated or
    targeting a large pelvic 21 μg from the 2nd time and beginning December shrank.
    lymph node was performed thereafter; 12, Year 1 (60Gy
    on June 26, Year 1. Intraperitoneal perfusion, 7 times, 2.5 × 24 times)..
    I-125 particle implantation 21 μg × 8 vials each time.
    was performed on July 18, Year 1.
    54 Female 46 Gastrointestinal Ib Duodenal tumorectorny Treatment by administering No signs of CR
    stromal was performed on July 13, Year 1. rSIFN-co began on December Year apparent
    tumors Radiotherapy was 1. 1 time every other day: tumor
    performed on November Intramuscular injection for 6 months recurrence
    16, Year 1 after duodenal 9 μg at the 1st time; and
    surgery. 21 μg from the 2nd time and thereafter;. metastasis
    The 2nd treatment was received for were
    3months from Year 3 to August Year 4. observed by
    The 3rd treatment of rSIFN-co was imaging
    received on September 26, Year 4. examination.
    55 Male 16 Embryonal IV Beginning on July 29, Year Treatment by administering PD
    rhabdomyosarcoma, 1: 4 courses of rSIFN-co began on February 2, Year
    with chemotherapy was 2, once every other day:
    metastases administered (main drugs: Intramuscular injection of 9 μg at the
    after the epirubicin and oxaliplatin). first time; intramuscular injection of
    surgery On September 1, Year 1: 15 μg at the 2nd time and thereafter;
    Radiotherapy of the left Intramuscular injection of 18 μg
    upper chest was every other day from April 21, Year
    administered. 2 to May 19, Year 2.
    Intramuscular injection of 21 μg
    every other day from May 21, Year
    2 to July 11, Year 2.
    Intramuscular injection of 9 μg every
    other day from July 13, Year 2 to
    November 5, Year 2.
    Intramuscular injection of 18 μg
    every other day from November 7,
    Year 2 to December 2, Year 2.
    Intramuscular injection of 21 μg
    every other day from December 4,
    Year 2 to March 25, Year 3.
    Lymph node and intratumoral
    injections, 4 times, 21 μg × 8 vials
    each time, from November 12, Year
    2 to November 28, Year 2.
    56 Female 17 Lymphoma III Treatment by administering Chemotherapy was Lymphoma PR
    rSIFN-co began on December 29, Year 1. received twice after apparently
    Intramuscular injection of 21 μg the Spring Festival of shrank;
    every other day from February 24, Year 2. breathing and
    Year 2 to April 22, Year 2; Treatment was in eating
    Intramuscular injection of 18 μg combination with functions
    every other day from April 24, Year TCM with returned to
    2 to June 5, Year 2; detoxifying function. normal; the
    Intratumoral injection in the neck, 1 hearing of the
    time every other day, 21 μg × right ear
    (8-10-12-12-12-13-15 vials) each recovered
    time, from December 29, Year 1 to from no
    February 18, Year 2; 21 μg × 10 hearing weak
    vials each time from March 24, Year hearing.
    2; 9 μg × 20-23 vials each time from
    April 25, Year 2 to May 5, Year 2; 1
    ml each time, 500 μg/ml from May
    7, Year 2 to May 25, Year 2.
    57 Female 19 malignant IIIc Surgeries were performed Treatment by administering TCM NC/SD
    neuroma of the in January Year 1and in rSIFN-co began on February 9, Year 4.
    right hip, September Year 1; Intramuscular injection of 21 μg
    recurrence after postoperative radiotherapy every other day.
    surgery and chemotherapy were Hip intratumoral injection every 2-3
    received (details unknown). days, 21 μg × 4 vials each time.
    Radiotherapy and
    chemotherapy were
    received again in January
    Year 2 (details unknown).
    Recurrence in January Year
    3. Radiotherapy and
    chemotherapy were
    received again (details
    unknown).
    Recurrence in January Year
    4; ultrasonic scalpel and
    TCM treatments were
    received.
    58 Female 61 Metastatic IIIa Tumor resection in the right Treatment by administering Postoperative NC/SD
    poorly anterior chest wall was rSIFN-co began on July 7, Year 1, radiotherapy after
    differentiated performed on June 11, Year1. intramuscular injection once time surgery of metastatic
    squamous cell every other day: cancer in the upper
    carcinoma in 9 μg at the 1st time, right chest wall was
    the right chest, 21 μg from the 2nd time and performed from July 7,
    after surgery for thereafter, until January 6, Year 2 Year 1 to August 8, Year 1.
    • Example 3 Clinical Data on Typical Patients Treated with the Recombinant Interferon of the Invention (19 Patients)
  • Clinical data collected until Jul. 1, 2012 of 19 patients treated with the recombinant interferon of the invention are provided below (Patients numbered by 1-19 correspond to Patients 1-19, respectively, in the “Summary of Clinical Treatment of Multiple Types of Cancers in 58 Patients” in aforementioned Table 2 of Example 2).
  • Patient 1.
  • Non-small-cell lung cancer; the primary lesions in the right pulmonary hilum and the mediastinal lymph node metastasis disappeared after treatment by intramuscular injection of recombinant super-compound interferon (rSIFN-co) in combination with radiotherapy.
  • Patient 1 Gender: Male Age: 53
    Pathological diagnosis: Squamous cell carcinoma
    Clinical and pathological staging{circle around (1)}: T3N2M0. IIIb
    Regimens before administration of DP Regimen{circle around (8)} was provided from October 14,
    rSIFN-co: Year 1 to November 25, Year 1: 75 mg of
    Taxotere and 75 mg of Cisplatin on Day 1. Two
    cycles of chemotherapy were performed in total,
    each lasting for 21 days.
    Regimens: administration of rSIFN-co The rSIFN-co therapy started in November, Year
    combined with radiotherapy 1. Intramuscular injection of rSIFN-co was done
    once every other day: 9 μg for the 1st time, 15 μg
    for the 2nd time and 18 μg for the 3rd time and
    thereafter. Therapy continued till February, Year
    3, during which rSIFN-co treatment had been
    stopped for 1 month in April, Year 2, leading to a
    total treatment duration of 15 months.
    Radiotherapy{circle around (3)} (DT40Gy) on right lung and
    mediastinal lymph nodes started on December 2,
    Year 1 followed by X-knife therapy (DT20Gy)
    Response to rSIFN-co treatment: CR{circle around (2)} (primary lesions on right pulmonary hilum
    disappeared and cured)
    Survival time: After about 80 months (from October Year 1~July
    Year 8), the patient remained alive and lived
    a normal life. No recurrence or metastasis was
    observed upon imaging examinations.
    Diagnostic imaging before administration CT scan on November 25, Year 1 after
    of rSIFN-co: chemotherapy:
    The right main bronchus was obstructed by the
    invasive masses originated from right hilum,
    resulting in atelectasis of upper lobe of the right
    lung; multiple nodules occurred at the lower lobe
    of right lung. These signs indicated progression of
    tumor.
    The patient had breathing difficulty and breath
    sound disappeared.
    Diagnostic imaging after administration CT scans on January 4, Year 2:
    of rSIFN-co: The masses at right hilum were reduced in size,
    relieving atelectasis at the upper lobe of the right
    lung. Part of mediastinal lymph nodes also
    decreased in size.
    CT scans on June 12, Year 2:
    The mediastinal lymph nodes continued to shrink
    and infiltration of right lung was absorbed.
    CT-scan on November 08, Year 2 (12 months after
    administration):
    Please refer to the location indicated by arrow in
    FIG. 3a where the lesions originally occurred.
    CT-scan on February 1, Year 3 (15 months after
    administration):
    Please refer to the location indicated by arrow in
    FIG. 3a where the lesions originally occurred.
    CT scan on October 19, Year 3:
    The blood vessels or lymph nodes on the right
    hilum were a little larger than normal and more
    infiltration on lower lobe of right lung was
    absorbed; other changes were not obvious.
    Description of FIGS. 3a-3b: After 12 months of treatment, the lesions on the
    right lung were obviously reduced in size. After
    15 months of rSIFN-co administration,
    progression or metastasis of lesions was not
    observed.
  • Patient 2.
  • Non-small-cell lung adenocarcinoma with systemic metastases on body parts including bilateral lungs, liver and lymph nodes/Intramuscular injection and aerosol inhalation of rSIFN-co combined with chemotherapy (GP regimen) and administration of recombinant human endostatin (Endostar). After treatment, the primary lesions in the lungs evidently became reduced in size and the metastatic lesions disappeared in the liver and in many of the lymph nodes.
  • Patient 2 Gender: Male Age: 40
    Pathological diagnosis: Lung Adenocarcinoma
    Clinical and pathological staging{circle around (1)}: T3N3M1.IV
    Regimens before administration of Systematic chemotherapy began at January, Year
    rSIFN-co: 1: Taxotere and Carboplatin. One cycle of 21 days
    was provided.
    Regimens: administration of rSIFN-co The rSIFN-co therapy began on April 14, Year 1.
    combined with chemotherapy and Intramuscular injection of rSIFN-co was done
    other biotherapies once every other day: 9 μg for the 1st time, 15 μg
    for the 2nd time, 18 μg for the 3rd time and 21 μg
    for the 4th time and thereafter. Meanwhile,
    aerosol inhalation of rSIFN-co was done once
    every day: 300 μg for the 1st time, 500 μg for the
    2nd time, 600 μg for the 3rd time and thereafter.
    Administration of rSIFN-co ended in April Year 2.
    From April 20, Year 1 to September 3, Year 1,
    Endostar5 was administrated every day: 7.5 mg/m2
    per dose, 1.2 × 10{circle around (5)} U/m2. Four cycles were
    performed totally with each lasting for 14 days.
    Meanwhile, GP regimen was combined: 1600 mg
    of Gemcitabine on days 1 and 8 and 40 mg of
    Cisplatin on days 1~3. Four cycles were
    performed, each being 15 days.
    One intrapericardial infusion with Cisplatin
    (30 mg) was performed on July 19, Year 1.
    Aerosol inhalation of Cisplatin was added from
    December 23, Year 1 to January 14, Year 2:
    10 mg/dose, 2 doses per day.
    The second course of Endostar treatment was
    provided from January 18, Year 2 to January 30,
    Year 2 with same dosage.
    Chemotherapy using Pemetrexed{circle around (6)} proceeded
    from December 25, Year 1 to January 19, Year 2:
    iv. 500 mg/m2, every 3 to 4 weeks.
    As none of the treatments had any obvious effect,
    the chemotherapy during February 15, Year 2 to
    April 25, Year 2 was replaced with DP regimen{circle around (8)}
    (75 mg/m2 of Taxotere and 75 mg/m2 of
    Cisplatin on day 1) in combination with
    administration with Tarceva (150 mg/day) for 4
    cycles with 21 days per cycle.
    A Gamma knife therapy was performed on head
    on June 29, Year 2.
    Response to rSIFN-co treatment: PR{circle around (2)} (the size of the primary lesions on upper lobe
    of right lung reduced from about 10.2 × 8.2 × 7.7 cm
    to 1.2 × 1.4 cm; metastatic lesions in the right liver
    and multiple lymph nodes disappeared; the
    metastatic lesions on the two lungs decreased in
    size and the radioactive
    concentration/accumulation decreased.)
    Survival: About 18 months from start of this treatment:
    (January 20, Year 1 to August 3, Year 2)
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    PET/CT on April 19, Year 1 (see the PET/CT on June 18, Year 1 (see the lesions
    lesions indicated by the arrow in FIG. indicated by arrow in FIG. 4b):
    4a): 1. The size of primary mass in the upper lobe of
    1. A mass shadow of was found in the right lung was 1.2 × 1.4 cm. Lesions shrank and
    upper lobe of right lung whose size was radioactive concentration reduced significantly.
    about 10.2 × 8.2 × 7.7 cm and CT value was The maximum SUV value was 2.9, and the
    about 38.8Hu, indicating the existence of average value was 2.1;
    a central lung cancer; 2. Multiple metastatic lesions of lymph nodes at
    2. Multiple lymph node metastases were the right side of trachea, root of neck (right-side)
    found at the right side of trachea, root of and the nearby regions beside the pancreas head
    neck (right-side) and the nearby regions at had all disappeared;
    the right-side of pancreas head,; size of 3. Patches, flocculent shadows and reticular
    the maximum lesions was about shadows were extensively distributed at other
    1.4 × 1.1 cm. parts of the lungs with slightly increased
    3. A large quantity of miliary nodule radioactive uptake. Space-occupying lesions and
    shadows were diffusely distributed on consolidation were not found. The size of lesions
    both lungs with radioactive uptake shrank evidently and the radioactive uptake
    increased. Diffuse metastases happened in reduced significantly.
    both lungs. 4. Two metastatic lesions on the right lobe of the
    4. The maximum size of the metastatic liver disappeared.
    lesions on the right lobe of liver is about
    1.2 × 0.9 cm.
    Description of FIGS. 4a-4b: After 2 months' treatment, lesions on the upper
    lobes of both lungs evidently shrank or
    disappeared.
  • Patient 3.
  • Non-small-cell lung cancer with brain metastases/Intramuscular injection and aerosol inhalation of rSIFN-co combined with Gamma knife treatment. After the treatment, primary lesions on right lung and brain metastatic lesions were cleared up.
  • Patient 3 Gender: Female Age: 51
    Pathological diagnosis: None
    Clinical and pathological staging{circle around (1)}: T2N2M1. IV
    Regimens before administration of None
    rSIFN-co:
    Regimens: administration of rSIFN-co Treatment with rSIFN-co started on May 29,
    combined with Gamma knife treatment Year 1. Intramuscular injection of rSIFN-co was
    done once every other day: 9 μg for the 1st time,
    18 μg for the 2nd time and 21 μg for the 3rd time
    and thereafter. Aerosol inhalation of rSIFN-co
    was simultaneously performed: 200 μg/every other
    day.
    From July 14, Year 1, 18 μg of rSIFN-co was used
    in intramuscular injection. Aerosol inhalation of
    400 μg of rSIFN-co was simultaneously performed
    every other day.
    The administration continued for more than 3
    months till September 16, Year 1.
    During this period, Gamma knife radiotherapy for
    the brain lesions was conducted.
    Response to rSIFN-co treatment: CR{circle around (2)}(the primary lesion of about 5.1 × 3.2 cm on
    the upper lobe of right lung disappeared; the
    enlarged lymph nodes in the mediastinum and the
    metastatic lesions in the brain of about 3.7 × 2.6 cm
    basically disappeared.)
    Survival: About 13 months from start of the treatment (from
    May Year 1 to June Year 2)
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    Lung CT scans on May 14, Year 1 (see CT scans on September 16, Year 1 for brain (FIG.
    the lesions indicated by arrow in FIG. 5a): 6b) and chest (FIG. 5b):
    An irregular soft-tissue density shadow of 1. Irregular increased density shadows were found
    about 5.1 × 3.2 cm was found at the apex of at upper lobe of right lung near mediastinum,
    right lung, which had an obscure suggesting the possible occurrence of
    boundary and connected to anterior inflammation in the right lung. The thorax was
    pleural membrane. Enlarged lymph nodes symmetrical, and the perivascular space in
    were found in neighboring mediastinum. mediastinum was clear with no enlarged lymph
    Diagnostic imaging showed that it was a node found. (See the original location of the
    space-occupying lesion in the apex of lesions indicated by arrow in FIG. 5b)
    right lung. 2. Irregular low-density shadows could be seen in
    Brain CT scans on May 14, Year 1 (see the right frontal lobe and left temporal lobe. The
    the lesion indicated by arrow in FIG. 6a): anterior horn of right lateral ventricle was
    Multiple hybrid-density shadows were narrowed. Cerebral fissures and sulcus were not
    found at frontal lobe, temporal lobe and widened and the midline structure was centered.
    parietal lobe of both sides, which were (See the original location of the lesions indicated
    surrounded by low density shadows by arrow in FIG. 6b)
    especially on the right side. The lateral
    ventricle was pressed to be narrower and
    the midline structure was shifted
    leftwards. The pathline of the lesions at
    the right frontal lobe was about
    3.7 × 2.6 cm.
    Description of FIGS. 5a-5b: After 3-month of treatment, the mass at the apex
    of right lung completely disappeared.
    Description of FIGS. 6a-6b: After treatment, the metastatic brain lesions
    disappeared.
  • Patient 4.
  • Small-cell lung cancer with metastases in the mediastinal lymph nodes and clavicles/Intramuscular injection and aerosol inhalation of rSIFN-co combined with chemotherapy (aerosol inhalation of Cisplatin and EP regimen) and interventional therapy for supraclavicular lesions. After the treatment, primary lesions in the right lung and metastases in mediastinal lymph nodes and clavicles cleared up.
  • Patient 4 Gender: Male Age: 49
    Pathological diagnosis: Small-cell lung cancer
    Clinical and pathological staging{circle around (1)}: T4N3M1. IV
    Regimes before administration of rSIFN-co: The first cycle of EP{circle around (7)} chemotherapy was
    conducted from March 25, Year 1 to Apr 9,
    Year 1: 100 mg of Etoposide and 30 mg of
    Cisplatin.
    Regimes: administration of rSIFN-co The treatment of rSIFN-co began on April 12,
    combined with chemotherapy and Year 1. Intramuscular injection was done
    interventional therapy once every other day: 9 μg for the 1st time,
    15 μg for the 2nd time and 18 μg for the 3rd
    time and thereafter. Aerosol inhalation of
    rSIFN-co was performed once every other
    day: 0.5~2 ml/dose (200 μg/ml).
    From July 16, Year 1, 21 μg of rSIFN-co was
    used in intramuscular injection. Aerosol
    inhalation of rSIFN-co continued but the
    amount per dose was changed to 200 μg.
    The first cycle finished by the end of March
    Year 2 (lasting for almost 1 year). The
    administration of rSIFN-co was stopped for 1
    month because Aerosol inhalation of
    Cisplatin (one dose per day and 10 mg per
    dose) was performed throughout September
    Year
    1.
    The 2nd cycle of treatment proceeded from
    October 9, Year 2 to January 26, Year 3
    during which 18 μg of rSIFN-co was
    intramuscularly injected every other day. Five
    cycles of EP chemotherapy were conducted
    from March 25, Year 1 to September 10,
    Year 1 and the same regimen as mentioned
    above was used.
    An interventional cryoablation was conducted
    on the supraclavicular lesions on September
    3, Year 2.
    From October Year 1, a 15-day regimen of
    aerosol inhalation of Cisplatin was added:
    10 mg per dose, 1 dose per day. Two cycles
    were done, each lasting for 15 days.
    Response to rSIFN-co treatment: CR{circle around (2)}(a primary lesion of about 0.6 × 0.4 cm, on
    the apex of right lung disappeared.; a lesion
    with a nodule of about 2.6 × 2.2 cm on the of
    right clavicle disappeared; Mutilple nodules
    appearing in neighboring areas of the
    mediastinal brachiocephalic trunk, right
    brachiocephalic veins, superior vena cava,
    and trachea, part of which fused and lesions
    of about 5.5 cm × 4.9 cm in size disappeared.)
    Survival: After about 39 months (from March 23, Year
    1 to July Year 4), the patient remained alive
    and had a normal life. No recurrence or
    metastasis was observed upon imaging.
    Diagnostic imaging before administration of Diagnostic imaging after administration of
    rSIFN-co: rSIFN-co:
    PET/CT scans on April 8, Year 1 (see the PET/CT scans on December 24, Year 1 (see
    lesions indicated by arrows in FIG. 7a-8a) the original lesion locations indicated by
    after the chemotherapy: arrows in FIG. 7a-8a):
    1. One nodule with coarse edge and slight 1. The nodule at the apex of right lung were
    lobulated appearance was found at the apex of not obviously shown;
    right lung (diameter: 0.6 × 0.4 cm). PET showed 2. The nodules on right clavicle were
    abnormal radioactive concentration and the significantly downsized. PET showed
    SUV value was 4.1. abnormal radioactive concentration with a
    2. Nodules of about 2.6 × 2.2 cm were SUV value of 4.7;
    observed at right clavicle, the boundaries of 3. The nodules around the mediastinal
    which were obscure. PET showed abnormal brachiocephalic trunk, right brachiocephalic
    radioactive concentration and the SUV value veins, and trachea were not clearly observed.
    was 9.1. superior vena cava;
    3. Multiple nodules of about 5.5 cm × 4.9 cm 4. Multiple nodules were found around the
    appeared around the mediastinal superior vena cava. PET did not show an
    brachiocephalic trunk, right brachiocephalic obvious radioactive concentration, indicating
    veins, superior vena cava, and trachea. The the suppression on the lesions' metabolism.
    boundaries of these nodules were not distinct PET/CT scans on July 26, Year 3:
    and some were partially fused together. PET 1. Streaky shadows were found in the upper
    showed abnormal radioactive concentration lobe of right lung while patchy shadows were
    and the SUV value was 11.5). Metastasis of found in dorsal segment of lower lobe. PET
    lymph nodes should be taken into account. scan did not show obvious radioactive
    4. The superior vena cava could not be concentration;
    excluded. 2. After cryotherapy was conducted for the
    right supraclavicular metastasis, no obvious
    nodules or masses were found in the right
    clavicle and PET image did not show obvious
    radioactive concentration. PET scans on other
    parts showed similar metabolic images as
    before.
    PET/CT on February 7, Year 4 (after
    treatment of “small-cell cancer of right lung”
    and compared to PET/CT scans taken on July
    26, Year 3):
    1. The posterior wall of left nasopharynx was
    thickened slightly and PET imaging showed
    radioactive concentration, suggesting the
    possible occurrence of an inflammatory
    lesion;
    2. Multiple nodules were at deep cervical and
    submentum and PET imaging did not show
    abnormal radioactive concentration,
    suggesting the possible occurrence of
    inflammatory hyperplasia of lymph nodes;
    3. The wall of greater gastric curvature was
    slightly thickened and PET imaging did not
    show radioactive concentration.
    Inflammatory lesion could be taken into
    consideration;
    4. PET/CT scans on other parts did not show
    significant changes.
    Description of FIGS. 7a-7b: After 8 months of treatment, the lesions on
    the apex of the right lung disappeared.
    Description of FIGS. 8a-8b: After 8 months of treatment, the metastatic
    lesions in mediastinum disappeared.
  • Patient 5.
  • Non-small-cell lung cancer with metastases to the right humerus, after surgeries/Intramuscular injection and aerosol inhalation of rSIFN-co combined with chemotherapy (aerosol inhalation of Cisplatin). After treatment, the metastatic lesions in right lung hilum, paratracheal lymph nodes and several sites of spinal metastases disappeared.
  • Patient 5 Gender: Female Age: 42
    Pathological diagnosis{circle around (1)}: Metastatic adenocarcinoma (in right humerus)
    (moderately differentiated adenocarcinoma)
    Clinical and pathological staging{circle around (1)}: T2N2M1. IV
    Regimes before administration of rSIFN-co: A surgical repair of right humerus was
    performed on February 23, Year 1.
    After that surgery, patient was given 4 courses
    of DP{circle around (8)} chemotherapy: 75 mg of Taxotere and
    75 mg of Cisplatin on day 1.
    Regimes: administration of rSIFN-co Treatment with rSIFN-co began on April 15,
    combined with chemotherapy Year 1. Intramuscular injection was performed
    once every other day: 9 μg for the 1st time and
    21 μg for the 2nd time and thereafter.
    The treatment was provided for a total of 3
    months till September 15, Year 1, during which
    rSIFN-co administration was suspended for 1
    month due to chemotherapy (the chemotherapy
    regimen shown below related to aerosol
    inhalation of Cisplatin) and for 1 month
    because of the patient's physical condition.
    Aerosol inhalation of rSIFN-co was added on
    September 16, Year 1: 1 ml (200 μg/ml) per day.
    Till February, Year 2, the co-administration
    regimen was provided for 5 months.
    From September 15, Year 2, intramuscular
    injection of 15 μg was provided every other day.
    Aerosol inhalation of Cisplatin began on
    September 16, Year 1: 10 mg per dose and 2
    doses per day. Eight cycles were conducted
    with each cycle being 15 days.
    Response to rSIFN-co treatment: CR{circle around (2)}(radioactive concentrations at the primary
    lesion of right lung tumor, right humerus and
    the T6 vertebra evidently decreased. Metastatic
    lesions on pelvis and lumbar vertebrae as well
    as enlarged paratracheal lymph nodes
    disappeared.)
    Survival: After about 40 months (February Year 1 to July
    Year 4), the patient remained alive with a
    normal life. No recurrence or metastasis was
    observed upon imaging.
    Diagnostic imaging before administration Diagnostic imaging after administration of
    of rSIFN-co: rSIFN-co:
    PET/CT scans on February 26, Year 1 after PET/CT scans on March 2, Year 2 (see original
    surgery (See lesions indicated by arrows in locations of lesions indicated by arrows in FIG.
    FIG. 9a-11a): 9b-11b):
    1. A circular nodule shadow of about 1. The mass on the soft tissue of anterior
    24 mm × 19 mm × 18 mm was found at the front segment of upper lobe of right lung did not
    end of right lung' upper lobe. change in shape, size and density. The extent of
    2. Metastases happened to the right upper radionuclide metabolism decreased (SUVmax
    lung hilum and lymph nodes on anterior reduced from 9.5 to 1.7);
    tracheal space. Metastatic lesions were also 2. The glucose metabolism of lymph nodes on
    observed at right humerus. anterior tracheal space became normal and
    3. Accumulated lesions on the right upper calcified lymph nodes at right upper lung hilum
    humerus were found which was considered showed a mild radioactive concentration.
    as changes during the recovery phase after 3. The radioactive concentration at upper
    the surgery. segment of right humerus and T6 vertebra
    4. Increased radionuclide metabolism was reduced (SUVmax decreased from 6.3 and 3.8
    observed at chest, lumbar and bilateral ilia. to 2.9 and 1.7, respectively);
    Multiple bone metastases probably 4. No abnormal distribution of radionuclide was
    happened. obviously found in lumbar, sacrum and pelvis.
    5. Tiny nodular shadows of 2 mm were 5. Tiny modules were almost the same as seen
    found on the posterior portion of the upper before in lateral segment of middle lobe of right
    lobe of right lung, which was recommended lung and the lateral basal segment of lower lobe
    to be continually observed. of left lung. No radionuclide was abnormally
    CT scans on April 13, Year 1 after distributed.
    chemotherapy:
    Cancer on upper portion of right lung, tiny
    nodules on right lung, circumscribed pleural
    thickening and enlarged mediastinal lymph
    nodes were found. The results suggested
    that the chemotherapy was not effective and
    the lesions had progressed.
    Description of FIGS. 9a-9b: After treatment, the radionuclide metabolism
    reduced significantly in the primary lesions of
    right lung.
    Description of FIGS. 10a-10b: The radioactive concentration of the lesions at
    upper segment of right humerus decreased.
    Description of FIGS. 11a-11b: Metastatic lesions on pelvis disappeared.
  • Patient 6.
  • Non-small-cell lung cancer with multiple lymph node metastases in mediastinum, left segment of neck, right and root segment of neck, left supraclavicular fossa; left-sided pleural effusion; multiple bone metastases in vertebral column, bilateral ribs, right clavicle joint, sternum and left sacrum, and obvious generalized pain/Intramuscular injection, aerosol inhalation and local spraying of rSIFN-co combined with chemotherapy (GP regimen) and Gefinitib (Iressa) therapy. After the treatment, primary lesions on left lung disappeared and metastatic lesions around the body shrank. Further, generalized pain was relieved.
  • Patient 6 Gender: Male Age: 39
    Pathological diagnosis: Moderately-poorly differentiated adenocarcinoma
    Clinical and pathological staging{circle around (1)}: T4N3M1b. IV
    Regimens before administration of The first cycle of GP Regimen {circle around (9)} began in
    rSIFN-co: September Year 1 with each cycle lasting for 21
    days: 1000 mg/m2 of Gemcitabine on day 1 and 8
    and 75 mg/m2 of Cisplatin on day 1.
    Regimens: administration of rSIFN-co Treatment with rSIFN-co began on October 12,
    combined with chemotherapy and other Year 1 with aerosol inhalation of 600 μg every
    biological therapies day.
    Intramuscular injection of rSIFN-co started on
    December 12, Year 1, once every other day: 9 μg
    for 1st time, 15 μg for 2nd time and 18 μg for 3rd
    time and thereafter.
    Local spraying on bone metastases began on
    March 12, Year 2: 70 μg~139 μg/does/site, 4~5
    doses/day.
    The second cycle of GP Regimen {circle around (9)} started on
    October 14, Year 1 (the regimen was exactly the
    same as mentioned above).
    Gefinitib was taken from November 24, Year 1: 1
    pill/dose (250 mg/pill), 1 dose/day.
    Response to rSIFN-co treatment: CR{circle around (2)}(primary lesion of about 9 × 3.5 cm in size at
    the left lung almost disappeared; enlarged lymph
    nodes of about 1.0 cm × 0.7 cm at left segment of
    neck, nodules of about 1.2 cm × 0.8 cm at left
    supraclavicular fossa and nodules of about
    1.4 cm × 1.1 cm at right and root segment of neck
    disappeared; metastatic lesions on sternum
    disappeared; and metastatic lesions at right
    sternoclavicular joints, ribs and pelvis shrank and
    relieved to some extent.)
    Survival: After 10 months (from September 27, Year 1 to
    July Year 2), the patient remained alive and had a
    normal life. Further, his condition was stable.
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    Chest CT scans on September 21, Year 1 CT scans on November 15, Year 1:
    (see primary lesions indicated by arrows Shadows of soft tissues of about 3.6 × 4.2 cm were
    in FIG. 12a): found; sheet-like density shadows were scattered
    A blocky shadow (9 × 3.5 cm) of high and had obscure boundaries; no enlarged lymph
    density was found around left nodes were seen in the mediastinum (the original
    mediastinum and CT value was 39Hu. ones disappeared).
    The boundaries between this shadow and CT scans on December 12, Year 1 (see original
    part of great vessels in mediastinum locations of lesions indicated by arrows in FIG.
    superius, left hilum and left posterior 12b):
    pleura were obscure. Patchy shadow of Sheet-like and single-sheet-like shadows with
    inflammatory exudation with high density increased density were scattered in both lungs.
    could be seen in lung. Enlarged lymph The boundaries were obscure and two hila were
    nodes were found in mediastinum. A few not larger. The tracheas were clear and no
    patchy shadows with high density were enlarged lymph nodes were seen in the
    seen inhomogeneous in upper segment of mediastinum. Pneumonia of both lungs might
    right lung, boundaries of which were happen.
    clear. Arched effusions were found on left Bone scans on December 6, Year 1:
    posterior side. Multiple spot-like, mass-like and sheet-like
    Diagnosis conclusion: lung cancer in left shadows with abnormal radioactive concentration
    mediastinum combined with pleural could be seen in right sternoclavicular joints, ribs,
    effusion and obstructive pneumonia; spinal column and pelvis. Radioactive
    multiple patchy shadows were present in distributions in other parts were basically uniform
    hilum, suggesting the possible occurrence and symmetrical.
    of metastases. Diagnosis conclusion: systemic bone metastases
    Color Doppler ultrasound on September shrank in size and were relieved to some extent
    30, Year 1: than before.
    Multiple hypoechoic nodules were at left PET/CT scans on December 29, Year 1:
    segment of neck, which had clear A nodule with diameter of about 8 mm was
    boundaries and had no hilum of lymph observed at the apex of left lung and radioactive
    nodes. The big hypoechoic nodule was distribution was slightly increased. Patchy
    1.0 cm × 0.7 cm in size. One hypoechoic shadows with slightly higher (than normal)
    nodule of about 1.2 cm × 0.8 cm was at left density and fabric lesions were found in
    supraclavicular fossa. It had clear surrounding area of lung and the radioactive
    boundary but had no hilum of lymph distribution was slight increased. Scattered,
    node. One hypoechoic nodule of about patchy shadows with slightly higher density were
    1.4 cm × 1.1 cm was at root segment of neck found in both lungs and the radioactive
    on the right side. It had clear boundary distribution was not obviously abnormal.
    but had no hilum of lymph node. Conclusion: 1. After treatment, no obvious
    Diagnosis conclusion: hypoechoic increase of FDG metabolism was found on at
    nodules were found at left segment of lesions of the apex of left lung, suggesting the
    neck, left supraclavicular fossa and root inactivation of most tumor cells; 2. Asymmetric
    segment of neck on the right side. hyperosteogeny was found in whole body and
    Bone scans on September 29, Year 1: FDG metabolism in some lesions was
    Multiple lesions with radioactive inhomogeneous with a few increased.
    concentrations were found in spinal
    column, bilateral ribs, right-sided
    sternoclavicular joints, sternum, left-sided
    sacroiliac joints and left-sided ilium.
    Conclusion: Systemic bone lesions with
    radioactive concentration were found,
    suggesting the possible occurrence of
    systematic bone metastases.
    Description of FIGS. 12a-12b: After treatment of 2 months, lesions in the left
    lung disappeared.
  • Patient 7.
  • Non-small-cell lung cancer with metastases in both lungs, both livers and bones of whole body/Intramuscular injection and aerosol inhalation of rSIFN-co combined with administration of Gefinitib (Iressa). After treatment, metastases disappeared or shrank in lungs and several bones, and metastatic lesions of lymph nodes disappeared in liver and mediastinum.
  • Patient 7 Gender: Female Age: 53
    Pathological diagnosis: metastatic adenocarcinoma (lymph nodes at left
    clavicle)
    Clinical and pathological staging{circle around (1)}: T4N3M1. IV
    Regimens before administration of None
    rSIFN-co:
    Regimens: administration of rSIFN-co Treatment with rSIFN-co began on July 31, Year
    combined with administration of other 1. Intramuscular injection was done once every
    biological agents other day: 9 μg for 1st time, 18 μg for 2nd time and
    21 μg for 3rd time and thereafter.
    Seventy-five times of intramuscular injection
    were done till January 2, Year 2 (totally 5
    months).
    Meanwhile, Iressa (Gefinitib) {circle around (10)} produced in India
    was administered in combination for 1 year: 1
    pill/dose (250 mg/pill), 1 dose/day.
    Response to rSIFN-co treatment: PR{circle around (2)}(primary lesions in right lung and metastatic
    lesions in both lungs and several bones shrank
    with radioactive concentration decreased;
    metastasis in liver disappeared.)
    Survival: About 28 months (From June 9, Year 1 to October
    15, Year 3)
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    CT scans on June 26, Year 1: CT scans on October 22, Year 1 (See original
    1. Sheet-like lesions with radioactive locations for lesions indicated by arrows in FIG.
    concentration could be found in the upper 13b):
    lobe of right lung and multiple lesions at 1. Lung cancer with metastases in two lungs and
    nodules were found in both lungs; liver (recovered compared with previous CT
    shadows with radioactive concentration scan);
    could be found in liver and lumbar, 2. Bone scans showed that metastatic lesions were
    suggesting the happening of metastases. widely spread in bones all over the body (slightly
    2. Bone scans all over the body showed recovered compared with previous CT scan).
    metastatic lesions were widely spread CT scans on January 2, Year 2 (see original
    (parietal bone, left shoulder joint, both locations of lesions indicated by arrows in FIG.
    shoulder blades and bilateral ribs) (See 14b):
    lesions indicated by arrows in FIG. 13a). 1. The disease was diagnosed as lung cancer in
    CT imaging on July 2, Year 1: July. Specifically, patchy nodular lesions in the
    see lesions indicated by arrows in FIG. lower lobe of right lung and circumjacent
    14a. spot-like shadows with high density were seen.
    Condition was improved as compared with
    previous CT scans.
    2. The size and shape of liver were normal.
    Density of liver is even and no focal density
    abnormality was found.
    CT scans on March 3, Year 2:
    Compared with the imaging on October 22, Year
    1, no new lesion was found and partial sclerotin
    radiation was reduced. Multiple bone metastases
    existed with lung cancer, but improved after
    treatment.
    Description of FIGS. 13a-13b: After treatment, systemic metastatic lesions at
    bones partially disappeared or shrank.
    Description of FIGS. 14a-14b: After treatment, metastatic lesions in both lungs
    disappeared and lesions in right lung evidently
    shrank.
  • Patient 8.
  • Non-small-cell lung cancer with bone metastases/Intramuscular injection and aerosol inhalation of rSIFN-co combined with administration of Gefinitib (Iressa). After treatment, the metastatic lesions in the lungs disappeared and the primary lesions in right lung shrank evidently.
  • Patient 8 Gender: Female Age: 68
    Clinical and pathological staging{circle around (1)}: T4N2M1. IV
    Regimens before administration of None
    rSIFN-co:
    Regimens: administration of rSIFN-co Treatment with rSIFN-co began on July 21, Year
    combined with other biological therapies 1 Intramuscular injection was done once every
    other day: 9 μg for 1st time, 15 μg for 2nd time and
    18 μg for 3rd time and thereafter. Meanwhile,
    aerosol inhalation of rSIFN-co of 600 μg was
    performed once a day. Administration of
    rSIFN-co continued for 3 months till October 31,
    Year 1.
    Administration of Gefinitib (Iressa) {circle around (10)} was added
    in July Year 1: 250 mg/pill, 1 pill/dose, 1
    dose/day.
    Response to rSIFN-co treatment: CR{circle around (2)}(lesions of about 3.0 × 3.9 cm at the lower lobe
    of right lung, and metastatic lesions in left ilium
    disappeared basically.)
    Survival: After about 12 months (from June 15, Year 1 to
    July Year 2), the patient remained alive and had
    stable conditions.
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    CT scans on July 17, Year 1 (see lesions CT scans on August 20, Year 1 (see original
    indicated by arrows in FIG. 15a): locations of lesions in FIG. 15b-16b):
    The thorax was symmetrical. The lung The lesions in the lower lobe of right lung and
    markings increased and disorganized and metastatic lesions in left Ilium were evidently
    transmittance of lung field was low. absorbed and shrank after one-month therapy.
    Spot-like and reticular density shadows CT scans on October 10, Year 1:
    were diffusely distributed in bilateral Thorax was symmetrical and barrel shaped. The
    lungs. A density shadow of soft tissue lung markings increased and disordered and
    mass (3.0 × 3.9 cm) was found in lower transmittance of lung field was elevated. Lesions
    lobe of right lung. The shadow had on the lower lobe of right lung were obviously
    obscure and irregular boundary and had absorbed and shrank, and spot-like calcified
    burrs and spinous protuberance at the shadows were in the lesions; the diffusely
    border. distributed spot-like density shadows in both
    CT imaging on July 17, Year 1: lungs were further absorbed and patchy calcified
    See lesions shown in FIG. 16a. shadows were found in right hilum. Mediastinal
    lymph nodes were seen and calcified shadows of
    lymph nodes were found below carina.
    Description of FIGS. 15a-15b: After treatment, lesions in the lower lobe of right
    lung was evidently absorbed and shrunk.
    Description of FIGS. 16a-16b: After treatment, metastatic lesions in left ilium
    was evidently absorbed and shrunk.
  • Patient 9.
  • Non-small-cell lung squamous cell carcinoma/Aerosol inhalation of rSIFN-co combined with chemotherapy (GP regimen) and administration of recombinant human endostatin (Endostar). After treatment, masses of soft tissue at hilum of lower lobe of right lung evidently shrank and enlarged lymph nodes at right lung hilum disappeared.
  • Patient 9 Gender: Male Age: 55
    Pathological diagnosis: Squamous cell carcinoma
    Clinical and pathological staging{circle around (1)}: T2N1M0. IIb
    Regimens before administration of None
    rSIFN-co:
    Regimens: rSIFN-co combined with Treatment with rSIFN-co began on March 18,
    chemotherapy. Year 1. Aerosol inhalation of rSIFN-co of 600 μg
    was performed once a day. A course completed
    till July 20, Year 1 (for 4 months) with 100 doses
    of aerosol inhalation done.
    Four cycles of chemotherapy (GP regimen{circle around (9)}) were
    performed with the first one beginning at April
    12, Year 1 and each cycle lasting for 21 days:
    1600 mg of Gemcitabine on days 1 and 8 and
    40 mg of Cisplatin on days 1 and 3. Meanwhile,
    3 cycles of Endostar{circle around (5)}administration were
    performed with 14 days as one cycle:
    7.5 mg/m2 (1.2 × 105 U/m2) per dose, 1 dose/day.
    Second cycle of chemotherapy began on May 10,
    Year 1 with the same regimen.
    Third cycle of chemotherapy began on June 7,
    Year 1 with the same regimen.
    Fourth cycle of chemotherapy began on July 7,
    Year 1 with the same regimen.
    Four cycles of chemotherapies were totally
    performed.
    Response to rSIFN-co treatment: CR{circle around (2)}(primary lesions of about 3.3 × 2.4 × 2.0 cm in
    right lung basically disappeared and enlarged
    lymph nodes in right hilum of about 2.0 × 2.2 cm
    disappeared.)
    Survival: After 16 months (from March 1, Year 1 to July
    Year 2), the patient remained alive and had
    normal life. His condition was stable.
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    CT scans on February 28, Year 1: CT scans on May 23, Year 1:
    see the size of lesions indicated by arrows 1. Irregular tissue shadows were seen in right
    in FIG. 17a. hilum and masses shrank. Spot-like calcified
    Chest PET/CT scans on March 18, Year 1: lesions were at right hilum.
    1. Soft tissue nodules of about 2. The enlarged lymph nodes at right hilum
    3.3 × 2.4 × 2.0 cm with obscure boundary shrank.
    from neighboring hilum and extremely CT scans on July 18, Year 1 (see size of tumors
    high radioactive uptake (SUVmax = 10.2) indicated by arrows in FIG. 17b):
    was observed at opening segment of Several density shadows of soft tissue could
    bronchus on lower lobe of right lung. be found at the right lower hilum. Enhancement
    2. Enlarged lymph nodes of about could be observed after enhancement scan.
    2.0 × 2.2 cm was observed at right hilum Spot-like calcified lesions could be found at right
    with increased radioactive uptake hilum; mediastinum was centered with no obvious
    (SUVmax = 6.6.) shadows of enlarged lymph nodes
    Description of FIGS. 17a-17b: After treatment of 4 months, soft tissue masses at
    hilum of lower lobe of right lung evidently
    shrank.
  • Patient 10.
  • Non-small-cell lung cancer with metastases in lung and pleura; pleural effusion/Intramuscular injection of rSIFN-co alone or intrapleural perfusion of rSIFN-co alone. After treatment, primary lesions on the apical segment of upper lobe of left lung were cleared up and metastatic lesions on lingual segment of left lung shrank.
  • Patient 10 Gender: Female Age: 48
    Clinical and pathological staging{circle around (1)}: T4N0M0. IIIb
    Regimens before administration of None
    rSIFN-co:
    Regimens: administration of rSIFN-co Treatment with rSIFN-co began on March 9, Year
    alone 1. Intramuscular injection of rSIFN-co was
    performed once every other day: 18 μg for 1st
    time, 21 μg for 2nd time and thereafter. Such
    administration continued for almost 1 year till
    March, Year 2.
    Intrapleural perfusion of rSIFN-co was done once
    every 8 days from April 29, Year 1: 9 μg × 4 vials
    for 1st and 2nd time and 9 μg × 5 vials for 3rd time.
    Three perfusions were provided totally.
    Four CT-guided interventional operations were
    performed in July and August Year 2. The
    rSIFN-co was injected into relatively large lesions
    in lungs and 21 μg × 10 vials were used each time.
    Response to rSIFN-co treatment: CR{circle around (2)}(primary lesions of about 2.0 × 2.0 cm in left
    lung basically disappeared and malignant pleural
    effusion disappeared.)
    Survival: Patient died after about 19 months later due to
    renal and hepatic failure caused by traditional
    Chinese medicine (from February 22, Year 1 to
    October Year 2).
    Cytological diagnosis before Cytological diagnosis after administration of
    administration of rSIFN-co: rSIFN-co:
    Pleural fluid smear (March 2, Year 1): Pleural fluid smear and cell mass (September 18,
    poorly differentiated cancer cells were Year 1):
    found. Lymphocytes, neutrophils and necrotic materials
    were found, no tumor cells was found.
    Diagnostic imaging before administration Diagnostic imaging after administration of
    of rSIFN-co: rSIFN-co:
    Chest CT scans on February 23, Year 1: CT scans on August 1, Year 1 (see original
    1. A mass of 2.0 × 2.0 cm was found at locations of lesions indicated by arrows in FIG.
    apical segment of the upper lobe of the 19b):
    left lung, suggesting the possible 1. After treatment on left lung, small nodular
    occurrence of lung cancer. shadows in the posterior segment of upper lobe of
    2. Multiple nodular lesions were seen in left lung were completely absorbed and
    the upper lobe of left lung, indicating the dissipated.
    possibility of metastases happening. 2. Nodular lesions in the lingual segment of left
    3. Pleural effusion was observed in left lung were absorbed and shrunken.
    thoracic cavity. 3. Left-sided pleural effusion was evidently
    CT imaging on March 6, Year 1: reduced and streaky nodular lesions on the left
    See lesions indicated by arrows in FIG. pleura were evidently absorbed and relieved.
    19a.
    Description of FIG. 18: After treatment, pleural effusion was reduced
    evidently.
    Description of FIGS. 19a-19b: After treatment, lesions in left lung shrank
    obviously and pleural effusion was evidently
    reduced.
  • Patient 11.
  • Non-hodgkin lymphoma/Aerosol inhalation (though nasopharynx and Oral Cavity) of rSIFN-co and local injection into enlarged lymph nodes at neck combined with radiotherapy. After local administration, lesions in the nasal cavity, oropharynx, neck and submaxillary region disappeared or shrank.
  • Patient 11 Gender: Male Age: 40
    Pathological diagnosis: Non-hodgkin lymphoma on mesenteric lymph
    nodes
    Clinical and pathological staging{circle around (1)}: IV
    Immunohistochemical examination: Non-Hodgkin malignant lymphoma
    (B-cell-originated) (see tumor cells shown by
    arrows in FIG. 20)
    Regimens before administration of Chemotherapy was performed for 7 times (five
    rSIFN-co: times of CHOPE regimen and two times of MTX
    regimen) began on August, Year 1.
    Autologous stem cell transplantation was done in
    March Year 2.
    Chemotherapy were provided for 4 times (1 time
    of GCE regimen and 3 times of ESAP regimen)
    began on August, Year 2. The forth one ended on
    November 26, Year 2.
    Chemotherapy was administered 6 times (3 times
    of large-dosed CHOPE regimen, 2 times of
    CMOP regimen and 1 time of a regimen of
    “bleomycin + CHOP(11) + Methotrexate”) began on
    January, Year 3, in combination with stem cell
    therapy.
    Regimens: rSIFN-co combined with Treatment with rSIFN-co began on June 9, Year 3.
    chemotherapy and radiotherapy An aerosol preparation of rSIFN-co (72 μg/ml)
    was sprayed onto the nasopharynx and Oral
    Cavity
    2~3 times every day. Administration
    continued till August 27, Year 3 with 5 days of
    suspension because of chemotherapy (see
    chemotherapy describebd below).
    Local injections on lymph nodes in neck started
    on June 11, Year 3. Injection was performed every
    other day by injection at multiple sites in a
    quincunx: 15 μg × 10 vials per treatment. Two
    times later, local subcutaneous injection was
    performed every other day: 30 μg per treatment.
    Till August 27, Year 3 (more than 2 months), for a
    total of 10 times.
    Four cycles of CHOP(11) chemotharepy were
    provided from July Year 3 to November 28, Year 3
    with each cycle lasting for 21 days.
    Radiotherapy began on June 11, Year 3 (scheduled
    for 25 times) and stopped on July 5, Year 3 as the
    patient was weak due to myelosuppression.
    Response to rSIFN-co treatment: PR2 (soft tissure around nasopharynx and
    oropharynx with the thickest part of 3.0 cm
    entirely disappeared, and the largest fused lymph
    node among those at submaxillary region, neck
    and clavicular region shrank from 7.4 cm × 2.4 cm ×
    14.6 cm to 1.1 cm × 1.5 cm.)
    Survival: about 32 months (August 2, Year 1 to April 17,
    Year 4)
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    PET/CT scans on July 8, Year 3 (see the PET/CT scans on August 27, Year 3 (see original
    lesions indicated by arrows in locations of lesions indicated by arrows in
    FIG. 21a-23a): FIG. 21b-23b):
    1. Nasopharyngeal cavity and 1. The thickening of soft tissue at nasopharyngeal
    oropharyngeal cavity become cavity and oropharyngeal cavity disappeared, and
    significantly narrower; surrounding soft radioactive uptake was significantly reduced.
    tissues were thickened with the thickest 2. The number, volume and radioactive uptake of
    part of 3.0 cm; and choanae was blocked. enlarged fused lymph nodes at bilateral mandible,
    2. A large number of lymph nodes were neck and supraclavicular and infraclavicular
    enlarged and fused at bilateral region reduced as compared to the previous
    submaxillay, neck and supraclavicular examination. Only two slightly bigger lymph
    and infraclavicular regions with the nodes of about 1.1 cm × 1.5 cm with elevated
    biggest of about 7.4 cm × 2.4 cm × radioactive uptake were seen in the left
    14.6 cm. submaxillay.
    Description of FIGS. 21a-21b: After treatment, a large number of primary
    enlarged lymph nodes at neck disappeared.
    Description of FIGS. 22a-22b: After treatment, primary lesions at bilateral
    mandible disappeared.
    Description of FIGS. 23a-23b: After treatment, primary lesions at pharyngeal
    disappeared.
  • Patient 12.
  • Non-small-cell lung cancer with metastasis in pleura/Intramuscular injection of rSIFN-co. After treatment, lesions on lower lobe of right lung evidently shrank.
  • Patient 12 Gender: Male Age: 67
    Cytologic diagnosis: Lung adenocarcinoma
    Clinical and pathological staging{circle around (1)}: T3N0M0. II b
    Regimens before administration of From August 16, Year 1, two cycles of GP
    rSIFN-co: regimen{circle around (9)}were provided: 1000 mg/m2 of
    Gemcitabine on day 1 and 8 and 75 mg/m2 of
    Cisplatin on day 1. Intrathoracic injection of
    Cisplatin was also performed for 5 times. 1 dose
    every 7 days, 30-40 mg per dose.
    Regimens: administration of rSIFN-co Treatment with rSIFN-co began on November
    alone 10, Year 1. Intramuscular injection of rSIFN-co
    was provided once every two days: 9 μg for 1st
    time, 18 μg for 2nd time and 21 μg for 3rd time
    and thereafter. Administration lasted for almost 1
    year till October 27, Year 2.
    Response to rSIFN-co treatment: PR{circle around (2)}(the mass reduced from about 3.1 × 4.2 cm to
    2.2 × 1.5 cm after 2 months' treatment, and the
    lesion further reduced in size after administration
    for 3 months.)
    Survival: about 28 months (from Augugst 11, Year 1 to
    Year 4)
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    Chest CT scans on October 10, Year 1 CT scans on January 10, Year 2:
    after chemotherapy: The mass was about 2.2 × 1.5 cm on lower
    A shadow of tumor mass of about segment of right hilum which was significantly
    3.1 × 4.2 cm was found at opening segment smaller than before.
    of bronchus on lower lobe of right lung, CT scans on February 12, Year 2 (see original
    probably to be central type lung cancer. locations of lesions indicated by arrows in
    Right-sided pneumothorax occurred. FIG. 24b):
    Lung tissue was compressed by about After 3 months' treatment, the mass on lower
    10% in size and not much pleural effusion segment of right hilum evedently shrank.
    were seen in right-sided thoracic cavity. CT scans on October 23, Year 2:
    CT imaging on November 15, Year 1 Masses were seen at dorsal segment of lower
    when administration was newly lobe of right lung. Not much effusion was in
    conducted: right thoracic cavity and right pleura was thicker.
    see lesions nidicated by arrows in There was not much changes compared with the
    FIG. 24a). previous CT.
    Description of FIGS. 24a-24b: After treatment of nearly 3 months', masses on
    lower segment of right hilum had significantly
    shrunk.
  • Patient 13.
  • Non-small-cell lung cancer, after surgeries/Intramuscular injection of rSIFN-co alone. After the treatment, no tumor recurrence or metastasis was found in right lung and the whole body.
  • Patient 13 Gender: Male Age: 63
    Pathological diagnosis: poorly differentiated adenocarcinoma (upper lobe
    of right lung)
    Clinical and pathological staging{circle around (1)}: T4N2M0. IIIb
    Regimens before administration of On October 15, Year 1, resection of upper lobe of
    rSIFN-co: right lung and lymph node dissection were done
    as well as wedge resection of nodules on lower
    lobe of right lung.
    Postoperative pathology report: Poorly differentiated adenocarcinoma occured on
    upper lobe of right lung; the tumor was 4.5 × 4.5 ×
    4 cm in size and grew to regions below visceral
    pleura. Poorly differentiated adenocarcinoma was
    found in two suture zones on nodules of dorsal
    and lower segment of lungs with diameters of
    0.8 cm and 1.2 cm. (lymph nodes): metastasis was
    found in: “Group 2” (1/8), group 4 (2/4), and
    Group 10 (1/2).
    Regimens: treatment with rSIFN-co alone Treatment with rSIFN-co began on December 10,
    Year 1. Intramuscular injection of rSIFN-co was
    provided once every other days: 9 μg for 1st time,
    21 μg for 2nd time and thereafter). The first course
    was finished on April 9, Year 2.
    The second course was performed from December
    Year
    2 to July Year 3 during which intramuscular
    injection was done every other day with 21 μg per
    dose.
    The third course was performed from February
    21, Year 4 to May 21, Year 4 during which
    intramuscular injection was done every other day
    with 18 μg per dose.
    Response to rSIFN-co: CR{circle around (2)}(After surgery on primary lesions, no tumor
    recurrence or metastasis occurred.)
    Survival: After 45 months (from September 13, Year 1 to
    July Year 5), the patient remained alive and had
    normal life. No recurrence or metastases was
    observed on imaging test.
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    CT scans on May 25, Year 3:
    see the suspicious lesion at lower lobe of right
    lung indicated by arrows in FIG. 25a.
    Chest CT scans on February 11, Year 4:
    1. After surgery on the lung cance in upper lobe
    of right lung, no recurrence signs were found in
    bronchial stump.
    2. Compared with previous CT, no significant
    change was found in the irregular nodular shadow
    of 1.6 cm on lateral basal segment of lower lobe of
    right lung.
    Chest CT scans on January 2, Year 5 (see original
    location of the suspicious lesion at lower lobe of
    right lung indicated by arrow in FIG. 25b):
    1. After surgery on lung cancer of upper lobe of
    right lung: no recurrence signs were found in
    bronchial stump compared to CT scans on
    February 11, Year 4; nodules in lateral basal
    segment of the lower lobe of right lung was not
    found.
    2. Inflammatory lesions were scattered in residue
    of right lung; the right-sided pleura was slightly
    thickened.
    Description of FIGS. 25a-25b: After treatment, the space occupying at lower lobe
    of right lung disappeared and no tumor recurrence
    or metastasis was found.
  • Patient 14.
  • Non-small-cell lung adenocarcinoma, after surgery/Intramuscular injection of rSIFN-co alone. After the treatment, no tumor recurrence and metastasis was found.
  • Patient 14 Gender: Male Age: 44
    Pathological diagnosis: Poorly differentiated adenocarcinoma
    Clinical and pathological staging{circle around (1)}: T4N3M0, IIIb
    Regimens before administration of Upper lobe of right lung was resected on October
    rSIFN-co: 20, Year 1.
    Postoperative pathology report: Examination on October 27, Year 1:
    (masses at upper lobe of the right lung) part of
    lung tissue was resected. Alveolar epithelium
    hyperplasia and chronic inflammatory cell
    infiltration were observed under microscope.
    Fibroplasia happened at the side of pleura with
    collagenization. Focal hemorrhage and necrosis
    were also observed while poorly differentiated
    adenocarcinoma was found.
    Immunohistochemistry of the cancer tissue
    showed CK7(+), P63(−)and TTF1(−).
    Regimens: administration of rSIFN-co Treatment of rSIFN-co began on November 6,
    alone Year 1. Intramuscular injection of rSIFN-co was
    administered once every other day: 18 μg for 1st
    time, 21 μg for 2nd time and thereafter. A first
    course of 6 months ended on May 10, Year 2.
    The second course started on March 18, Year 3
    and continued for the next following 3 months.
    Intramuscular injection of rSIFN-co was provided
    every other day with 15 μg per dose.
    Intramuscular injection of rSIFN-co and Aerosol
    inhalation were administered for 3 months from
    November Year 4. Intramuscular injection was
    done once every other day with 15 μg per dose.
    Aerosol inhalation was performed every day and a
    total of 300 μg was used for one day.
    Response to rSIFN-co treatment: CR{circle around (2)}(after surgery, no tumor recurrence or
    metastasis was found at primary lesions.)
    Survival: After about 44 months (from October 14, Year 1
    to July Year 5), the patient remained alive and had
    a normal life. No initial recurrence or metastases
    was observed upon imaging.
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    Chest CT scans on October 13, Year 1: CT scans on February 22, Year 3 (see the original
    Peripheral lung cancer was found in surgical site indicated by arrow in FIG. 26b):
    posterior segment of right upper lobe; the High-density stripe-like shadows were found in
    tumor of about 4.0 × 2.9 cm in size grew residual part of upper lobe of right lung and local
    into posterosuperior segment of bronchiectasia happened, which were mainly
    right-sided pleura and implantation postoperative changes. No significant change was
    metastasis happened at right-sided pleura; found in lesions as compared with previous CT.
    not much pleural effusion occurred in
    thoracic cavity.
    CT scans on November 13, Year 1,
    when drug use was just started (after
    surgery):
    See the surgical site of primary lesion
    indicated by arrows in FIG. 26a
    Description of FIGS. 26a-26b: After treatment, no tumor recurrence and
    metastasis was found in residual end of right lung
    and the neighering regions.
  • Patient 15.
  • Non-small-cell lung cancer with systemic metastases, local injection of rSIFN-co into enlarged lymph nodes in groin. After local injections, metastatic lesions in the lymph nodes in pelvic cavity and inguinal area were cleared up or shrank.
  • Patient 15 Gender: Male Age: 68
    Pathological diagnosis: none
    Clinical and pathological staging{circle around (1)}: T4N3M1. IV
    Regimens before administration of Treatment with Gamma Knife was done under
    rSIFN-co: local anesthesia on April 27, Year 3.
    Sr-89 therapy was done by Nuclear Medicine
    Department on April 30, Year 3.
    Oral administration of Gefitinib (Iressa) was
    provided from December Year 1 to June Year 3: 1
    dose/day, 1 pill/dose, 250 mg/pill.
    Regimens: administration of rSIFN-co Treatment of rSIFN-co began on June 25, Year 3.
    alone The rSIFN-co was injected into lymph nodes of
    groin Intramuscularly every day: 15 μg × 6 vials for
    1st time, 15 μg × 8 vials for 2nd time and
    15 μg × 10 vials for 3rd time and thereafter.
    Eleven injections were done till July 20, Year 3
    (Severe diarrhea occurred after 3 injections and
    administration was stopped for 2 weeks; after that
    injection was performed every day and 8
    injections in total were continuasly provided).
    Discontinuous local injection in lymph nodes
    were performed for 6 times from August 18, Year
    3 to September 16, Year 3: 15 μg × 10 vials for
    each time.
    Local injection in lymph nodes were performed
    every 3 days from October 8, Year 3 to October
    12, Year 3: 15 μg × 10 vials for each time.
    Response to rSIFN-co treatment: PR{circle around (2)}(mass of about 11.3 × 4.9 cm in pelvic cavity
    reduced in size to 7.52 × 7.67 × 6.72 cm).
    Survival: about 24 months (from December Year 1 to
    December 13, Year 3)
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    MRI of pelvic cavity on June 6, Year 3 MRI of pelvic cavity on July 28, Year 3 (see
    (see lesions indicated by arrows in original locations of lesions indicated by arrows
    FIG. 27a): in FIG. 27b):
    Bone distruction was found at left ilium, Bone destruction at left pubis was replaced by
    sacroiliac joint, left-sided corpora ossis shadow of soft tissue with long T2 signal and
    pubis, superior ramus of pubis and fused into block with the swollen soft tissue of
    femoral head with slightly longer T1 and pelvic wall within a range of 7.52 cm × 7.67 cm ×
    slightly longer T2 signal. The left gluteus 6.72 cm. Left acetabulum, ala of ilium, obturator
    minimus, obturator internus and obturator internus and obturator externus, vastus medialis
    externus, musculus adductor magnus and and soft tissue in groin were involved.
    longus, and rectus femoris were involved
    and the fascia was obviously swollen.
    Irregular mass of about 11.3 cm × 4.9 cm
    with slightly longer T2 signal were seen
    at acetabular plane in left pelvis which
    was slightly enhanced after
    reinforcement.
    Description of FIGS. 27a-27b: After 1 month's treatment, the enlarged lymph
    nodes in pelvis and groin disappeared or shrank.
  • Patient 16.
  • Rectal cancer, after a surgery/Intramuscular injection of rSIFN-co alone. After the treatment, no tumor recurrence or metastasis was found.
  • Patient 16 Gender: Female Age: 63
    Pathological diagnosis: Well to moderately differentiated adenocarcinoma
    was found in rectum and mucinous
    adenocarcinoma was found in part of rectum.
    Cancer invaded into deep muscularis of intestinal
    wall and formed cancerous nodules in
    mesorectum (see the cancer cells indicated by
    arrows in FIG. 28)
    Clinical and pathological staging{circle around (1)}: T4N1Mx. IIIb
    Regimens before administration of Laparoscopic-assisted abdominal perineal radical
    rSIFN-co: resection of rectal cancer was done on May 16,
    Year 1.
    Regimens: administration of rSIFN-co Treatment of rSIFN-co began on May 23, Year 1.
    alone Intramuscular injection of rSIFN-co was provided
    once every other day: 21 μg for each time.
    The first course of 8 months ended on February
    Year
    2.
    The second course was provided from January
    Year 3 to April Year 3. Intramuscular injection of
    rSIFN-co was provided once every other day with
    9 μg each time and continued for 3 months.
    The third course was administered from
    December Year 3 to March Year 4. Intramuscular
    injection was performed every other day with
    15 μg each time.
    Response to rSIFN-co treatment: CR{circle around (2)}(after surgery, no tumor recurrence or
    metastasis occurred at primary lesions.)
    Survival: After about 49 months (from May Year 1 to July
    Year 5), the patient remained alive. No recurrence
    or metastases was observed upon imaging.
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    PET/CT scans on April 30, Year 1 (see PET/CT scans on June 17, Year 3 (see the original
    primary lesions indicated by arrows in location of lesions indicated by arrows in
    FIG. 29a): FIG. 29b):
    1. Mass with high metabolic rate was seen No signs were found on recurrence of primary
    in rectum combined with intestinal wall lesions or systemic metastases.
    thickened, suggesting the posibility of PET/CT scans on March 3, Year 4:
    malignant tumor happening (rectal cancer 1. After surgery on rectal cancer, no signs of
    or lymphoma). malignant tumor were found in colorectum and
    2. A nodular lesion of high metabolic rate the artificial fistula in lower segment of left-sided
    was found beside the left-sided external abdomen.
    iliac vessels in pelvic cavity, suggesting 2. Two slightly enlarged lymph nodes beside the
    the possible occurrence of lymphatic left-sided external iliac vessels and great vessel in
    metastasis. No signs of malignant tumor pelvic cavity and metabolism was not increased. It
    were found in pelvic cavity, other parts might be caused by inflammation of lymph nodes
    and retroperitoneum. in view of sevel inmaging examination (It can be
    seen that the enlarged lymph nodes were not
    metastatic lesions.).
    Description of FIGS. 29a-29b: During 25 months after surgery, no recurrence or
    systemic metastasis occurred in the cured primary
    lesions.
  • Patient 17.
  • In situ cervical cancer in situ/Intramuscular injection of rSIFN-co alone or uterine perfusion of rSIFN-co alone. After treatment, cervical tumor was basically inhibited and test of high-risk HPV became negative. Also, no tumor cells were found in cervical smear.
  • Patient 17 Gender: Female Age: 25
    Cytologic diagnosis: Cervical smear on May 11, Year 1 showed
    high-grade intraepithelial lesion.
    Clinical and pathological staging{circle around (1)}: Ib1
    Regimens before administration of none
    rSIFN-co:
    Regimens: administration of rSIFN-co Treatment of rSIFN-co began on May 14, Year 1.
    alone Intramuscular injection of rSIFN-co was provided
    once every other day: 9 μg for 1st time, 15 μg for
    2nd time and 18 μg for 3rd time and thereafter.
    Meanwhile, uterine perfusion was done once a
    day: at 1000 μg per dose, for 2 hours.
    Uterine perfusion ended on June 28, Year 1 (lasted
    for more than 1 month) and intramuscular
    injection was stopped on September 12, Year 1
    (lasted for 4 months).
    Response to rSIFN-co treatmenr: CR{circle around (2)} (malignant cervical lesion disappeared, and
    test of high-risk HPV became negative. Also, no
    tumor cells were found in cervical smear.)
    Survival: After about 26 months (from May 5, Year 1 to
    July Year 3), the patient remained alive and had
    normal life. No recurrence or metastases was
    observed upon imaging.
    Pathological diagnosis before Pathological diagnosis after administration of
    administration of rSIFN-co: rSIFN-co:
    On May 5, Year 1, cervical intraepithelial Chronic endocervicitis was found on June 24,
    lesion of grade II~III was seen with Year 1.
    glands involved.
    Viral diagnosis (HC2HPV DNA) before Viral diagnosis (HC2HPV DNA) after
    administration of rSIFN-co: administration of rSIFN-co
    April 14, Year 1, High-risk subtypes (15 June 25, Year 1: RLU/CO 0.23 (negative)
    kinds): positive-HPV16
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    PET/CT scans on May 14, Year 1: PET/CT scans on November 8, Year 1:
    1. Cervical hypertrophy was found and The FDG metabolism in the cervix significantly
    FDG metabolism was slightly increased, reduced, indicating that the tumor activity was
    suggesting the possible occurrence of locally inhibited; FDG metabolism was
    low-grade malignant lesion. inhomogeneous and obscure, indicating that
    2. No metastatic lesion was found in inflammatory change might happen.
    pelvic cavity and pelvic wall.
  • Patient 18.
  • Prostatic cancer/Intramuscular injection of rSIFN-co and local spraying (to skin surface where prostate biopsy was done) of rSIFN-co combined with local radiotherapy. After treatment, the prostate tumor and two lymph nodes in right-sided ischiorectal fossa were eliminated; the posterior wall of fundus of urinary bladder, bilateral seminal vesicles and anterior rectal wall infected by lesions recovered; and the level of tumor marker (PSA) become normal.
  • Patient 18 Gender: Male Age: 64
    Pathological diagnosis: Adenocarcinoma was found in the 1st-10th
    prostate biopsy.
    Clinical and pathological staging{circle around (1)}: T4N1M0. IV
    Regimens before administration of none
    rSIFN-co:
    Regimens: administration of rSIFN-co Treatment of rSIFN-co began on November 15,
    combined with radiotherapy Year 1. Intramuscular injection of rSIFN-co was
    provided once every other day: 9 μg for 1st time,
    15 μg for 2nd time, 18 μg for 3rd time and 24 μg for
    4th time and thereafter. Meanwhile, the drug was
    locally applied by spraying to the skin surface
    where prostate biopsy was done: 4-5 doses per day
    and at 70 μg~139 μg per dose.
    The amount of rSIFN-co to be intramuscularly
    injected changed to 21 μg from December 15, Year
    1 to July 1, Year 2.
    Radiotherapy on prostate (EBRT){circle around (12)} was performed
    for 38 times from December 5, Year 1 to February
    26, Year 2.
    Response to rSIFN-co treatment: CR{circle around (2)} (prostate of 4.7 × 3.5 × 5.6 cm reduced normal
    size; two lymph nodes in right ischiorectal fossa
    were eliminated; the posterior wall of fundus of
    urinary bladder, bilateral seminal vesicles and
    anterior rectal wall infected by lesions recovered;
    and the level of specific antigen of Prostatic cancer
    (PSA) become normal.)
    Survival: After about 8 months (from November 11, Year 1
    to July Year 2), the patient remained alive.
    Level of specific antigen of Prostatic Level of specific antigen of Prostatic cancer (PSA)
    cancer (PSA) before administration of after administration of rSIFN-co:
    rSIFN-co:
    Examination on November 2, Year 1: Examination on March 7, Year 2:
    Total specific antigen of Prostatic cancer Total specific antigen of Prostatic cancer (T-PSA)::
    (T-PSA): 23.090 ng/ml (reference value 0.006 ng/ml (reference value <3)
    <3 ng/ml) Free PSA (F-PSA): <0.010 ng/ml (reference value
    Free PSA (F-PSA): 1.850 ng/ml <0.75 ng/ml)
    (reference value <0.75 ng/ml)
    Ratio of antigen of Prostatic cancer
    (F-PSA/PSA): 8.01%(reference value
    25~100)
    Diagnostic imaging before Diagnostic imaging after administration of
    administration of rSIFN-co: rSIFN-co:
    MRI scans on November 4, Year 1: MRI (March 31, Year 2):
    1. Prostate was significantly enlarged 1. The prostate was smaller in size and left
    and irregular mass shadows of about posterior part protruded slightly. No obvious
    4.7 × 4.3 × 5.6 cm in size were formed with abnormality was found in each imaging sequence
    obsecure border and inhomogeneous signal.
    signals. Inhomogeneous reinforcement 2. Bladder wall was inhomogeneously thickened:
    happened in enhanced scan. All these inflammation?
    suggested the occurrence of prostatic 3. No effusion and enlarged lymph nodes were
    cancer. found in pelvic cavity.
    2. Two lymph nodes in right-sided
    ischiorectal fossa were found with
    diameter of about 1 cm, suggesting the
    occurrence of metastasis.
    3. The posterior wall of fundus of
    urinary bladder, bilateral seminal
    vesicles and anterior rectal wall might be
    invaded.
  • Patient 19.
  • Melanoma of nose (after a surgery) combined with bone metastases at bilateral hip joints, bilateral femurs, bilateral humeri, ribs and bilateral shoulder joints/Intramuscular injection of rSIFN-co and local spraying of rSIFN-co on lesions. After treatment, multiple enlarged lymph nodes at bilateral shoulder joints and subaxillary were cleared up as well as recurrence and metastases at bilateral hip joints, upper femur, residual right paranasal sinuses and nasal cavity after surgery.
  • Patient 19 Gender: Female Age: 43
    Pathological diagnosis: Tumors were found in the neoplasma inside
    the right maxillary sinus. Malignant
    melanoma was proved by
    immunohistochemistry: (HMB45 (part+),
    MART1 (−), S100 (−), CD63 (+), NSE (−),
    PCK (−), EMA (+), CD56 (−) and KI671
    25%).
    Clinical and pathological staging{circle around (1)}: pT3NxM1. IV
    Regimens before administration of rSIFN-co: Two cycles were provided on October 30,
    Year 1 and November 30, Year 1: 15 mg of
    Endostar on day 1~10 and 200 mg of
    temozolomide on day 1~5, oral
    administration.
    Targeted radiotherapy (50Gy/25f) was done
    on November 2, Year 1 and the targets were
    right maxillary sinus + ¼ of the left
    maxillary sinus, bilateral ethmoid sinus,
    frontal sinus and the adjacent tissues of the
    right eyeball. Radiotherapy ended on
    December 7, Year 1.
    Regimens: administration of rSIFN-co alone Treatment of rSIFN-co began on December
    21, Year 1. Intramuscular injection of
    rSIFN-co was provided once every other
    day: 9 μg for 1st time, 15 μg for 2nd time,
    18 μg for 3rd time and thereafter. Meanwhile,
    the drug was locally applied by spraying onto
    the skin surface of the right shouder: 70 μg-139 μg/
    dose/site, 4-5 doses/day.
    Spraying was provided to skin surface of the
    left shoulder and other sites with bone
    metastasis began on February 27, Year 2:
    70 μg-139 μg/dose/site, 4-5 doses/day.
    Response to rSIFN-co treatment: CR{circle around (2)} (Multiple enlarged lymph nodes at
    bilateral shoulder joints and axillae
    disappeared; recurrence and metastatic
    lesions at residual right sinus and nasal cavity
    after surgery as well as multiple abnormal
    signals at bilateral hip joints and upper parts
    of femora disappeared.)
    Survival: After about 11 months (from August Year 1
    to July Year 2), the patient remained alive.
    Diagnostic imaging before administration of Diagnostic imaging after administration of
    rSIFN-co: rSIFN-co:
    MRI of paranasal sinus on December 8, Year MRI of shoulder joint on May 2, Year 2:
    1: No obvious bone destruction was found at
    1. Compared with the previous imaging (taken left shoulder. Spot-like shadows with long T2
    on October 26, Year 1, after surgery in right and long T1 signals were seen in humeral
    sinus and nasal cavity), soft tissues head, mostly small cystic lesions.
    surrounding residual cavity were thickened Pelvis MRI on May 2, Year 2:
    and intensification was apparent, suggesting Long T1 and long T2 signals changed at
    recurrence. upper branch of the left pubis and signals
    2. Several lymph nodes at the neck were were intensified significantly as shown in the
    enlarged. intensified image. No obvious abnormality
    3. Hypertrophy was found at left-sided inferior was seen in remaining part of the pelvis.
    nasal concha and inflammation was seen at Brain MRI on May 2, Year 2:
    left maxillary sinus, sphenoid sinus and 1. No intracranial abnormality; 2. Bilateral
    ethmoid sinus. otitis media and mastoiditis; 3. Nasal conchae
    4. Otitis media and mastoiditis was observed of middle and lower segments at right side
    at right side . . . were missing and inner wall of maxillary
    MRI scans of hip joint on December 8, Year 1: sinus at right side was missing, leading to an
    Lesions with long T1 and long T2 signal were empty cavity formed by connecting sinus
    seen at left acetabulum. And lesions extended cavity and nasal cavity; 4. Left maxillary
    to left ischium, High signals with significant sinusitis; 5. Sphenoid sinusitis and frontal
    enhancement in fat suppression sinusitis.
    sequences were found. Lesions with MRI of lumbar, head and shoulder joint on
    significantly intensified long T1 and long T2 June 26, Year 2:
    signals were seen at lower portions of bilateral 1. Fat deposition was found on lumbar 2 from
    ilia and right anterior acetabulum,. the back with the remaining corpus vertebrae
    Conclusion: multiple lesions were found in the and intervertebral disc being normal;
    bone mass of bilateral hip joints and bone 2. Intracranial brain tissue was normal;
    metastasis probably happened. 3. The lack of nasal conchae at right nasal
    MRI of shoulder joint on December 8, Year 1: cavity and inner wall of the right maxillary
    Sheet-like shadows with long T1 and long T2 sinus was as shown above;
    signals, inhomogeneous enhancement and 4 Bilateral ethmoiditis and sphenoid sinusitis,
    obscure boundaries were found at bilateral and bilateral mastoiditis were found;
    acromial ends of clavicles, right glenoid cavity 5. No further enlargement was found at the
    of scapula, bone surrounding bilateral scapula, lymph nodes on either side of the neck;
    upper parts of bilateral humeri and ribs. 6. Femoral heads of bilateral shoulder joints
    Multiple lymph nodes were found at bilateral were normal.
    axillae with part enlarged. Conclusion:
    multiple metastases of bilateral shoulder joints
    and axillae happened.
  • {circle around (1)} Standard for cancer staging, refer to AJCC Cancer Staging Manual (6th Edition)/Edited by F. L. Greene, D. L. Page and I. D. Fleming etc. Shenyang: Liaoning Science and Technology Press, 2005 August;
  • {circle around (2)} Standard for effect evaluation of antitumor drμgs, refer to Practical Therapeutics of Antitumor Drμgs/Edited by Liu Xinchun etc. (Beijing: People's Medication Publishing House, 2002) p 1100-1101;
  • {circle around (3)} Radiotherapy of lung cancer, refer to Modern Lung Cancer Pathology and Clinical Practice/Edited by Xiong Min and Wu Yilong, (Beijing: Science Press, 2003 June), p 324-365;
  • {circle around (4)} TC regimen, refer to Modern Lung Cancer Pathology and Clinical Practice/Edited by Xiong Min and Wu Yilong, (Beijing: Science Press, 2003 June), p 386;
  • {circle around (5)} “Endostar”, refer to Chemotherapy and Targeted Therapy of Lung Cancer/Edited by Liao Meilin, (Beijing: People's Medication Publishing House, 2009 August), p 261;
  • {circle around (6)} “Pemetrexed”, refer to Chemotherapy and Targeted Therapy of Lung Cancer/Edited by Liao Meilin, (Beijing: People's Medication Publishing House, 2009 August), p 94;
  • {circle around (7)} EP regimen, refer to Modern Lung Cancer Pathology and Clinical Practice/Edited by Xiong Min and Wu Yilong, (Beijing: Science Press, 2003 June), p 386;
  • {circle around (8)} DP regimen, refer to Modern Lung Cancer Pathology and Clinical Practice/Edited by Xiong Min and Wu Yilong, (Beijing: Science Press, 2003 June), p 386;
  • {circle around (9)} GP chemotherapy, refer to Chemotherapy and Targeted Therapy of Lung Cancer/Edited by Liao Meilin, (Beijing: People's Medication Publishing House, 2009 August), p 222-230;
  • {circle around (10)} “Gefitinib”, refer to Chemotherapy and Targeted Therapy of Lung Cancer/Edited by Liao Meilin, (Beijing: People's Medication Publishing House, 2009 August), p 222-230;
  • {circle around (11)} CHOP chemotherapy, refer to Practical Therapeutics of Antitumor Drμgs/Edited by Liu Xinchun etc. (Beijing: People's Medication Publishing House, 2002), p 931;
  • {circle around (12)} Radiotherapy of prostatic cancer, refer to Advance in Clinical Oncology/Edited by Sun Yan and Zhao Ping, (Beijing: Peking Union Medical College Press, 2005.9ISBN7-81072-711-7), p 1009-1010.
    • Example 4 Data of Clinical Effectiveness of rSIFN-Co of the Present Invention
  • In the following tables, the number listed before the brackets represents the number of patients conforming to the condition described in that row and column; the number between each pair of parenthesis represents the number as a percentage of all the patients listed in either that column or that row; finally, II/III/IV between parentheses represent cancer staging. The cancer staging was made in accordance with AJCC Cancer Staging Manual (6th Edition)/Edited by F. L. Greene, D. L. Page and I. D. Fleming etc. Shenyang: Liaoning Science and Technology Press, 2005 August.
  • TABLE 3
    Efficacy of rSIFN-co administration on lung cancer at different stages
    Tumor
    staging CR PR NC/SD PD Total
    II 1(20.00%) 2(40.00%) 2(40.00%) 0(0.00)     5
    III 5(50.00%) 2(20.00%) 1(10.00%) 2(20.00%) 10
    IV 6(40.00%) 7(46.67%) 1(6.67%)  1(6.67%)  15
    Total 12(40.00%)  11(36.67%)  4(13.33%) 3(10.00%) 30
    Note:
    for detailed regimens, refer to those described in example 2.
  • TABLE 4
    Efficacy of rSIFN-co administration on lung cancer after or without
    surgery*
    Group CR PR NC/SD PD Total
    After  2(33.33%)(III/IV)  0(0.00%) 3(50.00%)(II/III/IV) 1(16.67%)(III) 6
    surgery
    Without 10(41.67%)(II/III/IV) 11(45.83%)(II/III/IV) 1(4.17%)(IV) 2(8.33%)(III/IV) 24
    surgery
    Total 12(40.00%) 11(36.67%) 4(13.33%) 3(10.00%) 30
    Note:
    for detailed regimens, refer to those described in example 2.
    *In this table, surgery does not include cryoablation or radiofrequency ablation.
  • TABLE 5
    Efficacy of administration provided in different ways on lung cancer
    Way to
    administer CR PR NC/SD PD Total
    Systemic  4(44.44%)(III/IV)  3(33.33%)(II/III) 1(11.11%)(II) 1(11.11%)(III) 9
    administration
    Systemic +  6(33.33%)(III/IV)  7(38.89%)(II/III/IV) 3(16.67%)(II/III/IV) 2(11.11%)(III/IV) 18
    local
    Local  2(66.67%)(II/III/IV)  1(33.33%)(IV) 0(00.00%) 0(00.00%) 3
    Total 12(40.00%) 11(36.67%) 4(13.33%) 3(10.00%) 30
    Note:
    systemic administration refers to intramuscular or subcutaneous administration; local administration refers to aerosol inhalation and spraying on skin surface; refer to those described in example 2 for detailed regimens.
  • TABLE 6
    Efficacy of rSIFN-co administration on lung cancer with different durations
    Medication
    duration
    (month(s)) CR PR NC/SD PD Total
     <3  1(50.00%)(IV)  0(00.00%) 1(50.00%)(IV) 0(00.00%) 2
    3~6   3(50.00%)(IV)  3(50.00%)(III/IV) 0(00.00%) 0(00.00%) 6
    7~12  2(20.00%)(III)  4(40.00%)(II/IV) 2(20.00%)(II) 2(20.00%)(III/IV) 10
    >12  6(50.00%)(II/III/IV)  4(33.33%)(III/IV) 1(8.33%)(III) 1(8.33%)(III) 12
    Total 12(40.00%) 11(36.67%) 4(13.33%) 3(10.00%) 30
    Note:
    for detailed regimens, refer to those described in example 2.
  • TABLE 7
    Efficacy of drug combination on lung cancer
    drug
    combination CR PR NC/SD PD Total
    Yes  8(42.11%)(II/III/IV)  7(36.84%)(III/IV) 3(15.79%)(II/III/IV) 1(5.26%)(III) 19
    No  4(36.36%)(III/IV)  4(36.36%)(II/III/IV) 1(9.09%)(II) 2(18.18%)(III/IV) 11
    Total 12(40.00%) 11(36.67%) 4(13.33%) 3(10.00%) 30
    Note:
    drug combination or combined therapy includes: chemotherapy, radiotherapy, radiofrequency ablation, biological medicine and traditional Chinese medicine, but excludes surgery; for detailed regimens, refer to those described in example 2.
  • TABLE 8
    Efficacy of administration on lung cancer with/without metastasis
    Metastasis CR PR NC/PD PD Total
    Yes 11(44.00%)(II/III/IV)  9(36.00%)(II/IIII/IV) 4(16.00%)(II/IIII/IV) 1(4.00%)(IV) 25
    No  1(20.00%)(III)  2(40.00%)(II/III) 0(0.00%) 2(40.00%)(III) 5
    Total 12(40.00%) 11(36.67%) 4(13.33%) 3(10.00%) 30
    Note:
    for detailed regimens, refer to those described in example 2.
  • TABLE 9
    Efficacy of rSIFN-co administration on tumor of different stages
    Tumor
    staging CR PR NC/SD PD Total
    I  3(100.00%) 0(0.00%) 0(0.00%)  0(0.00%)  3
    II 2(33.33%)  2(33.33%) 2(33.33%) 0(0.00)     6
    III 6(35.29%)  5(29.41%) 3(17.64%) 3(17.64%) 17
    IV 8(25.00%) 12(37.50%) 5(15.62%) 7(21.88%) 32
    Total 19(32.76%)  19(32.76%) 10(17.24%)  10(17.24%)  58
    Note:
    for detailed regimens, refer to those described in example 2, wherein:
    Tumor of stage I includes: cervical cancer, gastrointestinal stromal tumor;
    Tumor of stage II includes: lung cancer, breast cancer;
    Tumor of stage III includes: lung cancer, ovarian cancer, cervical cancer, rectal cancer, breast cancer, pancreatic cancer, lymphoma, malignant neuroma and metastatic poorly differentiated squamous carcinoma;
    Tumor of stage IV includes: lung cancer, cervical cancer, endometrial or uterine papillary serous carcinoma with hybrid clear-cell carcinoma, colon cancer, cholangiocarcinoma, including cholangioadenocarcinoma, liver cancer including hepatocellular carcinoma, breast cancer, gastric cancer, prostate cancer, embryonal rhabdomyosarcoma, malignant melanoma and lymphoma, including Non-Hodgkin's lymphoma.
  • TABLE 10
    Efficacy of rSIFN-co administration on tumor after or without surgery
    Group CR PR NC/SD PD Total
    After  8(32.00%) 2(8.00%)  7(28.00%)  8(32.00%) 25
    surgery
    Without 11(33.33%) 17(51.52%) 3(9.09%) 2(6.06%) 33
    surgery
    Total 19(32.76%) 19(32.76%) 10(17.24%) 10(17.24%) 58
    Note:
    for detailed regimens, refer to those described in example 2.
  • TABLE 11
    Efficacy of administration provided in different ways
    Way to
    administrate CR PR NC/SD PD Total
    Systemic  8(34.78%) 8(34.78%) 2(8.70%)  5(21.74%) 23
    Systemic + local 10(32.26%) 8(25.81%) 8(25.81%) 5(16.13%) 31
    Local  1(25.00%) 3(75.00%) 0(00.00%) 0(00.00%) 4
    Total 19(32.76%) 19(32.76%)  10(17.24%)  10(17.24%)  58
    Note:
    for detailed regimens, refer to those described in example 2.
  • TABLE 12
    Efficacy of rSIFN-co administration with different durations
    Medication
    duration(month(s)) CR PR NC/PD PD Total
     <3 2(40.00%) 1(20.00%) 2(40.00%) 0(00.00%) 5
    3~6  4(25.00%) 6(37.50%) 3(18.75%) 3(18.75%) 16
    7~12 3(18.75%) 6(37.50%) 3(18.75%) 4(25.00%) 16
    >12 10(47.62%)  6(28.57%) 2(9.52%)  3(14.29%) 21
    Total 19(32.76%)  19(32.76%)  10(17.24%)  10(17.24%)  58
    Note:
    for detailed regimens, refer to those described in example 2.
  • TABLE 13
    Efficacy of drug combination
    drug
    combi-
    nation CR PR NC/PD PD Total
    Yes 10(34.48%) 10(34.48%) 6(20.69%) 3(10.34%) 29
    No  9(31.03%)  9(31.03%) 4(13.79%) 7(24.14%) 29
    Total 19(32.76%) 19(32.76%) 10(17.24%)  10(17.24%)  58
    Note:
    combined medication includes: chemotherapy, radiotherapy, radiofrequency ablation, biological medicine and traditional Chinese medicine; for detailed regimens, refer to those described in example 2.
  • TABLE 14
    Efficacy of administration on tumor with/without metastasis
    Me-
    tastasis CR PR NC/SD PD Total
    Yes 14(29.79%) 16(34.04%)  9(19.15%) 8(17.02%) 47
    No  5(45.45%)  3(27.27%) 1(9.09%) 2(18.18%) 11
    Total 19(32.76%) 19(32.76%) 10(17.24%) 10(17.24%)  58
    Note:
    for detailed regimens, refer to those described in example 2.
  • TABLE 15
    Patients in Complete Remission (CR) up until the date of last count.
    rSIFN-co
    Tx Amount of
    Patient Duration rSIFN-co rSIFN-co
    No. Cancer Cell type Stage Staging Therapies Response (months) admin per dose
    1 NSCLC sqamous cell IIIb T3N2M0 prior CTx, rSIFN-co + RTx CR 15 im, qod 9 ug, 15 ug,
    carcinoma 18 ug
    3 NSCLC lung IV T2N2M1 rSIFN-co + RTx CR  3+ im, qod + 9 ug, 18 ug,
    adenocarcinoma inhalation 21 ug, 200 ug,
    qod 400 ug
    4 SCLC IV T4N3M1 prior CTx, CR   16+ im, qod + 9 ug, 15 ug,
    rSIFN-co + CTx + cryoablation inhalation 18 ug, 200 ug,
    qod 21 ug,
    100 ug-400 ug
    5 NSCLC moderately IV T2N2M1 prior CTx, rSIFN-co + CTx CR  8+ im, qod + 9 ug, 21 ug,
    differentiated inhalation 200 ug, 15 ug
    adenocarcinoma qd
    6 NSCLC moderately to IV T4N3M1b prior CTx, CR  5+ im, qod + 600 ug, 9 ug,
    poorly rSIFN-co + CTx + Gefmitib inhalation 15 ug, 18 ug,
    differentiated (Iressa) qd + 70 ug-139 ug
    adenocarcinoma spraying qd
    4-5x/day
    8 NSCLC IV T4N2M1 rSIFN-co + Iressa CR  3 im, qod + 9 ug, 15 ug,
    inhalation 18 ug, 600 ug
    qd
    9 NSCLC squamous cell IIb T2N1M0 rSIFN-co + CTx + Endostar CR  4 inhalation, 600 ug
    carcinoma qd
    10 NSCLC IIIb T4N0M0 rSIFN-co CR 15 im, qod + 18 ug, 21 ug,
    thoracic 36 ug, 45 ug,
    perfusion 2100 ug
    every 7
    days +
    intralesion
    13 NSCLC poorly IIIb T4N2M0 prior surgery, rSIFN-co CR 15 im, qod 9 ug, 21 ug,
    differentiated 18 ug
    adenocarcinoma
    14 NSCLC poorly IIIb T4N3M0 prior surgery, rSIFN-co CR 12 im, qod + 18 ug, 21 ug,
    differentiated inhalation 15 ug, 300 ug
    adenocarcinoma qd
    16 rectum moderately IIIb T4N1Mx prior surgery, rSIFN-co CR 15 im, qod 21 ug, 9 ug,
    differentiated 15 ug
    adenocarcinoma
    17 uterine squamous 1b1 no rSIFN-co CR  4 im, qod + 9 ug, 15 ug,
    cervical intraepithelial metastasis uterine 18 g, 1000 ug
    lesion perfusion,
    qd
    18 prostate adenocarcinoma IV T4N1M0 rSIFN-co + RTx CR im, 9 ug, 15 ug,
    qod + spray 18 ug, 24 ug,
    topically, 70 ug-139 ug,
    qd, 21 ug
    4-5x/day
    19 malignant melanoma IV pT3NxM1 Prior Endostar + CTx + RTx, CR im, 9 ug, 15 ug,
    melanoma rSIFN-co qod + spray 18 ug,
    topically, 70 ug-139 ug
    qd,
    4-5x/day
    21 lung IIIb metastasis Prior TCM + Iressa, rSIFN-co + CR im, qod 9 ug, 15 ug,
    to bone Iressa 18 g
    23 lung adenocarcinoma IV metastasis prior CTx + rSIFN-co CR  2 im, qod 9 ug, 21 ug
    to pleural
    cavity,
    mediastinal
    lymph
    nodes &
    bone
    39 cervical poorly Ib2 prior surgery + CTx, CR  6 im, qod 9 ug, 15 ug
    differentiated rSIFN-co + NK cell Tx
    squamous cell
    carcinoma
    48 breast IIa prior surgery, rSIFN-co CR  4+ im, qod 9 ug, 15 ug,
    18 ug, 21 ug
    54 GI Ib prior surgery + RTx, CR  9+ im, qod 9 ug, 21 ug
    rSIFN-co
  • TABLE 16
    Patients in Partial Remission (PR) up until the date of last count.
    rSIFN-co
    Tx Amount of
    Patient Duration rSIFN-co rSIFN-co
    No. Cancer Cell type Stage Staging Therapies Response (months) admin per dose
    2 NSCLC lung IV T3N3M1 prior CTx, PR 12 im, qod + 9 ug, 15 ug,
    adenocarcinoma rSIFN-co + inhalation, qd 18 ug, 21 ug,
    Endostar + CTx 300 ug, 500 ug,
    600 ug
    7 NSCLC lung IV T4N3M1 rSIFN-co + PR  5 im, qod 9 ug, 18 ug,
    adenocarcinoma Iressa 21 ug
    11 Non-Hodgkin IV prior CTx, PR   4.5 inhalation, qd, 72 ug/ml,
    lymphoma prior stem 2-3x/day + 150 ug,
    cell Tx, intralesion, 30 ug
    rSIFN-co + qod + s.c.,
    CTx + RTx qod
    12 NSCLC lung IIb T3N0M0 prior CTx, PR 12 im, qod 9 ug, 18 ug,
    adenocarcinoma rSIFN-co 21 ug
    15 NSCLC IV T4N3M1 prior RTx + PR   1.5+ inj into part of 90 ug, 120 ug,
    Iressa, inguinal LN, 150 ug
    rSIFN-co qd
    20 lung IV rSIFN-co + CTx PR  3+ im, qod + 9 ug, 15 ug,
    inhalation, qd 21 ug, 200 ug,
    300 ug
    22 lung IIIa liver mets prior CTx + RFA, PR  2+ im, qod 18 ug, 21 ug
    rSIFN-co
    24 lung IIIb rrSIFN-co-co PR  2 im, qod + 9 ug, 13.5 ug,
    intrapleural 21 ug, 126 ug,
    injection 168 ug, 210 ug,
    252 ug
    26 lung IV brain mets prior Iressa, PR   24+ im, qod + 21 ug, 18 ug,
    rSIFN-co + inhalation qd 100 ug, 300 ug,
    Iressa 400 ug
    30 lung adenocarcinoma IV brain mets prior RTx + CTx, PR im, qod + 21 ug, 200 ug
    rSIFN-co inhalation, qd
    32 lung IIb prior CTx + Gefitinib, PR im, qod + 9 ug, 13.5 ug,
    rSIFN-co + Gefitinib inhalation, qd 18 ug, 300 ug
    35 lung adenocarcinoma IV prior CTx, rSIFN-co + PR im, qod + 15 ug, 18 ug,
    CTx + RFA inhalation, qd 600 ug
    36 ovarian IIIb prior surgery, rSIFN-co PR  3+ im, , qod 9 ug, 15 ug,
    18 ug, 21 ug
    37 cervical IV prior RTx + CTx, PR im, , qod 21 ug
    rSIFN-co
    42 Cholangioa- IV liver mets prior surgery + RTx, PR   18+ im, , qod 9 ug, 18 ug,
    denocarcinoma rSIFN-co + surgery 21 ug
    45 HCC IV intrahepatic prior surgery, rSIFN-co PR   5.5+ im, , qod 9 ug, 18 ug,
    mets 21 ug
    51 gastric IV abdominal prior CTx, rSIFN-co PR 8 days intraperitoneal 120 ug, 180 ug,
    mets perfusion, qod 210 ug, 240 ug
    52 pancreatic III rSIFN-co PR  9 im, qod 9 ug, 21 ug
    56 lymphoma III rSIFN-co + PR  6 im, qod + 21 ug, 18 ug,
    CTx + TCM intratumoral 168 ug, 210 ug,
    injection 252 ug, 273 ug,
    315 ug, 180 ug,
    189 ug, 198 ug,
    207 ug, 500 ug
  • TABLE 17
    Patients with No Change (NC) or Stable Disease (SD) up until the date of last count.
    rSIFN-co
    Tx Amount of
    Patient Duration rSIFN-co rSIFN-co
    No. Cancer Cell type Stage Metastases Therapies Response (months) admiin per dose
    27 lung IIb lung mets prior surgery + NC/SD im, qod 9 ug, 21 ug
    CTx + RTx,
    rSIFN-co
    28 lung IIb lung + prior surgery + NC/SD 7 im, qod + 9 ug, 21 ug,
    intrapleural Vivatuxin, nasal spray, 200 ug
    cavity mets rSIFN-co tid +
    inhalation, qd
    29 lung IIIa prior NC/SD   5.5+ im, qod + 9 ug,18 ug,
    surgery + nasal spray, 21 ug
    radioimmunotherapy, tid
    rSIFN-co +
    radiofrequency
    ablation (RFA)
    34 lung IV multiple rSIFN-co + NC/SD 2 im, qod + 18 ug,
    mets RTx + TCM inhalation, qd 200 ug
    38 uterine papillary mixed with IV rSIFN-co NC/SD im, qod + 18 ug,
    serous clear cell uterine drip, 200 ug
    adenocarcinoma carcinoma qd, then once
    every 5 days
    41 colonic carcinoma IV liver mets prior surgery, NC/SD   4+ im, qod, 9 ug, 21 ug,
    rSIFN-co intratumor 21-25.5 ug,
    injection 105 ug,
    168 ug,
    210 ug
    49 breast recurrence IV prior surgery + NC/SD 5 local injection + 90 ug,
    after breast CTx, rSIFN-co im, qod 21 ug., 9 ug
    surgery
    53 prostate IV prior antiandrogen + NC/SD im, qod, 9 ug, 21 ug,
    hormone + intraperitoneal 168 ug
    RFA + radioactive injection
    seeds,
    rSIFN-co + RTx
    57 neuroma recurrence IIIc Prior surgery + NC/SD im, qod + 21 ug,
    after surgery CTx + TCM, intratumoral 84 ug
    rSIFN-co
    58 poorly IIIa prior surgery, NC/SD 6 im, qod 9 ug, 21 ug
    differentiated rSIFN-co
    squamous cell
    carcinoma in right
    chest
  • TABLE 18
    Patients with Progressive Disease (PD) up until the date of last count.
    rSIFN-co
    Tx Amount of
    Patient Duration rSIFN-co rSIFN-co
    No. Cancer Stage Metastases Therapies Response (in months) admin per dose
    25 lung IIIa rSIFN-co + PD 5 im, qod 9 ug, 21 ug
    RTx
    31 lung IV bone rSIFN-co PD   3+ im, qod; spray 9 ug, 13.5 ug,
    metastasis 18 ug, 20 ug/ml,
    21 ug
    33 lung IIIb prior sugery, PD   1+ im, qod; im, 4.5 ug, 9 ug,
    rSIFN-co twice a week; 13.5 ug, 18 ug,
    pleural perfusion 105 ug, 126 ug,
    147 ug, 168 ug,
    189 ug, 210 ug
    40 colon IV lung prior PD im, qod 9 ug, 21 ug
    metastasis surgery + CTx +
    TCM, rSIFN-co +
    RFA + CTx +
    RTx
    43 intrahepatic IV liver prior PD 6 im, qod 9 ug, 21 ug
    cholangiocarcinoma metastasis sugery + CTx,
    rSIFN-co +
    surgery
    44 hepatocellular IV lung prior surgery, PD   5.5+ im, qod 9 ug, 18 ug,
    carcinoma metastasis rSIFN-co 21 ug
    46 breast IIIc LN prior PD 4 im, qod 18 ug
    metastasis surgery + CTx +
    RTx, rSIFN-co
    47 breast IV prior PD   7.5+ intrapleural 105 ug, 147 ug,
    surgery + CTx, injection; local 168 ug, 210 ug,
    rSIFN-co injection, once a 273 ug, 21 ug
    week; im, qod
    50 gastric IV prior PD  20.5 im, qod; 9 ug, 18 ug,
    surgery, intraperitoneal 15 ug, 21 ug,
    rSIFN-co injection 168 ug, 189 ug,
    210 ug
    55 embryonal IV metastasis prior PD 13  im, qod; lymph 9 ug, 15 ug,
    rhabdomyosarcoma surgery + CTx + node injection, 18 ug, 21 ug,
    RTx, rSIFN-co intratumor 168 ug
    injection

Claims (27)

1-481. (canceled)
482. A method for eliminating or reducing the malignant pleural effusion, malignant ascites, and/or malignant pericardial effusion in a subject with tumor, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
483. The method of claim 482, wherein the tumor is a solid tumor.
484. The method of claim 482, wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises one or more of: infiltration administration, intrapleural administration, abdominal administration, pericardial administration, thoracic administration and intraperitoneal administration.
485. The method of claim 482, wherein the recombinant interferon is administered in an amount in a range of about 30 μg to about 2000 μg by one administration.
486. The method of claim 484, wherein the recombinant interferon is additionally administered to the subject by systemic administration.
487. The method of claim 482, wherein the subject is administered with at least one other anti-cancer drug.
488. The method of claim 487, wherein said other anti-cancer drug is selected from the group consisting of chemotherapeutic drug, targeted drug, and biological drug.
489. A method for preventing tumor recurrence or metastasis, or prolonging or maintaining a tumor-free status in a subject with a tumor, comprising administering to said subject a recombinant interferon encoded by the nucleotide sequence SEQ ID NO: 2, wherein said subject has been treated with at least one anti-cancer therapy before the administration of said recombinant interferon.
490. The method of claim 489, wherein said anti-cancer therapy is selected from the group consisting of chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
491. The method of claim 489, wherein said recombinant interferon is administered to said subject in a single dose of the range of about 2 μg to about 2000 μg.
492. A method for eliminating or reducing metastatic tumor lesion in a subject, comprising administering a recombinant interferon encoded by SEQ ID NO: 2 topically or locally to the tumor lesion.
493. The method of claim 492, wherein the metastatic tumor lesion comprises at least one of: a bone lesion, a muscular lesion, a subcutaneous tissue lesion, a prostatic lesion, and a lymph node lesion.
494. The method of claim 492, wherein the recombinant interferon is administered to the lesion by an administration route, the administration route comprises at least one of: infiltration administration, percutaneous administration, transdermal administration, epidermal administration and transmucosal administration.
495. The method of claim 492, wherein the recombinant interferon is administered topically.
496. The method of claim 494, wherein the recombinant interferon is further administered systemically.
497. A non-surgical method for eliminating a tumor in a subject or reducing the size of a tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2.
498. The method of claim 497, wherein the tumor is a non-resectable tumor.
499. The method of claim 497, wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, local administration, and topical administration.
500. The method of claim 499, wherein the local administration or topical administration comprises one or more of: intratumoral administration and spray administration.
501. The method of claim 497, wherein the subject is administered at least one other anti-cancer therapy.
502. The method of claim 501, wherein said anti-cancer therapy is selected from the group consisting of chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.
503. A method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, topical administration, and local administration.
504. The method of claim 503, wherein the recombinant interferon is administered systemically and via inhalation.
505. The method of claim 504, wherein the systemic administration comprises at least one of: subcutaneous administration and intramuscular administration, and inhalation comprises at least one of: pulmonary inhalation and nasal inhalation.
506. The method of claim 503, wherein the recombinant interferon is administered locally by perfusion.
507. The method of claim 503, wherein the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.
US14/759,410 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration Abandoned US20160022778A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/759,410 US20160022778A1 (en) 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361749570P 2013-01-07 2013-01-07
US201361779711P 2013-03-13 2013-03-13
US14/759,410 US20160022778A1 (en) 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration
PCT/CN2014/000019 WO2014106459A2 (en) 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/000019 A-371-Of-International WO2014106459A2 (en) 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/038,704 Continuation US20180326012A1 (en) 2013-01-07 2018-07-18 Method for treating tumor by using recombinant interferon with changed spatial configuration

Publications (1)

Publication Number Publication Date
US20160022778A1 true US20160022778A1 (en) 2016-01-28

Family

ID=51062515

Family Applications (6)

Application Number Title Priority Date Filing Date
US14/759,410 Abandoned US20160022778A1 (en) 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration
US14/759,483 Abandoned US20150352188A1 (en) 2013-01-07 2014-01-07 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
US16/038,704 Abandoned US20180326012A1 (en) 2013-01-07 2018-07-18 Method for treating tumor by using recombinant interferon with changed spatial configuration
US16/044,582 Active US10874716B2 (en) 2013-01-07 2018-07-25 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
US17/136,656 Pending US20210260164A1 (en) 2013-01-07 2020-12-29 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
US17/548,598 Pending US20220339255A1 (en) 2013-01-07 2021-12-13 A method for treating tumor by using recombinant interferon with changed spatial configuration

Family Applications After (5)

Application Number Title Priority Date Filing Date
US14/759,483 Abandoned US20150352188A1 (en) 2013-01-07 2014-01-07 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
US16/038,704 Abandoned US20180326012A1 (en) 2013-01-07 2018-07-18 Method for treating tumor by using recombinant interferon with changed spatial configuration
US16/044,582 Active US10874716B2 (en) 2013-01-07 2018-07-25 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
US17/136,656 Pending US20210260164A1 (en) 2013-01-07 2020-12-29 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
US17/548,598 Pending US20220339255A1 (en) 2013-01-07 2021-12-13 A method for treating tumor by using recombinant interferon with changed spatial configuration

Country Status (10)

Country Link
US (6) US20160022778A1 (en)
EP (3) EP2941266B1 (en)
JP (5) JP2016506413A (en)
KR (4) KR20210077005A (en)
CN (2) CN104902917A (en)
AU (2) AU2014204386B2 (en)
CA (2) CA2897312C (en)
HK (4) HK1214528A1 (en)
TW (3) TWI718086B (en)
WO (2) WO2014106459A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718086B (en) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
CN107847564B (en) * 2015-05-12 2021-11-09 远东超级实验室有限公司 Method for identifying interferon with direct inhibition effect on tumor and application thereof
WO2018144999A1 (en) * 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CN108721603B (en) * 2017-04-14 2020-11-13 中国医学科学院基础医学研究所 Use of interferon alpha-1 a for the preparation of a medicament for the treatment of cancer
KR101880015B1 (en) * 2017-12-08 2018-07-19 아주대학교산학협력단 Composition comprising Interferon-gamma for preventing or treating of neurofibrosarcoma
JP2022513140A (en) * 2018-11-27 2022-02-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Compositions and Methods for Treating Cancer
US20220251605A1 (en) * 2019-06-14 2022-08-11 The Brigham And Women's Hospital, Inc. Membrane attack complexes and uses thereof
CA3206014A1 (en) * 2021-01-21 2022-07-28 Lu Zhuang Interferon-based cancer treatment method, and pharmaceutical combination
US11759434B2 (en) * 2022-02-03 2023-09-19 Sytheon Limited Methods and compositions for treating melanoma and non-melanoma skin cancers
CN114533706B (en) * 2022-02-15 2022-10-14 深圳市利云德生物技术有限公司 Aerosol inhalation preparation for preventing and treating respiratory diseases and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364724B2 (en) * 2001-02-28 2008-04-29 Sichuan Biotechnology Research Center Recombinant super-compound interferon
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
US20110268658A1 (en) * 2009-03-30 2011-11-03 Crawford Thomas C Polymer-agent conjugates, particles, compositions, and related methods of use
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2005169A (en) * 1932-08-27 1935-06-18 Rowe Andrew Reed Casting metal ingots
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4681930A (en) 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
SE448277B (en) 1985-04-12 1987-02-09 Draco Ab INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS
SE453566B (en) 1986-03-07 1988-02-15 Draco Ab POWDER INHALATOR DEVICE
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
ATE189124T1 (en) 1991-07-02 2000-02-15 Inhale Inc METHOD AND DEVICE FOR DELIVERING MEDICATIONS IN AEROSOL FORM
RU2054180C1 (en) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Method and aerosol for treating respiratory virus infections
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
SK51695A3 (en) 1992-10-19 1995-11-08 Dura Pharma Inc Dry powder medicament inhaler
AU5883694A (en) 1993-01-19 1994-08-15 Glaxo Group Limited Device
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
CA2180260A1 (en) * 1993-12-29 1995-07-06 Dennis M. Brown Methods and compositions for the treatment of a host with a cellular proliferative disease
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
CA2232230C (en) 1995-10-13 2005-06-28 Ralph H. Lambalot Phosphopantetheinyl transferases and uses thereof
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
PL327616A1 (en) 1996-01-03 1998-12-21 Glaxo Group Ltd Inhaler
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
CN1062565C (en) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 Recombination human alpha type composite interferon, prepn. method and use therefor
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
JP3983985B2 (en) * 2000-03-22 2007-09-26 株式会社東芝 Polymorphic gene of MxA protein and use thereof
CA2427850A1 (en) 2000-11-03 2002-05-10 Sidney Pestka Interferons, uses and compositions related thereto
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
FR2823764B1 (en) 2001-04-24 2003-12-12 Genodyssee NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFN ALPHA-17 GENE
CN1375502A (en) 2001-10-25 2002-10-23 南京药科大学 Polyglycol modified recombinant human interferon
AU2003211297B2 (en) 2002-02-19 2007-12-06 Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption type plaster
WO2004091571A2 (en) 2003-04-08 2004-10-28 New Jersey Institute Of Technology (Njit) Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
CN1910195A (en) 2003-08-28 2007-02-07 辉阳科技美国公司 Uses of spatial configuration to modulate protein function
MY141751A (en) * 2003-08-28 2010-06-30 Sichuan Biotechnology Res Ct Recombinant super-compound interferon
EP1663110B1 (en) 2003-08-28 2013-12-18 Superlab Far East Limited Uses of interferons with altered spatial structure
SI1663110T1 (en) * 2003-08-28 2014-04-30 Superlab Far East Limited Uses of interferons with altered spatial structure
FR2862541B1 (en) * 2003-11-21 2007-04-20 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR PROLONGED RELEASE OF INTERFERONS AND THEIR THERAPEUTIC APPLICATIONS
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2006088473A2 (en) * 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
CN1740197B (en) 2004-08-26 2010-05-12 辉阳科技美国公司 Recombination interferon with new space conformation and enhanced effect, its preparing method and application
WO2006134497A2 (en) 2005-03-09 2006-12-21 Guangwen Wei Uses of recombinant super-compound interferons
JP2006248978A (en) 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
WO2006133089A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
CN101370486B (en) 2005-12-09 2012-12-05 北京康倍得医药技术开发有限公司 Transdermal patch containing Isosorbide Dinitrate and bisoprolol
US7964574B2 (en) 2006-08-04 2011-06-21 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US8095213B1 (en) 2007-05-31 2012-01-10 Purdue Pharma L.P. Transdermal patch
ES2336873B1 (en) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT.
ES2413255T3 (en) 2009-04-09 2013-07-16 Lga Biotecnologie Srl Determination of the efficacy of 5-ASA in the prevention and / or treatment of CRC by analyzing gene expression
CN102101886A (en) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 Variable-conformation recombinant interferon crystal, and three-dimensional structure and use thereof
SG189095A1 (en) 2010-09-27 2013-05-31 Zestagen S A Compositions and methods for treating neoplasia
MX360254B (en) * 2011-03-10 2018-10-26 Pfizer Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer.
US20130184437A9 (en) 2011-06-08 2013-07-18 Guangwen Wei Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure
US10016484B2 (en) 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer
US20130273527A1 (en) 2012-04-13 2013-10-17 Superlab Far East Limited Method for inducing cell senescence by recombinant interferon with altered spatial configuration
AU2013293049A1 (en) * 2012-07-20 2015-02-26 La Trobe University Method of diagnosis and treatment
TWI718086B (en) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
US10677782B2 (en) 2013-11-13 2020-06-09 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364724B2 (en) * 2001-02-28 2008-04-29 Sichuan Biotechnology Research Center Recombinant super-compound interferon
US8425896B2 (en) * 2001-02-28 2013-04-23 Sichuan Biotechnology Research Center Treatment of tumors with recombinant interferon alpha
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
US20100061961A1 (en) * 2003-08-28 2010-03-11 Guangwen Wei Recombinant super-compound interferon
US20110268658A1 (en) * 2009-03-30 2011-11-03 Crawford Thomas C Polymer-agent conjugates, particles, compositions, and related methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yata et al. (2010), JHepatologica Japonica, Vol. 51, pp565-571. *

Also Published As

Publication number Publication date
HK1214528A1 (en) 2016-07-29
JP2020105223A (en) 2020-07-09
HK1217897A1 (en) 2017-01-27
KR20150139824A (en) 2015-12-14
EP2941264A4 (en) 2016-08-31
TW201940189A (en) 2019-10-16
WO2014106459A2 (en) 2014-07-10
KR20210077005A (en) 2021-06-24
TW201427681A (en) 2014-07-16
JP2016508987A (en) 2016-03-24
EP2941266B1 (en) 2022-05-25
JP2022031331A (en) 2022-02-18
EP3895725A3 (en) 2021-12-01
CA2897335A1 (en) 2014-07-10
US10874716B2 (en) 2020-12-29
US20180344811A1 (en) 2018-12-06
WO2014106492A2 (en) 2014-07-10
KR20150103284A (en) 2015-09-09
US20150352188A1 (en) 2015-12-10
WO2014106459A3 (en) 2014-09-04
WO2014106459A8 (en) 2015-08-06
WO2014106492A3 (en) 2014-08-28
US20180326012A1 (en) 2018-11-15
AU2014204386B2 (en) 2018-07-26
TW201427682A (en) 2014-07-16
HK1217178A1 (en) 2016-12-30
AU2014204368A1 (en) 2015-08-20
AU2014204386A1 (en) 2015-08-27
CA2897312C (en) 2022-11-01
JP2020023547A (en) 2020-02-13
AU2014204368B2 (en) 2018-08-23
KR20210069127A (en) 2021-06-10
EP2941266A4 (en) 2016-09-07
EP2941266A2 (en) 2015-11-11
HK1216394A1 (en) 2016-11-11
EP2941264B1 (en) 2021-03-10
EP2941264A2 (en) 2015-11-11
CN104902917A (en) 2015-09-09
US20210260164A1 (en) 2021-08-26
EP3895725A2 (en) 2021-10-20
TWI726291B (en) 2021-05-01
CN104994866A (en) 2015-10-21
CA2897312A1 (en) 2014-07-10
TWI718086B (en) 2021-02-11
JP2016506413A (en) 2016-03-03
US20220339255A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
US20220339255A1 (en) A method for treating tumor by using recombinant interferon with changed spatial configuration
Hermsen et al. Response to radiation therapy in adrenocortical carcinoma
TW201630597A (en) Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia
Chang et al. Stereotactic body radiotherapy for unresectable pancreatic cancer
Leon-Ferre et al. Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature
WO2022151335A2 (en) Method for tumor treatment by means of hyperbaric oxygen combined with immune drug
Chu et al. Hypofractionated Radiation Therapy Combined With Weekly Chemotherapy in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-Arm Phase 2 Study (GASTO-1042)
Greten Treatment of Liver Cancer
Tseng et al. Phase II Study of Definitive Chemoradiation Therapy Using S-1 for Esophageal Squamous Cell Carcinoma Patients---the ESO-Shanghai 7 Trial Protocol
Yamamoto et al. Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy
Wu et al. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report
Pingpank Jr Therapy for unresectable hepatocellular carcinoma: time for XRT?
Hickish et al. 3 Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigucs MA and Rausch M: Modificd therapy with 5-fluorouracil
TW200904404A (en) Methods and compositions for contributing to the treatment of cancers

Legal Events

Date Code Title Description
AS Assignment

Owner name: SUPERLAB FAR EAST LIMITED, VIRGIN ISLANDS, BRITISH

Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:WEI, GUANGWEN;REEL/FRAME:037107/0611

Effective date: 20151008

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION